"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,A1,US 2011/0080303 A1,108-327-863-124-692,2011-04-07,2011,US 87383310 A,2010-09-01,US 87383310 A;;US 23885009 P,2009-09-01,COMPUTERIZED TRAFFIC SIGNAL SYSTEM,"Traffic through a portion of a city formed of streets defining a grid includes clusters of traffic signs, each cluster being positioned at an intersection and having its own cluster process controller. The clusters also include cameras monitoring traffic through and at each intersection. The cameras provide information used locally or at remote localities to control traffic. The remote localities may include a traffic command center, fire/police stations or a home security office.",GOLDBERG ALLEN;;CRAIG ROBERT,GOLDBERG ALLEN;;CRAIG ROBERT,,https://lens.org/108-327-863-124-692,Patent Application,yes,11,23,1,1,0,G08G1/07;;G08G1/07;;H04N7/181;;H04N7/181,G08G1/07;;H04N7/18,340/909;;348/149;;X348E07085,0,0,,,,DISCONTINUED
2,US,S,US D0953766 S,055-899-767-523-776,2022-06-07,2022,US 201929714256 F,2019-11-21,US 201929714256 F;;US 201916670706 A;;US 201862754337 P,2018-11-01,Seating apparatus,,INHARMONY INTERACTIVE,CARNEVALE DOMINIC;;GOLDBERG CRAIG,HOLISTIC HEALTH SCIENCE LLC (2020-05-08);;INHARMONY INTERACTIVE (2020-09-21),https://lens.org/055-899-767-523-776,Design Right,no,32,0,2,2,0,A47C3/16;;A47C7/727;;A61M21/02;;A61M2021/0022;;A61M2021/0027;;A61M2205/502;;A61M2205/3592;;A61M2205/505;;A47C15/004;;A47C3/16;;A61M2021/0027;;A61M21/02;;A61M2021/0022;;A47C7/727,,0601;;D 6378;;D6/364,2,0,,,"Non-Final Office Action dated Sep. 28, 2021 in related U.S. Appl. No. 16/670,706, in 13 pages.;;Final Office Action dated Jan. 25, 2022 in related U.S. Appl. No. 16/670,706, in 16 pages.",ACTIVE
3,US,A1,US 2019/0182218 A1,154-002-180-029-373,2019-06-13,2019,US 201816208299 A,2018-12-03,US 201816208299 A;;US 94498510 A,2010-11-12,APPARATUS AND METHODS ENSURING DATA PRIVACY IN A CONTENT DISTRIBUTION NETWORK,"Methods and apparatus for ensuring the privacy of users and/or devices in a content delivery network from which data regarding the users' interaction with content is collected and distributed. In one embodiment, “tuning” records which describe the interaction of users with content or other activities of interest are collected. It is determined whether an opportunity for compromise of the user's privacy (e.g., by derivative association) is present. If it is determined that such an opportunity exists, at least portions of the data are modified (e.g., collapsed). The modification may comprise replacing a first explicit data value with a second descriptive data value, increasing a range for the value, generalizing the value, removing the value, or encoding the value. Further processing of the collected tuning records may include, validating the data, accounting for latency, and generating reports based thereon.",TIME WARMER CABLE ENTPR LLC,TIDWELL JUSTIN;;SAMAME EDUARDO;;ENGEL CRAIG;;GOLDBERG CRAIG,,https://lens.org/154-002-180-029-373,Patent Application,yes,6,5,4,4,0,G06F21/6254;;H04H60/31;;H04L63/0421;;G06F21/6254;;H04H60/31;;H04L63/0421,H04L29/06;;G06F21/62;;H04H60/31,,0,0,,,,ACTIVE
4,US,B2,US 10148623 B2,158-153-996-454-034,2018-12-04,2018,US 94498510 A,2010-11-12,US 94498510 A,2010-11-12,Apparatus and methods ensuring data privacy in a content distribution network,"Methods and apparatus for ensuring the privacy of users and/or devices in a content delivery network from which data regarding the users' interaction with content is collected and distributed. In one embodiment, “tuning” records which describe the interaction of users with content or other activities of interest are collected. It is determined whether an opportunity for compromise of the user's privacy (e.g., by derivative association) is present. If it is determined that such an opportunity exists, at least portions of the data are modified (e.g., collapsed). The modification may comprise replacing a first explicit data value with a second descriptive data value, increasing a range for the value, generalizing the value, removing the value, or encoding the value. Further processing of the collected tuning records may include, validating the data, accounting for latency, and generating reports based thereon.",TIDWELL JUSTIN;;SAMAME EDUARDO;;ENGEL CRAIG;;GOLDBERG CRAIG;;TIME WARNER CABLE ENTPR LLC,TIDWELL JUSTIN;;SAMAME EDUARDO;;ENGEL CRAIG;;GOLDBERG CRAIG,TIME WARNER CABLE INC (2011-01-28),https://lens.org/158-153-996-454-034,Granted Patent,yes,331,2,4,4,0,G06F21/6254;;H04H60/31;;H04L63/0421;;G06F21/6254;;H04H60/31;;H04L63/0421,G06F15/16;;G06F21/62;;H04H60/31;;H04L29/06,,4,0,,,"Denning et al. (Cryptography and data security, Addison-Wesley Publishing Company, ISBN 0-201-10150-5, 1982).;;Cantor, et al., Bindings for the OASIS Security Assertion Markup Language (SAML) V2.0, OASIS Standard, Mar. 2005 (http://docs.oasis-open.org/security/saml/v2.0/).;;DLNA (Digital Living Network Alliance) protocols described in DLNA Networked Device Interoperability Guidelines Expanded, Mar. 2006 and subsequent expanded version dated Oct. 2006.;;UTF-32 IBM, retrieved form http://publib.boulder.ibm.com/infocenter.iseriey/y5r3/index.isp?topic=%2Fnje%2Frhagsutl32.htm on Aug. 28, 2013.",ACTIVE
5,US,A1,US 2012/0124161 A1,060-910-611-782-97X,2012-05-17,2012,US 94498510 A,2010-11-12,US 94498510 A,2010-11-12,APPARATUS AND METHODS ENSURING DATA PRIVACY IN A CONTENT DISTRIBUTION NETWORK,"Methods and apparatus for ensuring the privacy of users and/or devices in a content delivery network from which data regarding the users' interaction with content is collected and distributed. In one embodiment, “tuning” records which describe the interaction of users with content or other activities of interest are collected. It is determined whether an opportunity for compromise of the user's privacy (e.g., by derivative association) is present. If it is determined that such an opportunity exists, at least portions of the data are modified (e.g., collapsed). The modification may comprise replacing a first explicit data value with a second descriptive data value, increasing a range for the value, generalizing the value, removing the value, or encoding the value. Further processing of the collected tuning records may include, validating the data, accounting for latency, and generating reports based thereon.",TIDWELL JUSTIN;;SAMAME EDUARDO;;ENGEL CRAIG;;GOLDBERG CRAIG,TIDWELL JUSTIN;;SAMAME EDUARDO;;ENGEL CRAIG;;GOLDBERG CRAIG,TIME WARNER CABLE INC (2011-01-28),https://lens.org/060-910-611-782-97X,Patent Application,yes,9,64,4,4,0,G06F21/6254;;H04H60/31;;H04L63/0421;;G06F21/6254;;H04H60/31;;H04L63/0421,G06F15/16,709/217,1,0,,,"Denning et al. (Cryptography and data security, Addison-Wesley Publishing Company, ISBN 0-201-10150-5, 1982).",ACTIVE
6,US,A1,US 2012/0005527 A1,037-514-680-985-22X,2012-01-05,2012,US 82910410 A,2010-07-01,US 82910410 A,2010-07-01,APPARATUS AND METHODS FOR DATA COLLECTION AND VALIDATION,"Methods and apparatus for collection, validation, analysis, and automated error correction of data regarding user interaction with content. In one embodiment, statistical methods are used to arrive at expected values for the collected data. The data is compared to the expected value and must meet one or more acceptance criteria (e.g., be within a prescribed range) to be considered valid. The prescribed range is determined by the network operator, or a computer program adapted to generate this value. The invention enables a network operator to assess a large volume of data without requiring significant amounts of manual monitoring and/or error correction. The ability to collect, validate and analyze data across multiple platforms is also provided. Still further, an automated system capable of learning evaluation and error correction patterns is disclosed.",ENGEL CRAIG;;GOLDBERG CRAIG;;SAMAME EDUARDO;;TIDWELL JUSTIN,ENGEL CRAIG;;GOLDBERG CRAIG;;SAMAME EDUARDO;;TIDWELL JUSTIN,TIME WARNER CABLE ENTERPRISES LLC (2013-04-29);;TIME WARNER CABLE INC (2010-06-29),https://lens.org/037-514-680-985-22X,Patent Application,yes,4,79,4,4,0,H04H60/64;;H04N21/44224;;H04N21/4667;;H04N21/6582;;H04N21/44204;;H04N21/4524;;H04N21/4532;;H04N21/458;;G06F11/008;;H04H60/33;;H04H60/46;;H04H60/64;;H04N21/44224;;H04N21/2408,G06F11/00;;G06F11/08;;H04H60/32,714/15;;725/14;;714/57;;X714E1103;;X714E1102,0,0,,,,ACTIVE
7,US,B2,US 11271909 B2,128-912-975-686-318,2022-03-08,2022,US 201816208299 A,2018-12-03,US 201816208299 A;;US 94498510 A,2010-11-12,Apparatus and methods ensuring data privacy in a content distribution network,"Methods and apparatus for ensuring the privacy of users and/or devices in a content delivery network from which data regarding the users' interaction with content is collected and distributed. In one embodiment, “tuning” records which describe the interaction of users with content or other activities of interest are collected. It is determined whether an opportunity for compromise of the user's privacy (e.g., by derivative association) is present. If it is determined that such an opportunity exists, at least portions of the data are modified (e.g., collapsed). The modification may comprise replacing a first explicit data value with a second descriptive data value, increasing a range for the value, generalizing the value, removing the value, or encoding the value. Further processing of the collected tuning records may include, validating the data, accounting for latency, and generating reports based thereon.",TIME WARNER CABLE ENTPR LLC,TIDWELL JUSTIN;;SAMAME EDUARDO;;ENGEL CRAIG;;GOLDBERG CRAIG,,https://lens.org/128-912-975-686-318,Granted Patent,yes,335,0,4,4,0,G06F21/6254;;H04H60/31;;H04L63/0421;;G06F21/6254;;H04H60/31;;H04L63/0421,G06F21/62;;H04H60/31,,4,0,,,"Cantor, et al., Bindings for the OASIS Security Assertion Markup Language (SAML) V2.0, OASIS Standard, Mar. 2005, Document ID saml-bindings-2.0-os ,(http://docs.oasis-open.org/security/saml/v2.0/saml-bindings-2.0-os.pdf).;;Denning, et al., Cryptography and Data Security, Addison-Wesley Publishing Company, ISBN 0-201-10150-5, 1982, pp. 62.;;DLNA (Digital Living Network Alliance) protocols described in DLNA Networked Device Interoperability Guidelines Expanded, Mar. 2006 and subsequent expanded version dated Oct. 2006.;;UTF-32, IBM, retrieved from http://publib.boulder.ibm.com/infocenter/iseries/v5r3/index.jsp?topic=%2Fnls%2Frbagsutf32.htm on Aug. 28, 2013.",ACTIVE
8,US,A1,US 2013/0018417 A1,006-789-857-664-148,2013-01-17,2013,US 201113180771 A,2011-07-12,US 201113180771 A,2011-07-12,SPINAL ALIGNMENT DEVICE AND METHOD,An adjustable head and neck support device with an adjustable head rest assembly and an adjustable neck rest assembly that attach to and move with respect to a base. The adjustable neck rest assembly is configured to move and non-fixedly lock on a z-axis and to rotate about non-fixedly lock on a y-axis. The head rest support assembly rotates about non-fixedly lock on an x-axis. The adjustable head rest assembly is configured to move and non-fixedly lock on the z-axis and to rotate about the x-axis.,SMC LTD;;GOLDBERG DAVID;;BELTON JASON;;RAE CRAIG,GOLDBERG DAVID;;BELTON JASON;;RAE CRAIG,,https://lens.org/006-789-857-664-148,Patent Application,yes,0,4,1,1,0,A61F5/01;;A61F5/055;;A61F5/01;;A61F5/055,A61F5/00,606/240,0,0,,,,DISCONTINUED
9,US,A1,US 2020/0108264 A1,185-734-146-365-232,2020-04-09,2020,US 201916706760 A,2019-12-08,US 201916706760 A,2019-12-08,METHOD TO IMPROVE OUTCOMES DURING NEGOTIATIONS,"Hyperscanning studies of the electrical activity of the brains of dyads and groups has shown that cooperative decision-making is associated with inter brain partial synchronization. Cooperative decision-making may be essential for long term resolution of conflict among nations. This invention demonstrates that synchronization of two Chua's circuits can be achieved through induction, and a single Chua's circuit can transition from chaotic to periodic activity with frequency dependent square wave inputs, models of action potentials. Extrapolating these in vitro findings suggests that conflict negotiations can be improved with electrophysiological monitoring of participants and with external electromagnetic energy targeted to brain activity.",GOLDBERG JOEL STEVEN;;JACKSON CRAIG L,GOLDBERG JOEL STEVEN;;JACKSON CRAIG L,,https://lens.org/185-734-146-365-232,Patent Application,yes,0,0,1,1,0,A61N2/006;;A61N2/006;;A61B5/369;;A61B5/369;;A61B5/4836;;A61B5/4836;;A61N2/02;;A61N2/02;;G16H20/30;;G16H20/70,A61N2/00;;A61B5/00;;A61B5/0476;;A61N2/02;;G16H20/30;;G16H20/70,,0,0,,,,DISCONTINUED
10,US,B1,US 8271326 B1,154-205-931-814-277,2012-09-18,2012,US 51684206 A,2006-09-07,US 51684206 A,2006-09-07,Referral processing and tracking system,"Systems and methods are disclosed for tracking, reporting and performing processing activities and transactions in association with referral data and related information for a variety of product and service offerings.",BRUNET CRAIG;;GOLDBERG MICHAEL S;;KOHN AVERY;;LIBIN JUDAH;;NEWTEK BUSINESS SERVICES INC,BRUNET CRAIG;;GOLDBERG MICHAEL S;;KOHN AVERY;;LIBIN JUDAH,NEWTEK BUSINESS SERVICES INC (2006-09-06);;NEWTEK BUSINESS SERVICES CORP (2014-11-12),https://lens.org/154-205-931-814-277,Granted Patent,yes,10,18,1,1,0,G06Q30/0214;;G06Q30/0214,G06Q30/00,705/14.16;;705/35;;705/300,0,0,,,,ACTIVE
11,US,A1,US 2010/0138263 A1,097-079-390-132-352,2010-06-03,2010,US 69893310 A,2010-02-02,US 69893310 A;;US 40691503 A,2003-04-04,CONCISE COMMUNICATION OF REAL-TIME BUSINESS INFORMATION IN AN ENTERPRISE NETWORK,"A method, system, computer program product, and related business methods for concisely communicating real-time business information to end users in an enterprise network is described. An integrated business system having at least ERP and CRM functionality is accessed via a browser-based user interface. A plurality of portlet windows are simultaneously displayed within a browser window, each portlet window occupying a relatively small area therein. The portlet windows are selected and arranged according to a customizable user profile for each user, and include reporting portlets displaying up-to-date business results retrieved from the integrated business system. Each reporting portlet further comprises report access links associated with at least one of the business results that, when selected by the user, invoke browser-based displays of up-to-date business data underlying those business results. Preferably, in accordance with a user-customizable alert setting stored in the user profile, regular electronic mail messages are sent to the user communicating up-to-date versions of those business results. Preferably, data labels that identify business items within the browser-based user interface and on the electronic mails are expressed in a business vernacular tuned to each user according to customizable business vernacular settings in their user profiles.",NETSUITE INC,GOLDBERG EVAN M;;SULLIVAN CRAIG S;;GOLDWASSER BARUCH;;BRAUD LUKE A,NETSUITE INC (2007-11-19),https://lens.org/097-079-390-132-352,Patent Application,yes,33,3,8,14,0,G06Q10/06;;G06Q10/063;;G06Q10/087;;G06Q10/10;;G06Q30/00;;G06Q10/06;;G06Q10/087;;G06Q30/00;;G06Q10/063;;G06Q10/10,G06F15/16;;G06F3/048;;G06F17/00;;G06F40/189;;G06F40/191;;G06Q30/00,705/7;;715/760;;709/206,0,0,,,,EXPIRED
12,US,A1,US 2011/0054966 A1,110-555-130-039-112,2011-03-03,2011,US 87155310 A,2010-08-30,US 87155310 A;;US 69893310 A;;US 40691503 A,2003-04-04,CONCISE COMMUNICATION OF REAL-TIME BUSINESS INFORMATION IN AN ENTERPRISE NETWORK,"A method, system, computer program product, and related business methods for concisely communicating real-time business information to end users in an enterprise network is described. An integrated business system having at least ERP and CRM functionality is accessed via a browser-based user interface. A plurality of portlet windows are simultaneously displayed within a browser window, each portlet window occupying a relatively small area therein. The portlet windows are selected and arranged according to a customizable user profile for each user, and include reporting portlets displaying up-to-date business results retrieved from the integrated business system. Each reporting portlet further comprises report access links associated with at least one of the business results that, when selected by the user, invoke browser-based displays of up-to-date business data underlying those business results. Preferably, in accordance with a user-customizable alert setting stored in the user profile, regular electronic mail messages are sent to the user communicating up-to-date versions of those business results. Preferably, data labels that identify business items within the browser-based user interface and on the electronic mails are expressed in a business vernacular tuned to each user according to customizable business vernacular settings in their user profiles.",NETSUITE INC,GOLDBERG EVAN M;;SULLIVAN CRAIG S;;GOLDWASSER BARUCH;;BRAUD LUKE A,NETSUITE INC (2007-11-19),https://lens.org/110-555-130-039-112,Patent Application,yes,1,5,8,14,0,G06Q10/06;;G06Q10/063;;G06Q10/087;;G06Q10/10;;G06Q30/00;;G06Q10/06;;G06Q10/087;;G06Q30/00;;G06Q10/063;;G06Q10/10,G06F17/00;;G06F40/189;;G06F40/191;;G06Q30/00,705/7,0,0,,,,EXPIRED
13,US,B2,US 8838465 B2,000-170-810-018-352,2014-09-16,2014,US 201213537364 A,2012-06-29,US 201213537364 A;;US 87155310 A;;US 69893310 A;;US 40691503 A,2003-04-04,Concise communication of real-time business information in an enterprise network,"A method, system, computer program product, and related business methods for concisely communicating real-time business information to end users in an enterprise network is described. An integrated business system having at least ERP and CRM functionality is accessed via browser-based user interface. A plurality of portlet windows are simultaneously displayed within a browser window, each portlet window occupying a relatively small area therein. The portlet windows are selected and arranged according to a customizable user profile for each user, and include reporting portlets displaying up-to-date business results retrieved from the integrated business system. Each reporting portlet further comprises report access links associated with at least one of the business results that, when selected by the user, invoke browser-based displays of up-to-date business data underlying those business results. Preferably, in accordance with a user-customizable alert setting stored in the user profile, regular electronic mail messages are sent to the user communicating up-to-date versions of those business results. Preferably, data labels that identify business items within the browser-based user interface and on the electronic mails are expressed in a business vernacular tuned to each user according to customizable business vernacular settings in their user profiles.",GOLDBERG EVAN M;;SULLIVAN CRAIG S;;GOLDWASSER BARUCH;;BRAUD LUKE A;;NETSUITE INC,GOLDBERG EVAN M;;SULLIVAN CRAIG S;;GOLDWASSER BARUCH;;BRAUD LUKE A,NETSUITE INC (2007-11-19),https://lens.org/000-170-810-018-352,Granted Patent,yes,38,2,8,14,0,G06Q10/06;;G06Q10/063;;G06Q10/087;;G06Q10/10;;G06Q30/00;;G06Q10/06;;G06Q10/087;;G06Q30/00;;G06Q10/063;;G06Q10/10,G06Q10/00;;G06F17/00;;G06F40/189;;G06F40/191;;G06Q30/00,705/7.11,11,0,,,"Babcock, Charles, ""Isomorphic Broadens Rich Web Client Appeal,"" The Foggy Mountain Report, No. 19, San Francisco, CA, charlesbabcock.com, Jan. 8, 2003, pp. 1-6.;;cio.com, ""Executive Summaries: Enterprise Resource Planning,"" CXO Media, Inc.; Aug. 22, 2002; http://www.cio.com/summaries/enterprise/erp/index.html; pp. 1-10.;;Dragan, Richard V., ""CRM Goes Mainstream,"" PC Magazine, New York, Jun. 12, 2001; vol. 20; Iss. 11; p. 28; pp. 1-3.;;Goodman, D., JavaScript Bible: Gold Edition, Hungry Minds, Inc. (2001); Cover Page and Table of Contents, pp. 1-17.;;Isomorphic Software, ""Isomorphic SmartClient (ISC) Historical/ Competitive Brief,"" Isomorphic Software, Inc., San Francisco, CA; Jun. 12, 2003; pp. 1-2.;;Isomorphic Software, ""Isomorphic SmartClient (ISC) Technology Brief,"" Isomorphic Software, Inc., San Francisco, CA; Jun. 10, 2003, p. 1.;;NetLedger 1 Day Test Drive Login NetLedger, Retrieved From: , archived Apr. 22, 2001, p. 1.;;Novotney, Jason et al. ""Gridlab Portal Design,"" Downloaded: http://www.gridlab.org/WorkPackages/wp-4/Documents/GridShpere.pdf, pp. Cover, 1-43.;;Patricia Seabold Group, ""An Executive's Guide to CRM: How to Evaluate CRM . . . "" (2002), from http://www.psgroup.com/freereport/imedia/CRM-EXECGUIDE3-02.pdf; pp. 1-41.;;Ray, D. and Ray, E., Mastering HTML and XHTML, SYBEX, Inc. (2002), Cover Page and Table of Contents; pp. 1-16.;;Wilson, Ralph E., ""A Simple Way to Format HTML E-Mail Newsletters,"" Web Marketing Today, Jan. 1, 2000; Issue 67, pp. 1-8.",EXPIRED
14,US,B2,US 8195493 B2,104-676-531-654-54X,2012-06-05,2012,US 69893310 A,2010-02-02,US 69893310 A;;US 40691503 A,2003-04-04,Concise communication of real-time business information in an enterprise network,"A method, system, computer program product, and related business methods for concisely communicating real-time business information to end users in an enterprise network is described. An integrated business system having at least ERP and CRM functionality is accessed via a browser-based user interface. A plurality of portlet windows are simultaneously displayed within a browser window, each portlet window occupying a relatively small area therein. The portlet windows are selected and arranged according to a customizable user profile for each user, and include reporting portlets displaying up-to-date business results retrieved from the integrated business system. Each reporting portlet further comprises report access links associated with at least one of the business results that, when selected by the user, invoke browser-based displays of up-to-date business data underlying those business results. Preferably, in accordance with a user-customizable alert setting stored in the user profile, regular electronic mail messages are sent to the user communicating up-to-date versions of those business results. Preferably, data labels that identify business items within the browser-based user interface and on the electronic mails are expressed in a business vernacular tuned to each user according to customizable business vernacular settings in their user profiles.",GOLDBERG EVAN M;;SULLIVAN CRAIG S;;GOLDWASSER BARUCH;;BRAUD LUKE A;;NETSUITE INC,GOLDBERG EVAN M;;SULLIVAN CRAIG S;;GOLDWASSER BARUCH;;BRAUD LUKE A,NETSUITE INC (2007-11-19),https://lens.org/104-676-531-654-54X,Granted Patent,yes,33,2,8,14,0,G06Q10/06;;G06Q10/063;;G06Q10/087;;G06Q10/10;;G06Q30/00;;G06Q10/06;;G06Q10/087;;G06Q30/00;;G06Q10/063;;G06Q10/10,G06F17/00;;G06Q10/00;;G06F17/21;;G06F17/22;;G06F17/24;;G06F17/27;;G06F17/28;;G06F40/189;;G06F40/191;;G06Q30/00,705/7.11;;715/204;;715/253,13,0,,,"Wilson, Ralph F.; ""A Simply Way to Format HTML E-Mail Newsletters"". Jan. 1, 2000. Web Marketing Today. Issue 67.;;Babcock, Charles, ""Isomoric Broadens Rich Web Client Appeal,"" The Foggy Mountain Report, No. 19, San Francisco, CA, published at www.charlesbabcock.com, (Jan. 13, 2003).;;CIO.Com, ""Executive Summaries: Enterprise Resource Planning,"" CXO Media, inc. (Aug. 22, 2002), as printed on Mar. 27, 2003 from www.cio.com/summaries/enterprise/erp/index.html.;;Dragan, Richard V., ""CRM Goes Mainstream,"" PC Magazine, New York, vol. 20, Iss. 11, p. 28 (Jun. 12, 2001).;;Goodman, D., JavaScript Bible: Gold Edition, Hungry Minds, Inc. (2001). (cover page and table of contents only).;;Isomorphic Software, ""Isomorphic SmartClient (ISC) Historical/Competitive Brief,"" Isomorphic Software, Inc., San Francisco, CA (Jun. 12, 2003).;;Isomorphic Software, ""Isomorphic SmartClient (ISC) Technology Brief,"" Isomorphic Software, Inc., San Francisco, CA (Jun. 10, 2003).;;""Netledger 1 Day Test Drive Login"" NetLedger, retrieved from internet from: archived Apr. 22, 2001.;;""NetLedger Launches NetSuite, the First Online Suite That Combines ERP and CRM Functionality Aimed at Companies With Fewer Than 500 Employees,"" Internet retailer. Retrieved from Internet <http://www.internetretailer.com/internet/marketing-conference/566678728-netledger-launches-netsuitetm.html> (Oct. 15, 2002).;;Novotny, Jason, et al. ""Gridlab Portal Design,"" downloaded from http://www.gridlab.org/WorkPackages/wp-4/Documents/GridSphere.pdf, pp. Cover, 1-43 (2001).;;Patricia Seybold Group, ""An Executive's Guide to CRM: How to Evaluate CRM Alternatives by Functionality, Architecture & Analytics"" (2002), as printed on Mar. 27, 2003 from www.psgroup.com/freereport/imedia/CRM-EXCELGUIDE3-02.pdf.;;Ray, D. and Ray, E., Mastering HTML and XHTML, SYBEX, Inc., (2002) (cover page and table of contents only).;;Wilson, Ralph F., ""A Simple Way to Format HTML Email Newsletters,"" Web Marketing Today, Jan. 1, 2000, Issue 67.",EXPIRED
15,US,B2,US 7685010 B2,183-563-103-448-779,2010-03-23,2010,US 40691503 A,2003-04-04,US 40691503 A,2003-04-04,Concise communication of real-time business information in an enterprise network,"A method, system, computer program product, and related business methods for concisely communicating real-time business information to end users in an enterprise network is described. An integrated business system having at least ERP and CRM functionality is accessed via a browser-based user interface. A plurality of portlet windows are simultaneously displayed within a browser window, each portlet window occupying a relatively small area therein. The portlet windows are selected and arranged according to a customizable user profile for each user, and include reporting portlets displaying up-to-date business results retrieved from the integrated business system. Each reporting portlet further comprises report access links associated with at least one of the business results that, when selected by the user, invoke browser-based displays of up-to-date business data underlying those business results. Preferably, in accordance with a user-customizable alert setting stored in the user profile, regular electronic mail messages are sent to the user communicating up-to-date versions of those business results. Preferably, data labels that identify business items within the browser-based user interface and on the electronic mails are expressed in a business vernacular tuned to each user according to customizable business vernacular settings in their user profiles.",NETSUITE INC,GOLDBERG EVAN M;;SULLIVAN CRAIG S;;GOLDWASSER BARUCH;;BRAUD LUKE A,NETSUITE INC (2003-07-22),https://lens.org/183-563-103-448-779,Granted Patent,yes,33,42,8,14,0,G06Q10/06;;G06Q10/063;;G06Q10/087;;G06Q10/10;;G06Q30/00;;G06Q10/06;;G06Q10/087;;G06Q30/00;;G06Q10/063;;G06Q10/10,G06F17/00;;G06F9/44;;G06F40/189;;G06F40/191;;G06Q30/00,705/7;;715/204;;715/253,12,0,,,"""NetLedger 1 Day Test Drive Login"" NetLedger. retrieved from: archived Apr. 22, 2001.;;Dragan, Richard V.; ""CRM Goes Mainstream"". PC Magazine. New York: Jun 12, 2001. vol. 20, Iss. 11; p. 28.;;""NetLedger Launches NetSuite, the First Online Suite That Combines ERP and CRM Functionality Aimed at Companies With Fewer Than 500 Employees"". Oct. 15, 2002. Internet Retailer. retrieved from <http://www.internetretailer.com/internet/marketing-conference/566678728-netledger-launches-netsuitetm.html>.;;Wilson, Ralph F. ""A Simply Way to Format HTML E-Mail Newsletters"". Jan. 1, 2000. Web Marketing Today. Issue 67.;;Patricia Seybold Group, ""An Executive's Guide to CRM: How to Evaluate CRM Alternatives by Functionality, Architecture, & Analytics"" (2002), as printed on Mar. 27, 2003 from http://www.psgroup.com/freereport/imedia/CRM-EXECGUIDE3-02.pdf.;;CIO.COM, ""Executive Summaries: Enterprise Resource Planning,"" CXO Media, Inc. (Aug. 22, 2002), as printed on Mar. 27, 2003 from http://www.cio.com/summaries/enterprise/erp/index.html.;;Ray, D. and Ray, E., Mastering HTML and XHTML, Sybex, Inc. (2002) (cover page and table of contents only).;;Goodman, D., JavaScript Bible: Gold Edition, Hungry Minds, Inc. (2001). (cover page and table of contents only).;;Babcock, Charles, ""Isomorphic Broadens Rich Web Client Appeal,"" The Foggy Mountain Report, No. 19, San Francisco, CA, published at www.charlesbabcock.com, (Jan. 8, 2003).;;Isomorphic Software, ""Isomorphic SmartClient (ISC) Historical/Competitive Brief,"" Isomorphic Software, Inc., San Francisco, CA (Jun. 12, 2003).;;Isomorphic Software, ""Isomorphic SmartClient (ISC) Technology Brief,"" Isomorphic Software, Inc., San Francisco, CA (Jun. 10, 2003).;;Novotny, Jason, et al. ""Gridlab Portal Design,"" downloaded from http://www.gridlab.org/WorkPackages/wp-4/Documents/GridSphere.pdf, pp. Cover, 1-43 (2001).",ACTIVE
16,US,A1,US 2004/0199541 A1,107-302-249-046-500,2004-10-07,2004,US 40691503 A,2003-04-04,US 40691503 A,2003-04-04,Concise communication of real-time business information in an enterprise network,"
   A method, system, computer program product, and related business methods for concisely communicating real-time business information to end users in an enterprise network is described. An integrated business system having at least ERP and CRM functionality is accessed via a browser-based user interface. A plurality of portlet windows are simultaneously displayed within a browser window, each portlet window occupying a relatively small area therein. The portlet windows are selected and arranged according to a customizable user profile for each user, and include reporting portlets displaying up-to-date business results retrieved from the integrated business system. Each reporting portlet further comprises report access links associated with at least one of the business results that, when selected by the user, invoke browser-based displays of up-to-date business data underlying those business results. Preferably, in accordance with a user-customizable alert setting stored in the user profile, regular electronic mail messages are sent to the user communicating up-to-date versions of those business results. Preferably, data labels that identify business items within the browser-based user interface and on the electronic mails are expressed in a business vernacular tuned to each user according to customizable business vernacular settings in their user profiles. 
",GOLDBERG EVAN M.;;SULLIVAN CRAIG S.;;GOLDWASSER BARUCH;;BRAUD LUKE A.,GOLDBERG EVAN M;;SULLIVAN CRAIG S;;GOLDWASSER BARUCH;;BRAUD LUKE A,NETSUITE INC (2003-07-22),https://lens.org/107-302-249-046-500,Patent Application,yes,37,104,8,14,0,G06Q10/06;;G06Q10/063;;G06Q10/087;;G06Q10/10;;G06Q30/00;;G06Q10/06;;G06Q10/087;;G06Q30/00;;G06Q10/063;;G06Q10/10,G06F17/00;;G06F40/189;;G06F40/191;;G06Q30/00,707/104.1,0,0,,,,EXPIRED
17,US,A1,US 2013/0060590 A1,190-410-357-978-362,2013-03-07,2013,US 201213537364 A,2012-06-29,US 201213537364 A;;US 87155310 A;;US 69893310 A;;US 40691503 A,2003-04-04,CONCISE COMMUNICATION OF REAL-TIME BUSINESS INFORMATION IN AN ENTERPRISE NETWORK,"A method, system, computer program product, and related business methods for concisely communicating real-time business information to end users in an enterprise network is described. An integrated business system having at least ERP and CRM functionality is accessed via browser-based user interface. A plurality of portlet windows are simultaneously displayed within a browser window, each portlet window occupying a relatively small area therein. The portlet windows are selected and arranged according to a customizable user profile for each user, and include reporting portlets displaying up-to-date business results retrieved from the integrated business system. Each reporting portlet further comprises report access links associated with at least one of the business results that, when selected by the user, invoke browser-based displays of up-to-date business data underlying those business results. Preferably, in accordance with a user-customizable alert setting stored in the user profile, regular electronic mail messages are sent to the user communicating up-to-date versions of those business results. Preferably, data labels that identify business items within the browser-based user interface and on the electronic mails are expressed in a business vernacular tuned to each user according to customizable business vernacular settings in their user profiles.",GOLDBERG EVAN M;;SULLIVAN CRAIG S;;GOLDWASSER BARUCH;;BRAUD LUKE A;;NETSUITE INC,GOLDBERG EVAN M;;SULLIVAN CRAIG S;;GOLDWASSER BARUCH;;BRAUD LUKE A,NETSUITE INC (2007-11-19),https://lens.org/190-410-357-978-362,Patent Application,yes,0,3,8,14,0,G06Q10/06;;G06Q10/063;;G06Q10/087;;G06Q10/10;;G06Q30/00;;G06Q10/06;;G06Q10/087;;G06Q30/00;;G06Q10/063;;G06Q10/10,G06F17/00;;G06Q10/00;;G06F40/189;;G06F40/191;;G06Q30/00,705/7.11,0,0,,,,EXPIRED
18,US,B2,US 8214239 B2,030-095-086-585-444,2012-07-03,2012,US 87155310 A,2010-08-30,US 87155310 A;;US 69893310 A;;US 40691503 A,2003-04-04,Concise communication of real-time business information in an enterprise network,"A method, system, computer program product, and related business methods for concisely communicating real-time business information to end users in an enterprise network is described. An integrated business system having at least ERP and CRM functionality is accessed via a browser-based user interface. A plurality of portlet windows are simultaneously displayed within a browser window, each portlet window occupying a relatively small area therein. The portlet windows are selected and arranged according to a customizable user profile for each user, and include reporting portlets displaying up-to-date business results retrieved from the integrated business system. Each reporting portlet further comprises report access links associated with at least one of the business results that, when selected by the user, invoke browser-based displays of up-to-date business data underlying those business results. Preferably, in accordance with a user-customizable alert setting stored in the user profile, regular electronic mail messages are sent to the user communicating up-to-date versions of those business results. Preferably, data labels that identify business items within the browser-based user interface and on the electronic mails are expressed in a business vernacular tuned to each user according to customizable business vernacular settings in their user profiles.",GOLDBERG EVAN M;;SULLIVAN CRAIG S;;GOLDWASSER BARUCH;;BRAUD LUKE A;;NETSUITE INC,GOLDBERG EVAN M;;SULLIVAN CRAIG S;;GOLDWASSER BARUCH;;BRAUD LUKE A,NETSUITE INC (2007-11-19),https://lens.org/030-095-086-585-444,Granted Patent,yes,33,4,8,14,0,G06Q10/06;;G06Q10/063;;G06Q10/087;;G06Q10/10;;G06Q30/00;;G06Q10/06;;G06Q10/087;;G06Q30/00;;G06Q10/063;;G06Q10/10,G06Q10/00;;G06F17/00;;G06F40/189;;G06F40/191;;G06Q30/00,705/7.11,12,0,,,"Babcock, Charles, ""Isomoric Broadens Rich Web Client Appeal,"" The Foggy Mountain Report, No. 19, San Francisco, CA, published at www.charlesbabcock.com (Jan. 13, 2003).;;CIO.Com, ""Executive Summaries: Enterprise Resource Planning,"" CXO Media, Inc., [online] Aug. 22, 2002 [retrieved on Mar. 27, 2003] Retrieved from the Internet: .;;Dragan, Richard V., ""CRM Goes Mainstream,"" PC Magazine, New York, vol. 20 (11), p. 28 (Jun. 12, 2001).;;Goodman, D. Javascript Bible: Gold Edition, 2001, Hungry Minds, Inc., cover page and table of contents.;;Isomorphic Software, Inc. ""Isomorphic SmartClient (ISC) Historical/Competitive Brief,"" San Francisco, CA (Jun. 12, 2003).;;Isomorphic Software, Inc. ""Isomorphic SmartClient (ISC) Technology Brief,"" San Francisco, CA (Jun. 10, 2003).;;Netledger, ""Netledger 1 Day Test Drive Login,"" [online] Apr. 22, 2001, Retrieved from the Internet: archive.;;""NetLedger Launches NetSuite, the First Online Suite that Combines ERP and CRM Functionality Aimed at Companies with Fewer than 500 Employees,"" Internet Retailer, [online] Oct. 15, 2002, Retrieved from the Internet: <URL: http://internetretailer.com/internet/marketing-conference/566678728-netledger-launches-netsuitetm.html>.;;Novotny, Jason et al., ""Gridlab Portal Design,"" [online] 2001, Retrieved from the Internet: .;;Patricia Seybold Group, ""An Executive's Guide to CRM: How to Evaluate CRM Alternatives by Functionality, Architecture and Analytics,"" [online] 2002 [retrieved on Mar. 27, 2003] Retrieved from the Internet: .;;Ray, D. and E. Ray, Mastering HTML and XHTML, 2002, SYBEX, Inc., cover page and table of contents.;;Wilson, Ralph E., ""A Simply Way to Format HTML E-Mail Newsletters,"" Web Marketing Today, Jan. 1, 2000, Issue 67.",EXPIRED
19,CA,A1,CA 2524081 A1,182-799-299-362-188,2004-11-11,2004,CA 2524081 A,2004-04-07,US 46762803 P;;EP 2004003781 W,2003-05-02,METHOD AND KIT FOR REDUCING IRRITATION OF SKIN DELIPATORY COMPOSITIONS,"A method and kit is provided for removing hair. The method includes applying to an area of skin from which hair is to be removed a skin pre-treatment composition that includes a lipophilic material. Thereafter applied onto the pre-treated area is a depilatory composition including a keratin degrading agent in an effective amount to chemically react with hair to allow wipe-awa y removal. A kit is also provided which includes a skin pre-treatment product formed with a skin pre-treatment composition including a lipophilic material delivered to the skin by a carrier. The kit further includes a depilatory product having a depilatory composition with a keratin degrading agent chemically reactive with hair to weaken the hair for removal, the depilatory composition being delivered from a carrier.",UNILEVER PLC,KENNEDY CHRISTINE ELIZABETH;;MASSARO MICHAEL;;SHILOACH ANAT;;SLAVTCHEFF CRAIG STEPHEN;;GOLDBERG JESSICA WEISS,,https://lens.org/182-799-299-362-188,Patent Application,no,0,0,12,12,0,A61K8/31;;A61K8/46;;A61K8/92;;A61K2800/874;;A61K2800/88;;A61Q9/04;;A61K8/31;;A61K8/89;;A61Q9/04;;A61K8/85;;A61K8/92;;A61K2800/874;;A61K8/46;;A61Q9/04;;A61K8/31;;A61K2800/88,A61K8/31;;A61K8/46;;A61K8/92;;A61Q9/04,,0,0,,,,DISCONTINUED
20,AU,A1,AU 2004/233558 A1,083-706-305-442-789,2004-11-11,2004,AU 2004/233558 A,2004-04-07,US 46762803 P;;EP 2004003781 W,2003-05-02,Method and kit for reducing irritation of skin delipatory compositions,,UNILEVER PLC,KENNEDY CHRISTINE ELIZABETH;;SHILOACH ANAT;;SLAVTCHEFF CRAIG STEPHEN;;MASSARO MICHAEL;;GOLDBERG JESSICA WEISS,,https://lens.org/083-706-305-442-789,Patent Application,no,0,0,12,12,0,A61K8/31;;A61K8/46;;A61K8/92;;A61K2800/874;;A61K2800/88;;A61Q9/04;;A61K8/31;;A61K8/89;;A61Q9/04;;A61K8/85;;A61K8/92;;A61K2800/874;;A61K8/46;;A61Q9/04;;A61K8/31;;A61K2800/88,A61K8/31;;A61K8/46;;A61K8/92;;A61Q9/04,,0,0,,,,INACTIVE
21,KR,A,KR 20060015569 A,061-083-915-308-660,2006-02-17,2006,KR 20057020736 A,2005-11-01,US 46762803 P,2003-05-02,METHOD AND KIT FOR REDUCING IRRITATION OF SKIN DELIPATORY COMPOSITIONS,"A method and kit is provided for removing hair. The method includes applying to an area of skin from which hair is to be removed a skin pre- treatment composition that includes a lipophilic material. Thereafter applied onto the pre-treated area is a depilatory composition including a keratin degrading agent in an effective amount to chemically react with hair to allow wipe-away removal. A kit is also provided which includes a skin pre-treatment product formed with a skin pre-treatment composition including a lipophilic material delivered to the skin by a carrier. The kit further includes a depilatory product having a depilatory composition with a keratin degrading agent chemically reactive with hair to weaken the hair for removal, the depilatory composition being delivered from a carrier.",UNILEVER NV,SLAVTCHEFF CRAIG STEPHEN;;GOLDBERG JESSICA WEISS;;SHILOACH ANAT;;MASSARO MICHAEL;;KENNEDY CHRISTINE ELIZABETH,,https://lens.org/061-083-915-308-660,Patent Application,no,0,1,12,12,0,A61K8/31;;A61K8/46;;A61K8/92;;A61K2800/874;;A61K2800/88;;A61Q9/04;;A61K8/31;;A61K8/89;;A61Q9/04;;A61K8/85;;A61K8/92;;A61K2800/874;;A61K8/46;;A61Q9/04;;A61K8/31;;A61K2800/88,A61K8/31;;A61K8/46;;A61K8/85;;A61K8/89;;A61K8/92;;A61Q9/04,,0,0,,,,DISCONTINUED
22,CN,C,CN 100358491 C,028-315-755-806-188,2008-01-02,2008,CN 200480017133 A,2004-04-07,US 46762803 P,2003-05-02,Method and kit for reducing irritation of skin depilatory compositions,,UNILEVER HOME & PERSONAL CARE,STEPHEN SLAVTCHEFF CRAIG;;WEISS GOLDBERG JESSICA;;ANAT SHILOACH;;MICHAEL MASSARO;;ELIZABETH KENNEDY CHRISTINE,,https://lens.org/028-315-755-806-188,Granted Patent,no,3,0,12,12,0,A61K8/31;;A61K8/46;;A61K8/92;;A61K2800/874;;A61K2800/88;;A61Q9/04;;A61K8/31;;A61K8/89;;A61Q9/04;;A61K8/85;;A61K8/92;;A61K2800/874;;A61K8/46;;A61Q9/04;;A61K8/31;;A61K2800/88,A61K8/92;;A61K8/31;;A61K8/46;;A61Q9/00;;A61Q9/04,,0,0,,,,INACTIVE
23,AU,B2,AU 2004/233558 B2,050-006-351-636-969,2007-05-31,2007,AU 2004/233558 A,2004-04-07,US 46762803 P;;EP 2004003781 W,2003-05-02,Method and kit for reducing irritation of skin depilatory compositions,,UNILEVER PLC,KENNEDY CHRISTINE ELIZABETH;;SHILOACH ANAT;;SLAVTCHEFF CRAIG STEPHEN;;MASSARO MICHAEL;;GOLDBERG JESSICA WEISS,,https://lens.org/050-006-351-636-969,Granted Patent,no,1,0,12,12,0,A61K8/31;;A61K8/46;;A61K8/92;;A61K2800/874;;A61K2800/88;;A61Q9/04;;A61K8/31;;A61K8/89;;A61Q9/04;;A61K8/85;;A61K8/92;;A61K2800/874;;A61K8/46;;A61Q9/04;;A61K8/31;;A61K2800/88,A61K8/31;;A61K8/46;;A61K8/92;;A61Q9/04,,0,0,,,,INACTIVE
24,WO,A1,WO 2004/096164 A1,167-853-610-259-476,2004-11-11,2004,EP 2004003781 W,2004-04-07,US 46762803 P,2003-05-02,METHOD AND KIT FOR REDUCING IRRITATION OF SKIN DELIPATORY COMPOSITIONS,"A method and kit is provided for removing hair. The method includes applying to an area of skin from which hair is to be removed a skin pre-treatment composition that includes a lipophilic material. Thereafter applied onto the pre-treated area is a depilatory composition including a keratin degrading agent in an effective amount to chemically react with hair to allow wipe-away removal. A kit is also provided which includes a skin pre-treatment product formed with a skin pre-treatment composition including a lipophilic material delivered to the skin by a carrier. The kit further includes a depilatory product having a depilatory composition with a keratin degrading agent chemically reactive with hair to weaken the hair for removal, the depilatory composition being delivered from a carrier.",UNILEVER PLC;;UNILEVER NV;;LEVER HINDUSTAN LTD;;SLAVTCHEFF CRAIG STEPHEN;;GOLDBERG JESSICA WEISS;;SHILOACH ANAT;;MASSARO MICHAEL;;KENNEDY CHRISTINE ELIZABETH,SLAVTCHEFF CRAIG STEPHEN;;GOLDBERG JESSICA WEISS;;SHILOACH ANAT;;MASSARO MICHAEL;;KENNEDY CHRISTINE ELIZABETH,,https://lens.org/167-853-610-259-476,Patent Application,yes,3,21,12,12,0,A61K8/31;;A61K8/46;;A61K8/92;;A61K2800/874;;A61K2800/88;;A61Q9/04;;A61K8/31;;A61K8/89;;A61Q9/04;;A61K8/85;;A61K8/92;;A61K2800/874;;A61K8/46;;A61Q9/04;;A61K8/31;;A61K2800/88,A61K8/31;;A61K8/46;;A61K8/92;;A61Q9/04,,0,0,,,,PATENTED
25,CN,A,CN 101601025 A,146-163-111-768-890,2009-12-09,2009,CN 200780049658 A,2007-11-13,US 85861306 P,2006-11-13,System and method for providing multiple participants with a central access portal to geographic point of interest,"A system and method of providing multiple participants with a centrally accessible content portal for geographic point of interest (POI) data, for subsequent use in creating map-based or spatial applications. Different entities can dynamically upload, update, retrieve, and use digital map and POI data. Additional features include the ability to handle the large amounts of POI data needed by multiple Application Developers, including data that is dynamic, or frequently changing; the ability to update POI attribute information and deliver it to the Application Developers; the ability to associate multiple points of entry (POE) with a POI, and to aggregate data from multiple Content Providers; and the use of a common geocoding engine and common digital map reference across all Content Providers, which ensures the consistency of the geocoding throughout all the POI data.",TELE ATLAS NORTH AMERICA INC,PATRICK SABBEY CRAIG;;RICHARD COHEN;;RIK TEMMINK;;DAVID GOLDBERG;;MICHELLE JONES;;JENNIFER PARKER,,https://lens.org/146-163-111-768-890,Patent Application,no,0,9,1,7,0,,G06F15/16,,0,0,,,,DISCONTINUED
26,ZA,B,ZA 200508772 B,072-315-938-933-898,2006-12-27,2006,ZA 200508772 A,2004-04-07,US 46762803 P,2003-05-02,Method and kit for reducing irritation of skin delipatory compositions,,UNILEVER PLC,STEPHEN SLAVTCHEFF CRAIG;;WEISS GOLDBERG JESSICA;;ANAT SHILOACH;;MICHAEL MASSARO;;ELIZABETH KENNEDY CHRISTINE,,https://lens.org/072-315-938-933-898,Granted Patent,no,0,0,12,12,0,A61K8/31;;A61K8/46;;A61K8/92;;A61K2800/874;;A61K2800/88;;A61Q9/04;;A61K8/31;;A61K8/89;;A61Q9/04;;A61K8/85;;A61K8/92;;A61K2800/874;;A61K8/46;;A61Q9/04;;A61K8/31;;A61K2800/88,A61K/;;A61K8/31;;A61K8/46;;A61K8/92;;A61Q9/04,,0,0,,,,ACTIVE
27,US,A1,US 2004/0219118 A1,084-593-843-036-313,2004-11-04,2004,US 66954703 A,2003-09-24,US 66954703 A;;US 46762803 P,2003-05-02,Method and kit for reducing irritation of skin depilatory compositions,"
   A method and kit is provided for removing hair. The method includes applying to an area of skin from which hair is to be removed a skin pretreatment composition that includes a lipophilic material. Thereafter applied onto the pretreated area is a depilatory composition including a keratin degrading agent in an effective amount to chemically react with hair to allow wipe-away removal. A kit is also provided which includes a skin pretreatment product formed with a skin pretreatment composition including a lipophilic material delivered to the skin by a carrier. The kit further includes a depilatory product having a depilatory composition with a keratin degrading agent chemically reactive with hair to weaken the hair for removal, the depilatory composition being delivered from a carrier. 
",UNILEVER HOME & PERSONAL CARE,SLAVTCHEFF CRAIG STEPHEN;;GOLDBERG JESSICA WEISS;;SHILOACH ANAT;;MASSARO MICHAEL;;KENNEDY CHRISTINE ELIZABETH,UNILEVER HOME & PERSONAL CARE USA DIVISION OF CONOPCO INC (2003-07-15),https://lens.org/084-593-843-036-313,Patent Application,yes,5,66,12,12,0,A61K8/31;;A61K8/46;;A61K8/92;;A61K2800/874;;A61K2800/88;;A61Q9/04;;A61K8/31;;A61K8/89;;A61Q9/04;;A61K8/85;;A61K8/92;;A61K2800/874;;A61K8/46;;A61Q9/04;;A61K8/31;;A61K2800/88,A61K8/31;;A61K8/46;;A61K8/92;;A61Q9/04,424/70.1,0,0,,,,DISCONTINUED
28,GB,A,GB 2516595 A,023-749-571-361-66X,2015-01-28,2015,GB 201421101 A,2013-05-24,US 201213488643 A;;US 2013/0042629 W,2012-06-05,Electronic communicating,"Among other things, we describe enabling two or more users to share a workspace that is dynamically populated by artifacts of electronic communications among the users that are expressed in a form of at least one of social network posts and email messages, and in which the users can interact using the artifacts in any of the forms.",MIMECAST NORTH AMERICA INC,MURRAY NEIL HAMILTON;;FULLERTON CRAIG;;GOLDBERG DAVID;;TYLER SIMON PAUL;;BORENSTEIN NATHANIEL;;BAUER PETER,,https://lens.org/023-749-571-361-66X,Patent Application,no,9,0,4,4,0,G06Q10/10;;G06Q50/01;;H04L51/52;;G06Q10/107;;G06Q50/01;;G06Q10/10;;H04L51/52,G06Q10/10,,0,0,,,,DISCONTINUED
29,US,A1,US 2007/0066499 A1,134-281-229-574-081,2007-03-22,2007,US 22975105 A,2005-09-19,US 22975105 A,2005-09-19,Self-supporting aerosol cleansing composition,"An aerosol cleansing composition that is self-supporting after dispensing is described whose volume does not noticeably shrink with time. The inventive composition can be used in place of toilet bars when it is inconvenient to use such bars and provides the user with substantial lather and optionally warming agents, skin conditioners and/or skin active agents. A method for cleansing the skin without rinsing with water is also disclosed where the inventive aerosol cleansing composition is applied to the skin and wiped off.",CONOPCO INC DBA UNILEVER,SLAVTCHEFF CRAIG S;;BRENNAN MICHAEL A;;MERAVIGLIA SANDRA D;;GOLDBERG JESSICA W;;MASSARO MICHAEL,CONOPCO INC. D/B/A UNILEVER (2005-09-20),https://lens.org/134-281-229-574-081,Patent Application,yes,18,14,1,1,0,A61K8/046;;A61K8/361;;A61K8/466;;A61Q5/02;;A61Q19/00;;A61Q19/08;;A61Q19/10;;A61Q5/02;;A61Q19/00;;A61Q19/08;;A61K8/466;;A61Q19/10;;A61K8/361;;A61K8/046,A61K8/00,510/130,0,0,,,,DISCONTINUED
30,US,A1,US 2004/0091446 A1,065-009-173-122-620,2004-05-13,2004,US 29060902 A,2002-11-08,US 29060902 A,2002-11-08,Liquid cleansing composition having simultaneous exfoliating and moisturizing properties.,"
   Liquid lamellar cleansing compositions are described that contain synthetic surfactants, hydrophilic emollients and exfoliant particles where 80% or more of the particles have a major axis length of between 100 and 1000 microns. The combination of the mild surfactants, moisturizers, and exfoliants provide the user with simultaneous moisturization and exfoliation in a convenient liquid cleansing product. 
",UNILEVER HOME & PERSONAL CARE;;DIVISION OF CONOPCO INC,MASSARO MICHAEL;;GOLDBERG JESSICA WEISS;;SUBRAMANYAN KRISHNA KUMAR;;JOHNSON ANTHONY WILLIAM;;SLAVTCHEFF CRAIG STEPHEN,UNILEVER HOME & PERSONAL CARE USA DIVISION OF CONOPCO INC (2002-11-18),https://lens.org/065-009-173-122-620,Patent Application,yes,13,40,12,12,0,A61K8/03;;A61K8/92;;A61K8/92;;A61K8/0241;;A61K8/0241;;A61K8/361;;A61K8/361;;A61K8/37;;A61K8/37;;A61K2800/28;;A61K2800/28;;A61K2800/412;;A61K2800/412;;A61K2800/651;;A61K2800/651;;A61Q5/02;;A61Q5/02;;A61Q19/00;;A61Q19/00;;A61Q19/10;;A61Q19/10;;A61Q19/10,A61K8/04;;A61K8/92;;A61Q19/00,424/70.21;;424/70.31,0,0,,,,EXPIRED
31,US,A1,US 2013/0326362 A1,006-225-051-728-727,2013-12-05,2013,US 201213488643 A,2012-06-05,US 201213488643 A,2012-06-05,ELECTRONIC COMMUNICATING,"Among other things, we describe enabling two or more users to share a workspace that is dynamically populated by artifacts of electronic communications among the users that are expressed in a form of at least one of social network posts and email messages, and in which the users can interact using the artifacts in any of the forms.",MURRAY NEIL HAMILTON;;FULLERTON CRAIG;;GOLDBERG DAVID;;TYLER SIMON PAUL;;BORENSTEIN NATHANIEL;;BAUER PETER,MURRAY NEIL HAMILTON;;FULLERTON CRAIG;;GOLDBERG DAVID;;TYLER SIMON PAUL;;BORENSTEIN NATHANIEL;;BAUER PETER,MIMECAST NORTH AMERICA INC (2012-09-12);;MIMECAST SERVICES LTD (2017-06-01),https://lens.org/006-225-051-728-727,Patent Application,yes,9,22,4,4,0,G06Q10/10;;G06Q50/01;;H04L51/52;;G06Q10/107;;G06Q50/01;;G06Q10/10;;H04L51/52,G06F3/048,715/750;;715/752,3,1,083-219-788-868-910,10.1109/enabl.1999.805185,"""Yahoo! Hacks"", by Paul Bausch, published by O'Reilly Media, Inc., October 17, 2005, selections downloaded December 18, 2012;;""How to implement Web-based Groupware Systems based on WebDAV"" June 18th, 1999 by Fredj Dridi et al;;""Collaborative Information Gathering"", 1998, by Grasso et al",DISCONTINUED
32,WO,A1,WO 2023/133098 A1,020-730-432-106-256,2023-07-13,2023,US 2023/0010047 W,2023-01-03,US 202263296319 P,2022-01-04,EQUIPMENT KIT AND CONTAINER WITH TOOLS FOR PERFORMING BLOOD DRAW PROCEDURES AND METHODS OF USE,"A container configured to store tools used by a healthcare worker when performing a blood draw and collection procedure includes a tray and packaging. The tray includes a plurality of chambers sized to receive the tools used by the healthcare worker for the blood draw and collection procedure. The tools include at least one disposable disinfecting device for disinfecting portions of the tools and at least one tube for storing a blood sample. The packing, when in a closed or prior-to-use position, is over openings of the plurality of chambers of the tray, thereby securely containing the tools within the chambers of the tray. In an open or ready-for-use position, the packaging is separated from the openings of the plurality of chambers of the tray so that the healthcare worker can access the tools contained within the chambers while performing the blood draw and collection procedure.",BECTON DICKINSON CO,RUSS CRAIG;;ALUR ASHAY;;GOLDBERG EDWARD;;PETERSON BART;;WILKINSON BRADLEY;;MATEJKA MARTIN;;NEWBY C,,https://lens.org/020-730-432-106-256,Patent Application,yes,12,0,1,1,0,A61B5/15003;;A61B5/150343;;A61B5/150992;;A61B5/154;;A61B5/153;;A61M5/008;;A61M2209/06;;A61B5/150305;;A61B5/150312,A61B5/15;;A61B50/20;;A61B50/33;;A61B50/37;;A61B50/39,,0,0,,,,PENDING
33,US,B2,US 6924256 B2,023-075-115-421-659,2005-08-02,2005,US 29060902 A,2002-11-08,US 29060902 A,2002-11-08,Liquid cleansing composition having simultaneous exfoliating and moisturizing properties,"Liquid lamellar cleansing compositions are described that contain synthetic surfactants, hydrophilic emollients and exfoliant particles where 80% or more of the particles have a major axis length of between 100 and 1000 microns. The combination of the mild surfactants, moisturizers, and exfoliants provide the user with simultaneous moisturization and exfoliation in a convenient liquid cleansing product.",UNILEVER HOME & PERSONAL CARE,MASSARO MICHAEL;;GOLDBERG JESSICA WEISS;;SUBRAMANYAN KRISHNA KUMAR;;JOHNSON ANTHONY WILLIAM;;SLAVTCHEFF CRAIG STEPHEN,UNILEVER HOME & PERSONAL CARE USA DIVISION OF CONOPCO INC (2002-11-18),https://lens.org/023-075-115-421-659,Granted Patent,yes,19,60,12,12,0,A61K8/03;;A61K8/92;;A61K8/92;;A61K8/0241;;A61K8/0241;;A61K8/361;;A61K8/361;;A61K8/37;;A61K8/37;;A61K2800/28;;A61K2800/28;;A61K2800/412;;A61K2800/412;;A61K2800/651;;A61K2800/651;;A61Q5/02;;A61Q5/02;;A61Q19/00;;A61Q19/00;;A61Q19/10;;A61Q19/10;;A61Q19/10,A61K8/04;;A61K8/92;;A61Q19/00,510/119;;424/70.19;;510/129,1,0,,,"International Search Report No. PCT/EP 03/11812 dated Feb. 23, 2004, 3 pp.",EXPIRED
34,WO,A1,WO 2013/184407 A1,199-228-590-209-662,2013-12-12,2013,US 2013/0042629 W,2013-05-24,US 201213488643 A,2012-06-05,ELECTRONIC COMMUNICATING,"Among other things, we describe enabling two or more users to share a workspace that is dynamically populated by artifacts of electronic communications among the users that are expressed in a form of at least one of social network posts and email messages, and in which the users can interact using the artifacts in any of the forms.",MIMECAST NORTH AMERICA INC,MURRAY NEIL HAMILTON;;FULLERTON CRAIG;;GOLDBERG DAVID;;TYLER SIMON PAUL;;BORENSTEIN NATHANIEL S;;BAUER PETER,,https://lens.org/199-228-590-209-662,Patent Application,yes,9,0,4,4,0,G06Q10/10;;G06Q50/01;;H04L51/52;;G06Q10/107;;G06Q50/01;;G06Q10/10;;H04L51/52,G06Q10/10,,0,0,,,,PENDING
35,US,A1,US 2002/0058426 A1,099-284-142-191-527,2002-05-16,2002,US 92520901 A,2001-08-09,US 92520901 A;;US 22433900 P;;US 22746600 P,2000-08-11,Chemical mechanical planarization of metal substrates,"
   A method of polishing a wafer in a carrier by a polishing pad, controlling a ratio of platen speed to carrier speed (PS to CS) within a specific range, or controlling a first polishing step with a PS to CS ratio in the range of about 150:1 to about 1:150 followed by a second polishing step with a platen speed of about 0 to 20 rpm while maintaining the carrier speed used in the first polishing step, which maximizes clearing of residual material removed from a patterned wafer surface by polishing. 
",MANDIGO GLENN C.;;BARKER ROSS E.;;LACK CRAIG D.;;SULLIVAN IAN G.;;GOLDBERG WENDY B.,MANDIGO GLENN C;;BARKER ROSS E;;LACK CRAIG D;;SULLIVAN IAN G;;GOLDBERG WENDY B,ROHM AND HAAS ELECTRONIC MATERIALS CMP HOLDINGS INC (2001-10-11),https://lens.org/099-284-142-191-527,Patent Application,yes,0,11,8,8,0,B24B37/0056;;B24B37/04;;B24B37/044;;C09G1/02;;H01L21/304;;C09G1/02;;B24B37/0056;;B24B37/04;;B24B37/044,B24B37/04;;C09G1/02;;C09K3/14;;H01L21/304,438/792,0,0,,,,EXPIRED
36,US,A1,US 2009/0048269 A1,142-796-427-922-975,2009-02-19,2009,US 19000808 A,2008-08-12,US 19000808 A;;US 95548607 P,2007-08-13,CHEMICAL COMPOUNDS-821,"The invention relates to chemical compounds of the formula (I), or pharmaceutically acceptable salts thereof, which possess ALK5 (TGFβR1) inhibitory activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an anti-cancer effect in a warm-blooded animal such as man.",ASTRAZENECA AB,FINLAY MAURICE RAYMOND;;GOLDBERG FREDERICK WOOLF;;ROBERTS CRAIG ANTHONY;;ROBERTS NICOLA JANE;;RUDGE DAVID ALAN,ASTRAZENECA AB (2008-07-25),https://lens.org/142-796-427-922-975,Patent Application,yes,1,14,7,7,0,A61P35/00;;C07D213/74;;C07D213/74;;C07D401/14;;C07D401/14;;C07D409/14;;C07D409/14;;C07D417/14;;C07D417/14,A61K31/497;;A61K31/444;;C07D401/12;;C07D401/14,514/255.05;;546/261;;514/335;;544/405,0,0,,,,DISCONTINUED
37,PE,A1,PE 20090601 A1,118-201-013-439-865,2009-06-12,2009,PE 2008001368 A,2008-08-13,US 95548607 P,2007-08-13,DERIVADOS DE PIRIDIN-IL-OXI-PIRIDINAS COMO INHIBIDORES DE ALK5,"REFERIDA A UN COMPUESTO DE FORMULA I, DONDE R1 ES H, HALO, NITRO, CIANO, SULFO, ENTRE OTROS; R3 ES HALO, NITRO, CIANO, SULFO, HIDROXI, ENTRE OTROS; R2 ES H, HALO, CIANO, MERCAPTO, ENTRE OTROS; n ES 0-3; A ES ANILLO CARBOCICLICO, HETEROCICLICO SUSTIUIDOS O NO POR HALO, CIANO, NITRO, HIDROXI, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 4-(5,6-DIMETIL-2-PIRIDIN-2-IL-PIRIDIN-3-IL)OXI-N-PIRIDIN-2-IL-PIRIDIN-2-AMINA; N-(2-AMINO-2-OXOETIL)-3-{[4-(2,6-DIMETILPIRIDIN-3-IL)-OXIPIRIDIN-2-IL]AMINO}BENZAMIDA; 4-(2,6-DIMETIL-PIRIDIN-3-IL)OXI-N-{3-[(4-METILSULFONIL-PIPERAZIN-1-IL)METIL]FENIL}PIRIDIN-2-AMINA; ENTRE OTROS.DICHOS COMPUESTOS SON INHIBIDORES DE ALK5 UTILES EN EL TRATAMIENTO DE CANCER",ASTRAZENECA AB,FINLAY MAURICE RAYMOND VERSCHOYLE;;GOLDBERG FREDERICK WOOLF;;ROBERTS CRAIG ANTHONY;;ROBERTS NICOLA JANE;;RUDGE DAVID ALAN,,https://lens.org/118-201-013-439-865,Patent Application,no,0,0,7,7,0,A61P35/00;;C07D213/74;;C07D213/74;;C07D401/14;;C07D401/14;;C07D409/14;;C07D409/14;;C07D417/14;;C07D417/14,A61K31/444;;C07D401/12;;C07D401/14;;C07D405/14,,0,0,,,,DISCONTINUED
38,EP,A1,EP 4297903 A1,016-225-175-308-68X,2024-01-03,2024,EP 22760482 A,2022-02-25,US 202163154660 P;;US 202263306951 P;;US 2022/0017907 W,2021-02-26,APPARATUS FOR BIOMOLECULE ASSAY,,SEER INC,HORNBURG DANIEL;;STOLARCZYK CRAIG;;TANGEYSH BEHZAD;;SIDDIQUI ASIM;;BROWN TRISTAN;;ROSHDIFERDOSI SHADI;;GOLDBERG MARTIN;;HASAN MOARAJ,,https://lens.org/016-225-175-308-68X,Patent Application,yes,0,0,3,4,0,G01N33/6848;;G01N33/6842;;G01N33/54346,B01L3/00;;G01N33/543,,0,0,,,,PENDING
39,CL,A1,CL 2008002369 A1,150-664-492-560-355,2009-07-17,2009,CL 2008002369 A,2008-08-12,US 95548607 P,2007-08-13,"Compuestos derivados de piridin-3-il-oxipiridin-2-il-amino, inhibidores de alk5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del cancer.","Compuestos derivados de piridin-3-il-oxipiridin-2-il-amino, inhibidores de alk5; composición farmacéutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del cáncer.",ASTRAZENECA AB,RUDGE DAVID ALAN;;FINLAY MAURICE R VERSCHOYLE;;GOLDBERG FREDERICK W;;ROBERTS CRAIG ANTHONY;;ROBERTS NICOLA JANE,,https://lens.org/150-664-492-560-355,Patent Application,no,0,0,7,7,0,A61P35/00;;C07D213/74;;C07D213/74;;C07D401/14;;C07D401/14;;C07D409/14;;C07D409/14;;C07D417/14;;C07D417/14,A61K31/444;;A61P35/00;;C07D401/12,,0,0,,,,PENDING
40,US,B2,US 6602436 B2,031-797-940-806-430,2003-08-05,2003,US 92520901 A,2001-08-09,US 92520901 A;;US 22433900 P;;US 22746600 P,2000-08-11,Chemical mechanical planarization of metal substrates,"
    A method of polishing a wafer in a carrier by a polishing pad, controlling a ratio of platen speed to carrier speed (PS to CS) within a specific range, or controlling a first polishing step with a PS to CS ratio in the range of about 150:1 to about 1:150 followed by a second polishing step with a platen speed of about 0 to 20 rpm while maintaining the carrier speed used in the first polishing step, which maximizes clearing of residual material removed from a patterned wafer surface by polishing. 
",RODEL INC,MANDIGO GLENN C;;BARKER II ROSS E;;LACK CRAIG D;;SULLIVAN IAN G;;GOLDBERG WENDY B,ROHM AND HAAS ELECTRONIC MATERIALS CMP HOLDINGS INC (2001-10-11),https://lens.org/031-797-940-806-430,Granted Patent,yes,20,39,8,8,0,B24B37/0056;;B24B37/04;;B24B37/044;;C09G1/02;;H01L21/304;;C09G1/02;;B24B37/0056;;B24B37/04;;B24B37/044,B24B37/04;;C09G1/02;;C09K3/14;;H01L21/304,216/88;;216/89;;438/692;;438/693;;451/57,0,0,,,,EXPIRED
41,AR,A1,AR 067931 A1,117-331-062-942-933,2009-10-28,2009,AR P080103535 A,2008-08-13,US 95548607 P,2007-08-13,DERIVADOS DE (PIRIDIN-3-IL-OXI)-PIRIDIN,"Sales farmacéuticamente aceptables de los mismos, que poseen actividad inhibidora de ALK5 (TGFR1) y por consiguiente son utiles por su actividad anticancerosa y por lo tanto en métodos de tratamiento del cuerpo del ser humano o de animales. También se refiere a procesos para la fabricacion de dichos compuestos químicos, a composiciones farmacéuticas que los contienen y a su uso en la fabricacion de medicamentos para uso en la produccion de un efecto anticanceroso en un animal de sangre caliente tal como el ser humano. Reivindicacion 1: Un compuesto caracterizado porque es de formula (1) en la que: R1 es hidrogeno, halo, nitro, ciano, mercapto, sulfo, hidroxi, carbamoilo, sulfamoilo, amino, carboxi o un grupo seleccionado entre alquilo C1-3, alquenilo C2-3, alquinilo C2-3, alcoxi C1-3, alcoxicarbonilo C1-3, alcanoílo C1-3, alcanoiloxi C1-3, alquilsulfoniloxi C1-3, N-(alquil C1-3)amino, N,N-(alquil C1-3)2amino, N-(alcanoil C1-3)-N(R4)amino, N-(alcoxicarbonil C1-3)-N-(R5)amino, N-(alquil C1-3)carbamoílo, N,N-(alquil C1-3)2carbamoílo, N-(alquil C1-3)sulfamoilo, N,N-(alquil C1-3)2sulfamoilo, N-[(alquil C1-3)sulfonil]-N-(R6)amino, 3,3-(R7)(R8)-1-(R9)ureido, ciclopropil-R10-, azetidin-1-il-R11- y (alquil C1-3)-S(O)a- donde a es de 0 a 2; donde dicho grupo puede estar opcionalmente sustituido independientemente sobre carbono con uno o más R12; cada R3 es independientemente halo, nitro, ciano, mercapto, sulfo, hidroxi, carbamoílo, sulfamoílo, amino, carboxi o un grupo seleccionado entre alquilo C1-3, alquenilo C2-3, alquinilo C2-3, alcoxi C1-3, alcoxicarbonilo C1-3, alcanoílo C1-3, alcanoiloxi C1-3, alquilsulfoniloxi C1-3, N-(alquil C1-3)amino, N,N-(alquil C1-3)2amino, N-(alcanoil C1-3)-N(R4)amino, N-(alcoxicarbonil C1-3)-N-(R5)amino, N-(alquil C1-3)carbamoílo, N,N-(alquil C1-3)2carbamoílo, N-(alquil C1-3)sulfamoilo, N,N-(alquil C1-3)2sulfamoilo, N-[(alquil C1-3)sulfonil]-N-(R6)amino, 3,3-(R7)(R8)-1-(R9)ureido, ciclopropil-R10-, azetidin-1-il-R11- y (alquil C1-3)-S(O)a- donde a es de 0 a 2; donde dicho grupo puede estar opcionalmente sustituido independientemente sobre carbono con uno o más R12; cada R2 es hidrogeno, halo, ciano, nitro, mercapto, sulfo, hidroxi, carboxi, carbamoílo. sulfamoílo o un grupo seleccionado entre alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alcoxiC1-6, alquilsulfoniloxi C1-6, N-(alquil C1-6)sulfamoiloxi, N,N-(alquil C1-6)2sulfamoiloxi, alcoxicarbonilo C1-6, alcanoilo C1-6, alcanoiloxi C1-6, N,N-(alquil C1-6)2amino, N-(alquil C1-6)carbamoílo, N,N-(alquil C1-6)2carbamoílo, N-(alquil C1-6)sulfamoílo, N,N-(alquil C1-6)2sulfamoílo, carbociclil-R19-, heterociclil-R20- y (alquil C1-6)-S(O)a- donde a es de 0 a 2; donde dicho grupo puede estar opcionalmente sustituido independientemente sobre carbono con uno o más R21 y donde si dicho heterociclilo contiene un resto -NH- ese nitrogeno puede estar opcionalmente sustituido con R22; R21 es halo, ciano, nitro, mercapto, sulfo, hidroxi. amino, carboxi, carbamoilo. sulfamoilo o un grupo seleccionado entre alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alcoxiC1-6, alquilsulfoniloxi C1-6, N-(alquil C1-6)sulfamoiloxi, N,N-(alquil C1-6)2sulfamoiloxi, alcoxicarbonilo C1-6, alcanoilo C1-6, alcanoiloxi C1-6, N-(alquil C1-6)amino, N,N-(alquil C1-6)2amino, N-(alcanoil C1-6)-N-(R23)amino, N-(alcoxicarbonil C1-6)-N-(R24)amino, N-(alquil C1-6)carbamoíIo, N,N-(alquil C1-6)2carbamoíIo, N-(alquil C1-6)sulfamoílo, N,N-(alquil C1-6)2sulfamoílo, N-[(alquil C1-6)sulfonil]-N-(R25)amino, 3,3-(R26)(R27)-1-(R28)ureido, carbociclil-R29-, heterociclil-R30- y (alquil C1-6)-S(O)a donde a es de 0 a 2; donde dicho grupo puede estar opcionalmente sustituido sobre carbono con uno o más R31; y donde si dicho heterociclilo contiene un resto -NH- ese nitrogeno puede estar opcionalmente sustituido con R32, n es de 0 a 3; donde los valores de R3 pueden ser iguales o diferentes; el Anillo A es un grupo carbocíclico o un grupo heterocíclico, donde dicho grupo heterocíclico o grupo carbocíclico puede estar opcionalmente sustituido sobre uno o más carbonos con R33; y donde si dicho grupo heterocíclico contiene un resto -NH- ese nitrogeno puede estar opcionalmente sustituido con R34; R33 es independientemente halo, ciano, nitro, mercapto, sulfo, hidroxi, carboxi, carbamimnidoilo, amino, carbamoilo, sulfamoilo o un grupo seleccionado entre alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alcoxi C1-6, alquilsulfoniloxi C1-6, N-(alquil C1-6)sulfamoiloxi, N,N-(alquil C1-6)2sulfamoiloxi, alcoxicarbonilo C1-6, alcanoílo C1-6, alcanoiloxi C1-6, N-(alquil C1-6)amino, N,N-(alquil C1-6)2amino, N-(alcanoil C1-6)-N-(R35)amino, N-(alcoxicarbonil C1-6)-N-(R36)amino, N-(alquil C1-6)carbamoílo, N,N-(alquil C1-6)2carbamoilo, N-(alquil C1-6)sulfamoílo, N,N-(alquil C1-6)2sulfarnoílo, N-(alcanoil C1-6)-N-(R75)-sulfamoílo, N-[(alquil C1-6)sulfonil]-N-(R37)amino, 3,3(R38)(R39)-1-(R40)ureido, (R76)(R77)N-S(O)2-N(R78)-, N-(alquil C1-6)carbamimidoílo, N,N-(alquil C1- 6)2carbamimidoílo, N-[N',N'-(R98)(R99)carbamimidoil]-N-(R100)amino, carbociclil-R41-, heterociclil-R42- y (alquil C1-6)-S(O)a- donde a es de 0 a 2; donde dicho grupo puede estar opcionalmente sustituido sobre carbono con uno o más R43 y donde si dicho heterociclilo contiene un resto -NH- ese nitrogeno puede estar opcionalmente sustituido con R44; R34 es carbamoílo, sulfamoílo o un grupo seleccionado entre alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alcoxicarbonilo C1-6, alcanoilo C1-6, N-(alquil C1-6)carbamoílo, N,N(alquil C1-6)2carbamoílo, N-(alquil C1-)sulfamoílo, N,N-(alquil C1-6)2sulfamoílo, carbociclil-R45-, heterociclil-R46- y (alquil C1-6)-S(O)a- donde a es de 1 a 2; donde dicho grupo puede estar opcionalmente sustituido sobre carbono con uno o más R47; y donde si dicho heterociclilo contiene un resto -NH- ese nitrogeno puede estar opcionalmente sustituido con R48; R45 y R46 se seleccionan independientemente entre un enlace directo. -C(O)-, -C(=NH)-, -N(R101)-C(=NH)-, -N(R49)C(O)-, -N(R50)SO2-, -O-C(O)- y S(O)a donde a es 1 o 2; R43 y R47 son independientemente halo, ciano, nitro, mercapto, sulfo, hidroxi. amino, carbamimidoílo, carboxi, carbamoílo, sulfamoílo o un grupo seleccionado entre alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alcoxi C1-6, alquilsulfoniloxi C1-6, N-(alquil C1-6)sulfamoiloxi, N,N-(alquil C1-6)2sulfamoiloxi, alcoxicarbonilo C1-6, alcanoílo C1-6, alcanoiloxi C1-6, N-(alquil C1-6)amino, N,N-(alquil C1-6)2amino, N-(alcanoil C1-6)-N-(R51)amino. N-(alcoxicarbonil C1-6)-N-(R52)amino, N-(alquil C1-6)carbamoílo, N,N-(alquil C1-6)2carbamoílo, N-(alquil C1-6)sulfamoílo, N,N-(alquil C1-6)2sulfamoílo, N-[(alquil C1-6)sulfonil]-N-(R53)amino, 3,3-(R54)(R55)-1-(R56)ureido, N-(alcanoil C1-6)-N-(R95)-sulfamoilo, (R79)(R80)N-S(O)2-N(R81)-, N-(alquil C1-6)carbamimidoílo, N,N-(alquil C1-6)2carbamimidoílo, N-[N',N'-(R102)(R103)carbamimidoil]-N-(R104)amino, carbociclil-R57-, heterociclil-R58- y (alquil C1-6)-S(O)a donde a es de 0 a 2; donde cada uno de dichos grupos puede estar opcionalmente sustituido independientemente sobre carbono con uno o más R59, y donde si dicho heterociclilo contiene un resto -NH- ese nitrogeno puede estar opcionalmente sustituido con R60; R22 y R32 se seleccionan independientemente entre alquilo C1-6, cicloalquilo C3-6, alcanoilo C1-6, alquilsulfonilo C1-6, alcoxicarbonilo C1-6, carbamoílo, N-(alquil C1-6)carbamoílo, N,N-(alquil C1-6)2carbamoílo, bencilo, benciloxicarbonilo, benzoilo y fenilsulfonilo; R44, R48 y R60 se seleccionan independientemente entre carbamimidoílo, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alcanoílo C1-6, alquilsulfonilo C1-6, N-(alquil C1-6)sulfamoílo, N,N-(alquil C1-6)2sulfamoilo, alcoxicarbonilo C1-6, carbamoilo, sulfamoílo, N-(alquil C1-6)carbamoílo, N,N-(alquil C1-6)2carbamoílo, N-(alquil C1-6)carbamimidoílo, N,N-(alquil C1-6)2carbamimidoílo, carbociclil-R82- y heterociclil-R83-; donde cada uno de R44 R48 y R60 está opcionalmente sustituido independientemente sobre carbono con uno o más R84, y donde si dicho heterociclilo contiene un resto -NH- ese nitrogeno puede estar opcionalmente sustituido con R85; R84 se selecciona entre halo, hidroxi, ciano, carbamimidoílo, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alcoxi C1-6, amino, N-(alquil C1-6)amino, N,N-(alquil C1-6)2amino, carbamoílo, sulfamoilo, N-(alquil C1-6)carbamoílo, N,N-(alquil C1-6)2carbamoílo, alcoxicarbonilo C1-6, N-(alcoxicarbonil C1-6)-N-(R86)-amino, (R96)(R97)N-S(O)2-N(R98)-, 3,3-(R92)(R93)-1-(R94)ureido, N-(alquil C1-6)carbamimidoílo, N,N-(alquil C1-6)2carbamimidoílo, N-[N',N'-(R105)(R106)carbamimidoil]-N-(R107)amino, heterociclil-R87- carbociclil-R88- y (alquil C1-6)S(O)a donde a es de 0 a 2; y donde si dicho heterociclilo contiene un resto -NH- ese nitrogeno puede estar opcionalmente sustituido con R89; cada uno de R82, R83, R87 y R88 se selecciona independientemente entre un enlace directo, -C(O)-, -C(=NH)-, -N(R108)-C(=NH)-, -C(=NH)-N(R109)-, -N(R90)C(O)-, -N(R91)SO2-, -OC(O)- y -S(O)a- donde a es 1 o 2; cada uno de R85 y R89 se selecciona independientemente entre alquilo C1-6. alcanoilo C1-6, alquilsulfonilo C1-6; R19 y R20 se seleccionan independientemente entre un enlace directo, -CH(R61)-, -CH(OR62)-, -C(R63)=C(R64)-, etinileno, -O-, -C(O)-, -N(R66)C(O)-, -N(R69)SO2- y -S(O)a-, donde a es de 0 a 2; R10, R11, R29, R30, R41, R42, R57 y R58 se seleccionan independientemente entre un enlace directo, -O-, -N(R70)-. -C(O)-, -C(=NH)-, -N(R110)-C(=NH)-, -C(=NH)-N(R111)-, -N(R71)C(O)-, -C(O)N(R72)-, -SO2N(R73)-, -N(R74)SO2- y S(O)a donde a es de 0 a 2; R12, R31 y R59 se seleccionan independientemente entre fluoro, cloro, ciano, nitro, hidroxi, trifluorometoxi, trifluorometilo, amino, carboxi, sulfo, carbamoilo, mercapto, sulfamoilo, carbamimidoilo, carbamimidoilamino, metilo, etilo, etenilo, metoxi, etoxi, formilo, acetilo, acetoxi, N-metilamino, N-etilamino, N,N-dimetilamino, N,N-dietilamino, N-etil-N-metilamino, N-formilamino, N-acetilamino, N-metilcarbamoilo, N-etilcarbamoílo, N,N-dimetilcarbamoílo, N,N-dietilcarbamoílo, N-et",ASTRAZENECA AB,FINLAY MAURICE RAYMOND VERSCHOYLE;;WOOLF GOLDBERG FREDERICK;;ROBERTS NICOLA JANE;;RUDGE DAVID ALAN;;ROBERTS CRAIG ANTHONY,,https://lens.org/117-331-062-942-933,Patent Application,no,0,0,7,7,0,A61P35/00;;C07D213/74;;C07D213/74;;C07D401/14;;C07D401/14;;C07D409/14;;C07D409/14;;C07D417/14;;C07D417/14,,,0,0,,,,PENDING
42,WO,A3,WO 2002/014014 A3,111-692-178-361-466,2002-05-02,2002,US 0125038 W,2001-08-09,US 22433900 P;;US 22746600 P,2000-08-11,CHEMICAL MECHANICAL PLANARIZATION OF METAL SUBSTRATES,"A method of polishing a wafer in a carrier with a polishing pad by controlling a ratio of platen speed to carrier speed (PS to CS) within a specific range, or by controlling a first polishing step with a ratio of PS to CS in the range of about 150:1 to about 1:150 followed by a second polishing step with a platen speed of about 0 to 20 rpm while maintaining the carrier speed used in the first polishing step, which maximizes clearing of residual material removed from a patterned wafer surface by polishing.",RODEL INC,MANDIGO GLENN C;;BARKER ROSS E II;;LACK CRAIG D;;SULLIVAN IAN G;;GOLDBERG WENDY B,,https://lens.org/111-692-178-361-466,Search Report,yes,7,0,8,8,0,B24B37/0056;;B24B37/04;;B24B37/044;;C09G1/02;;H01L21/304;;C09G1/02;;B24B37/0056;;B24B37/04;;B24B37/044,B24B37/04;;C09G1/02;;C09K3/14;;H01L21/304,,0,0,,,,PENDING
43,WO,A2,WO 2002/014014 A2,018-084-663-124-480,2002-02-21,2002,US 0125038 W,2001-08-09,US 22433900 P;;US 22746600 P,2000-08-11,CHEMICAL MECHANICAL PLANARIZATION OF METAL SUBSTRATES,"A method of polishing a wafer in a carrier with a polishing pad by controlling a ratio of platen speed to carrier speed (PS to CS) within a specific range, or by controlling a first polishing step with a ratio of PS to CS in the range of about 150:1 to about 1:150 followed by a second polishing step with a platen speed of about 0 to 20 rpm while maintaining the carrier speed used in the first polishing step, which maximizes clearing of residual material removed from a patterned wafer surface by polishing.",RODEL INC,MANDIGO GLENN C;;BARKER ROSS E II;;LACK CRAIG D;;SULLIVAN IAN G;;GOLDBERG WENDY B,,https://lens.org/018-084-663-124-480,Patent Application,yes,0,0,8,8,0,B24B37/0056;;B24B37/04;;B24B37/044;;C09G1/02;;H01L21/304;;C09G1/02;;B24B37/0056;;B24B37/04;;B24B37/044,B24B37/04;;C09G1/02;;C09K3/14;;H01L21/304,,0,0,,,,PENDING
44,EP,A2,EP 1307319 A2,163-228-001-995-348,2003-05-07,2003,EP 01962036 A,2001-08-09,US 0125038 W;;US 22433900 P;;US 22746600 P,2000-08-11,CHEMICAL MECHANICAL PLANARIZATION OF METAL SUBSTRATES,,RODEL INC,MANDIGO GLENN C;;BARKER ROSS E II;;LACK CRAIG D;;SULLIVAN IAN G;;GOLDBERG WENDY B,"ROHM AND HAAS ELECTRONIC MATERIALS CMP HOLDINGS, I (2005-02-09)",https://lens.org/163-228-001-995-348,Patent Application,yes,0,0,8,8,0,B24B37/0056;;B24B37/04;;B24B37/044;;C09G1/02;;H01L21/304;;C09G1/02;;B24B37/0056;;B24B37/04;;B24B37/044,B24B37/04;;C09G1/02;;C09K3/14;;H01L21/304,,0,0,,,,DISCONTINUED
45,TW,A,TW 200911783 A,084-429-104-512-289,2009-03-16,2009,TW 97130816 A,2008-08-13,US 95548607 P,2007-08-13,Chemical compounds,"The invention relates to chemical compounds of the formula (I), or pharmaceutically acceptable salts thereof, which possess ALK5 (TGFβ R1) inhibitory activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an anti-cancer effect in a warm-blooded animal such as man.",ASTRAZENECA AB,FINLAY MAURICE RAYMOND VERSCHOYLE;;GOLDBERG FREDERICK WOOLF;;ROBERTS CRAIG ANTHONY;;ROBERTS NICOLA JANE;;RUDGE DAVID ALAN,,https://lens.org/084-429-104-512-289,Patent of Addition,no,0,1,7,7,0,A61P35/00;;C07D213/74;;C07D213/74;;C07D401/14;;C07D401/14;;C07D409/14;;C07D409/14;;C07D417/14;;C07D417/14,C07D401/12;;A61K31/444;;A61P35/00;;C07D401/14,,0,0,,,,PENDING
46,WO,A1,WO 2009/022171 A1,107-373-723-299-440,2009-02-19,2009,GB 2008050689 W,2008-08-11,US 95548607 P,2007-08-13,PYRIDINYIIOXY PYRIDINES AS ALK5 INHIBITORS,"The invention relates to chemical compounds of the formula (I) or pharmaceutically acceptable salts thereof, which possess ALK5 (TGFβRl) inhibitory activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an anti¬ cancer effect in a warm-blooded animal such as man.",ASTRAZENECA AB;;ASTRAZENECA UK LTD;;FINLAY MAURICE RAYMOND VERSCHO;;GOLDBERG FREDERICK WOOLF;;ROBERTS CRAIG ANTHONY;;ROBERTS NICOLA JANE;;RUDGE DAVID ALAN,FINLAY MAURICE RAYMOND VERSCHOYLE;;GOLDBERG FREDERICK WOOLF;;ROBERTS CRAIG ANTHONY;;ROBERTS NICOLA JANE;;RUDGE DAVID ALAN,,https://lens.org/107-373-723-299-440,Patent Application,yes,4,30,7,7,0,A61P35/00;;C07D213/74;;C07D213/74;;C07D401/14;;C07D401/14;;C07D409/14;;C07D409/14;;C07D417/14;;C07D417/14,C07D401/12;;A61K31/444;;A61P35/00;;C07D401/14;;C07D405/14;;C07D407/14;;C07D417/14,,0,0,,,,PENDING
47,TW,B,TW 516119 B,075-134-234-792-296,2003-01-01,2003,TW 90119649 A,2001-08-10,US 22433900 P;;US 22746600 P,2000-08-11,Chemical mechanical planarization of metal substrates,"A method of polishing a wafer in a carrier with a polishing pad by controlling a ratio of platen speed to carrier speed (PS to CS) within a specific range, or by controlling a first polishing step with a ratio of PS to CS in the range of about 150:1 to about 1:150 followed by a second polishing step with a platen speed of about 0 to 20 rpm while maintaining the carrier speed used in the first polishing step, which maximizes clearing of residual material removed from a patterned wafer surface by polishing.",RODEL INC,MANDIGO GLENN C;;SULLIVAN IAN G;;BARKER ROSS E II;;GOLDBERG WENDY B;;LACK CRAIG D,,https://lens.org/075-134-234-792-296,Granted Patent,no,0,0,8,8,0,B24B37/0056;;B24B37/04;;B24B37/044;;C09G1/02;;H01L21/304;;C09G1/02;;B24B37/0056;;B24B37/04;;B24B37/044,B24B37/04;;C09G1/02;;C09K3/14;;H01L21/304,,0,0,,,,EXPIRED
48,UY,A1,UY 31281 A1,185-011-761-206-664,2009-03-31,2009,UY 31281 A,2008-08-11,US 95548607 P,2007-08-13,"AMINAS, BENZAMIDAS Y SULFONAMIDAS {[4-(5,6-DIMETIL-2-PIRIDIN-2-IL-PIRIDIN-3-IL) OXIPIRIDIN-2-IL]AMINO} SUSTITUIDAS, SUS SALES FARMACÉUTICAMENTE ACEPTABLES, COMPOSICIONES CONTENNIÉNDOLAS Y APLICACIONES.","La invencion se refiere a compuestos químicos de la formula (I), o sales faramacéuticamente aceptables de los mismos, que poseen actividad inhibidora de ALK5 (TGFBR1) y por consiguiente son utiles por su actividad anticancerosa y por lo tanto en métodos de tratamiento del cuerpo del ser humano o de animales. La invencion también se refiere a porcesos para la fabricacion de dichos compuestos químicos, a composiciones farmacéuticas que los contienen y a su uso en la fabricacion de medicamentos para uso en la produccion de un efecto anticanceroso en un animal de sangre caliente tal como el ser humano.",,ROBERTS NICOLA JANE;;GOLDBERG FREDERICK WOOLF;;RUDGE DAVID ALAN;;ROBERTS CRAIG ANTHONY;;FINLAY MAURICE RAYMOND VERSCHOYLE,,https://lens.org/185-011-761-206-664,Patent Application,no,0,0,7,7,0,A61P35/00;;C07D213/74;;C07D213/74;;C07D401/14;;C07D401/14;;C07D409/14;;C07D409/14;;C07D417/14;;C07D417/14,A61K31/444;;A61P35/00;;C07D401/12;;C07D401/14,,0,0,,,,DISCONTINUED
49,US,A1,US 2005/0170979 A1,126-603-240-579-173,2005-08-04,2005,US 9163605 A,2005-03-28,US 9163605 A;;US 29060902 A,2002-11-08,Liquid cleansing composition having simultaneous exfoliating and moisturizing properties,"Liquid lamellar cleansing compositions are described that contain synthetic surfactants, hydrophilic emollients and exfoliant particles where 80% or more of the particles have a major axis length of between 100 and 1000 microns. The combination of the mild surfactants, moisturizers, and exfoliants provide the user with simultaneous moisturization and exfoliation in a convenient liquid cleansing product.",UNILEVER HOME & PERSONAL CARE,MASSARO MICHAEL;;GOLDBERG JESSICA W;;SUBRAMANYAN KRISHNA K;;JOHNSON ANTHONY W;;SLAVTCHEFF CRAIG S;;GENCARELLI SUZANNE L,UNILEVER HOME & PERSONAL CARE USA DIVISION OF CONOPCO INC (2005-05-12),https://lens.org/126-603-240-579-173,Patent Application,yes,5,34,12,12,0,A61K8/03;;A61K8/92;;A61K8/92;;A61K8/0241;;A61K8/0241;;A61K8/361;;A61K8/361;;A61K8/37;;A61K8/37;;A61K2800/28;;A61K2800/28;;A61K2800/412;;A61K2800/412;;A61K2800/651;;A61K2800/651;;A61Q5/02;;A61Q5/02;;A61Q19/00;;A61Q19/00;;A61Q19/10;;A61Q19/10;;A61Q19/10,A61K8/04;;A61K8/92;;A61Q19/00,510/130,0,0,,,,DISCONTINUED
50,CA,A1,CA 2504156 A1,072-010-629-221-582,2004-05-21,2004,CA 2504156 A,2003-10-22,EP 0311812 W;;US 29060902 A,2002-11-08,LIQUID CLEANSING COMPOSITION HAVING SIMULTANEOUS EXFOLIATINGAND MOISTURIZING PROPERTIES,"Liquid lamellar cleansing compositions are described that contain synthetic surfactants, hydrophilic emollients and exfoliant particles where 80 % or mo re of the particles have a major axis length of between 100 and 1000 microns. T he combination of the mild surfactants, moisturizers, and exfoliants provide th e user with simultaneous moisturization and exfoliation in a convenient liquid cleansing product.",UNILEVER PLC,MASSARO MICHAEL;;JOHNSON ANTHONY WILLIAM;;SUBRAMANYAN KRISHAN KUMAR;;GOLDBERG JESSICA WEISS;;GENCARELLI SUZANNE LYNN;;SLAVTCHEFF CRAIG STEPHEN,,https://lens.org/072-010-629-221-582,Patent Application,no,0,0,12,12,0,A61K8/03;;A61K8/92;;A61K8/92;;A61K8/0241;;A61K8/0241;;A61K8/361;;A61K8/361;;A61K8/37;;A61K8/37;;A61K2800/28;;A61K2800/28;;A61K2800/412;;A61K2800/412;;A61K2800/651;;A61K2800/651;;A61Q5/02;;A61Q5/02;;A61Q19/00;;A61Q19/00;;A61Q19/10;;A61Q19/10;;A61Q19/10,A61K8/04;;A61K8/92;;A61Q19/00,,0,0,,,,DISCONTINUED
51,MY,A,MY 134406 A,162-626-962-039-301,2007-12-31,2007,MY PI20034277 A,2003-11-07,US 29060902 A,2002-11-08,LIQUID CLEANSING COMPOSITION HAVING SIMULTANEOUS EXFOLIATING AND MOISTURIZING PROPERTIES,"LIQUID LAMELLAR CLEANSING COMPOSITIONS ARE DESCRIBED THAT CONTAIN SYNTHETIC SURFACTANTS, HYDROPHILIC EMOLLIENTS AND EXFOLIANT PARTICLES WHERE 80 OR MORE OF THE PARTICLES HAVE A MAJOR AXIS LENGTH OF BETWEEN 100 AND 1000 MICRONS. THE COMBINATION OF THE MILD SURFACTANTS, MOISTURIZERS, AND EXFOLIANTS PROVIDE THE USER WITH SIMULTANEOUS MOISTURIZATION AND EXFOLIATION IN A CONVENIENT LIQUID CLEANSING PRODUCT.",UNILEVER PLC,MASSARO MICHAEL;;GOLDBERG JESSICA WEISS;;SUBRAMANYAN KRISHNA KUMAR;;JOHNSON ANTHONY WILLIAM;;SLAVTCHEFF CRAIG STEPHEN;;GENCARELLI SUZANNE LYNN,,https://lens.org/162-626-962-039-301,Granted Patent,no,0,0,12,12,0,A61K8/03;;A61K8/92;;A61K8/92;;A61K8/0241;;A61K8/0241;;A61K8/361;;A61K8/361;;A61K8/37;;A61K8/37;;A61K2800/28;;A61K2800/28;;A61K2800/412;;A61K2800/412;;A61K2800/651;;A61K2800/651;;A61Q5/02;;A61Q5/02;;A61Q19/00;;A61Q19/00;;A61Q19/10;;A61Q19/10;;A61Q19/10,A61K8/04;;A61K8/92;;A61Q19/00,,0,0,,,,EXPIRED
52,WO,A1,WO 2004/041218 A1,192-535-987-756-07X,2004-05-21,2004,EP 0311812 W,2003-10-22,US 29060902 A,2002-11-08,LIQUID CLEANSING COMPOSITION HAVING SIMULTANEOUS EXFOLIATING AND MOISTURIZING PROPERTIES,"Liquid lamellar cleansing compositions are described that contain synthetic surfactants, hydrophilic emollients and exfoliant particles where 80 % or more of the particles have a major axis length of between 100 and 1000 microns. The combination of the mild surfactants, moisturizers, and exfoliants provide the user with simultaneous moisturization and exfoliation in a convenient liquid cleansing product.",UNILEVER PLC;;UNILEVER NV;;LEVER HINDUSTAN LTD,MASSARO MICHAEL;;GOLDBERG JESSICA WEISS;;SUBRAMANYAN KRISHAN KUMAR;;JOHNSON ANTHONY WILLIAM;;SLAVTCHEFF CRAIG STEPHEN;;GENCARELLI SUZANNE LYNN,,https://lens.org/192-535-987-756-07X,Patent Application,yes,4,1,12,12,0,A61K8/03;;A61K8/92;;A61K8/92;;A61K8/0241;;A61K8/0241;;A61K8/361;;A61K8/361;;A61K8/37;;A61K8/37;;A61K2800/28;;A61K2800/28;;A61K2800/412;;A61K2800/412;;A61K2800/651;;A61K2800/651;;A61Q5/02;;A61Q5/02;;A61Q19/00;;A61Q19/00;;A61Q19/10;;A61Q19/10;;A61Q19/10,A61K8/04;;A61K8/92;;A61Q19/00,,0,0,,,,PENDING
53,KR,A,KR 20050074548 A,102-099-914-300-079,2005-07-18,2005,KR 20057008089 A,2005-05-06,US 29060902 A,2002-11-08,LIQUID CLEANSING COMPOSITION HAVING SIMULTANEOUS EXFOLIATING AND MOISTURIZING PROPERTIES,"Liquid lamellar cleansing compositions are described that contain synthetic surfactants, hydrophilic emollients and exfoliant particles where 80 % or more of the particles have a major axis length of between 100 and 1000 microns. The combination of the mild surfactants, moisturizers, and exfoliants provide the user with simultaneous moisturization and exfoliation in a convenient liquid cleansing product.",UNILEVER NV,MASSARO MICHAEL;;GOLDBERG JESSICA WEISS;;SUBRAMANYAN KRISHAN KUMAR;;JOHNSON ANTHONY WILLIAM;;SLAVTCHEFF CRAIG STEPHEN;;GENCARELLI SUZANNE LYNN,,https://lens.org/102-099-914-300-079,Patent Application,no,0,6,12,12,0,A61K8/03;;A61K8/92;;A61K8/92;;A61K8/0241;;A61K8/0241;;A61K8/361;;A61K8/361;;A61K8/37;;A61K8/37;;A61K2800/28;;A61K2800/28;;A61K2800/412;;A61K2800/412;;A61K2800/651;;A61K2800/651;;A61Q5/02;;A61Q5/02;;A61Q19/00;;A61Q19/00;;A61Q19/10;;A61Q19/10;;A61Q19/10,A61K8/04;;A61K8/92;;A61Q19/00,,0,0,,,,DISCONTINUED
54,AU,A1,AU 2003/278135 A1,014-687-955-943-645,2004-06-07,2004,AU 2003/278135 A,2003-10-22,EP 0311812 W;;US 29060902 A,2002-11-08,LIQUID CLEANSING COMPOSITION HAVING SIMULTANEOUS EXFOLIATING AND MOISTURIZING PROPERTIES,,UNILEVER PLC,MASSARO MICHAEL;;GOLDBERG JESSICA WEISS;;SUBRAMANYAN KRISHAN KUMAR;;JOHNSON ANTHONY WILLIAM;;SLAVTCHEFF CRAIG STEPHEN;;GENCARELLI SUZANNE LYNN,,https://lens.org/014-687-955-943-645,Patent Application,no,0,0,12,12,0,A61K8/03;;A61K8/92;;A61K8/92;;A61K8/0241;;A61K8/0241;;A61K8/361;;A61K8/361;;A61K8/37;;A61K8/37;;A61K2800/28;;A61K2800/28;;A61K2800/412;;A61K2800/412;;A61K2800/651;;A61K2800/651;;A61Q5/02;;A61Q5/02;;A61Q19/00;;A61Q19/00;;A61Q19/10;;A61Q19/10;;A61Q19/10,A61K8/04;;A61K8/92;;A61Q19/00,,0,0,,,,DISCONTINUED
55,AR,A1,AR 041904 A1,085-457-878-618-25X,2005-06-01,2005,AR P030104070 A,2003-11-06,US 29060902 A,2002-11-08,UNA COMPOSICION LIQUIDA DE LIMPIEZA QUE TIENE PROPIEDADES SIMULTANEAS DE EXFOLIACION E HIDRATACION,"Se describen composiciones lamelares líquidas de limpieza que contienen tensioactivos sintéticos, emolientes hidrófilos y partículas exofilantes donde 80% o más de las partículas tienen una longitud de eje principal entre 100 y 1000 micrones. La combinación de los tensioactivos suaves, hidratantes y exfoliantes le proveen al usuario hidratación y exfoliación simultáneas en un producto líquido de limpieza. Método para exfoliar y humectar la piel.",UNILEVER NV,MASSARO MICHAEL;;SUBRAMANYAN KRISHNA KUMAR;;SLAVTCHEFF CRAIG STEPHEN;;GOLDBERG JESSICA WEISS;;JOHNSON ANTHONY WILLIAM;;GENCARELLI SUZANNE LYNN,,https://lens.org/085-457-878-618-25X,Patent Application,no,0,0,12,12,0,A61K8/03;;A61K8/92;;A61K8/92;;A61K8/0241;;A61K8/0241;;A61K8/361;;A61K8/361;;A61K8/37;;A61K8/37;;A61K2800/28;;A61K2800/28;;A61K2800/412;;A61K2800/412;;A61K2800/651;;A61K2800/651;;A61Q5/02;;A61Q5/02;;A61Q19/00;;A61Q19/00;;A61Q19/10;;A61Q19/10;;A61Q19/10,A61K8/04;;A61K8/92;;A61Q19/00,,0,0,,,,DISCONTINUED
56,US,A1,US 2005/0060058 A1,083-124-410-992-221,2005-03-17,2005,US 85062904 A,2004-05-20,US 85062904 A;;US 47249303 P,2003-05-22,Embroidery network control system and method,"A method and system of remotely communicating embroidery pattern data to embroidery machines involving providing an embroidery pattern in response to a pattern selection input from a remote user at a local node, the input communicated through a communications connection between the local node and a server, receiving an identification address for an embroidery machine, communicating the embroidery pattern to the embroidery machine for application of the embroidery pattern to a work piece. The system includes a server having circuitry for receiving wireless electronic communications, a local node having a graphical user interface for receiving input from a remote user, the local node in wireless electronic communication with the server, a database of electronically encoded data, the data comprising embroidery patterns, the database in communication with the server, and responsive to the local node input, to retrieve embroidery patterns and to display the embroidery patterns through the server to the remote user, and an embroidery machine in communication with the server, the embroidery machine receiving embroidery patterns from the database through the server.",CAMERON MARION;;CARABENCIOV IOAN;;COLLINS WILLIAM;;DAVIS WILLIAM J.;;GOLDBERG BRIAN;;RAO MOHAN;;TSONIS ANASTASIOS;;WEST CRAIG,CAMERON MARION;;CARABENCIOV IOAN;;COLLINS WILLIAM;;DAVIS WILLIAM J;;GOLDBERG BRIAN;;RAO MOHAN;;TSONIS ANASTASIOS;;WEST CRAIG,,https://lens.org/083-124-410-992-221,Patent Application,yes,4,35,1,1,0,D05B19/08;;D05B19/08;;D05C5/00;;D05C5/00,D05B19/08;;D05C5/00,700/138,0,0,,,,DISCONTINUED
57,WO,A1,WO 2022/182989 A1,149-001-998-316-744,2022-09-01,2022,US 2022/0017907 W,2022-02-25,US 202163154660 P;;US 202263306951 P,2021-02-26,APPARATUS FOR BIOMOLECULE ASSAY,Disclosed herein are methods for identifying physicochemical properties associated with protein corona formation at the level of proteins and NP- functionalization. Further disclosed herein are compositions comprising combinations of particles configured for low abundance protein collection and deep proteomic analysis.,SEER INC,HORNBURG DANIEL;;STOLARCZYK CRAIG;;TANGEYSH BEHZAD;;SIDDIQUI ASIM SAROSH;;BROWN TRISTAN;;ROSHDIFERDOSI SHADI;;GOLDBERG MARTIN;;HASAN MOARAJ,,https://lens.org/149-001-998-316-744,Patent Application,yes,1,2,3,4,0,G01N33/6848;;G01N33/6842;;G01N33/54346,B01L3/00;;G01N33/543,,4,3,082-676-490-237-558;;121-327-248-899-139;;027-767-469-362-185,10.1038/s41467-020-17033-7;;32699280;;pmc7376165;;10.1021/ac070352p;;17583911;;10.1186/1556-276x-9-668;;26089000;;pmc4493834,"BLUME JOHN E., MANNING WILLIAM C., TROIANO GREGORY, HORNBURG DANIEL, FIGA MICHAEL, HESTERBERG LYNDAL, PLATT THEODORE L., ZHAO XIAO: ""Rapid, deep and precise profiling of the plasma proteome with multi-nanoparticle protein corona"", NATURE COMMUNICATIONS, vol. 11, no. 1, 1 December 2020 (2020-12-01), pages 3662, XP055965598, DOI: 10.1038/s41467-020-17033-7;;ANONYMOUS: ""Multi Affinity Removal Column, Human-14"", AGILENT TECHNOLOGIES - INSTRUCTION MANUAL VERSION A 1, 1 December 2018 (2018-12-01), pages 1 - 27, XP055965600, Retrieved from the Internet <URL:https://us.vwr.com/assetsvc/asset/en_US/id/27711688/contents/manual-multi-affinity-removal-column-human-14.pdf> [retrieved on 20220928];;DE MALSCHE, WILM, HAMED EGHBALI, DAVID CLICQ, JORIS VANGELOOVEN, GERT DESMET: ""Pressue-Driven Reverse-Phase Liquid Chromatogrpahy Separations in Ordered Nonporous Pillar Array Columns"", ANALYTICAL CHEMISTRY, vol. 79, no. 15, 1 August 2007 (2007-08-01), pages 5915, XP055965601;;HATA KATSUTOMO, HIGASHISAKA KAZUMA, NAGANO KAZUYA, MUKAI YOHEI, KAMADA HARUHIKO, TSUNODA SHIN-ICHI, YOSHIOKA YASUO, TSUTSUMI YASUO: ""Evaluation of silica nanoparticle binding to major human blood proteins"", NANOSCALE RESEARCH LETTERS, vol. 9, no. 1, 1 December 2014 (2014-12-01), pages 668, XP055965602, DOI: 10.1186/1556-276X-9-668",PENDING
58,CN,A,CN 117202991 A,195-439-444-009-691,2023-12-08,2023,CN 202280029507 A,2022-02-25,US 202263306951 P;;US 2022/0017907 W,2022-02-04,Device for biomolecule assay,Disclosed herein are methods of identifying physicochemical properties associated with protein coronal formation at protein and NP functionalization levels. Further disclosed herein are compositions comprising a combination of particles configured for low abundance protein collection and deep proteomic analysis.,XIER CO LTD,HORNBERG DANIEL;;STOLARCZYK CRAIG;;TANGASH BEHZAD;;SIDDIQUI ASIM;;BROWN TRISTAN;;ROCHDI FERDOSSI CHADI;;GOLDBERG MARTIN;;HASSAN MORAJI,,https://lens.org/195-439-444-009-691,Patent Application,no,0,0,1,4,0,,B01L3/00,,0,0,,,,PENDING
59,CN,U,CN 217505762 U,048-449-522-249-252,2022-09-27,2022,CN 202220393596 U,2022-02-25,US 202163154660 P;;US 202263306951 P,2021-02-26,Device for assaying biological sample,"Disclosed herein are methods of identifying physicochemical properties associated with protein crown formation at protein and NP functionalization levels, and compositions comprising combinations of particles configured for low abundance protein collection and deep proteomic analysis. Further disclosed herein is a device for assaying a biological sample.",XIER CO LTD,HORNBERG DANIEL;;STOLARCZYK CRAIG;;TANGASH BEHZAD;;SIDDIQUI ASIM SAROSH;;BROWN TRISTAN;;ROCHDI FERDOSSI CHADI;;GOLDBERG MARTIN;;HASSAN MORAJI,,https://lens.org/048-449-522-249-252,Limited Patent,no,0,0,3,4,0,G01N33/6848;;G01N33/6842;;G01N33/54346,G01N30/88;;G01N30/06;;G01N30/60,,0,0,,,,ACTIVE
60,US,A1,US 2006/0276496 A1,101-106-243-344-148,2006-12-07,2006,US 27693306 A,2006-03-17,US 27693306 A;;US 71916405 P;;US 66293605 P,2005-03-17,Anti-Cytokine Heterocyclic Compounds,"Heterocyclic compounds and analogues thereof and their use as inhibitors of Mitogen-Activated Protein Kinase-Activated Protein kinase-2 (MAPKAP-k2), and also to a method for preventing or treating a disease or disorder that can be treated or prevented by modulating the activity of MAPKAP-K2 in a subject and to pharmaceutical compositions and kits that include these MAPKAP-K2 inhibitors.",BOEHRINGER INGELHEIM PHARMA,GOLDBERG DANIEL;;ABEYWARDANE ASITHA;;MILLER CRAIG;;MORWICK TINA;;NETHERTON MATTHEW;;SNOW ROGER;;WANG JI;;WU JIANG-PING;;XIONG ZHAOMING,BOEHRINGER INGELHEIM INTERNATIONAL GMBH (2008-08-27);;BOEHRINGER INGELHEIM PHARMACEUTICALS INC (2006-06-14),https://lens.org/101-106-243-344-148,Patent Application,yes,1,19,2,2,0,C07D471/02;;A61P1/00;;A61P11/06;;A61P19/02;;A61P25/28;;A61P9/04;;A61P3/10;;C07D471/02,A61K31/4745;;A61K31/403;;C07D471/02,514/291;;514/411;;548/444;;546/85,0,0,,,,DISCONTINUED
61,US,A1,US 2006/0276453 A1,168-125-948-888-828,2006-12-07,2006,US 27693506 A,2006-03-17,US 27693506 A;;US 71901705 P;;US 66256705 P,2005-03-17,Anti-Cytokine Heterocyclic Compounds,"Heterocyclic compounds and analogues thereof and their use as inhibitors of Mitogen-Activated Protein Kinase-Activated Protein kinase-2 (MAPKAP-k2), and also to a method for preventing or treating a disease or disorder that can be treated or prevented by modulating the activity of MAPKAP-K2 in a subject and to pharmaceutical compositions and kits that include these MAPKAP-K2 inhibitors.",BOEHRINGER INGELHEIM PHARMA,GOLDBERG DANIEL;;ABEYWARDANE ASITHA;;MILLER CRAIG;;MORWICK TINA;;NETHERTON MATTHEW;;SNOW ROGER;;WANG JI;;WU JIANG-PING;;XIONG ZHAOMING,BOEHRINGER INGELHEIM INTERNATIONAL GMBH (2008-09-10);;BOEHRINGER INGELHEIM PHARMACEUTICALS INC (2006-06-14),https://lens.org/168-125-948-888-828,Patent Application,yes,2,18,2,2,0,A61P37/06;;C07D487/04;;C07D487/04;;C07D471/04;;C07D471/04,A61K31/551;;A61K31/498;;A61K31/55;;C07D487/04,514/214.01;;514/220;;514/250;;514/291;;544/344;;540/558;;540/586,0,0,,,,ACTIVE
62,US,A1,US 2018/0071939 A1,033-408-773-536-904,2018-03-15,2018,US 201715701099 A,2017-09-11,US 201715701099 A;;US 201662394063 P;;US 201762532914 P,2016-09-13,SYSTEMS AND METHOD RELATED TO A FOOD-ITEM CUTTER AND ASSOCIATED COVER,"Systems and methods are disclosed for cutting a food item when preparing it to be served to a customer. In some implementations, the cutting system may include a cover that may be used to at least partially surround a portion of a the cutting system. The cover may include one or more doors, drawers, or other movable components that may be used to engage the cutting assembly of the cutting system by activating one or more sensors located along or proximate to the path traveled by the movable component. The movable component may activate the sensor when the movable component has appropriately positioned the food item under the cutting assembly to be cut. Additionally, the cover may include one or more user-engageable switches that may be used to selectively engage cutting assembly when the movable component of the cover is appropriately positioned to be cut by the cutting assembly.",ZUME PIZZA INC,GARDEN ALEXANDER JOHN;;GOLDBERG JOSHUA GOULED;;GOEL VAIBHAV;;COLLINS JULIA;;SWITEK JR ROBERT EUGENE;;MILLS EDWARD VALENTIN;;JOHNSON CRAIG ALAN,,https://lens.org/033-408-773-536-904,Patent Application,yes,3,28,8,8,0,B26D3/24;;B26D7/088;;B26D7/088;;B26D3/24;;B26D3/24;;B26D5/04;;B26D5/04;;B26D5/04;;B26D5/06;;B26D5/06;;B26D5/06;;B26D7/088;;B26D7/22;;B26D7/22;;B26D7/22;;B26D7/2614;;B26D7/2614;;B26D7/2614;;B26D2007/0018;;B26D2007/0018;;B26D2210/02;;B26D2210/02,B26D7/08;;B26D3/24;;B26D5/04;;B26D5/06;;B26D7/22;;B26D7/26,,0,0,,,,DISCONTINUED
63,TW,A,TW 201811517 A,103-038-930-083-112,2018-04-01,2018,TW 106130965 A,2017-09-11,US 201662394063 P;;US 201762532914 P,2016-09-13,Systems and method related to a food-item cutter and associated cover,"Systems and methods are disclosed for cutting a food item when preparing it to be served to a customer. In some implementations, the cutting system may include a cover that may be used to at least partially surround a portion of a the cutting system. The cover may include one or more doors, drawers, or other movable components that may be used to engage the cutting assembly of the cutting system by activating one or more sensors located along or proximate to the path traveled by the movable component. The movable component may activate the sensor when the movable component has appropriately positioned the food item under the cutting assembly to be cut. Additionally, the cover may include one or more user-engageable switches that may be used to selectively engage cutting assembly when the movable component of the cover is appropriately positioned to be cut by the cutting assembly.",ZUME PIZZA INC,GARDEN ALEXANDER JOHN;;GOLDBERG JOSHUA GOULED;;GOEL VAIBHAV;;COLLINS JULIA ELIZABETH;;SWITEK ROBERT EUGENE;;MILLS EDWARD VALENTIN;;JOHNSON CRAIG ALAN,,https://lens.org/103-038-930-083-112,Patent of Addition,no,0,0,8,8,0,B26D3/24;;B26D7/088;;B26D7/088;;B26D3/24;;B26D3/24;;B26D5/04;;B26D5/04;;B26D5/04;;B26D5/06;;B26D5/06;;B26D5/06;;B26D7/088;;B26D7/22;;B26D7/22;;B26D7/22;;B26D7/2614;;B26D7/2614;;B26D7/2614;;B26D2007/0018;;B26D2007/0018;;B26D2210/02;;B26D2210/02,B26D1/09,,0,0,,,,PENDING
64,US,B2,US 11345666 B2,111-989-794-435-147,2022-05-31,2022,US 201916442864 A,2019-06-17,US 201916442864 A;;US 201862686323 P,2018-06-18,Phenyl and pyridinyl substituted imidazoles as modulators of RORγT,"The present invention comprises compounds of Formula I. wherein: R 1 , R 2 , R 3 , R 4 , R 5 , R a , R b , Q 1 , and Q 2 are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-γ-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.",JANSSEN PHARMACEUTICA NV,GOLDBERG STEVEN;;MARTIN CONNOR L;;FENNEMA ELIZABETH G;;KUMMER DAVID A;;NISHIMURA RACHEL T;;TANIS VIRGINIA M;;WOODS CRAIG R,JANSSEN PHARMACEUTICA NV (2020-01-14),https://lens.org/111-989-794-435-147,Granted Patent,yes,80,0,10,10,4,C07D233/66;;C07D401/04;;A61P29/00;;C07D233/90;;C07D401/04,C07D233/54;;C07D233/90;;C07D401/04,,77,50,096-841-656-118-220;;118-307-749-079-773;;002-405-354-697-844;;156-601-101-421-818;;007-924-207-867-846;;078-731-621-499-369;;021-032-916-096-988;;066-119-584-271-19X;;021-966-133-884-768;;064-399-651-040-903;;068-503-038-383-863;;000-951-373-751-063;;065-682-394-873-532;;006-384-711-859-473;;095-361-043-889-533;;004-514-663-069-206;;015-723-750-303-611;;093-144-517-257-295;;014-408-820-938-035;;060-797-640-900-566;;042-371-686-427-160;;020-545-279-619-551;;068-508-663-743-396;;028-713-636-085-561;;093-884-198-693-922;;035-586-215-470-490;;018-908-523-184-712;;039-642-981-580-110;;048-384-949-179-543;;026-128-338-578-202;;016-505-509-019-957;;106-524-118-716-284;;049-931-466-317-688;;011-663-094-062-663;;093-649-439-334-809;;000-649-437-049-891;;180-631-728-571-083;;058-874-856-370-984;;078-205-757-883-386;;039-460-067-637-00X;;098-868-304-673-40X;;102-770-086-354-044;;011-549-952-564-856;;044-653-508-978-443;;030-303-530-555-166;;057-603-192-746-115;;023-187-898-049-000;;011-872-379-895-774;;041-951-775-835-195;;002-380-530-828-658,10.1002/anie.198205671;;12814161;;10.1053/rmed.2003.1507;;pmc3582833;;23174342;;10.1016/j.biopsych.2012.09.021;;20875338;;pmc4474185;;10.1002/art.38272;;24574218;;10.1016/j.psychres.2010.10.029;;21129782;;10.1002/0471264180.or028.02;;12610626;;10.1038/nature01355;;21920821;;10.1016/j.clim.2011.08.005;;10.1038/nri1807;;16557264;;24502334;;10.1021/jm401901d;;10.1056/nejmoa1602773;;27959607;;10.18103/mra.v0i4.334;;10.1136/gut.52.1.65;;pmc1773503;;12477762;;21747375;;10.1038/nbt.1906;;pmc2852824;;10.3748/wjg.v16.i14.1753;;20380008;;29192397;;10.1007/s40273-017-0593-2;;20926833;;10.1126/scitranslmed.3001107;;16990136;;10.1016/j.cell.2006.07.035;;10.1111/cei.12670;;26080615;;pmc4687521;;20453841;;10.1038/ng.583;;15485625;;10.1016/j.immuni.2004.08.018;;10.1146/annurev.immunol.021908.132710;;19132915;;10.1016/j.jaci.2012.04.024;;pmc3470466;;22677045;;pmc2812071;;10.1124/mol.109.060905;;19887649;;pmc2212798;;10.1084/jem.20041257;;15657292;;22455413;;10.1056/nejmoa1109997;;10.1002/chin.200930099;;11984595;;10.1038/nm0502-500;;10.1021/bi048135v;;15794662;;10.1016/j.it.2005.10.003;;16290228;;24918373;;10.1056/nejmoa1315231;;21853531;;pmc3377107;;10.1002/emmm.201100172;;10.1038/gene.2008.16;;18368064;;10.1089/108705701753364922;;10.1177/108705710100600609;;11788061;;22455412;;10.1056/nejmoa1109017;;10.1351/pac197645010011;;23075178;;10.1056/nejmoa1203572;;14984588;;10.1111/j.1440-1711.2004.01212.x;;20956338;;pmc3776381;;10.4049/jimmunol.1001538;;10.1002/eji.201546095;;27019190;;10.1517/14712598.2014.890587;;24555741;;10.1016/j.tips.2014.07.006;;25131183;;10.1155/2016/6470364;;26941484;;pmc4749797;;16670770;;pmc1451201;;10.1172/jci21404;;10.1021/ol1019597;;20866102;;10.18632/oncotarget.12673;;27750219;;pmc5352448;;10.1371/journal.pone.0188391;;29155882;;pmc5695821;;22949321;;10.1002/eji.201242740;;pmc3609417;;24792721;;10.1016/j.drudis.2014.04.012,"Sanis Health Inc. Product Monograph. “ENALAPRIL: Enalapril Maleate.” Revision Date Jun. 10, 2016. Accessed on Jul. 3, 2021. Available from: « https://pdf.hres.ca/dpd_pm/00035279.PDF ». (Year: 2016).;;Angew. Chem. Int. Ed. Engl. 1982, 21, 567-583.;;Barczyk, A., W. Pierzchala, et al. (2003). “Interleukin-17 in sputum correlates with airway hyperresponsiveness to methacholine.” Respir Med 97(6): 726-33.;;Beurel, E., Harrington, L. E., Jope, R. S. (2013) “Inflammatory T helper 17 cells promote depression-like behavior in mice.” Biol Psychiatry 73(7): 622-30.;;Bimekizumab demonstrates impressive joint and skin responses for psoriatic arthritis patients. Dec. 20, 2017. https://www.ucb.com/stories-media/Press-Releases/article/Bimekizumab-demonstrates-impressive-joint-and-skin-responses-for-psoriatic-arthritis-patients-nbsp.;;Bowes, J. and A. Barton “The genetics of psoriatic arthritis: lessons from genome-wide association studies.” Discov Med 10(52): 177-83 (2010).;;Chang M, “Pharmacologic Repression of Retinoic Acid Receptor-Related Orphan Nuclear Receptor Is Therapeutic in the Collagen-Induced Arthritis Experimental Model”, Arthritis & Rheumatology (2014), 66(3), 579-588.;;Chang, M. R. et al. (2015) “Antiobesity Effect of a Small Molecule Repressor of RORγ.” Mol Pharmacol. 88(1): 48-56.;;Chen, Y., et al. (2011). “Emerging tendency towards autoimmune process in major depressive patients: A novel insight from Th17 cells.” Psychiatry Research 188(2): 224-230.;;Cheng, Chia-Chung et al., The Friedlander synthesis of quinolines, Organic Reactions, 1982, 28, pp. 37-201.;;Cua, D. J., J. Sherlock, et al. (2003). “Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain.” Nature 421(6924): 744-8.;;De Wit et al., RORγt inhibitors suppress TH17 responses in inflammatory arthritis and inflammatory bowel disease. Journal of Allergy and Clinical Immunology, vol. 137 , Issue 3, (2016), 960-963.;;Dolff S et al., Disturbed Th1, Th2, Th17 and T-reg balance in patients with systemic lupus erythematosus, Clinical Immunology 141(2):197-204 ⋅ Aug. 2011.;;Dong, C. (2006). “Diversification of T-helper-cell lineages: finding the family root of IL-17-producing cells.” Nat Rev Immunol 6(4): 329-33.;;Fauber et al., J. Med. Chem. 2014, 57, 5871-5892.;;Feagan BG, et al. Ustekinumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2016;375(20):1946-60.;;Fitzpatrick, Leo Robert. Ror-gamma T inhibition as a Pharmacological Approach for Inflammatory Bowel Disease. Medical Research Archives, [S.1.], v. 2, n. 2, Aug. 2015.;;Fujino, S., A. Andoh, et al. (2003). “Increased expression of interleukin 17 in inflammatory bowel disease.” Gut 52(1): 65-70.;;Garber K. (2011). “Psoriasis: from bed to bench and back” Nat Biotech 29, 563-566.;;Gazouli, M., I. Pachoula, et al. “NOD2/CARD15, ATG16L1 and IL23R gene polymorphisms and childhood-onset of Crohn's disease.” World J Gastroenterol 16(14): 1753-8 (2010).;;Hodgson et al., Ustekinumab for Treating Moderately to Severely Active Crohn's Disease after Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics (2018) 36:4, 387-398.;;Hueber, W., Patel, D.D., Dryja, T., Wright, A.M., Koroleva, I., Bruin, G., Antoni, C., Draelos, Z., Gold, M.H., Durez, P., Tak, P.P., Gomez-Reino, J.J., Foster, C.S., Kim, R.Y., Samson, C.M., Falk, N.S., Chu, D.S., Callanan, D., Nguyen, Q.D., Rose, K., Haider, A., Di Padova, F. (2010) Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2, 5272.;;Innovimmune: ROR Gamma Inhibitor (INV-17) Tested in Lupus Model. 2015 Eular Congress News. https://static1.squarespace.com/static/577aff0015db17f97d2d57/t/584f44f9725e254d6b032644/148159004360/150611_INV-17+Lupus+Thursday_EULAR_2015+small+size.pdf.;;Ivanov, II, B. S. McKenzie, et al. (2006). “The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells.” Cell 126(6): 1121-33.;;Jethwa H at al., The interleukin (IL)-23/IL-17 axis in ankylosing spondylitis: new advances and potentials for treatment, Clinical and Experimental Immunology, 2015, 183: 30-36.;;Kochi, Y., Y. Okada, et al. (2010) “A regulatory variant in CCR6 is associated with rheumatoid arthritis susceptibility.” Nat Genet 42(6): 515-9.;;Kolls, J. K. and A. Linden (2004). “Interleukin-17 family members and inflammation.” Immunity 21(4): 467-76.;;Korn, T., E. Bettelli, et al. (2009). “IL-17 and Th17 Cells.” Annu Rev Immunol 27: 485-517.;;Krueger, J. G., S. Fretzin, et al. “IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis.” J Allergy Clin Immunol 130(1): 145-154 e9 (2012).;;Kumar N, “The Benzenesulfoamide T0901317 [N-(2,2,2-Trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-benzenesulfonamide] Is a Novel Retinoic Acid Receptor-Related Orphan Receptor-Inverse Agonist”, Molecular Pharmacology (2010), 77(2), 228-236.;;Langrish, C. L., Y. Chen, et al. (2005). “IL-23 drives a pathogenic T cell population that induces autoimmune inflammation.” J Exp Med 201(2): 233-40.;;Leonardi, C., R. Matheson, et al. “Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis.” N Engl J Med 366(13): 1190-9 (2012).;;Liegault, et al., “Establishment of Broadly Applicable reaction condisions for the Palladium-Catalyzed Direct Arylation of Heteroatom-Containing Aromatic Compounds”, The Journal of Organic Chemistry, (2009), vol. 74, No. 5, 6, pp. 1826-1834.;;Lock, C., G. Hermans, et al. (2002). “Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis.” Nat Med 8(5): 500-8.;;Matulis, D., Kranz, J. K., Salemme, F. R., and Todd, M. J. (2005) Thermodynamic stability of carbonic anhydrase: measurements of binding affinity and stoichiometry using ThermoFluor. Biochemistry 44, 5258-66.;;McGinley et al., (2018) Th17 cells, γδ T cells and their interplay in EAE and multiple sclerosis. Journal of Autoimmunity 87, 97-108.;;McKenzie, B. S., R. A. Kastelein, et al. (2006). “Understanding the IL-23-IL-17 immune pathway.” Trends Immunol 27(1): 17-23.;;Mease, P. J. et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis, The New England Journal of Medicine 370, 2295-2306 (2014).;;Meissburger, B. et al. (2011) “Adipogenesis and insulin sensitivity in obesity are regulated by retinoid-related orphan receptor gamma.” EMBO Mol Med. 3(11): 637-651.;;Nunez, C., B. Dema, et al. (2008). “IL23R: a susceptibility locus for celiac disease and multiple sclerosis?” Genes Immun 9(4): 289-93.;;Pantoliano, M. W., Petrella, E. C., Kwasnoski, J. D., Lobanov, V. S., Myslik, J., Graf, E., Carver, T., Asel, E., Springer, B. A., Lane, P., and Salemme, F. R. (2001) High-density miniaturized thermal shift assays as a general strategy for drug discovery. J Biomol Screen 6, 429-40.;;Papp, K. A., “Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.” N Engl J Med 2012 366(13): 1181-9.;;Poddhubnyy et al., Ann Rheum Dis 2014;0:1-7.;;Pure & Appl. Chem. 45, 1976, 11-30.;;Qian et al., Clin. Invest. (2012) 2(4), 417-421.;;Registry(STN)[online], [Search Date: May 13, 2019]CAS Registration No. 791058-42-9,263386-02-3.;;Sandborn WJ et al. Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease N Engl J Med 2012; 367:1519-1528.;;Silva MJ et al, Glucocorticoid Resistant Asthma: The Potential Contribution of IL-17. Biomark J. 2016, 1:6.;;Stamp, L. K., M. J. James, et al. (2004). “Interleukin-17: the missing link between T-cell accumulation and effector cell actions in rheumatoid arthritis” Immunol Cell Biol 82(1): 1-9.;;Tonel, G., C. Conrad, et al. “Cutting edge: A critical functional role for IL-23 in psoriasis.” J Immunol 185(10): 5688-91 (2010).;;Wang X, Wei Y, Xiao H, et al. A novel IL-23p19/Ebi3 (IL-39) cytokine mediates inflammation in Lupus-like mice. Eur J Immunol. 2016;46(6):1343-1350.;;Weitz JE et al., Ustekinumab: Targeting the IL-17 Pathway to Improve Outcomes in Psoriatic Arthritis. Expert Opin Biol Ther 2104 14, 515-526.;;Withers DR, et al. Transient inhibition of ROR-γt therapeutically limits intestinal inflammation by reducing TH17 cells and preserving group 3 innate lymphoid cells Nature Medicine 2016, 22, 319.;;Yang et al., Trends in Pharmacological Sciences, Oct. 2014, vol. 35, No. 10, 493-500.;;Yang X et al. Does IL-17 Respond to the Disordered Lung Microbiome and Contribute to the Neutrophilic Phenotype in Asthma? Mediators of Inflammation. vol. 2016 (2016), Article ID 6470364, pp. 1-7.;;Yao, et al, “Preparation Method of N-butyl-5-phenylthiazole-4-Formamide Derivative Via Coupling Reaction Under Catalysis of Copper Catalyst”, Database accession No. 2014:924023.;;Yen, D., J. Cheung, et al. (2006). “IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6.” J Clin Invest 116(5): 1310-6.;;Zhang, et al., “Decarboxylative Cross-Coupling of Azoyl Carboxylic Acids with Aryl Halides”, Organic Letters, (2010) vol. 12, No. 21, pp. 4745-47457.;;PCT/US2015/058193, Written Opinion dated Jan. 26, 2016.;;PCT/US2015/058198, Written Opinion dated Jan. 21, 2016.;;PCT/US2015/058200, Written Opinion dated Jan. 27, 2016.;;PCT/US2015/058193, International Search Report, dated Jan. 26, 2016.;;PCT/US2015/058198, International Search Report, dated Jan. 21, 2016.;;PCT/US2015/058200, International Search Report, dated Jan. 27, 2016.;;PCT/US2017/029531, International Search Report, dated Sep. 15, 2017.;;PCT/US2017/029531, International Preliminary Report on Patentability, dated Oct. 30, 2018.;;PCT/IB2019/055043, International Search Report, dated Sep. 30, 2019.;;PCT/IB2019/055045, International Search Report, dated Sep. 30, 2019.;;PCT/IB2019/055046, International Search Report, dated Oct. 4, 2019.;;PCT/IB2019/055048, International Search Report, dated Sep. 27, 2019.;;Eastman; Oncotarget. 2017, 8, 8854-8866. DOI: 10.18632/oncotarget.12673 (Year: 2017).;;Guendisch; PLoS ONE 2017, 12, e0188391. DOI: 10.1371/journal.pone.0188391 (Year: 2017).;;Huh; Eur. J. Immunol. 2012. 42, 2232-2237. DOI: 10.1002/eji.201242740 (Year: 2012).;;Isono; Drug Discovery Today, 2014, 19, 1205-1211. DOI: 10.1016/j.drudis.2014.04.012 (Year: 2014).;;Kiaei; Basic Clin Neurosci. 2013, 4, 3-4. URL: http://bcn.jurns.ac.ir/article-1-307-en.html (Year: 2013).;;Xue; Scientific Reports 2016, 6, Article No. 37977. DOI: 10.1038/srep37977 (Year: 2016).;;Yao Chongzheng et al., Hydrolysis of carboxylate, Principles of Fine Chemical Product Synthesis, published on Dec. 31, 2000 (see English translation as provided).",ACTIVE
65,US,A1,US 2006/0234886 A1,170-039-603-426-688,2006-10-19,2006,US 45613306 A,2006-07-07,US 45613306 A;;US 9163605 A;;US 29060902 A,2002-11-08,LIQUID CLEANSING COMPOSITION HAVING SIMULTANEOUS EXFOLIATING AND MOISTURIZING PROPERTIES,"Liquid lamellar cleansing compositions are described that contain synthetic surfactants, hydrophilic emollients and exfoliant particles where 80% or more of the particles have a major axis length of between 100 and 1000 microns. The combination of the mild surfactants, moisturizers, and exfoliants provide the user with simultaneous moisturization and exfoliation in a convenient liquid cleansing product.",UNILEVER HOME & PERSONAL CARE,MASSARO MICHAEL;;GOLDBERG JESSICA W;;SUBRAMANYAN KRISHNA K;;JOHNSON ANTHONY W;;SLAVTCHEFF CRAIG S;;GENCARELLI SUZANNE L;;MINER PHILIP E,,https://lens.org/170-039-603-426-688,Patent Application,yes,15,24,12,12,0,A61K8/03;;A61K8/92;;A61K8/92;;A61K8/0241;;A61K8/0241;;A61K8/361;;A61K8/361;;A61K8/37;;A61K8/37;;A61K2800/28;;A61K2800/28;;A61K2800/412;;A61K2800/412;;A61K2800/651;;A61K2800/651;;A61Q5/02;;A61Q5/02;;A61Q19/00;;A61Q19/00;;A61Q19/10;;A61Q19/10;;A61Q19/10,A61K8/00;;A61K8/04;;A61K8/92;;A61Q19/00,510/130;;510/156;;510/424,0,0,,,,DISCONTINUED
66,AU,A1,AU 2017/327841 A1,173-402-964-817-847,2019-04-04,2019,AU 2017/327841 A,2017-09-11,US 201662394063 P;;US 201762532914 P;;US 2017/0050950 W,2016-09-13,Systems and method related to a food-item cutter and associated cover,"Systems and methods are disclosed for cutting a food item when preparing it to be served to a customer. In some implementations, the cutting system may include a cover that may be used to at least partially surround a portion of a the cutting system. The cover may include one or more doors, drawers, or other movable components that may be used to engage the cutting assembly of the cutting system by activating one or more sensors located along or proximate to the path traveled by the movable component. The movable component may activate the sensor when the movable component has appropriately positioned the food item under the cutting assembly to be cut. Additionally, the cover may include one or more user-engageable switches that may be used to selectively engage cutting assembly when the movable component of the cover is appropriately positioned to be cut by the cutting assembly.",ZUME INC,GARDEN ALEXANDER JOHN;;GOLDBERG JOSHUA GOULED;;GOEL VAIBHAV;;COLLINS JULIA ELIZABETH;;SWITEK JR ROBERT EUGENE;;MILLS EDWARD VALENTIN;;JOHNSON CRAIG ALAN,,https://lens.org/173-402-964-817-847,Patent Application,no,0,0,8,8,0,B26D3/24;;B26D5/04;;B26D5/06;;B26D7/088;;B26D7/22;;B26D7/2614;;B26D2007/0018;;B26D2210/02;;B26D3/24;;B26D5/04;;B26D5/06;;B26D7/088;;B26D7/22;;B26D7/2614;;B26D3/24;;B26D5/04;;B26D5/06;;B26D7/088;;B26D7/22;;B26D7/2614;;B26D2007/0018;;B26D2210/02,B26D3/24;;B26D7/26;;B26D7/27,,0,0,,,,DISCONTINUED
67,GB,A,GB 2571642 A,016-755-589-437-666,2019-09-04,2019,GB 201904356 A,2017-09-11,US 2017/0050950 W;;US 201662394063 P;;US 201762532914 P,2016-09-13,Systems and method related to a food-item cutter and associated cover,"Systems and methods are disclosed for cutting a food item when preparing it to be served to a customer. In some implementations, the cutting system may include a cover that may be used to at least partially surround a portion of a the cutting system. The cover may include one or more doors, drawers, or other movable components that may be used to engage the cutting assembly of the cutting system by activating one or more sensors located along or proximate to the path traveled by the movable component. The movable component may activate the sensor when the movable component has appropriately positioned the food item under the cutting assembly to be cut. Additionally, the cover may include one or more user-engageable switches that may be used to selectively engage cutting assembly when the movable component of the cover is appropriately positioned to be cut by the cutting assembly.",ZUME INC,ALEXANDER JOHN GARDEN;;JOSHUA GOULED GOLDBERG;;VAIBHAV GOEL;;JULIA ELIZABETH COLLINS;;ROBERT EUGENE JR SWITEK;;EDWARD VALENTIN MILLS;;CRAIG ALAN JOHNSON,,https://lens.org/016-755-589-437-666,Patent Application,no,5,0,8,8,0,B26D3/24;;B26D7/088;;B26D7/088;;B26D3/24;;B26D3/24;;B26D5/04;;B26D5/04;;B26D5/04;;B26D5/06;;B26D5/06;;B26D5/06;;B26D7/088;;B26D7/22;;B26D7/22;;B26D7/22;;B26D7/2614;;B26D7/2614;;B26D7/2614;;B26D2007/0018;;B26D2007/0018;;B26D2210/02;;B26D2210/02,B26D3/24;;B26D7/26;;B26D7/27,,0,0,,,,DISCONTINUED
68,CN,A,CN 109952179 A,024-142-920-595-92X,2019-06-28,2019,CN 201780069397 A,2017-09-11,US 201662394063 P;;US 201762532914 P;;US 2017/0050950 W,2016-09-13,SYSTEMS AND METHOD RELATED TO FOOD-ITEM CUTTER AND ASSOCIATED COVER,"The present invention discloses systems and methods for cutting a food item when preparing it to be served to a customer. In some implementations, the cutting system may include a cover that may be used to at least partially surround a portion of a the cutting system. The cover may include one or more doors, drawers, or other movable components that may be used to engage the cutting assembly of the cutting system by activating one or more sensors located along or proximate to the path traveled by the movable component. The movable component may activate the sensor when the movable component has appropriately positioned the food item under the cutting assembly to be cut. Additionally, the cover may include one or more user-engageable switches that may be used to selectively engage cutting assembly when the movable component of the cover is appropriately positioned to be cut by the cutting assembly.",ZUME PIZZA INC,GARDEN ALEXANDER JOHN;;GOLDBERG JOSHUA GOULED;;GOEL VAIBHAV;;COLLINS JULIA ELIZABETH;;SWITEK ROBERT EUGENE JR;;MILLS EDWARD VALENTIN;;JOHNSON CRAIG ALAN,,https://lens.org/024-142-920-595-92X,Patent Application,no,9,2,8,8,0,B26D3/24;;B26D7/088;;B26D7/088;;B26D3/24;;B26D3/24;;B26D5/04;;B26D5/04;;B26D5/04;;B26D5/06;;B26D5/06;;B26D5/06;;B26D7/088;;B26D7/22;;B26D7/22;;B26D7/22;;B26D7/2614;;B26D7/2614;;B26D7/2614;;B26D2007/0018;;B26D2007/0018;;B26D2210/02;;B26D2210/02,B26D3/24;;B26D7/26;;B26D7/27,,0,0,,,,DISCONTINUED
69,DE,T5,DE 112017004603 T5,068-114-972-395-151,2019-07-11,2019,DE 112017004603 T,2017-09-11,US 201662394063 P;;US 201762532914 P;;US 2017/0050950 W,2016-09-13,Systeme und Verfahren für eine Lebensmittelschneidevorrichtung und eine dazugehörige Abdeckung,"Es werden Systeme und Verfahren zum Schneiden eines Lebensmittelstücks, wenn dieses bereit gemacht wird, einem Kunden serviert zu werden, offenbart. In einigen Umsetzungen kann das Schneidesystem eine Abdeckung umfassen, die dazu verwendet werden kann, einen Abschnitt des Schneidesystems zumindest partiell zu umschließen. Die Abdeckung kann eine oder mehrere Türen, Schubladen oder oder andere bewegliche Komponenten beinhalten, die dazu verwendet werden können, die Schneidanordnung des Schneidesystems in Anspruch zu nehmen, indem einer oder mehrere Sensoren aktiviert werden, die sich entlang oder in der Nähe des Wegs befinden, den die bewegliche Komponente zurückgelegt hat. Die bewegliche Komponente kann den Sensor aktivieren, wenn die bewegliche Komponente das Lebensmittelstück unter der Schneidanordnung positioniert hat, um geschnitten zu werden. Darüber hinaus kann die Abdeckung einen oder mehrere benutzerbetätigbare Schalter beinhalten, die dazu verwendet werden können, die Schneidanordnung selektiv zu verwenden, wenn die bewegliche Komponente der Abdeckung entsprechend positioniert ist, von der Schneidvorrichtung geschnitten zu werden.",ZUME INC,GARDEN JOHN ALEXANDER;;GOLDBERG GOULED JOSHUA;;GOEL VAIBHAV;;COLLINS ELIZABETH JULIA;;SWITEK JR EUGENE ROBERT;;MILLS VALENTIN EDWARD;;JOHNSON ALAN CRAIG,,https://lens.org/068-114-972-395-151,Patent Application,no,13,0,8,8,0,B26D3/24;;B26D5/04;;B26D5/06;;B26D7/088;;B26D7/22;;B26D7/2614;;B26D2007/0018;;B26D2210/02;;B26D3/24;;B26D5/04;;B26D5/06;;B26D7/088;;B26D7/22;;B26D7/2614;;B26D3/24;;B26D5/04;;B26D5/06;;B26D7/088;;B26D7/22;;B26D7/2614;;B26D2007/0018;;B26D2210/02,B26D3/24;;B26D7/26;;B26D7/27,,0,0,,,,DISCONTINUED
70,WO,A1,WO 2018/052842 A1,050-124-629-045-352,2018-03-22,2018,US 2017/0050950 W,2017-09-11,US 201662394063 P;;US 201762532914 P,2016-09-13,SYSTEMS AND METHOD RELATED TO A FOOD-ITEM CUTTER AND ASSOCIATED COVER,"Systems and methods are disclosed for cutting a food item when preparing it to be served to a customer. In some implementations, the cutting system may include a cover that may be used to at least partially surround a portion of a the cutting system. The cover may include one or more doors, drawers, or other movable components that may be used to engage the cutting assembly of the cutting system by activating one or more sensors located along or proximate to the path traveled by the movable component. The movable component may activate the sensor when the movable component has appropriately positioned the food item under the cutting assembly to be cut. Additionally, the cover may include one or more user-engageable switches that may be used to selectively engage cutting assembly when the movable component of the cover is appropriately positioned to be cut by the cutting assembly.",ZUME PIZZA INC,GARDEN ALEXANDER JOHN;;GOLDBERG JOSHUA GOULED;;GOEL VAIBHAV;;COLLINS JULIA ELIZABETH;;SWITEK ROBERT EUGENE JR;;MILLS EDWARD VALENTIN;;JOHNSON CRAIG ALAN,,https://lens.org/050-124-629-045-352,Patent Application,yes,5,2,8,8,0,B26D3/24;;B26D7/088;;B26D7/088;;B26D3/24;;B26D3/24;;B26D5/04;;B26D5/04;;B26D5/04;;B26D5/06;;B26D5/06;;B26D5/06;;B26D7/088;;B26D7/22;;B26D7/22;;B26D7/22;;B26D7/2614;;B26D7/2614;;B26D7/2614;;B26D2007/0018;;B26D2007/0018;;B26D2210/02;;B26D2210/02,B26D3/24;;B26D7/26;;B26D7/27,,0,0,,,,PENDING
71,US,B2,US 7790712 B2,083-700-066-213-120,2010-09-07,2010,US 27693506 A,2006-03-17,US 27693506 A;;US 71901705 P;;US 66256705 P,2005-03-17,"Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors","The application relates to compounds of formula Ia and analogues thereof wherein R 1 to R 13 and X are as defined herein. The invention also relates to the use of the compounds of formula Ia as inhibitors of Mitogen-Activated Protein Kinase-Activated Protein kinase-2 (MAPKAP-k2), and also to a method for preventing or treating a disease or disorder that can be treated or prevented by modulating the activity of MAPKAP-K2 in a subject and to pharmaceutical compositions and kits that include these MAPKAP-K2 inhibitors.",BOEHRINGER INGELHEIM PHARMA,COGAN DEREK;;GAO DONGHONG A;;GOLDBERG DANIEL R;;MILLER CRAIG ANDREW;;MOSS NEIL;;NETHERTON MATTHEW RUSSELL;;RAMSDEN PHILIP DEAN;;XIONG ZHAOMING,BOEHRINGER INGELHEIM INTERNATIONAL GMBH (2008-09-10);;BOEHRINGER INGELHEIM PHARMACEUTICALS INC (2006-06-14),https://lens.org/083-700-066-213-120,Granted Patent,yes,4,5,2,2,0,A61P37/06;;C07D487/04;;C07D487/04;;C07D471/04;;C07D471/04,C07D487/04;;A61K31/4985;;A61K31/519;;A61K31/5365;;A61P37/06;;C07D471/04,514/220;;514/214.01;;514/250;;514/294;;540/496;;540/522;;540/558;;546/94;;544/344,8,7,023-883-510-416-96X;;033-530-932-325-24X;;022-215-528-119-154;;049-095-122-744-095;;011-624-569-855-121;;003-917-183-621-559;;097-152-464-603-961,17480064;;10.1021/jm0611004;;16178737;;10.2174/1568026054985902;;10.1016/j.bmcl.2007.12.037;;18221871;;10.1016/j.bmcl.2008.10.039;;18945615;;17576063;;10.1016/j.bmcl.2007.05.101;;10.1016/j.bmcl.2008.01.119;;18291646;;10.1002/jps.2600790218;;2324967,"Anderson et al, ""Pyrrolopyridine Inhibitors of Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MK-2)"" Journal of Medicinal Chemistry, vol. 50, pp. 2647-2654 (2007).;;Scheiven, G. ""The Biology of p38 Kinase: A Central Role in Inflammation"" Current Topics in Medicinal Chemistry, vol. 5, pp. 921-928 (2005).;;Goldberg, D. R., et al., ""Pyrazinoindolone inhibitors of MAPKAP-K2,"" Bioorganic & Medicinal Chemistry Letters (2008), 18(3), 938-941.;;Schlapbach, Achim et al., ""Pyrrolo-pyrimidones: A novel class of MK2 inhibitors with potent cellular activity,"" Bioorganic & Medicinal Chemistry Letters (2008), 18(23), 6142-6146.;;Wu, Jiang-Ping, et al., ""The discovery of carboline analogs as potent MAPKAP-K2 inhibitors,"" Bioorganic & Medicinal Chemistry Letters (2007), 17(16), 4664-4669.;;Xiong, Zhaoming et al., ""Synthesis and SAR studies of indole-based MK2 inhibitors,"" Bioorganic & Medicinal Chemistry Letters (2008), 18(6), 1994-1999.;;Hendi, Shivakumar B., et al; Synthesis of II-Methyl-2,3,4,5-tetrahydro-IH-[I,4]diazepino[I,2a]indoles & I-(3-Aminopropyl)-2-hydroxymethyl-3-methylindoles; Indian Journal of Chemistry (1981) vol. 20B pp. 288-289.;;Rajur, Sharanabasava, B., et al; Synthesis of II-phenyl-2,3,4,5-tetrahydro-1 H-(1,4)diazepino(1,2-a)indoles and 1-(3-Aminopropyl)-2-hydroxymethyl-3-phenylindoles as 5-Hydroxytryptamine Antagonists; Journal of Pharmaceutical Sciences (1990) vol. 79, No. 2, pp. 168-172.",ACTIVE
72,AU,A1,AU 2007/323838 A1,021-337-903-384-179,2008-05-29,2008,AU 2007/323838 A,2007-11-13,US 85861306 P;;US 94975707 P;;US 2007/0084584 W,2006-11-13,System and method for providing multiple participants with a central access portal to geographic point of interest,,TELE ATLAS NORTH AMERICA INC,SABBEY CRAIG PATRICK;;PARKER JENNIFER;;COHEN RICHARD;;BROWN ROGER W;;BECKER MARY R;;TEMMINK RIK;;GOLDBERG DAVID;;UNDERCOFFLER JAY W;;JONES MICHELLE,,https://lens.org/021-337-903-384-179,Patent Application,no,0,0,6,7,0,G06Q30/00;;G06Q30/00,G06F3/048;;G06F15/16,,0,0,,,,DISCONTINUED
73,US,A1,US 2008/0163073 A1,028-156-417-534-954,2008-07-03,2008,US 93943507 A,2007-11-13,US 93943507 A;;US 85861306 P;;US 94975707 P,2006-11-13,SYSTEM AND METHOD FOR PROVIDING MULTIPLE PARTICIPANTS WITH A CENTRAL ACCESS PORTAL TO GEOGRAPHIC POINT OF INTEREST DATA,"A system and method of providing multiple participants with a centrally accessible content portal for geographic point of interest (POI) data, for subsequent use in creating map-based or spatial applications. Different entities can dynamically upload, update, retrieve, and use digital map and POI data. Additional features include the ability to handle the large amounts of POI data needed by multiple Application Developers, including data that is dynamic, or frequently changing; the ability to update POI attribute information and deliver it to the Application Developers; the ability to associate multiple points of entry (POE) with a POI, and to aggregate data from multiple Content Providers; and the use of a common geocoding engine and common digital map reference across all Content Providers, which ensures the consistency of the geocoding throughout all the POI data.",TELE ATLAS NORTH AMERICA INC,BECKER MARY R;;SABBEY CRAIG PATRICK;;UNDERCOFFLER JAY W;;COHEN RICHARD;;TEMMINK RIK;;GOLDBERG DAVID;;JONES MICHELLE;;BROWN ROGER W;;PARKER JENNIFER,TELE ATLAS NORTH AMERICA INC (2008-01-31),https://lens.org/028-156-417-534-954,Patent Application,yes,9,116,6,7,0,G06Q30/00;;G06Q30/00,G06F15/16;;G06F3/048,715/753,0,0,,,,DISCONTINUED
74,US,A1,US 2023/0081548 A1,102-071-683-714-375,2023-03-16,2023,US 202217576535 A,2022-01-14,US 202217576535 A;;US 202117242512 A;;US 202063017682 P,2020-04-30,IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17,"The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , R 4 and R 5 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.",JANSSEN PHARMACEUTICA NV,GOLDBERG STEVEN;;WOODS CRAIG;;RHORER TIMOTHY B;;MARTIN CONNOR;;MEDUNA STEVEN P;;MCCARVER STEFAN;;VALDES ALEXANDER;;LOSKOT STEVEN;;BEHENNA DOUGLAS;;XUE XIAOHUA,CILAG AG (2021-02-09);;JANSSEN RESEARCH & DEVELOPMENT LLC (2021-10-13);;JANSSEN PHARMACEUTICA NV (2021-07-21);;JANSSEN BIOTECH INC (2021-02-17),https://lens.org/102-071-683-714-375,Patent Application,yes,0,0,21,21,2,A61P11/00;;C07D487/04;;A61P11/00;;C07D487/04;;C07D487/04;;A61K31/519;;A61K31/5025;;A61P29/00;;A61P17/06;;A61P19/02;;A61P11/06;;C07D487/04,C07D487/04,,0,0,,,,ACTIVE
75,EP,A2,EP 2115610 A2,087-584-728-857-890,2009-11-11,2009,EP 07864347 A,2007-11-13,US 2007/0084584 W;;US 85861306 P;;US 94975707 P,2006-11-13,SYSTEM AND METHOD FOR PROVIDING MULTIPLE PARTICIPANTS WITH A CENTRAL ACCESS PORTAL TO GEOGRAPHIC POINT OF INTEREST,,TELE ATLAS NORTH AMERICA INC,BECKER MARY R;;SABBEY CRAIG PATRICK;;UNDERCOFFLER JAY W;;COHEN RICHARD;;TEMMINK RIK;;GOLDBERG DAVID;;JONES MICHELLE;;BROWN ROGER W;;PARKER JENNIFER,,https://lens.org/087-584-728-857-890,Patent Application,yes,0,0,6,7,0,G06Q30/00;;G06Q30/00,G06F15/16,,0,0,,,,DISCONTINUED
76,WO,A3,WO 2008/064020 A3,024-911-505-301-094,2008-07-17,2008,US 2007/0084584 W,2007-11-13,US 85861306 P;;US 94975707 P,2006-11-13,SYSTEM AND METHOD FOR PROVIDING MULTIPLE PARTICIPANTS WITH A CENTRAL ACCESS PORTAL TO GEOGRAPHIC POINT OF INTEREST,"A system and method of providing multiple participants with a centrally accessible content portal for geographic point of interest (POI) data, for subsequent use in creating map-based or spatial applications. Different entities can dynamically upload, update, retrieve, and use digital map and POI data. Additional features include the ability to handle the large amounts of POI data needed by multiple Application Developers, including data that is dynamic, or frequently changing; the ability to update POI attribute information and deliver it to the Application Developers; the ability to associate multiple points of entry (POE) with a POI, and to aggregate data from multiple Content Providers; and the use of a common geocoding engine and common digital map reference across all Content Providers, which ensures the consistency of the geocoding throughout all the POI data.",TELE ATLAS NORTH AMERICA INC;;BECKER MARY R;;SABBEY CRAIG PATRICK;;UNDERCOFFLER JAY W;;COHEN RICHARD;;TEMMINK RIK;;GOLDBERG DAVID;;JONES MICHELLE;;BROWN ROGER W;;PARKER JENNIFER,BECKER MARY R;;SABBEY CRAIG PATRICK;;UNDERCOFFLER JAY W;;COHEN RICHARD;;TEMMINK RIK;;GOLDBERG DAVID;;JONES MICHELLE;;BROWN ROGER W;;PARKER JENNIFER,,https://lens.org/024-911-505-301-094,Search Report,yes,5,0,6,7,0,G06Q30/00;;G06Q30/00,G06F15/16,,0,0,,,,PENDING
77,WO,A2,WO 2008/064020 A2,036-582-987-680-509,2008-05-29,2008,US 2007/0084584 W,2007-11-13,US 85861306 P;;US 94975707 P,2006-11-13,SYSTEM AND METHOD FOR PROVIDING MULTIPLE PARTICIPANTS WITH A CENTRAL ACCESS PORTAL TO GEOGRAPHIC POINT OF INTEREST,"A system and method of providing multiple participants with a centrally accessible content portal for geographic point of interest (POI) data, for subsequent use in creating map-based or spatial applications. Different entities can dynamically upload, update, retrieve, and use digital map and POI data. Additional features include the ability to handle the large amounts of POI data needed by multiple Application Developers, including data that is dynamic, or frequently changing; the ability to update POI attribute information and deliver it to the Application Developers; the ability to associate multiple points of entry (POE) with a POI, and to aggregate data from multiple Content Providers; and the use of a common geocoding engine and common digital map reference across all Content Providers, which ensures the consistency of the geocoding throughout all the POI data.",TELE ATLAS NORTH AMERICA INC;;BECKER MARY R;;SABBEY CRAIG PATRICK;;UNDERCOFFLER JAY W;;COHEN RICHARD;;TEMMINK RIK;;GOLDBERG DAVID;;JONES MICHELLE;;BROWN ROGER W;;PARKER JENNIFER,BECKER MARY R;;SABBEY CRAIG PATRICK;;UNDERCOFFLER JAY W;;COHEN RICHARD;;TEMMINK RIK;;GOLDBERG DAVID;;JONES MICHELLE;;BROWN ROGER W;;PARKER JENNIFER,,https://lens.org/036-582-987-680-509,Patent Application,yes,0,4,6,7,0,G06Q30/00;;G06Q30/00,G06F15/16;;G06F3/048,,0,0,,,,PENDING
78,CR,A,CR 20180505 A,158-281-688-844-547,2019-03-14,2019,CR 20180505 A,2017-04-26,US 201662328074 P;;US 2017/0029531 W,2016-04-27,6-AMINOPIRIDIN-3-IL TIAZOLES COMO MODULADORES DE RORyT,"La presente invención comprende compuestos de la Fórmula (I) en donde: A1, A2, A3, A4, A5, R1 y R2 se definen en la especificación.La invención comprende, además, un método para tratar o mejorar un síndrome, trastorno o enfermedad, en donde el síndrome, trastorno o enfermedad son artritis reumatoide o soriasis. La invención comprende, además, un método para modular la actividad de ROR¿t en un mamífero por medio de la administración de una cantidad terapéuticamente eficaz de al menos un compuesto de la Fórmula I.",JANSSEN PHARMACEUTICA NV,VENKATESAN HARIHARAN;;GOLDBERG STEVEN;;WOODS CRAIG R;;FENNEMA ELIZABETH G;;XUE XIAOHUA;;MCCLURE KELLY;;TANIS VIRGINIA;;LEBSACK ALEC D;;MARTIN CONNOR L,,https://lens.org/158-281-688-844-547,Patent Application,no,0,0,35,35,0,C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P25/24;;A61P29/00;;A61P3/00;;A61P37/00;;A61P37/02;;A61P43/00;;A61P29/00;;A61K31/4439;;C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07B59/002;;C07B2200/05;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,C07D417/14;;C07D417/04;;C07D491/08,,0,0,,,,PENDING
79,EP,A2,EP 1251621 A2,049-934-799-115-359,2002-10-23,2002,EP 02252697 A,2002-04-16,US 83689201 A,2001-04-17,Electric motor armature,"In the disclosed embodiment of this invention, sets of straight wire bundles (12) are molded or otherwise encased about a cylindrical rotor casing (11). The straight wire bundles lie parallel to the axis of the cylindrical rotor casing. This process is an alternative to a traditional type of electric motor armature which uses a wire that is coiled around the cylindrical rotor casing. Since the wire bundles are straight and not pulled from a single wire roll, breaking and stretching of the wire is greatly reduced. The straight wire bundles are connected at their ends using a circuit cap (14) to form a complete electrical circuit.",MERITOR LIGHT VEHICLE TECH,KRAMER DENNIS;;QUERE JEROME;;FOWLER CRAIG RAE;;FIN ENRICO;;CHENE GEORGE;;GOLDBERG IRA;;CHIU STEPHEN;;HOPSON CHARLES;;GARRIDO PASCAL;;BARRY DAVID;;ROGOVIN DAN,,https://lens.org/049-934-799-115-359,Patent Application,yes,0,0,3,3,0,H02K3/12;;H02K3/12,H02K3/12,,0,0,,,,DISCONTINUED
80,EP,A3,EP 1251037 A3,096-542-657-008-939,2004-05-19,2004,EP 02252691 A,2002-04-16,US 83689801 A,2001-04-17,Electrical motor system,"A plurality of motors (14, 16, 18) for use in driving accessories (15, 17, 19) on a vehicle, are each powered by three-phase current. A single controller (12) controls the supply three-phase current to the plurality of motors. In another aspect of the invention, pseudothree-phase current is created from a direct current voltage source (42). A chopping circuit (40) chops the voltage into a plurality of pulses, and a phase shift circuit (64) then creates phase-shifted power signals from those pulses. The present invention thus enables the use of three-phase alternating current motors on a vehicle to drive accessories. This reduces the cost and size of the required motors.",MERITOR LIGHT VEHICLE TECH,KRAMER DENNIS;;FOWLER CRAIG RAE;;QUERE JEROME;;FIN ENRICO;;CHENE GEORCE;;GOLDBERG IRA;;CHIU STEPHEN;;HOPSON CHARLES;;GARRIDO PASCAL;;BARRY DAVID;;ROGOVIN DAN,"ARVINMERITOR TECHNOLOGY, LLC (2006-06-07)",https://lens.org/096-542-657-008-939,Search Report,yes,7,0,7,7,0,B60R16/03;;H02M7/48;;H02J2207/20;;H02J2310/46;;H02M7/48;;B60R16/03;;H02J2207/20,B60R16/02;;H02J7/00;;H02M7/48,,0,0,,,,EXPIRED
81,SG,A,SG 11201809162X A,133-376-128-094-674,2018-11-29,2018,SG 11201809162X A,2017-04-26,US 201662328074 P;;US 2017/0029531 W,2016-04-27,6-AMINOPYRIDIN-3-YL THIAZOLES AS MODULATORS OF ROR?T,,JANSSEN PHARMACEUTICA NV,MCCLURE KELLY;;TANIS VIRGINIA M;;FENNEMA ELIZABETH G;;LEBSACK ALEC D;;MARTIN CONNOR L;;VENKATESAN HARIHARAN;;XUE XIAOHUA;;WOODS CRAIG R;;GOLDBERG STEVEN,,https://lens.org/133-376-128-094-674,Unknown,no,0,0,35,35,0,C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P25/24;;A61P29/00;;A61P3/00;;A61P37/00;;A61P37/02;;A61P43/00;;A61P29/00;;A61K31/4439;;C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07B59/002;;C07B2200/05;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,C07D417/04;;A61K31/4439;;A61P29/00;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,,0,0,,,,PENDING
82,BR,A2,BR 112018071942 A2,003-155-159-381-374,2019-02-05,2019,BR 112018071942 A,2017-04-26,US 2017/0029531 W;;US 201662328074 P,2016-04-27,tiazóis de 6-aminopiridin-3-ila como moduladores de rorgamat,"a presente invenção compreende compostos da fórmula i em que: a1, a2, a3, a4, a5, r1, e r2 são definidos na especificação. a invenção também compreende um método de tratamento ou alívio de uma síndrome, distúrbio ou doença, sendo que a dita síndrome, distúrbio ou doença é artrite reumatoide ou psoríase. a invenção também compreende um método de modulação da atividade de rorgamat em um mamífero por meio da administração de uma quantidade terapeuticamente eficaz de ao menos um composto da fórmula i.",JANSSEN PHARMACEUTICA NV,ALEC D LEBSACK;;CONNOR L MARTIN;;CRAIG R WOODS;;ELIZABETH G FENNEMA;;HARIHARAN VENKATESAN;;KELLY MCCLURE;;STEVEN GOLDBERG;;VIRGINIA M TANIS;;XIAOHUA XUE,,https://lens.org/003-155-159-381-374,Patent Application,no,0,0,35,35,0,C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P25/24;;A61P29/00;;A61P3/00;;A61P37/00;;A61P37/02;;A61P43/00;;A61P29/00;;A61K31/4439;;C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07B59/002;;C07B2200/05;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,C07D417/04;;A61K31/4439;;A61P29/00;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,,0,0,,,,DISCONTINUED
83,US,A1,US 2021/0188836 A1,102-268-780-080-166,2021-06-24,2021,US 202117182387 A,2021-02-23,US 202117182387 A;;US 201715497565 A;;US 201662328074 P,2016-04-27,6-AMINOPYRIDIN-3-YL THIAZOLES AS MODULATORS OF RORyT,"The present invention comprises compounds of Formula I. wherein: A 1 , A 2 , A 3 , A 4 , A 5 , R 1 , and R 2 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.",JANSSEN PHARMACEUTICA NV,GOLDBERG STEVEN;;MCCLURE KELLY;;TANIS VIRGINIA M;;FENNEMA ELIZABETH G;;LEBSACK ALEC D;;MARTIN CONNOR L;;VENKATESAN HARIHARAN;;XUE XIAOHUA;;WOODS CRAIG R,,https://lens.org/102-268-780-080-166,Patent Application,yes,1,0,35,35,4,C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P25/24;;A61P29/00;;A61P3/00;;A61P37/00;;A61P37/02;;A61P43/00;;A61P29/00;;A61K31/4439;;C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07B59/002;;C07B2200/05;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,C07B59/00;;C07D417/14;;C07D417/04;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,,0,0,,,,PENDING
84,EP,A1,EP 3448856 A1,113-338-061-115-019,2019-03-06,2019,EP 17733165 A,2017-04-26,US 201662328074 P;;US 2017/0029531 W,2016-04-27,6-AMINOPYRIDIN-3-YL THIAZOLES AS MODULATORS OF ROR T,,JANSSEN PHARMACEUTICA NV,GOLDBERG STEVEN;;MCCLURE KELLY;;TANIS VIRGINIA M;;FENNEMA ELIZABETH G;;LEBSACK ALEC D;;MARTIN CONNOR L;;VENKATESAN HARIHARAN;;XUE XIAOHUA;;WOODS CRAIG R,,https://lens.org/113-338-061-115-019,Patent Application,yes,0,0,35,35,0,C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P25/24;;A61P29/00;;A61P3/00;;A61P37/00;;A61P37/02;;A61P43/00;;A61P29/00;;A61K31/4439;;C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07B59/002;;C07B2200/05;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,C07D417/04;;A61K31/4439;;A61P29/00;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,,0,0,,,,ACTIVE
85,EC,A,EC SP18088146 A,151-734-274-536-805,2018-11-30,2018,EC DI201888146 A,2018-11-26,US 201662328074 P,2016-04-27,6-AMINOPIRIDIN-3-IL TIAZOLES COMO MODULADORES DE RORyT,"La presente invención comprende compuestos de la Fórmula (I) en donde: A1, A2, A3, A4, A5, R1 y R2 se definen en la especificación. La invención comprende, además, un método para tratar o mejorar un síndrome, trastorno o enfermedad, en donde el síndrome, trastorno o enfermedad son artritis reumatoide o soriasis. La invención comprende, además, un método para modular la actividad de RORγt en un mamífero por medio de la administración de una cantidad terapéuticamente eficaz de al menos un compuesto de la Fórmula I.",JANSSEN PHARMACEUTICA NV,TANIS VIRGINIA M;;MCCLURE KELLY;;XUE XIAOHUA;;GOLDBERG STEVEN;;FENNEMA ELIZABETH G;;VENKATESAN HARIHARAN;;LEBSACK ALEC D;;WOODS CRAIG R;;MARTIN CONNOR L,,https://lens.org/151-734-274-536-805,Patent Application,no,0,0,35,35,0,C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P25/24;;A61P29/00;;A61P3/00;;A61P37/00;;A61P37/02;;A61P43/00;;A61P29/00;;A61K31/4439;;C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07B59/002;;C07B2200/05;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,C07D417/04;;A61K31/4439;;A61P29/00;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,,0,0,,,,PENDING
86,DE,D1,DE 60217571 D1,189-526-244-908-367,2007-03-08,2007,DE 60217571 T,2002-04-16,US 83689801 A,2001-04-17,Elektrisches Motorensystem,,ARVINMERITOR TECHNOLOGY LLC,KRAMER DENNIS;;FOWLER CRAIG RAE;;QUERE JEROME;;FIN ENRICO;;CHENE GEORCE;;GOLDBERG IRA;;CHIU STEPHEN;;HOPSON CHARLES;;GARRIDO PASCAL;;BARRY DAVID;;ROGOVIN DAN,,https://lens.org/189-526-244-908-367,Granted Patent,no,0,0,7,7,0,B60R16/03;;B60R16/03;;H02M7/48;;H02M7/48;;H02J2207/20;;H02J2207/20;;H02J2310/46,B60R16/02;;B60R16/00;;H02J7/00;;H02M7/48,,0,0,,,,EXPIRED
87,US,B2,US 10975068 B2,039-257-973-858-871,2021-04-13,2021,US 201715497565 A,2017-04-26,US 201715497565 A;;US 201662328074 P,2016-04-27,6-aminopyridin-3-yl thiazoles as modulators of RORγT,"The present invention comprises compounds of Formula I. wherein: A 1 , A 2 , A 3 , A 4 , A 5 , R 1 , and R 2 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.",JANSSEN PHARMACEUTICA NV,GOLDBERG STEVEN;;MCCLURE KELLY;;TANIS VIRGINIA M;;FENNEMA ELIZABETH G;;LEBSACK ALEC D;;MARTIN CONNOR L;;VENKATESAN HARIHARAN;;XUE XIAOHUA;;WOODS CRAIG R,JANSSEN PHARMACEUTICA NV (2017-03-30),https://lens.org/039-257-973-858-871,Granted Patent,yes,75,1,35,35,4,C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P25/24;;A61P29/00;;A61P3/00;;A61P37/00;;A61P37/02;;A61P43/00;;A61P29/00;;A61K31/4439;;C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07B59/002;;C07B2200/05;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,C07D417/14;;A61K31/427;;C07B59/00;;C07D417/04;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,,80,51,011-549-952-564-856;;007-924-207-867-846;;068-503-038-383-863;;093-884-198-693-922;;039-642-981-580-110;;011-549-952-564-856;;057-603-192-746-115;;118-307-749-079-773;;002-405-354-697-844;;156-601-101-421-818;;078-731-621-499-369;;066-119-584-271-19X;;064-399-651-040-903;;006-384-711-859-473;;095-361-043-889-533;;004-514-663-069-206;;093-144-517-257-295;;014-408-820-938-035;;042-371-686-427-160;;020-545-279-619-551;;068-508-663-743-396;;028-713-636-085-561;;035-586-215-470-490;;018-908-523-184-712;;048-384-949-179-543;;026-128-338-578-202;;016-505-509-019-957;;049-931-466-317-688;;011-663-094-062-663;;093-649-439-334-809;;000-649-437-049-891;;078-205-757-883-386;;039-460-067-637-00X;;030-303-530-555-166;;021-032-916-096-988;;021-966-133-884-768;;000-951-373-751-063;;065-682-394-873-532;;015-723-750-303-611;;060-797-640-900-566;;106-524-118-716-284;;058-874-856-370-984;;098-868-304-673-40X;;102-770-086-354-044;;044-653-508-978-443;;096-841-656-118-220;;180-631-728-571-083;;023-187-898-049-000;;011-872-379-895-774;;041-951-775-835-195;;002-380-530-828-658,10.1016/j.tips.2014.07.006;;25131183;;pmc4474185;;10.1002/art.38272;;24574218;;24502334;;10.1021/jm401901d;;pmc2812071;;10.1124/mol.109.060905;;19887649;;10.1002/chin.200930099;;10.1016/j.tips.2014.07.006;;25131183;;10.1021/ol1019597;;20866102;;12814161;;10.1053/rmed.2003.1507;;pmc3582833;;23174342;;10.1016/j.biopsych.2012.09.021;;20875338;;10.1016/j.psychres.2010.10.029;;21129782;;12610626;;10.1038/nature01355;;10.1038/nri1807;;16557264;;10.1136/gut.52.1.65;;pmc1773503;;12477762;;21747375;;10.1038/nbt.1906;;pmc2852824;;10.3748/wjg.v16.i14.1753;;20380008;;20926833;;10.1126/scitranslmed.3001107;;16990136;;10.1016/j.cell.2006.07.035;;20453841;;10.1038/ng.583;;15485625;;10.1016/j.immuni.2004.08.018;;10.1146/annurev.immunol.021908.132710;;19132915;;10.1016/j.jaci.2012.04.024;;pmc3470466;;22677045;;pmc2212798;;10.1084/jem.20041257;;15657292;;22455413;;10.1056/nejmoa1109997;;11984595;;10.1038/nm0502-500;;10.1021/bi048135v;;15794662;;10.1016/j.it.2005.10.003;;16290228;;21853531;;pmc3377107;;10.1002/emmm.201100172;;10.1038/gene.2008.16;;18368064;;10.1089/108705701753364922;;10.1177/108705710100600609;;11788061;;22455412;;10.1056/nejmoa1109017;;14984588;;10.1111/j.1440-1711.2004.01212.x;;20956338;;pmc3776381;;10.4049/jimmunol.1001538;;16670770;;pmc1451201;;10.1172/jci21404;;10.1002/0471264180.or028.02;;21920821;;10.1016/j.clim.2011.08.005;;10.1056/nejmoa1602773;;27959607;;10.18103/mra.v0i4.334;;29192397;;10.1007/s40273-017-0593-2;;10.1111/cei.12670;;26080615;;pmc4687521;;24918373;;10.1056/nejmoa1315231;;23075178;;10.1056/nejmoa1203572;;10.1002/eji.201546095;;27019190;;10.1517/14712598.2014.890587;;24555741;;10.1155/2016/6470364;;26941484;;pmc4749797;;10.1002/anie.198205671;;10.1351/pac197645010011;;10.18632/oncotarget.12673;;27750219;;pmc5352448;;10.1371/journal.pone.0188391;;29155882;;pmc5695821;;22949321;;10.1002/eji.201242740;;pmc3609417;;24792721;;10.1016/j.drudis.2014.04.012,"Yang et al., “:Targeting Th17, etc.,” Trends in Pharmacological Sciences, 35(10), 493-500. (Year: 2014).;;Chang M, “Pharmacologic Repression of Retinoic Acid Receptor—Related Orphan Nuclear Receptor □ Is Therapeutic in the Collagen-Induced Arthritis Experimental Model”, Arthritis & Rheumatology (2014), 66(3), 579-588.;;Fauber et al., J. Med. Chem. 2014, 57, 5871-5892.;;Kumar N, “The Benzenesulfoamide T0901317 [N-(2,2,2-Trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-benzenesulfonamide] Is a Novel Retinoic Acid Receptor-Related Orphan Receptor-□/□ Inverse Agonist”, Molecular Pharmacology (2010), 77(2), 228-236.;;Liegault, et al., “Establishment of Broadly Applicable reaction condisions for the Palladium-Catalyzed Direct Arylation of Heteroatom-Containing Aromatic Compounds”, The Journal of Organic Chemistry, (2009), vol. 74, No. 5, 6, pp. 1826-1834.;;Yang et al., Trends in Pharmacological Sciences, Oct. 2014, vol. 35, No. 10, 493-500.;;Yao, et al, “Preparation Method of N-butyl-5-phenylthiazole-4-Formamide Derivative Via Coupling Reaction Under Catalysis of Copper Catalyst”, Database accession No. 2014:924023.;;Zhang, et al., “Decarboxylative Cross-Coupling of Azoyl Carboxylic Acids with Aryl Halides”, Organic Letters, (2010) vol. 12, No. 21, pp. 4745-47457.;;PCT/US2015/058193, Written Opinion dated Jan. 26, 2016.;;PCT/US2015/058198, Written Opinion dated Jan. 21, 2016.;;PCT/US2015/058200, Written Opinion dated Jan. 27, 2016.;;PCT/US2015/058193, International Search Report, dated Jan. 26, 2016.;;PCT/US2015/058198, International Search Report, dated Jan. 21, 2016.;;PCT/US2015/058200, International Search Report, dated Jan. 27, 2016.;;Barczyk, a., W. Pierzchala, et al. (2003). “Interleukin-17 in sputum correlates with airway hyperresponsiveness to methacholine.” Respir Med 97(6): 726-33.;;Beurel, E., Harrington, L. E., Jope, R. S. (2013) “Inflammatory T helper 17 cells promote depression-like behavior in mice.” Biol Psychiatry 73(7): 622-30.;;Bowes, J. and A. Barton “The genetics of psoriatic arthritis: lessons from genome-wide association studies.” Discov Med 10(52): 177-83 (2010).;;Chang, M. R. et al. (2015) “Antiobesity Effect of a Small Molecule Repressor of RORγ.” Mol Pharmacol. 88(1): 48-56.;;Chen, Y., et al. (2011). “Emerging tendency towards autoimmune process in major depressive patients: A novel insight from Th17 cells.” Psychiatry Research 188(2): 224-230.;;Cua, D. J., J. Sherlock, et al. (2003). “Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain.” Nature 421(6924): 744-8.;;Dong, C. (2006). “Diversification of T-helper-cell lineages: finding the family root of IL-17-producing cells.” Nat Rev Immunol 6(4): 329-33.;;Fujino, S., A. Andoh, et al. (2003). “Increased expression of interleukin 17 in inflammatory bowel disease.” Gut 52(1): 65-70.;;Garber K. (2011). “Psoriasis: from bed to bench and back” Nat Biotech 29, 563-566.;;Gazouli, M., I. Pachoula, et al. “NOD2/CARD15, ATG16L1 and IL23R gene polymorphisms and childhood-onset of Crohn's disease.” World J Gastroenterol 16(14): 1753-8 (2010).;;Hueber, W., Patel, D.D., Dryja, T., Wright, A.M., Koroleva, I., Bruin, G., Antoni, C., Draelos, Z., Gold, M.H., Durez, P., Tak, P.P., Gomez-Reino, J.J., Foster, C.S., Kim, R.Y., Samson, C.M., Falk, N.S., Chu, D.S., Callanan, D., Nguyen, Q.D., Rose, K., Haider, A., Di Padova, F. (2010) Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2, 5272.;;Ivanov, II, B. S. McKenzie, et al. (2006). “The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells.” Cell 126(6): 1121-33.;;Kochi, Y., Y. Okada, et al. (2010) “A regulatory variant in CCR6 is associated with rheumatoid arthritis susceptibility.” Nat Genet 42(6): 515-9.;;Kolls, J. K. and A. Linden (2004). “Interleukin-17 family members and inflammation.” Immunity 21(4): 467-76.;;Korn, T., E. Bettelli, et al. (2009). “IL-17 and Th17 Cells.” Annu Rev Immunol 27: 485-517.;;Krueger, J. G., S. Fretzin, et al. “IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis.” J Allergy Clin Immunol 130(1): 145-154 e9 (2012).;;Langrish, C. L., Y. Chen, et al. (2005). “IL-23 drives a pathogenic T cell population that induces autoimmune inflammation.” J Exp Med 201(2): 233-40.;;Leonardi, C., R. Matheson, et al. “Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis.” N Engl J Med 366(13): 1190-9 (2012).;;Lock, C., G. Hermans, et al. (2002). “Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomvelitis.” Nat Med 8(5): 500-8.;;Matulis, D., Kranz, J. K., Salemme, F. R., and Todd, M. J. (2005) Thermodynamic stability of carbonic anhydrase: measurements of binding affinity and stoichiometry using ThermoFluor. Biochemistry 44, 5258-66.;;McKenzie, B. S., R. A. Kastelein, et al. (2006). “Understanding the IL-23-IL-17 immune pathway.” Trends Immunol 27(1): 17-23.;;Meissburger, B. et al. (2011) “Adipogenesis and insulin sensitivity in obesity are regulated by retinoid-related orphan receptor gamma.” EMBO Mol Med. 3(11): 637-651.;;Nunez, C., B. Dema, et al. (2008). “IL23R: a susceptibility locus for celiac disease and multiple sclerosis?” Genes Immun 9(4): 289-93.;;Pantoliano, M. W., Petrella, E. C., Kwasnoski, J. D., Lobanov, V. S., Myslik, J., Graf, E., Carver, T., Asel, E., Springer, B. A., Lane, P., and Salemme, F. R. (2001) High-density miniaturized thermal shift assays as a general strategy for drug discovegy. J Biomol Screen 6, 429-40.;;Papp, K. A., “Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.” N Engl J Med 2012 366(13): 1181-9.;;Stamp, L. K., M. J. James, et al. (2004). “Interleukin-17: the missing link between T-cell accumulation and effector cell actions in rheumatoid arthritis” Immunol Cell Biol 82(1): 1-9.;;Tonel, G., C. Conrad, et al. “Cutting edge: A critical functional role for IL-23 in psoriasis.” J Immunol 185(10): 5688-91 (2010).;;Yen, D., J. Cheung, et al. (2006). “IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6.” J Clin Invest 116(5): 1310-6.;;De Wit et al., ,RORγt inhibitors suppress TH17 responses in inflammatory arthritis and inflammatory bowel disease. Journal of Allergy and Clinical Immunology, vol. 137 , Issue 3, (2016), 960-963.;;Bimekizumab demonstrates impressive joint and skin responses for psoriatic arthritis patients. Dec. 20, 2017. https://www.ucb.com/stories-media/Press-Releases/article/Bimekizumab-demonstrates-impressive-joint-and-skin-responses-for-psoriatic-arthritis-patients-nbsp.;;Cheng, Chia-Chung et al., The Friedlander synthesis of quinolines, Organic Reactions, 1982, 28, pp. 37-201.;;Dolff S et al., Disturbed Th1, Th2, Th17 and T-reg balance in patients with systemic lupus erythematosus, Clinical Immunology 141(2):197-204 Aug. 2011.;;Feagan BG, et al. Ustekinumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2016;375(20):1946-60.;;Fitzpatrick, Leo Robert. Ror-gamma T inhibition as a Pharmacological Approach for Inflammatory Bowel Disease. Medical Research Archives, [S.l.], v. 2, n. 2, Aug. 2015.;;Hodgson et al., Ustekinumab for Treating Moderately to Severely Active Crohn's Disease after Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics (2018) 36:4, 387-398.;;Innovimmune: ROR Gamma Inhibitor (INV-17) Tested in Lupus Model. 2015 EULAR Congress News. https://static1.squarespace.com/static/577aff0015d5db17f97d2d57/t/584f44f9725e254d6b032644/1481590043630/150611_INV-17+Lupus+Thursday_EULAR_2015+small+size.pdf.;;Jethwa H at al., The interleukin (IL)-23/IL-17 axis in ankylosing spondylitis: new advances and potentials for treatment, Clinical and Experimental Immunology, 2015, 183: 30-36.;;McGinley et al., (2018) Th17 cells, γδ T cells and their interplay in EAE and multiple sclerosis. Journal of Autoimmunity 87, 97-108.;;Mease, P. J. et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis, The New England Journal of Medicine 370, 2295-2306 (2014).;;Poddhubnyy et al., Ann Rheum Dis 2014;0:1-7.;;Qian et al., Clin. Invest. (2012) 2(4), 417-421.;;Registry(STN)[online], [Search Date: May 13, 2019]CAS Registration No. 791058-42-9,263386-02-3.;;Sandborn WJ et al. Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease N Engl J Med 2012; 367:1519-1528.;;Silva MJ et al, Glucocorticoid Resistant Asthma: The Potential Contribution of IL-17. Biomark J. 2016, 1:6.;;Wang X, Wei Y, Xiao H, et al. A novel IL-23p19/Ebi3 (IL-39) cytokine mediates inflammation in Lupus-like mice. Eur J Immunol. 2016;46(6):1343-1350.;;Weitz JE et al., Ustekinumab: Targeting the IL-17 Pathway to Improve Outcomes in Psoriatic Arthritis. Expert Opin Biol Ther 2104 14, 515-526.;;Withers DR, et al. Transient inhibition of ROR-γt therapeutically limits intestinal inflammation by reducing TH17 cells and preserving group 3 innate lymphoid cells Nature Medicine 2016, 22, 319.;;Yang X et al. Does IL-17 Respond to the Disordered Lung Microbiome and Contribute to the Neutrophilic Phenotype in Asthma? Mediators of Inflammation. vol. 2016 (2016), Article ID 6470364, pp. 1-7.;;PCT/US2017/029531, International Search Report, dated Sep. 15, 2017.;;PCT/US2017/029531, International Preliminary Report on Patentability, dated Oct. 30, 2018.;;PCT/IB2019/055043, International Search Report, dated Sep. 30, 2019.;;PCT/IB2019/055043, Written Opinion, dated Sep. 30, 2019.;;PCT/IB2019/055045, International Search Report, dated Sep. 30, 2019.;;PCT/IB2019/055045, Written Opinion, dated Sep. 30, 2019.;;PCT/IB2019/055046, International Search Report, dated Oct. 4, 2019.;;PCT/IB2019/055046, Written Opinion, dated Oct. 4, 2019.;;PCT/IB2019/055048, International Search Report, dated Sep. 27, 2019.;;PCT/IB2019/055048, Written Opinion, dated Sep. 27, 2019.;;Angew. Chem. Int. Ed. Engl. 1982, 21, 567-583.;;Pure & Appl. Chem. 45, 1976, 11-30.;;Eastman; Oncotarget. 2017, 8, 8854-8866. DOI: 10.18632/oncotarget.12673 (Year: 2017).;;Guendisch; PLoS One 2017, 12, e0188391. DOI: 10.1371/journal.pone.0188391 (Year: 2017).;;Huh; Eur. J. Immunol. 2012. 42, 2232-2237. DOI: 10.1002/eji.201242740 (Year: 2012).;;Isono; Drug Discovery Today, 2014, 19, 1205-1211. DOI: 10.1016/j.drudis.2014.04.012 (Year: 2014).;;Kiaei; Basic Clin Neurosci. 2013, 4, 3-4. URL: http://bcn.iums.ac.ir/article-1-307-en.html (Year: 2013).;;Xue; Scientific Reports 2016, 6, Article No. 37977. DOI: 10.1038/srep37977 (Year: 2016).",ACTIVE
88,MX,A,MX 2018013143 A,110-485-653-012-559,2019-04-24,2019,MX 2018013143 A,2017-04-26,US 201662328074 P;;US 2017/0029531 W,2016-04-27,6-AMINOPYRIDIN-3-YL THIAZOLES AS MODULATORS OF RORyT.,"The present invention comprises compounds of Formula (I) wherein: A1, A2, A3, A4, A5, R1, and R2 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORyt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.",JANSSEN PHARMACEUTICA NV,STEVEN GOLDBERG;;KELLY MCCLURE;;VIRGINIA M TANIS;;ELIZABETH G FENNEMA;;ALEC D LEBSACK;;CONNOR L MARTIN;;HARIHARAN VENKATESAN;;XIAOHUA XUE;;CRAIG R WOODS,,https://lens.org/110-485-653-012-559,Patent Application,no,0,0,35,35,0,C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P25/24;;A61P29/00;;A61P3/00;;A61P37/00;;A61P37/02;;A61P43/00;;A61P29/00;;A61K31/4439;;C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07B59/002;;C07B2200/05;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,A61K31/4439;;A61P29/00;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,,0,0,,,,PENDING
89,MA,A,MA 44772 A,003-077-397-086-951,2019-03-06,2019,MA 44772 A,2017-04-26,US 201662328074 P,2016-04-27,6-AMINOPYRIDINE-3-YL THIAZOLES UTILISÉS EN TANT QUE MODULATEURS DE ROR T,,JANSSEN PHARMACEUTICA NV,FENNEMA ELIZABETH G;;GOLDBERG STEVEN;;LEBSACK ALEC D;;MARTIN CONNOR L;;MCCLURE KELLY;;TANIS VIRGINIA M;;VENKATESAN HARIHARAN;;WOODS CRAIG R;;XUE XIAOHUA,,https://lens.org/003-077-397-086-951,Unknown,no,0,0,35,35,0,C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P25/24;;A61P29/00;;A61P3/00;;A61P37/00;;A61P37/02;;A61P43/00;;A61P29/00;;A61K31/4439;;C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07B59/002;;C07B2200/05;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,A61K31/4439;;A61P29/00;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,,0,0,,,,PENDING
90,EP,A2,EP 1249917 A2,017-181-363-942-631,2002-10-16,2002,EP 02252452 A,2002-04-05,US 83316501 A,2001-04-11,Electric motor and its manufacturing method,"A method of forming a relatively low cost motor (22) provides a motor rotor (26) and/or stator (24) which has a generally solid body (30). The core of the body is formed of a less conductive material, and a more conductive material is at circumferentially spaced locations (32) on the core. In one embodiment, the conductive material and the less conductive material are coextruded. In a second embodiment, the core material is formed by powdered metal technology, and the conductive material is deposited onto the core.",MERITOR LIGHT VEHICLE TECH,FOWLER CRAIG RAE;;QUERE JEROME;;KRAMER DENNIS;;FIN ENRICO;;CHENE GEORGE;;GOLDBERG IRA;;CHIU STEPHEN;;HOPSON CHARLES;;GARRIDO PASCAL;;ROGOVIN DAN;;BARRY DAVID,"ARVINMERITOR TECHNOLOGY, LLC (2006-06-07)",https://lens.org/017-181-363-942-631,Patent Application,yes,8,2,3,3,0,H02K1/02;;H02K3/02;;H02K15/00;;H02K15/02;;H02K15/02;;H02K3/02;;H02K15/00;;H02K1/02,H02K1/02;;H02K3/02;;H02K15/00;;H02K15/02,,1,0,,,"PATENT ABSTRACTS OF JAPAN vol. 016, no. 325 (M - 1280) 15 July 1992 (1992-07-15)",DISCONTINUED
91,EP,B1,EP 3448856 B1,138-267-488-534-329,2022-01-05,2022,EP 17733165 A,2017-04-26,US 201662328074 P;;US 2017/0029531 W,2016-04-27,6-AMINOPYRIDIN-3-YL THIAZOLES AS MODULATORS OF ROR GAMMA T,,JANSSEN PHARMACEUTICA NV,GOLDBERG STEVEN;;MCCLURE KELLY;;TANIS VIRGINIA M;;FENNEMA ELIZABETH G;;LEBSACK ALEC D;;MARTIN CONNOR L;;VENKATESAN HARIHARAN;;XUE XIAOHUA;;WOODS CRAIG R,,https://lens.org/138-267-488-534-329,Granted Patent,yes,2,0,35,35,0,C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P25/24;;A61P29/00;;A61P3/00;;A61P37/00;;A61P37/02;;A61P43/00;;A61P29/00;;A61K31/4439;;C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07B59/002;;C07B2200/05;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,C07D417/04;;A61K31/4439;;A61P29/00;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,,0,0,,,,ACTIVE
92,EP,A3,EP 1249927 A3,148-474-440-604-572,2004-03-17,2004,EP 02252464 A,2002-04-05,US 83267701 A,2001-04-11,Method and system for converting single phase alternating current to multiple phase alternating current,"A system (10) for controlling multiple vehicle includes a twelve volt (12V) / forty-two volt (42V) battery power distribution system that provides direct current (14). The system converts single phase alternating current (22) to multiple phase alternating current (34) to simultaneously power multiple vehicle systems (18). A single pulse width modulation generator (20) converts the direct current from the 12V/42V battery power distribution system to alternating current. This provides one power supply path of alternating current (22), which has a first phase (28). A splitter device (24) splits the one power supply path of alternating current into three power paths (26a, 26b, 26c). A lead/lag circuit (36) is used to shift the alternating current of the second path to a second phase (30) different than the first phase of the first power supply path. A second lead/lag circuit (36) for shifts the alternating current of the third path to a third phase (32) different than the first phase or the second phase. This creates a three-phase alternating current power (34) from a single direct current source. The three-phase alternating current is used to power a plurality of induction motors (16) that operate multiple vehicle systems (18).",MERITOR LIGHT VEHICLE TECH,FOWLER CRAIG RAE;;QUERE JEROME;;KRAMER DENNIS;;FIN ENRICO;;CHENE GEORGE;;GOLDBERG IRA;;CHIU STEPHEN;;HOPSON CHARLES;;GARRIDO PASCAL;;BARRY DAVID;;ROGOVIN DAN,"ARVINMERITOR TECHNOLOGY, LLC (2006-06-07)",https://lens.org/148-474-440-604-572,Search Report,yes,3,0,4,4,0,H02M5/14;;H02M5/14,H02M5/14,,0,0,,,,DISCONTINUED
93,EP,B1,EP 1251037 B1,161-579-292-649-948,2007-01-17,2007,EP 02252691 A,2002-04-16,US 83689801 A,2001-04-17,Electrical motor system,,ARVINMERITOR TECHNOLOGY LLC,KRAMER DENNIS;;FOWLER CRAIG RAE;;QUERE JEROME;;FIN ENRICO;;CHENE GEORCE;;GOLDBERG IRA;;CHIU STEPHEN;;HOPSON CHARLES;;GARRIDO PASCAL;;BARRY DAVID;;ROGOVIN DAN,"ARVINMERITOR TECHNOLOGY, LLC (2006-06-07)",https://lens.org/161-579-292-649-948,Granted Patent,yes,7,0,7,7,0,B60R16/03;;B60R16/03;;H02M7/48;;H02M7/48;;H02J2207/20;;H02J2207/20;;H02J2310/46,B60R16/02;;B60R16/00;;H02J7/00;;H02M7/48,,0,0,,,,EXPIRED
94,PE,A1,PE 20190150 A1,189-409-370-719-361,2019-01-22,2019,PE 2018002176 A,2017-04-26,US 201662328074 P,2016-04-27,6-AMINOPIRIDIN-3-IL TIAZOLES COMO MODULADORES DE RORyT,"SE REFIERE A COMPUESTOS DERIVADOS DE 6-AMINOPIRIDIN-3-IL-TIAZOLES DE FORMULA (I) DONDE A1 Y A2 JUNTO AL NITROGENO AL QUE ESTAN UNIDOS FORMAN ANILLOS DE FORMULA (i), (ii), ENTRE OTROS; A3 ES H, ALQUILO C1-6, ENTRE OTROS; A4 ES H, CH3, ENTRE OTROS; A5 ES CICLOALQUILO C4-6, ALQUILO C1-6, ENTRE OTROS; R1 ES H, ALQUILO C1-3, CHF2, CF3, ENTRE OTROS; R2 ES H, F, CHF2, CF3, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 5-(6-(((S)-1-CICLOPROPIL-2,2,2-TRIFLUOROETIL)AMINO)-4-(DIFLUOROMETIL)PIRIDIN-3-IL)-N-((1r,3S)-3-HIDROXICICLOBUTIL)-4-((S)-2-METILPIRROLIDIN-1-CARBONIL)TIAZOL-2-CARBOXAMIDA; 5-(6-(((S)-1-CICLOPROPIL-2,2,2-TRIFLUOROETIL)AMINO)-4-(DIFLUOROMETIL)PIRIDIN-3-IL)-N-((R)-3-HIDROXI-3-METILBUTAN-2-IL)-4-((S)-2-METILPIRROLIDIN-1-CARBONIL)TIAZOL-2-CARBOXAMIDA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DEL RECEPTOR NUCLEAR RORyt SIENDO UTILES PARA EL TRATAMIENTO DE ARTRITIS SORIASICA O SORIASIS",JANSSEN PHARMACEUTICA NV,MCCLURE KELLY;;TANIS VIRGINIA M;;FENNEMA ELIZABETH G;;LEBSACK ALEC D;;MARTIN CONNOR L;;VENKATESAN HARIHARAN;;XUE XIAOHUA;;WOODS CRAIG R;;GOLDBERG STEVEN,,https://lens.org/189-409-370-719-361,Patent Application,no,0,0,35,35,0,C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P25/24;;A61P29/00;;A61P3/00;;A61P37/00;;A61P37/02;;A61P43/00;;A61P29/00;;A61K31/4439;;C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07B59/002;;C07B2200/05;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,C07D417/04;;A61K31/4439;;A61P29/00;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,,0,0,,,,PENDING
95,WO,A1,WO 2017/189661 A1,194-001-110-483-622,2017-11-02,2017,US 2017/0029531 W,2017-04-26,US 201662328074 P,2016-04-27,6-AMINOPYRIDIN-3-YL THIAZOLES AS MODULATORS OF RORγT,"The present invention comprises compounds of Formula (I) wherein: A 1 , A 2 , A 3 , A 4 , A 5 , R 1 , and R 2 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.",JANSSEN PHARMACEUTICA NV;;GOLDBERG STEVEN,GOLDBERG STEVEN;;MCCLURE KELLY;;TANIS VIRGINIA M;;FENNEMA ELIZABETH G;;LEBSACK ALEC D;;MARTIN CONNOR L;;VENKATESAN HARIHARAN;;XUE XIAOHUA;;WOODS CRAIG R,,https://lens.org/194-001-110-483-622,Patent Application,yes,2,0,35,35,4,C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P25/24;;A61P29/00;;A61P3/00;;A61P37/00;;A61P37/02;;A61P43/00;;A61P29/00;;A61K31/4439;;C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07B59/002;;C07B2200/05;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,C07D417/04;;A61K31/4439;;A61P29/00;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,,30,28,068-508-663-743-396;;020-545-279-619-551;;078-205-757-883-386;;064-399-651-040-903;;016-505-509-019-957;;014-408-820-938-035;;066-119-584-271-19X;;035-586-215-470-490;;030-303-530-555-166;;039-460-067-637-00X;;002-405-354-697-844;;078-731-621-499-369;;088-727-134-679-160;;049-931-466-317-688;;118-307-749-079-773;;006-384-711-859-473;;048-384-949-179-543;;028-713-636-085-561;;004-514-663-069-206;;011-663-094-062-663;;156-601-101-421-818;;042-371-686-427-160;;095-361-043-889-533;;000-649-437-049-891;;018-908-523-184-712;;093-144-517-257-295;;180-631-728-571-083;;077-295-491-167-117,10.1146/annurev.immunol.021908.132710;;19132915;;15485625;;10.1016/j.immuni.2004.08.018;;14984588;;10.1111/j.1440-1711.2004.01212.x;;10.1038/nri1807;;16557264;;10.1016/j.it.2005.10.003;;16290228;;16990136;;10.1016/j.cell.2006.07.035;;12610626;;10.1038/nature01355;;pmc2212798;;10.1084/jem.20041257;;15657292;;16670770;;pmc1451201;;10.1172/jci21404;;20956338;;pmc3776381;;10.4049/jimmunol.1001538;;pmc3582833;;23174342;;10.1016/j.biopsych.2012.09.021;;10.1016/j.psychres.2010.10.029;;21129782;;25904554;;pmc4468634;;10.1124/mol.114.097485;;21853531;;pmc3377107;;10.1002/emmm.201100172;;12814161;;10.1053/rmed.2003.1507;;10.1136/gut.52.1.65;;pmc1773503;;12477762;;11984595;;10.1038/nm0502-500;;10.1016/j.jaci.2012.04.024;;pmc3470466;;22677045;;pmc2852824;;10.3748/wjg.v16.i14.1753;;20380008;;10.1038/gene.2008.16;;18368064;;20875338;;20453841;;10.1038/ng.583;;21747375;;10.1038/nbt.1906;;22455412;;10.1056/nejmoa1109017;;22455413;;10.1056/nejmoa1109997;;20926833;;10.1126/scitranslmed.3001107;;10.1351/pac197645010011;;10.1002/0471220574,"KORN, T., E. BETTELLI ET AL.: ""IL-17 and Th17 Cells."", ANNU REV IMMUNOL, vol. 27, 2009, pages 485 - 517;;KOLLS, J. K.; A. LINDEN: ""Interleukin-17 family members and inflammation."", IMMUNITY, vol. 21, no. 4, 2004, pages 467 - 76, XP001205649, DOI: doi:10.1016/j.immuni.2004.08.018;;STAMP, L. K.; M. J. JAMES ET AL.: ""Interleukin-17: the missing link between T-cell accumulation and effector cell actions in rheumatoid arthritis"", IMMUNOL CELL BIOL, vol. 82, no. 1, 2004, pages 1 - 9, XP009092747, DOI: doi:10.1111/j.1440-1711.2004.01212.x;;DONG, C.: ""Diversification of T-helper-cell lineages: finding the family root of IL-17-producing cells."", NAT REV IMMUNOL, vol. 6, no. 4, 2006, pages 329 - 33;;MCKENZIE, B. S.; R. A. KASTELEIN ET AL.: ""Understanding the IL-23-IL-17 immune pathway."", TRENDS IMMUNOL, vol. 27, no. 1, 2006, pages 17 - 23, XP028058535, DOI: doi:10.1016/j.it.2005.10.003;;IVANOV, II, B. S. MCKENZIE ET AL.: ""The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells."", CELL, vol. 126, no. 6, 2006, pages 1121 - 33, XP008091324, DOI: doi:10.1016/j.cell.2006.07.035;;CUA, D. J.; J. SHERLOCK ET AL.: ""Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain."", NATURE, vol. 421, no. 6924, 2003, pages 744 - 8, XP002971969, DOI: doi:10.1038/nature01355;;LANGRISH, C. L.; Y. CHEN ET AL.: ""IL-23 drives a pathogenic T cell population that induces autoimmune inflammation."", J EXP MED, vol. 201, no. 2, 2005, pages 233 - 40, XP001206021, DOI: doi:10.1084/jem.20041257;;YEN, D.; J. CHEUNG ET AL.: ""IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6."", J CLIN INVEST, vol. 116, no. 5, 2006, pages 1310 - 6, XP009127727, DOI: doi:10.1172/JCI21404;;TONEL, G.; C. CONRAD ET AL.: ""Cutting edge: A critical functional role for IL-23 in psoriasis."", J IMMUNOL, vol. 185, no. 10, pages 5688 - 91, XP055203326, DOI: doi:10.4049/jimmunol.1001538;;BEUREL, E.; HARRINGTON, L. E.; JOPE, R. S.: ""Inflammatory T helper 17 cells promote depression-like behavior in mice."", BIOL PSYCHIATRY, vol. 73, no. 7, 2013, pages 622 - 30, XP028997121, DOI: doi:10.1016/j.biopsych.2012.09.021;;CHEN, Y. ET AL.: ""Emerging tendency towards autoimmune process in major depressive patients: A novel insight from Thl7 cells."", PSYCHIATRY RESEARCH, vol. 188, no. 2, 2011, pages 224 - 230;;CHANG, M. R. ET AL.: ""Antiobesity Effect of a Small Molecule Repressor of RORy."", MOL PHARMACOL., vol. 88, no. 1, 2015, pages 48 - 56;;MEISSBURGER, B. ET AL.: ""Adipogenesis and insulin sensitivity in obesity are regulated by retinoid-related orphan receptor gamma."", EMBO MOL MED., vol. 3, no. 11, 2011, pages 637 - 651;;BARCZYK, A.; W. PIERZCHALA ET AL.: ""Interleukin-17 in sputum correlates with airway hyperresponsiveness to methacholine."", RESPIR MED, vol. 97, no. 6, 2003, pages 726 - 33;;FUJINO, S.; A. ANDOH ET AL.: ""Increased expression of interleukin 17 in inflammatory bowel disease."", GUT, vol. 52, no. 1, 2003, pages 65 - 70;;LOCK, C.; G. HERMANS ET AL.: ""Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis."", NAT MED, vol. 8, no. 5, 2002, pages 500 - 8, XP002542559, DOI: doi:10.1038/nm0502-500;;KRUEGER, J. G.; S. FRETZIN ET AL.: ""IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis."", J ALLERGY CLIN IMMUNOL, vol. 130, no. 1, pages 145 - 154;;GAZOULI, M.; I. PACHOULA ET AL.: ""NOD2/CARD15, ATG16L1 and IL23R gene polymorphisms and childhood-onset of Crohn's disease."", WORLD J GASTROENTEROL, vol. 16, no. 14, pages 1753 - 8;;NUNEZ, C.; B. DEMA ET AL.: ""IL23R: a susceptibility locus for celiac disease and multiple sclerosis?"", GENES IMMUN, vol. 9, no. 4, 2008, pages 289 - 93;;BOWES, J.; A. BARTON: ""The genetics of psoriatic arthritis: lessons from genome-wide association studies."", DISCOV MED, vol. 10, no. 52, pages 177 - 83;;KOCHI, Y.; Y. OKADA ET AL.: ""A regulatory variant in CCR6 is associated with rheumatoid arthritis susceptibility."", NAT GENET, vol. 42, no. 6, pages 515 - 9, XP055019443, DOI: doi:10.1038/ng.583;;GARBER K.: ""Psoriasis: from bed to bench and back"", NAT BIOTECH, vol. 29, 2011, pages 563 - 566, XP055307288, DOI: doi:10.1038/nbt.1906;;PAPP, K. A.: ""Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis."", N ENGL J MED, vol. 366, no. 13, 2012, pages 1181 - 9, XP002726554, DOI: doi:10.1056/NEJMoa1109017;;LEONARDI, C.; R. MATHESON ET AL.: ""Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis."", N ENGL J MED, vol. 366, no. 13, pages 1190 - 9, XP002681513, DOI: doi:10.1056/NEJMoa1109997;;HUEBER, W.; PATEL, D.D.; DRYJA, T.; WRIGHT, A.M.; KOROLEVA, I.; BRUIN, G.; ANTONI, C.; DRAELOS, Z.; GOLD, M.H.; DUREZ, P.: ""Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis"", SCI TRANSL MED, vol. 2, 2010, pages 5272;;""Design of Prodrugs"", 1985, ELSEVIER;;PURE & APPL. CHEM., vol. 45, 1976, pages 11 - 30;;""Protective Groups in Organic Chemistry"", 1973, PLENUM PRESS;;T.W. GREENE; P.G.M. WUTS: ""Protective Groups in Organic Synthesis"", 1991, JOHN WILEY & SONS",PENDING
96,EP,A2,EP 1251037 A2,080-528-152-774-193,2002-10-23,2002,EP 02252691 A,2002-04-16,US 83689801 A,2001-04-17,Electrical motor system,"A plurality of motors (14, 16, 18) for use in driving accessories (15, 17, 19) on a vehicle, are each powered by three-phase current. A single controller (12) controls the supply three-phase current to the plurality of motors. In another aspect of the invention, pseudothree-phase current is created from a direct current voltage source (42). A chopping circuit (40) chops the voltage into a plurality of pulses, and a phase shift circuit (64) then creates phase-shifted power signals from those pulses. The present invention thus enables the use of three-phase alternating current motors on a vehicle to drive accessories. This reduces the cost and size of the required motors.",MERITOR LIGHT VEHICLE TECH,KRAMER DENNIS;;FOWLER CRAIG RAE;;QUERE JEROME;;FIN ENRICO;;CHENE GEORCE;;GOLDBERG IRA;;CHIU STEPHEN;;HOPSON CHARLES;;GARRIDO PASCAL;;BARRY DAVID;;ROGOVIN DAN,"ARVINMERITOR TECHNOLOGY, LLC (2006-06-07)",https://lens.org/080-528-152-774-193,Patent Application,yes,0,1,7,7,0,B60R16/03;;B60R16/03;;H02M7/48;;H02M7/48;;H02J2207/20;;H02J2207/20;;H02J2310/46,B60R16/02;;H02J7/00;;H02M7/48,,0,0,,,,EXPIRED
97,TW,A,TW 201803869 A,138-916-714-254-294,2018-02-01,2018,TW 106113710 A,2017-04-25,US 201662328074 P,2016-04-27,6-aminopyridin-3-yl thiazoles as modulators of ROR[gamma]t,"The present invention comprises compounds of Formula I. wherein: A1, A2, A3, A4, A5, R1, and R2 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR[gamma]t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.",JANSSEN PHARMACEUTICA NV,GOLDBERG STEVEN;;MCCLURE KELLY;;TANIS VIRGINIA M;;FENNEMA ELIZABETH G;;LEBSACK ALEC D;;MARTIN CONNOR L;;VENKATESAN HARIHARAN;;XUE XIAOHUA;;WOODS CRAIG R,,https://lens.org/138-916-714-254-294,Patent of Addition,no,0,0,35,35,0,C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P25/24;;A61P29/00;;A61P3/00;;A61P37/00;;A61P37/02;;A61P43/00;;A61P29/00;;A61K31/4439;;C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07B59/002;;C07B2200/05;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,C07D417/14;;A61K31/4439;;A61K31/4545;;A61K31/5377;;A61K31/5383;;A61K31/541;;A61P29/00;;A61P37/02;;C07B59/00;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,,0,0,,,,PENDING
98,AU,A1,AU 2017/255525 A1,006-738-882-421-826,2018-10-25,2018,AU 2017/255525 A,2017-04-26,US 201662328074 P;;US 2017/0029531 W,2016-04-27,6-aminopyridin-3-yl thiazoles as modulators of rorgammat,The present invention comprises compounds of Formula (I) wherein: A,JANSSEN PHARMACEUTICA NV,MCCLURE KELLY;;TANIS VIRGINIA M;;FENNEMA ELIZABETH G;;LEBSACK ALEC D;;MARTIN CONNOR L;;VENKATESAN HARIHARAN;;XUE XIAOHUA;;WOODS CRAIG R;;GOLDBERG STEVEN,,https://lens.org/006-738-882-421-826,Patent Application,no,0,0,35,35,0,C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P25/24;;A61P29/00;;A61P3/00;;A61P37/00;;A61P37/02;;A61P43/00;;A61P29/00;;A61K31/4439;;C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07B59/002;;C07B2200/05;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,C07D417/04;;A61K31/4439;;A61P29/00;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,,0,0,,,,DISCONTINUED
99,EP,A3,EP 1249917 A3,047-025-832-814-848,2004-06-16,2004,EP 02252452 A,2002-04-05,US 83316501 A,2001-04-11,Electric motor and its manufacturing method,"A method of forming a relatively low cost motor (22) provides a motor rotor (26) and/or stator (24) which has a generally solid body (30). The core of the body is formed of a less conductive material, and a more conductive material is at circumferentially spaced locations (32) on the core. In one embodiment, the conductive material and the less conductive material are coextruded. In a second embodiment, the core material is formed by powdered metal technology, and the conductive material is deposited onto the core.",MERITOR LIGHT VEHICLE TECH,FOWLER CRAIG RAE;;QUERE JEROME;;KRAMER DENNIS;;FIN ENRICO;;CHENE GEORGE;;GOLDBERG IRA;;CHIU STEPHEN;;HOPSON CHARLES;;GARRIDO PASCAL;;ROGOVIN DAN;;BARRY DAVID,"ARVINMERITOR TECHNOLOGY, LLC (2006-06-07)",https://lens.org/047-025-832-814-848,Search Report,yes,5,0,3,3,0,H02K1/02;;H02K3/02;;H02K15/00;;H02K15/02;;H02K15/02;;H02K3/02;;H02K15/00;;H02K1/02,H02K1/02;;H02K3/02;;H02K15/00;;H02K15/02,,2,0,,,"PATENT ABSTRACTS OF JAPAN vol. 010, no. 027 (E - 378) 4 February 1986 (1986-02-04);;PATENT ABSTRACTS OF JAPAN vol. 010, no. 259 (E - 434) 4 September 1986 (1986-09-04)",DISCONTINUED
100,US,A1,US 2021/0221804 A1,045-697-227-492-931,2021-07-22,2021,US 202117182363 A,2021-02-23,US 202117182363 A;;US 201715497565 A;;US 201662328074 P,2016-04-27,6-AMINOPYRIDIN-3-YL THIAZOLES AS MODULATORS OF RORyT,"The present invention comprises compounds of Formula I. wherein: A 1 , A 2 , A 3 , A 4 , A 5 , R 1 , and R 2 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.",JANSSEN PHARMACEUTICA NV,GOLDBERG STEVEN;;MCCLURE KELLY;;TANIS VIRGINIA M;;FENNEMA ELIZABETH G;;LEBSACK ALEC D;;MARTIN CONNOR L;;VENKATESAN HARIHARAN;;XUE XIAOHUA;;WOODS CRAIG R,,https://lens.org/045-697-227-492-931,Patent Application,yes,0,0,35,35,4,C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P25/24;;A61P29/00;;A61P3/00;;A61P37/00;;A61P37/02;;A61P43/00;;A61P29/00;;A61K31/4439;;C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07B59/002;;C07B2200/05;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,C07D417/14;;C07B59/00;;C07D417/04;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,,0,0,,,,PENDING
101,KR,A,KR 20180135962 A,138-531-002-736-212,2018-12-21,2018,KR 20187033945 A,2017-04-26,US 201662328074 P;;US 2017/0029531 W,2016-04-27,RORγt 조절제로서의 6-아미노피리딘-3-일 티아졸,"본 발명은 화학식 (I)의 화합물을 포함한다.(I) 상기 식에서, A, A, A, A, A, R및 R는 본 명세서에 정의된 바와 같다. 본 발명은 또한 류머티스성 관절염 또는 건선인 증후군, 장애 또는 질환을 치료하거나 개선시키는 방법을 포함한다. 본 발명은 또한 적어도 하나의 화학식 I의 화합물의 치료적 유효량을 투여함으로써 포유동물에서 RORγt 활성을 조절하는 방법을 포함한다.",JANSSEN PHARMACEUTICA NV,MCCLURE KELLY;;TANIS VIRGINIA M;;FENNEMA ELIZABETH G;;LEBSACK ALEC D;;MARTIN CONNOR L;;VENKATESAN HARIHARAN;;XUE XIAOHUA;;WOODS CRAIG R;;GOLDBERG STEVEN,,https://lens.org/138-531-002-736-212,Patent Application,no,0,0,35,35,8,C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P25/24;;A61P29/00;;A61P3/00;;A61P37/00;;A61P37/02;;A61P43/00;;A61P29/00;;A61K31/4439;;C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07B59/002;;C07B2200/05;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,C07D417/04;;A61K31/4439;;A61P29/00;;C07B59/00;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,,0,0,,,,DISCONTINUED
102,ES,T3,ES 2906258 T3,046-202-463-776-740,2022-04-13,2022,ES 17733165 T,2017-04-26,US 201662328074 P;;US 2017/0029531 W,2016-04-27,6-aminopiridin-3-ilo tiazoles como moduladores de ROR gamma t,"Un compuesto de Fórmula I **(Ver fórmula)** en el que R1 es H, -C(1-3)alquilo, -CHF2, -CF3, -CN, -OCH3, -OCH2CH3, ciclopropilo, OCF3, o OCHF2; R2 es H, F, -CHF2, -CF3, -CN, -OCH3, -OCHF2, o OCF3; con la condición de que R2 no sea H si R1 es H; A1 y A2 se toman junto con su nitrógeno unido para formar un anillo seleccionado del grupo que consiste de **(Ver fórmula)** A3 es H, -C(1-6)alquilo, **(Ver fórmula)** -SO2CH(CH3)2, -SO2CH3, **(Ver fórmula)** o **(Ver fórmula)** en el que dicho -alquilo C(1-6)está opcionalmente sustituido con un grupo -NH2, uno o dos grupos -OH, y puede estar adicionalmente sustituido con hasta seis átomos de flúor; A4 es -H, o -CH3; o A3 y A4 pueden tomarse junto con su nitrógeno unido para formar un anillo seleccionado del grupo que consiste en **(Ver fórmula)** A5 es -C(4-6)cicloalquilo, -C(1-6)alquilo, **(Ver fórmula)** en el que dicho -C(1-6)alquilo y -C(4-6)cicloalquilo están opcionalmente sustituidos con hasta tres átomos de flúor; y dicho -C(1-6)alquilo está independientemente opcionalmente sustituido con un ciclobutilo, o hasta dos grupos ciclopropilo; y sales farmacéuticamente aceptables de los mismos.",JANSSEN PHARMACEUTICA NV,GOLDBERG STEVEN;;MCCLURE KELLY;;TANIS VIRGINIA M;;FENNEMA ELIZABETH G;;LEBSACK ALEC D;;MARTIN CONNOR L;;VENKATESAN HARIHARAN;;XUE XIAOHUA;;WOODS CRAIG R,,https://lens.org/046-202-463-776-740,Granted Patent,no,0,0,35,35,0,C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P25/24;;A61P29/00;;A61P3/00;;A61P37/00;;A61P37/02;;A61P43/00;;A61P29/00;;A61K31/4439;;C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07B59/002;;C07B2200/05;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,C07D417/04;;A61K31/4439;;A61P29/00;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,,0,0,,,,ACTIVE
103,PH,A1,PH 12018502209 A1,161-818-613-473-169,2019-10-28,2019,PH 12018502209 A,2018-10-16,US 201662328074 P;;US 2017/0029531 W,2016-04-27,6-AMINOPYRIDIN - 3 - YL THIAZOLES AS MODULATORS OF ROR GAMMA T,"The present invention comprises compounds of Formula (I) wherein: A1, A2, A3, A4, A5, R1, and R2 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.",JANSSEN PHARMACEUTICA NV,MCCLURE KELLY;;TANIS VIRGINIA M;;FENNEMA ELIZABETH G;;LEBSACK ALEC D;;MARTIN CONNOR L;;VENKATESAN HARIHARAN;;XUE XIAOHUA;;WOODS CRAIG R;;GOLDBERG STEVEN,,https://lens.org/161-818-613-473-169,Patent Application,no,0,0,35,35,0,C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P25/24;;A61P29/00;;A61P3/00;;A61P37/00;;A61P37/02;;A61P43/00;;A61P29/00;;A61K31/4439;;C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07B59/002;;C07B2200/05;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,A61K31/4439;;A61P29/00;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,,0,0,,,,PENDING
104,SV,A,SV 2018005772 A,078-742-213-492-962,2019-03-28,2019,SV 2018005772 A,2018-10-26,US 201662328074 P,2016-04-27,6-AMINOPIRIDIN-3-IL TIAZOLES COMO MODULADORES DE RORYT,"LA PRESENTE INVENCIÓN COMPRENDE COMPUESTOS DE LA FÓRMULA (I) (VER FÓRMULA), EN DONDE: A1, A2, A3, A4, A5, R1 Y R2 SE DEFINEN EN LA ESPECIFICACIÓN. LA INVENCIÓN COMPRENDE, ADEMÁS, UN MÉTODO PARA TRATAR O MEJORAR UN SÍNDROME, TRANSTORNO O ENFERMEDAD EN DONDE EL SÍNDROME, TRANSTORNO O ENFERMEDAD SON ARTRITIS REUMATOIDE O SORIASIS. LA INVENCIÓN COMPRENDE, ADEMÁS, UN MÉTODO PARA MODULAR LA ACTIVIDAD DE RORYT EN UN MAMIFERO POR MEDIO DE LA ADMINISTRACIÓN DE UNA CANTIDAD TERAPÉUTICAMENTE EFICAZ DE AL MENOS UN COMPUESTO DE LA FÓRMULA I.",JANSSEN PHARMACEUTICA NV,GOLDBERG STEVEN;;MCCLURE KELLY;;TANIS VIRGINIA M;;FENNEMA ELIZABETH G;;LEBSACK ALEC D;;MARTIN CONNOR L;;VENKATESAN HARIHARAN;;XUE XIAOHUA;;WOODS CRAIG R,,https://lens.org/078-742-213-492-962,Patent Application,no,0,0,35,35,0,C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P25/24;;A61P29/00;;A61P3/00;;A61P37/00;;A61P37/02;;A61P43/00;;A61P29/00;;A61K31/4439;;C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07B59/002;;C07B2200/05;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,A61K31/4439;;A61P29/00;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,,0,0,,,,PENDING
105,CA,A1,CA 3022318 A1,102-552-571-729-06X,2017-11-02,2017,CA 3022318 A,2017-04-26,US 201662328074 P;;US 2017/0029531 W,2016-04-27,6-AMINOPYRIDIN-3-YL THIAZOLES AS MODULATORS OF ROR.GAMMA.T,"The present invention comprises compounds of Formula (I) wherein: A1, A2, A3, A4, A5, R1, and R2 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.",JANSSEN PHARMACEUTICA NV,GOLDBERG STEVEN;;MCCLURE KELLY;;TANIS VIRGINIA M;;FENNEMA ELIZABETH G;;LEBSACK ALEC D;;MARTIN CONNOR L;;VENKATESAN HARIHARAN;;XUE XIAOHUA;;WOODS CRAIG R,,https://lens.org/102-552-571-729-06X,Patent Application,no,0,0,35,35,4,C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P25/24;;A61P29/00;;A61P3/00;;A61P37/00;;A61P37/02;;A61P43/00;;A61P29/00;;A61K31/4439;;C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07B59/002;;C07B2200/05;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,C07D417/04;;A61K31/4439;;A61P29/00;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,,0,0,,,,PENDING
106,CN,A,CN 109415358 A,153-952-414-041-491,2019-03-01,2019,CN 201780040332 A,2017-04-26,US 201662328074 P;;US 2017/0029531 W,2016-04-27,6-AMINOPYRIDIN-3-YL THIAZOLES AS MODULATORS OF ROR gamma T,"The present invention comprises compounds of Formula (I) wherein: A1, A2, A3, A4, A5, R1, and R2 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR gamma t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.",JANSSEN PHARMACEUTICA NV,GOLDBERG STEVEN;;MCCLURE KELLY;;TANIS VIRGINIA M;;FENNEMA ELIZABETH G;;LEBSACK ALEC D;;MARTIN CONNOR L;;VENKATESAN HARIHARAN;;XUE XIAOHUA;;WOODS CRAIG R,,https://lens.org/153-952-414-041-491,Patent Application,no,4,0,35,35,0,C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P25/24;;A61P29/00;;A61P3/00;;A61P37/00;;A61P37/02;;A61P43/00;;A61P29/00;;A61K31/4439;;C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07B59/002;;C07B2200/05;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,C07D417/04;;A61K31/4439;;A61P29/00;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,,0,0,,,,ACTIVE
107,CL,A1,CL 2018003044 A1,163-281-325-259-745,2019-02-01,2019,CL 2018003044 A,2018-10-25,US 201662328074 P,2016-04-27,6-aminopiridina-3-yl tiazoles como moduladores de ror.,"LA PRESENTE INVENCIÓN COMPRENDE COMPUESTOS DE LA FÓRMULA (1), EN DONDE: A1, A2, A3, A4, A5, R1 Y R2 SE DEFINEN EN LA ESPECIFICACIÓN. LA INVENCIÓN COMPRENDE, ADEMÁS, UN MÉTODO PARA TRATAR O MEJORAR UN SÍNDROME, TRASTORNO O ENFERMEDAD, EN DONDE EL SÍNDROME, TRASTORNO O ENFERMEDAD SON ARTRITIS REUMATOIDE O SORIASIS. LA INVENCIÓN COMPRENDE, ADEMÁS, UN MÉTODO PARA MODULAR LA ACTIVIDAD DE RORYT EN UN MAMÍFERO POR MEDIO DE LA ADMINISTRACIÓN DE UNA CANTIDAD TERAPÉUTICAMENTE EFICAZ DE AL MENOS UN COMPUESTO DE LA FÓRMULA I.",JANSSEN PHARMACEUTICA NV,VENKATESAN HARIHARAN;;XUE XIAOHUA;;MCCLURE KELLY;;TANIS VIRGINIA M;;FENNEMA ELIZABETH G;;LEBSACK ALEC D;;MARTIN CONNOR L;;WOODS CRAIG R;;GOLDBERG STEVEN,,https://lens.org/163-281-325-259-745,Patent Application,no,0,0,35,35,0,C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P25/24;;A61P29/00;;A61P3/00;;A61P37/00;;A61P37/02;;A61P43/00;;A61P29/00;;A61K31/4439;;C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07B59/002;;C07B2200/05;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,A61K31/4439;;A61P29/00;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,,0,0,,,,PENDING
108,DE,T2,DE 60217571 T2,157-051-275-775-889,2007-10-25,2007,DE 60217571 T,2002-04-16,US 83689801 A,2001-04-17,Elektrisches Motorensystem,,ARVINMERITOR TECHNOLOGY LLC,KRAMER DENNIS;;FOWLER CRAIG RAE;;QUERE JEROME;;FIN ENRICO;;CHENE GEORCE;;GOLDBERG IRA;;CHIU STEPHEN;;HOPSON CHARLES;;GARRIDO PASCAL;;BARRY DAVID;;ROGOVIN DAN,,https://lens.org/157-051-275-775-889,Granted Patent,no,0,1,7,7,0,B60R16/03;;B60R16/03;;H02M7/48;;H02M7/48;;H02J2207/20;;H02J2207/20;;H02J2310/46,B60R16/02;;B60R16/00;;H02J7/00;;H02M7/48,,0,0,,,,EXPIRED
109,EP,A2,EP 1249915 A2,078-131-847-709-104,2002-10-16,2002,EP 02252507 A,2002-04-08,US 83316401 A,2001-04-11,Vehicle closure system,"An AC motor (28) is utilized to drive a closure (36) on a vehicle. The use of the AC motor provides valuable benefits with regard to cost and size. Further, a three-phase AC motor may be utilized, and the pulses in its power supply monitored to determine an obstruction in the path of the closure. Frequency control may also be utilized to provide optimum control of the drive of the component at both startup and stop.",MERITOR LIGHT VEHICLE TECH,FOWLER CRAIG RAE;;QUERE JEROME;;KRAMER DENNIS;;FIN ENRICO;;CHENE GEORGE;;GOLDBERG IRA;;CHIU STEPHEN;;HOPSON CHARLES;;GARRIDO PASCAL;;BARRY DAVID;;ROGOVIN DAN,"ARVINMERITOR TECHNOLOGY, LLC (2006-06-07)",https://lens.org/078-131-847-709-104,Patent Application,yes,0,1,4,4,0,H02H7/0851;;E05Y2900/542;;E05Y2900/55;;E05F15/41;;H02H7/0851;;E05Y2900/542;;E05Y2900/55;;E05F15/41,E05F15/00;;H02H7/085,,0,0,,,,DISCONTINUED
110,EP,A3,EP 1251621 A3,125-153-564-156-95X,2004-06-16,2004,EP 02252697 A,2002-04-16,US 83689201 A,2001-04-17,Electric motor armature,"In the disclosed embodiment of this invention, sets of straight wire bundles (12) are molded or otherwise encased about a cylindrical rotor casing (11). The straight wire bundles lie parallel to the axis of the cylindrical rotor casing. This process is an alternative to a traditional type of electric motor armature which uses a wire that is coiled around the cylindrical rotor casing. Since the wire bundles are straight and not pulled from a single wire roll, breaking and stretching of the wire is greatly reduced. The straight wire bundles are connected at their ends using a circuit cap (14) to form a complete electrical circuit.",MERITOR LIGHT VEHICLE TECH,KRAMER DENNIS;;QUERE JEROME;;FOWLER CRAIG RAE;;FIN ENRICO;;CHENE GEORGE;;GOLDBERG IRA;;CHIU STEPHEN;;HOPSON CHARLES;;GARRIDO PASCAL;;BARRY DAVID;;ROGOVIN DAN,,https://lens.org/125-153-564-156-95X,Search Report,yes,2,0,3,3,0,H02K3/12;;H02K3/12,H02K3/12,,0,0,,,,DISCONTINUED
111,US,A1,US 2017/0313691 A1,038-365-676-161-770,2017-11-02,2017,US 201715497565 A,2017-04-26,US 201715497565 A;;US 201662328074 P,2016-04-27,6-AMINOPYRIDIN-3-YL THIAZOLES AS MODULATORS OF RORyT,"The present invention comprises compounds of Formula I. wherein: A 1 , A 2 , A 3 , A 4 , A 5 , R 1 , and R 2 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.",JANSSEN PHARMACEUTICA NV,GOLDBERG STEVEN;;MCCLURE KELLY;;TANIS VIRGINIA M;;FENNEMA ELIZABETH G;;LEBSACK ALEC D;;MARTIN CONNOR L;;VENKATESAN HARIHARAN;;XUE XIAOHUA;;WOODS CRAIG R,JANSSEN PHARMACEUTICA NV (2017-03-30),https://lens.org/038-365-676-161-770,Patent Application,yes,1,9,35,35,4,C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P25/24;;A61P29/00;;A61P3/00;;A61P37/00;;A61P37/02;;A61P43/00;;A61P29/00;;A61K31/4439;;C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07B59/002;;C07B2200/05;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,C07D417/14;;C07B59/00;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,,1,1,011-549-952-564-856,10.1016/j.tips.2014.07.006;;25131183,"Yang et al., "":Targeting Th17, etc.,"" Trends in Pharmacological Sciences, 35(10), 493-500. (Year: 2014)",ACTIVE
112,CO,A2,CO 2018011633 A2,133-750-015-294-917,2018-11-13,2018,CO 2018011633 A,2018-10-29,US 2017/0029531 W;;US 201662328074 P,2016-04-27,6-aminopiridin-3-il tiazoles como moduladores de rorγt,"RESUMEN La presente invención comprende compuestos de la Fórmula (I) en donde: A1, A2, A3, A4, A5, R1 y R2 se definen en la especificación. La invención comprende, además, un método para tratar o mejorar un síndrome, trastorno o enfermedad, en donde el síndrome, trastorno o enfermedad son artritis reumatoide o soriasis. La invención comprende, además, un método para modular la actividad de RORγt en un mamífero por medio de la administración de una cantidad terapéuticamente eficaz de al menos un compuesto de la Fórmula I.",JANSSEN PHARMACEUTICA NV,MCCLURE KELLY;;TANIS VIRGINIA M;;FENNEMA ELIZABETH G;;LEBSACK ALEC D;;MARTIN CONNOR L;;VENKATESAN HARIHARAN;;XUE XIAOHUA;;WOODS CRAIG R;;GOLDBERG STEVEN,,https://lens.org/133-750-015-294-917,Patent Application,no,0,0,35,35,0,C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P25/24;;A61P29/00;;A61P3/00;;A61P37/00;;A61P37/02;;A61P43/00;;A61P29/00;;A61K31/4439;;C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07B59/002;;C07B2200/05;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,C07D417/04;;A61K31/4439;;A61P29/00;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,,0,0,,,,PENDING
113,EP,A2,EP 1249927 A2,122-689-966-004-197,2002-10-16,2002,EP 02252464 A,2002-04-05,US 83267701 A,2001-04-11,Method and system for converting single phase alternating current to multiple phase alternating current,"A system (10) for controlling multiple vehicle includes a twelve volt (12V) / forty-two volt (42V) battery power distribution system that provides direct current (14). The system converts single phase alternating current (22) to multiple phase alternating current (34) to simultaneously power multiple vehicle systems (18). A single pulse width modulation generator (20) converts the direct current from the 12V/42V battery power distribution system to alternating current. This provides one power supply path of alternating current (22), which has a first phase (28). A splitter device (24) splits the one power supply path of alternating current into three power paths (26a, 26b, 26c). A lead/lag circuit (36) is used to shift the alternating current of the second path to a second phase (30) different than the first phase of the first power supply path. A second lead/lag circuit (36) for shifts the alternating current of the third path to a third phase (32) different than the first phase or the second phase. This creates a three-phase alternating current power (34) from a single direct current source. The three-phase alternating current is used to power a plurality of induction motors (16) that operate multiple vehicle systems (18).",MERITOR LIGHT VEHICLE TECH,FOWLER CRAIG RAE;;QUERE JEROME;;KRAMER DENNIS;;FIN ENRICO;;CHENE GEORGE;;GOLDBERG IRA;;CHIU STEPHEN;;HOPSON CHARLES;;GARRIDO PASCAL;;BARRY DAVID;;ROGOVIN DAN,"ARVINMERITOR TECHNOLOGY, LLC (2006-06-07)",https://lens.org/122-689-966-004-197,Patent Application,yes,1,0,4,4,0,H02M5/14;;H02M5/14,H02M5/14,,0,0,,,,DISCONTINUED
114,EA,B1,EA 036318 B1,164-972-242-130-451,2020-10-26,2020,EA 201892438 A,2017-04-26,US 201662328074 P;;US 2017/0029531 W,2016-04-27,6-AMINOPYRIDIN-3-YL THIAZOLES AS MODULATORS OF RORt,"The present invention comprises compounds of Formula (I)wherein A1, A2, A3, A4, A5, R1 and R2 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.",JANSSEN PHARMACEUTICA NV,GOLDBERG STEVEN;;MCCLURE KELLY;;TANIS VIRGINIA M;;FENNEMA ELIZABETH G;;LEBSACK ALEC D;;MARTIN CONNOR L;;VENKATESAN HARIHARAN;;XUE XIAOHUA;;WOODS CRAIG R,,https://lens.org/164-972-242-130-451,Granted Patent,no,2,0,35,35,0,C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P25/24;;A61P29/00;;A61P3/00;;A61P37/00;;A61P37/02;;A61P43/00;;A61P29/00;;A61K31/4439;;C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07B59/002;;C07B2200/05;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,C07D417/04;;A61K31/4439;;A61P29/00;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,,0,0,,,,ACTIVE
115,US,A1,US 2021/0198251 A1,004-067-170-959-647,2021-07-01,2021,US 202117182375 A,2021-02-23,US 202117182375 A;;US 201715497565 A;;US 201662328074 P,2016-04-27,6-AMINOPYRIDIN-3-YL THIAZOLES AS MODULATORS OF RORyT,"The present invention comprises compounds of Formula I. wherein:A 1 , A 2 , A 3 , A 4 , A 5 , R 1 , and R 2 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.",JANSSEN PHARMACEUTICA NV,GOLDBERG STEVEN;;MCCLURE KELLY;;TANIS VIRGINIA M;;FENNEMA ELIZABETH G;;LEBSACK ALEC D;;MARTIN CONNOR L;;VENKATESAN HARIHARAN;;XUE XIAOHUA;;WOODS CRAIG R,,https://lens.org/004-067-170-959-647,Patent Application,yes,0,0,35,35,4,C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P25/24;;A61P29/00;;A61P3/00;;A61P37/00;;A61P37/02;;A61P43/00;;A61P29/00;;A61K31/4439;;C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07B59/002;;C07B2200/05;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,C07D417/14;;C07B59/00;;C07D417/04;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,,0,0,,,,PENDING
116,NI,A,NI 201800109 A,160-590-641-018-812,2019-02-18,2019,NI 201800109 A,2018-10-26,US 201662328074 P,2016-04-27,TIAZOLES DE 6-AMINOPIRIDIN-3-IL COMO MODULADORES DE RORyT,"La presente invención comprende compuestos de Fórmula (I) en donde: A1, A2, A3, A4, A5, R1 y R2 se definen en la memoria descriptiva. La invención también comprende un método para tratar o mejorar un síndrome, trastorno o enfermedad, en el que el síndrome, trastorno o enfermedad es artritis reumatoide o psoriasis. La invención también comprende un método para modular la actividad de RORyt en un mamífero mediante la administración de una cantidad terapéuticamente eficaz de al menos un compuesto de Fórmula I.",JANSSEN PHARMACEUTICA NV,STEVEN GOLDBERG;;KELLY MCCLURE;;VIRGINIA M TANIS;;ELIZABETH G FENNEMA;;ALEC D LEBSACK;;CONNOR L MARTIN;;HARIHARAN VENKATESAN;;XIAOHUA XUE;;CRAIG R WOODS,,https://lens.org/160-590-641-018-812,Granted Patent,no,0,0,35,35,0,C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P25/24;;A61P29/00;;A61P3/00;;A61P37/00;;A61P37/02;;A61P43/00;;A61P29/00;;A61K31/4439;;C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07B59/002;;C07B2200/05;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,C07D417/04;;A61K31/4439;;A61P29/00;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,,0,0,,,,ACTIVE
117,EP,A3,EP 1249915 A3,159-528-583-215-97X,2005-02-02,2005,EP 02252507 A,2002-04-08,US 83316401 A,2001-04-11,Vehicle closure system,"An AC motor (28) is utilized to drive a closure (36) on a vehicle. The use of the AC motor provides valuable benefits with regard to cost and size. Further, a three-phase AC motor may be utilized, and the pulses in its power supply monitored to determine an obstruction in the path of the closure. Frequency control may also be utilized to provide optimum control of the drive of the component at both startup and stop.",MERITOR LIGHT VEHICLE TECH,FOWLER CRAIG RAE;;QUERE JEROME;;KRAMER DENNIS;;FIN ENRICO;;CHENE GEORGE;;GOLDBERG IRA;;CHIU STEPHEN;;HOPSON CHARLES;;GARRIDO PASCAL;;BARRY DAVID;;ROGOVIN DAN,"ARVINMERITOR TECHNOLOGY, LLC (2006-06-07)",https://lens.org/159-528-583-215-97X,Search Report,yes,3,0,4,4,0,H02H7/0851;;E05Y2900/542;;E05Y2900/55;;E05F15/41;;H02H7/0851;;E05Y2900/542;;E05Y2900/55;;E05F15/41,E05F15/00;;H02H7/085,,0,0,,,,DISCONTINUED
118,UY,A,UY 37213 A,185-418-059-929-576,2017-10-31,2017,UY 37213 A,2017-04-27,US 201662328074 P,2016-04-27,6-AMINOPIRIDIN-3-IL TIAZOLES COMO MODULADORES DE RORyT,"La presente invención comprende compuestos de Fórmula I. en donde: A1, A2, A3, A4, A5, R1 y R2 se definen en la especificación. La invención comprende, además, un método para tratar o mejorar un síndrome, trastorno o enfermedad, en donde el síndrome, trastorno o enfermedad son artritis reumatoide o soriasis. La invención comprende, además, un método para modular la actividad de RORy t en un mamífero al administrar una cantidad terapéuticamente eficaz de al menos un compuesto de Fórmula I.",JANSSEN PHARMACEUTICA NV,STEVEN GOLDBERG (US);;MCCLURE KELLY;;VIRGINIA M TANIS;;ELIZABETH G FENNEMA;;ALEC D LEBSACK;;CONNOR L MARTIN;;VENKATESAN HARIHARAN;;XUE XIAOHUA;;CRAIG R WOODS,,https://lens.org/185-418-059-929-576,Patent Application,no,0,0,35,35,0,C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P25/24;;A61P29/00;;A61P3/00;;A61P37/00;;A61P37/02;;A61P43/00;;A61P29/00;;A61K31/4439;;C07B59/002;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08;;C07B2200/05;;C07D417/04;;C07B59/002;;C07B2200/05;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/107;;C07D498/08,A61P11/00;;A61K31/4439;;A61K31/444;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/24;;A61P37/00;;C07D417/02;;C07D417/14;;C07D491/107;;C07D498/08,,0,0,,,,PENDING
119,EP,A1,EP 3807251 A1,017-135-591-982-187,2021-04-21,2021,EP 19758804 A,2019-06-17,US 201862686323 P;;IB 2019055045 W,2018-06-18,PHENYL AND PYRIDINYL SUBSTITUTED IMIDAZOLES AS MODULATORS OF RORYT,,JANSSEN PHARMACEUTICA NV,MARTIN CONNOR L;;FENNEMA ELIZABETH G;;KUMMER DAVID A;;NISHIMURA RACHEL T;;TANIS VIRGINIA M;;WOODS CRAIG R;;FOURIE ANNE M;;XUE XIAOHUA;;GOLDBERG STEVEN,,https://lens.org/017-135-591-982-187,Patent Application,yes,0,0,10,10,0,C07D233/66;;C07D401/04;;A61P29/00;;C07D233/90;;C07D401/04,C07D233/66;;A61K31/4178;;A61P29/00;;C07D401/04,,0,0,,,,ACTIVE
120,CA,A1,CA 3103770 A1,142-294-863-424-956,2019-12-26,2019,CA 3103770 A,2019-06-17,US 201862686323 P;;IB 2019055045 W,2018-06-18,PHENYL AND PYRIDINYL SUBSTITUTED IMIDAZOLES AS MODULATORS OF RORYT,"The present invention comprises compounds of Formula I. Formula I wherein: R1, R2, R3, R4, R5, Ra, Rb, Q1, and Q2 are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-?-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.",JANSSEN PHARMACEUTICA NV,GOLDBERG STEVEN;;MARTIN CONNOR L;;FENNEMA ELIZABETH G;;KUMMER DAVID A;;NISHIMURA RACHEL T;;TANIS VIRGINIA M;;WOODS CRAIG R;;FOURIE ANNE M;;XUE XIAOHUA,,https://lens.org/142-294-863-424-956,Patent Application,no,0,0,10,10,4,C07D233/66;;C07D401/04;;A61P29/00;;C07D233/90;;C07D401/04,C07D233/66;;A61K31/4178;;A61P29/00;;C07D401/04,,0,0,,,,PENDING
121,ES,T3,ES 2929140 T3,064-007-530-422-459,2022-11-25,2022,ES 19758804 T,2019-06-17,US 201862686323 P;;IB 2019055045 W,2018-06-18,Imidazoles sustituidos con fenilo y piridinilo como moduladores de RORgammat,"La presente invención comprende compuestos de fórmula I. Fórmula I en la que: R1, R2, R3, R4, R5, Ra, Rb, Q1 y Q2 se definen en la memoria descriptiva. La invención también comprende un método para tratar o mejorar un síndrome, trastorno o enfermedad mediada por ROR-γ-t, incluso cuando el síndrome, trastorno o enfermedad se selecciona del grupo que consiste en artritis reumatoide, artritis psoriásica y psoriasis. La invención también comprende un método para modular la actividad de RORγt en un mamífero mediante la administración de una cantidad terapéuticamente eficaz de al menos un compuesto de fórmula I. (Traducción automática con Google Translate, sin valor legal)",JANSSEN PHARMACEUTICA NV,MARTIN CONNOR L;;FENNEMA ELIZABETH G;;KUMMER DAVID A;;NISHIMURA RACHEL T;;TANIS VIRGINIA M;;WOODS CRAIG R;;FOURIE ANNE M;;XUE XIAOHUA;;GOLDBERG STEVEN,,https://lens.org/064-007-530-422-459,Granted Patent,no,0,0,10,10,0,C07D233/66;;C07D401/04;;A61P29/00;;C07D233/90;;C07D401/04,C07D233/66;;A61K31/4178;;A61P29/00;;C07D401/04,,0,0,,,,ACTIVE
122,CN,A,CN 112334450 A,164-473-182-428-443,2021-02-05,2021,CN 201980041111 A,2019-06-17,US 201862686323 P;;IB 2019055045 W,2018-06-18,PHENYL AND PYRIDINYL SUBSTITUTED IMIDAZOLES AS MODULATORS OF RORYT,"The present invention comprises compounds of Formula I. Formula I wherein: R1, R2, R3, R4, R5, Ra, Rb, Q1, and Q2 are defined in the specification. The invention also comprises a method of treating orameliorating a ROR-Gamma-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR-Gamma-t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.",JANSSEN PHARMACEUTICA NV,GOLDBERG STEVEN;;MARTIN CONNOR L;;FENNEMA ELIZABETH G;;KUMMER DAVID A;;NISHIMURA RACHEL T;;TANIS VIRGINIA M;;WOODS CRAIG R;;FOURIE ANNE M;;XUE XIAOHUA,,https://lens.org/164-473-182-428-443,Patent Application,no,6,1,10,10,0,C07D233/66;;C07D401/04;;A61P29/00;;C07D233/90;;C07D401/04,C07D233/66;;A61K31/4178;;A61P29/00;;C07D401/04,,0,0,,,,PENDING
123,US,A1,US 2022/0281823 A1,109-900-948-654-532,2022-09-08,2022,US 202217737113 A,2022-05-05,US 202217737113 A;;US 201916442864 A;;US 201862686323 P,2018-06-18,PHENYL AND PYRIDINYL SUBSTITUTED IMIDAZOLES AS MODULATORS OF RORgT,"The present invention comprises compounds of Formula I. wherein: R 1 , R 2 , R 3 , R 4 , R 5 , R a , R b , Q 1 , and Q 2 are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-γ-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.",JANSSEN PHARMACEUTICA NV,GOLDBERG STEVEN;;MARTIN CONNOR L;;FENNEMA ELIZABETH G;;KUMMER DAVID A;;NISHIMURA RACHEL T;;TANIS VIRGINIA M;;WOODS CRAIG R;;FOURIE ANNE M;;XUE XIAOHUA,,https://lens.org/109-900-948-654-532,Patent Application,yes,0,0,10,10,4,C07D233/66;;C07D401/04;;A61P29/00;;C07D233/90;;C07D401/04,C07D233/90;;C07D401/04,,0,0,,,,DISCONTINUED
124,WO,A1,WO 2019/244000 A1,126-725-086-897-143,2019-12-26,2019,IB 2019055045 W,2019-06-17,US 201862686323 P,2018-06-18,PHENYL AND PYRIDINYL SUBSTITUTED IMIDAZOLES AS MODULATORS OF RORYT,"The present invention comprises compounds of Formula I. Formula I wherein: R 1 , R 2 , R 3 , R 4 , R 5 , R a , R b , Q 1 , and Q 2 are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-ꝩ-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating RORꝩt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.",JANSSEN PHARMACEUTICA NV;;GOLDBERG STEVEN,GOLDBERG STEVEN;;MARTIN CONNOR L;;FENNEMA ELIZABETH G;;KUMMER DAVID A;;NISHIMURA RACHEL T;;TANIS VIRGINIA M;;WOODS CRAIG R;;FOURIE ANNE M;;XUE XIAOHUA,,https://lens.org/126-725-086-897-143,Patent Application,yes,3,0,10,10,4,C07D233/66;;C07D401/04;;A61P29/00;;C07D233/90;;C07D401/04,C07D233/66;;A61K31/4178;;A61P29/00;;C07D401/04,,34,31,068-508-663-743-396;;020-545-279-619-551;;078-205-757-883-386;;064-399-651-040-903;;016-505-509-019-957;;014-408-820-938-035;;066-119-584-271-19X;;035-586-215-470-490;;030-303-530-555-166;;039-460-067-637-00X;;002-405-354-697-844;;078-731-621-499-369;;088-727-134-679-160;;049-931-466-317-688;;118-307-749-079-773;;006-384-711-859-473;;048-384-949-179-543;;028-713-636-085-561;;004-514-663-069-206;;011-663-094-062-663;;156-601-101-421-818;;042-371-686-427-160;;095-361-043-889-533;;000-649-437-049-891;;018-908-523-184-712;;093-144-517-257-295;;180-631-728-571-083;;096-841-656-118-220;;077-295-491-167-117;;093-649-439-334-809;;026-128-338-578-202,10.1146/annurev.immunol.021908.132710;;19132915;;15485625;;10.1016/j.immuni.2004.08.018;;14984588;;10.1111/j.1440-1711.2004.01212.x;;10.1038/nri1807;;16557264;;10.1016/j.it.2005.10.003;;16290228;;16990136;;10.1016/j.cell.2006.07.035;;12610626;;10.1038/nature01355;;pmc2212798;;10.1084/jem.20041257;;15657292;;16670770;;pmc1451201;;10.1172/jci21404;;20956338;;pmc3776381;;10.4049/jimmunol.1001538;;pmc3582833;;23174342;;10.1016/j.biopsych.2012.09.021;;10.1016/j.psychres.2010.10.029;;21129782;;25904554;;pmc4468634;;10.1124/mol.114.097485;;21853531;;pmc3377107;;10.1002/emmm.201100172;;12814161;;10.1053/rmed.2003.1507;;10.1136/gut.52.1.65;;pmc1773503;;12477762;;11984595;;10.1038/nm0502-500;;10.1016/j.jaci.2012.04.024;;pmc3470466;;22677045;;pmc2852824;;10.3748/wjg.v16.i14.1753;;20380008;;10.1038/gene.2008.16;;18368064;;20875338;;20453841;;10.1038/ng.583;;21747375;;10.1038/nbt.1906;;22455412;;10.1056/nejmoa1109017;;22455413;;10.1056/nejmoa1109997;;20926833;;10.1126/scitranslmed.3001107;;10.1351/pac197645010011;;10.1002/anie.198205671;;10.1002/0471220574;;10.1089/108705701753364922;;10.1177/108705710100600609;;11788061;;10.1021/bi048135v;;15794662,"KORN, T.E. BETTELLI ET AL.: ""IL-17 and Thl7 Cells"", ANNU REV IMMUNOL, vol. 27, 2009, pages 485 - 517;;KOLLS, J. K.A. LINDEN: ""Interleukin-17 family members and inflammation"", IMMUNITY, vol. 21, no. 4, 2004, pages 467 - 76, XP001205649, doi:10.1016/j.immuni.2004.08.018;;STAMP, L. K.M. J. JAMES ET AL.: ""Interleukin-17: the missing link between T-cell accumulation and effector cell actions in rheumatoid arthritis"", IMMUNOL CELL BIOL, vol. 82, no. 1, 2004, pages 1 - 9, XP009092747, doi:10.1111/j.1440-1711.2004.01212.x;;DONG, C.: ""Diversification of T-helper-cell lineages: finding the family root of IL-17-producing cells"", NAT REV IMMUNOL, vol. 6, no. 4, 2006, pages 329 - 33;;MCKENZIE, B. S.R. A. KASTELEIN ET AL.: ""Understanding the IL-23-IL-17 immune pathway"", TRENDS IMMUNOL, vol. 27, no. 1, 2006, pages 17 - 23, XP028058535, doi:10.1016/j.it.2005.10.003;;IVANOV, IIB. S. MCKENZIE ET AL.: ""The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells"", CELL, vol. 126, no. 6, 2006, pages 1121 - 33, XP008091324, doi:10.1016/j.cell.2006.07.035;;CUA, D. J.J. SHERLOCK ET AL.: ""Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain"", NATURE, vol. 421, no. 6924, 2003, pages 744 - 8, XP002971969, doi:10.1038/nature01355;;LANGRISH, C. L.Y. CHEN ET AL.: ""IL-23 drives a pathogenic T cell population that induces autoimmune inflammation"", J EXP MED, vol. 201, no. 2, 2005, pages 233 - 40, XP001206021, doi:10.1084/jem.20041257;;YEN, D.J. CHEUNG ET AL.: ""IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6"", J CLIN INVEST, vol. 116, no. 5, 2006, pages 1310 - 6, XP009127727, doi:10.1172/JCI21404;;TONEL, G.C. CONRAD ET AL.: ""Cutting edge: A critical functional role for IL-23 in psoriasis"", J IMMUNOL, vol. 185, no. 10, pages 5688 - 91, XP055203326, doi:10.4049/jimmunol.1001538;;BEUREL, E.HARRINGTON, L. E.JOPE, R. S.: ""Inflammatory T helper 17 cells promote depression-like behavior in mice"", BIOL PSYCHIATRY, vol. 73, no. 7, 2013, pages 622 - 30, XP028997121, doi:10.1016/j.biopsych.2012.09.021;;CHEN, Y. ET AL.: ""Emerging tendency towards autoimmune process in major depressive patients: A novel insight from Thl7 cells"", PSYCHIATRY RESEARCH, vol. 188, no. 2, 2011, pages 224 - 230;;CHANG, M. R. ET AL.: ""Antiobesity Effect of a Small Molecule Repressor of RORy"", MOL PHARMACOL., vol. 88, no. 1, 2015, pages 48 - 56;;MEISSBURGER, B. ET AL.: ""Adipogenesis and insulin sensitivity in obesity are regulated by retinoid-related orphan receptor gamma"", EMBO MOL MED., vol. 3, no. 11, 2011, pages 637 - 651;;BARCZYK, A.W. PIERZCHALA ET AL.: ""Interleukin-17 in sputum correlates with airway hyperresponsiveness to methacholine"", RESPIR MED, vol. 97, no. 6, 2003, pages 726 - 33;;FUJINO, S.A. ANDOH ET AL.: ""Increased expression of interleukin 17 in inflammatory bowel disease"", GUT, vol. 52, no. 1, 2003, pages 65 - 70;;LOCK, C.G. HERMANS ET AL.: ""Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis"", NAT MED, vol. 8, no. 5, 2002, pages 500 - 8, XP002542559, doi:10.1038/nm0502-500;;KRUEGER, J. G.S. FRETZIN ET AL.: ""IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis"", J ALLERGY CLIN IMMUNOL, vol. 130, no. 1, pages 145 - 154;;GAZOULI, M.I. PACHOULA ET AL.: ""NOD2/CARD15, ATG16L1 and IL23R gene polymorphisms and childhood-onset of Crohn's disease"", WORLD J GASTROENTEROL, vol. 16, no. 14, pages 1753 - 8;;NUNEZ, C.B. DEMA ET AL.: ""IL23R: a susceptibility locus for celiac disease and multiple sclerosis?"", GENES IMMUN, vol. 9, no. 4, 2008, pages 289 - 93;;BOWES, J.A. BARTON: ""The genetics of psoriatic arthritis: lessons from genome-wide association studies"", DISCOV MED, vol. 10, no. 52, pages 177 - 83;;KOCHI, Y.Y. OKADA ET AL.: ""A regulatory variant in CCR6 is associated with rheumatoid arthritis susceptibility"", NAT GENET, vol. 42, no. 6, pages 515 - 9, XP055019443, doi:10.1038/ng.583;;GARBER K.: ""Psoriasis: from bed to bench and back"", NAT BIOTECH, vol. 29, 2011, pages 563 - 566, XP055307288, doi:10.1038/nbt.1906;;PAPP, K. A.: ""Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis"", N ENGL J MED, vol. 366, no. 13, 2012, pages 1181 - 9, XP002726554, doi:10.1056/NEJMoa1109017;;LEONARDI, C.R. MATHESON ET AL.: ""Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis"", N ENGL J MED, vol. 366, no. 13, pages 1190 - 9, XP002681513, doi:10.1056/NEJMoa1109997;;HUEBER, W.PATEL, D.D.DRYJA, T.WRIGHT, A.M.KOROLEVA, I.BRUIN, G.ANTONI, C.DRAELOS, Z.GOLD, M.H.DUREZ, P.: ""Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis"", SCI TRANSL MED, vol. 2, 2010, pages 5272;;""Design of Prodrugs"", 1985, ELSEVIER;;PURE & APPL. CHEM., vol. 45, 1976, pages 11 - 30;;ANGEW. CHEM. INT. ED. ENGL., vol. 21, 1982, pages 567 - 583;;""Protective Groups in Organic Chemistry"", 1973, PLENUM PRESS;;T.W. GREENEP.G.M. WUTS: ""Protective Groups in Organic Synthesis"", 1991, JOHN WILEY & SONS;;PANTOLIANO, M. W.PETRELLA, E. C.KWASNOSKI, J. D.LOBANOV, V. S.MYSLIK, J.GRAF, E.CARVER, T.ASEL, E.SPRINGER, B. A.LANE, P.: ""High-density miniaturized thermal shift assays as a general strategy for drug discovery"", J BIOMOL SCREEN, vol. 6, 2001, pages 429 - 40, XP055027496, doi:10.1177/108705710100600609;;MATULIS, D.KRANZ, J. K.SALEMME, F. R.TODD, M. J.: ""Thermodynamic stability of carbonic anhydrase: measurements of binding affinity and stoichiometry using ThermoFluor"", BIOCHEMISTRY, vol. 44, 2005, pages 5258 - 66;;MATULIS, D.KRANZ, J. K.SALEMME, F. R.TODD, M. J.: ""Thermodynamic stability of carbonic anhydrase: measurements of binding affinity and stoichiometry using ThermoFluor®"", BIOCHEMISTRY, vol. 44, 2005, pages 5258 - 66",PENDING
125,US,A1,US 2019/0382354 A1,182-247-343-596-198,2019-12-19,2019,US 201916442864 A,2019-06-17,US 201916442864 A;;US 201862686323 P,2018-06-18,PHENYL AND PYRIDINYL SUBSTITUTED IMIDAZOLES AS MODULATORS OF RORyT,"The present invention comprises compounds of Formula I. wherein: R 1 , R 2 , R 3 , R 4 , R 5 , R a , R b , Q 1 , and Q 2 are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-γ-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.",JANSSEN PHARMACEUTICA NV,GOLDBERG STEVEN;;MARTIN CONNOR L;;FENNEMA ELIZABETH G;;KUMMER DAVID A;;NISHIMURA RACHEL T;;TANIS VIRGINIA M;;WOODS CRAIG R;;FOURIE ANNE M;;XUE XIAOHUA,JANSSEN PHARMACEUTICA NV (2020-01-14),https://lens.org/182-247-343-596-198,Patent Application,yes,1,5,10,10,4,C07D233/66;;C07D401/04;;A61P29/00;;C07D233/90;;C07D401/04,C07D233/90;;C07D401/04,,0,0,,,,ACTIVE
126,US,B2,US 11691979 B2,133-463-399-575-635,2023-07-04,2023,US 202117242512 A,2021-04-28,US 202117242512 A;;US 202063017682 P,2020-04-30,Imidazopyridazines as modulators of IL-17,"The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , R 4 and R 5 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.",JANSSEN PHARMACEUTICA NV,GOLDBERG STEVEN;;WOODS CRAIG;;RHORER TIMOTHY B;;MARTIN CONNOR;;MEDUNA STEVEN P;;MCCARVER STEFAN;;VALDES ALEXANDER;;LOSKOT STEVEN;;BEHENNA DOUGLAS;;ROVIRA ALEXANDER RAYMOND;;XUE XIAOHUA,CILAG AG (2021-02-09);;JANSSEN RESEARCH & DEVELOPMENT LLC (2021-02-02);;JANSSEN PHARMACEUTICA NV (2021-07-21);;JANSSEN BIOTECH INC (2021-10-07),https://lens.org/133-463-399-575-635,Granted Patent,yes,36,1,21,21,2,A61P11/00;;C07D487/04;;A61P11/00;;C07D487/04;;C07D487/04;;A61K31/519;;A61K31/5025;;A61P29/00;;A61P17/06;;A61P19/02;;A61P11/06;;C07D487/04,C07D487/04,,67,64,025-952-159-780-367;;058-789-884-920-166;;010-579-552-237-152;;105-951-486-462-687;;027-089-613-263-553;;114-680-606-910-881;;000-741-398-771-460;;025-108-977-939-014;;034-596-672-073-434;;009-864-444-828-040;;061-479-402-388-686;;191-412-303-262-33X;;008-703-631-616-103;;147-839-336-026-699;;021-966-133-884-768;;017-998-842-042-637;;149-506-609-878-449;;042-913-374-585-50X;;054-802-024-202-015;;008-027-654-197-334;;136-423-172-061-579;;055-333-219-420-597;;012-297-050-482-286;;023-332-188-728-162;;068-332-664-903-404;;021-252-678-469-447;;087-285-135-148-968;;003-280-341-006-389;;038-941-857-044-672;;030-484-724-366-406;;023-034-514-079-124;;048-384-949-179-543;;041-043-878-985-539;;020-676-452-752-488;;007-448-039-571-717;;073-818-014-761-580;;033-396-476-290-463;;084-764-362-530-285;;037-994-008-331-813;;014-780-366-494-964;;048-539-201-653-261;;000-478-646-057-608;;034-017-376-658-324;;034-225-124-078-880;;014-416-216-201-301;;017-862-476-027-388;;004-860-868-419-945;;013-724-187-099-739;;048-496-134-706-820;;078-205-757-883-386;;042-652-742-080-407;;017-399-513-974-156;;009-483-825-408-761;;088-960-339-875-350;;104-840-740-454-175;;053-984-061-730-021;;143-102-097-264-216;;000-339-990-213-470;;048-343-961-635-600;;020-760-468-731-878;;094-824-941-012-161;;029-486-145-073-303;;047-632-501-021-733;;002-124-596-251-49X,pmc4346500;;10.1038/nrrheum.2014.198;;25422000;;28254169;;10.1016/j.it.2017.01.006;;pmc5411326;;pmc3218910;;10.1186/ar3370;;21689402;;29945918;;10.1136/annrheumdis-2018-213328;;pmc6104676;;10.3410/f.733519001.793552052;;10.1007/s12016-018-8702-3;;pmc6244934;;30109481;;10.3389/fimmu.2017.01835;;pmc5760512;;29379497;;30219389;;10.1016/j.jaut.2018.09.003;;10.1067/mai.2003.1557;;12789232;;10.1007/s10875-009-9365-x;;20107878;;pmc3068165;;21479174;;10.1371/journal.pone.0018139;;10.1172/jci121087;;pmc6307967;;30383540;;10.15227/orgsyn.036.0016;;30225992;;10.1002/art.40728;;10.1016/j.ophtha.2012.09.040;;23290985;;21920821;;10.1016/j.clim.2011.08.005;;30233389;;10.3389/fphys.2018.01183;;pmc6134017;;pmc4470702;;10.1111/pcmr.12284;;24935676;;10.1016/j.clim.2011.01.014;;21334264;;19575028;;pmc2821718;;10.1038/nri2586;;27142710;;10.1007/s00415-016-8128-x;;28887948;;10.1016/j.jaci.2017.07.004;;pmc5600287;;25288779;;10.1093/rheumatology/keu382;;23957503;;pmc5569243;;10.3109/09273948.2013.815786;;10.1111/bjd.14075;;26282467;;10.1111/exd.13112;;27304428;;pmc5502835;;18432274;;10.1038/jid.2008.111;;30874446;;10.1080/1744666x.2019.1593141;;10.1016/j.ajo.2011.01.031;;21570674;;pmc4227922;;10.1038/jid.2014.263;;24945093;;22207110;;pmc3560674;;10.12659/msm.882204;;25638011;;10.1016/j.ophtha.2014.12.033;;11984595;;10.1038/nm0502-500;;10.1007/s10067-010-1510-7;;20563617;;10335518;;10.1191/135245899678847275;;10.1177/135245859900500206;;10.5152/eurjrheum.2019.19057;;31364979;;pmc6668637;;10.1136/annrheumdis-2019-215386;;pmc6937408;;10.3410/f.736683688.793565708;;31563894;;24470327;;10.1002/art.38376;;pmc4158887;;11544464;;10.1067/mai.2001.117929;;10.1016/j.jid.2017.05.033;;28652108;;28833973;;10.1111/dth.12527;;10.1007/s40744-018-0106-6;;29605841;;pmc5935619;;10.1055/s-1979-28898;;26293646;;10.1038/leu.2015.228;;pmc4740263;;30801662;;10.1111/bjd.17822;;30693283;;10.3389/fmed.2018.00364;;pmc6339915;;21641076;;10.1016/j.jaad.2010.07.010;;10.1016/j.jneuroim.2019.04.011;;31034962;;10.1002/art.24568;;19479869;;26804758;;10.1016/j.autrev.2016.01.004;;pmc4769658;;14984588;;10.1111/j.1440-1711.2004.01212.x;;10.2217/cer-2018-0141;;30806520;;pmc6128497;;29617527;;10.1001/jamadermatol.2018.0141;;pmc2189615;;18156204;;10.2353/ajpath.2008.070690;;10.1016/s0140-6736(18)32167-6;;30249507;;10.1016/j.rmed.2011.05.017;;21763119;;23472149;;pmc3589375;;10.1371/journal.pone.0058161;;10.1016/j.jbspin.2006.11.005;;17369068;;10.4049/jimmunol.1701213;;29298833;;18373953;;10.1016/j.clim.2008.01.019;;11035433;;10.1191/096120300678828703;;21243492;;10.1007/s00296-010-1771-0;;22485125;;10.1371/journal.pone.0031000;;pmc3317658;;10.1080/02713680902741696;;19373578;;19347604;;10.1007/s11033-009-9533-3,"Adamopoulos et al, Alternative pathways of osteoclastogenesis in inflammatory arthritis, Nat. Rev. Rheumatol., 11, pp. 189-194, 2015.;;Amatya et al, IL-17 Signaling: The Yin and the Yang, Trends Immunol. 38, pp. 310-322, May 2017.;;Appel et al, Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response, Arthritis Res. Ther., 13(3), R95, Jun. 2011.;;Baeten et al, Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study, Ann. Rheum. Dis., 77(9), pp. 1295-1302, Jun. 2018.;;Blauvelt et al, The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis, Clin. Rev. Allergy Immunol., 55(3), pp. 379-390, 2018.;;Camargo et al, Effects of Anti-IL-17 on Inflammation, Remodeling, and Oxidative Stress in an Experimental Model of Asthma Exacerbated by LPS, Front. Immunol., 8, p. 1835, 2018.;;Chakievska et al, IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid, J. Autoimmun., 96, pp. 104-112, 2019.;;Chakir et al, Airway remodeling-associated mediators in moderate to severe asthma: effect of steroids on TGF-beta, IL-11, IL-17, and type I and type III collagen expression, J. Allergy Clin. Immunol., 111(6) pp. 1293-1298, 2003.;;Chen et al, Plasma IL-17A is increased in new-onset SLE patients and associated with disease activity, J. Clin. Immunol., 30(2), pp. 221-225, 2010.;;Chen et al, The Effects of Th17 Cytokines on the Inflammatory Mediator Production and Barrier Function of ARPE-19 Cells, PLoS One, 6, e18139, Mar. 2011.;;Christenson et al, An airway epithelial IL-17A response signature identifies a steroid-unresponsive COPD patient subgroup, J. Clin. Invest., 129(1), pp. 169-181, 2019.;;De Boer et al, Diazomethane, Org. Synth., 36, pp. 16-19, 1956.;;Deodhar et al, Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis, Arthritis Rheumatol., 71(2), pp. 258-270, Feb. 2019.;;Dick et al, Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials, Ophthalmology, 120(4), pp. 777-787, 2013.;;Dolff et al, Disturbed Th1, Th2, Th17 and T(reg) balance in patients with systemic lupus erythematosus, Clin. Immunol., 141(2), pp. 197-204, 2011.;;Dos Santos et al, Effect of Anti-IL17 Antibody Treatment Alone and in Combination With Rho-Kinase Inhibitor in a Murine Model of Asthma, Front. Physiol., 9, p. 1183, 2018.;;Eby et al, Immune Responses in A Mouse Model of Vitiligo with Spontaneous Epidermal De- and Repigmentation, Pigment Cell Melanoma Res., 27(6), pp. 1075-1085, 2014.;;El-Asrar et al, Cytokine profiles in aqueous humor of patients with different clinical entities of endogenous uveitis, Clin. Immunol., 139(2), pp. 177-184, 2011.;;Gaffen, Structure and signaling in the IL-17 receptor family, Nat. Rev., Immunol., 9, pp. 556-567, 2009.;;Havrdova et al, Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study, J. Neurol., 263, pp. 1287-1295, 2016.;;Hawkes et al., Psoriasis Pathogenesis and the Development of Novel, Targeted Immune Therapies. J Allergy Clin. Immunol., 140(3), pp. 645-653, 2017.;;Jansen et al, IL-17-producing CD4+ T cells are increased in early, active axial spondyloarthritis including patients without imaging abnormalities, Rheumatology (Oxford), 54(4), pp. 728-735, 2014.;;Jawad et al, Elevated Serum Levels of Interleukin-17A in Uveitis Patients, Ocul. Immunol. Inflamm., 21(6), pp. 434-439, 2013.;;Kelly et al, Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa, Br. J. Dermatol., 173(6), pp. 1431-1439, 2015.;;Khattri et al, Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis, Exp. Dermatol., 26(1), pp. 28-35, 2016.;;Koga et al, Possible pathogenic role of Th17 cells for atopic dermatitis, J. Invest. Dermatol., 128, pp. 2625-2630, 2008.;;Koga et al, The role of IL-17 in systemic lupus erythematosus and its potential as a therapeutic target, Expert Rev. Clin. Immunol., 15(6), pp. 629-637, Jun. 2019.;;Kuiper et al, Intraocular interleukin-17 and proinflammatory cytokines in HLA-A29-associated birdshot chorioretinopathy, Am. J. Ophthalmol., 152(2), pp. 177-182, 2011.;;Le Jan et al, Innate immune cell-produced IL-17 sustains inflammation in bullous pemphigoid, J. Invest. Dermatol., 134(12), pp. 2908-2917, 2014.;;Lemancewicz et al, The role of Interleukin-17A and Interleukin-17E in multiple myeloma patients, Med. Sci. Monit., 18(1), pp. BR54-BR59, 2012.;;Letko et al, Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy, Ophthalmology, 122(5), pp. 939-948, 2015.;;Lock et al, Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis, Nat. Med. 8, pp. 500-508, May 2002.;;Ma et al, The imbalance between regulatory and IL-17-secreting CD4+ T cells in lupus patients, Clin. Rheumatol., 29(11), pp. 1251-1258, 2010.;;Matusevicius et al, Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis, Mult. Scler., 5, pp. 101-104, 1999.;;Mease et al, Comparative effectiveness of secukinumab and etanercept in biologic-naïve patients with psoriatic arthritis assessed by matching-adjusted indirect comparison, Eur. J. Rheumatol., 6(3), pp. 113-121, 2019.;;Mease et al, A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial, Ann. Rheum. Diss., 79, pp. 123-131, 2020.;;Menon et al, Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression, Arthritis Rheumatol., 66, pp. 1272-1281, May 2014.;;Molet et al, IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines, J. Allergy Clin. Immunol., 108(3), pp. 430-438, 2001.;;Moran et al, Hidradenitis Suppurativa Is Characterized by Dysregulation of the Th17:Treg Cell Axis, Which Is Corrected by Anti-TNF Therapy, J. Invest. Dermatol., 137(11), pp. 2389-2395, 2017.;;Mugheddu et al, Successful ustekinumab treatment of noninfectious uveitis and concomitant severe psoriatic arthritis and plaque psoriasis, Dermatol. Ther. 30(5), e12527, 2017.;;Nash et al, Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison, Rheumatol. Ther., 5(1) pp. 99-122, 2018.;;Mayo Clinic, Ixekizumab in the Treatment of Bullous Pemphigoid, ClinicalTrials.gov. http://clinicaltrials.gov/show/NCT03099538, [Last Accessed on Jul. 2, 2021]. Apr. 2017.;;Pollet et al, Tetronic Acids and Derivatives; Part VI. A Convenient Synthesis of New 4-Oxo-2-phenyl-2H-4,6-dihydrofuro[3,4-d]triazole and 4-Oxo-4,6-dihydrofuro[3,4-c]furazan Systems, Synthesis, 12, pp. 977-979, 1979.;;Prabhala et al, Targeting IL-17A in multiple myeloma: a potential novel therapeutic approach in myeloma, Leukemia, 30(2), 379-389, 2016.;;Prussick et al, Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa, Br. J. Dermatol., 181(3), pp. 609-611, 2019.;;Robert et al, IL-17 in Rheumatoid Arthritis and Precision Medicine: From Synovitis Expression to Circulating Bioactive Levels, Front. Med., 5, p. 364, Jan. 2019.;;Schlapbach et al, Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa, J. Am. Acad. Dermatol., 65(4), pp. 790-798, Oct. 2011.;;Setiadi et al, IL-17A is associated with the breakdown of the blood-brain barrier in relapsing-remitting multiple sclerosis, J. Neuroimmunol., 332, pp. 147-154, 2019.;;Shen et al, Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis, Arthritis Rheum., 60(6), pp. 1647-1656, Jun. 2009.;;Singh et al, The role of IL-17 in vitiligo: A review, Autoimmun. Rev., 15(4), pp. 397-404, 2016.;;Stamp et al, Interleukin-17: the missing link between T-cell accumulation and effector cell actions in rheumatoid arthritis?, Immunol. Cell Biol., 82(1), pp. 1-9, 2004.;;Strand et al, Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naive patients with psoriatic arthritis, J. Comp. Eff. Res., 8(7) pp. 497-510, 2019.;;Thomi et al, Association of Hidradenitis Suppurativa With T Helper 1/T Helper 17 Phenotypes: A Semantic Map Analysis, JAMA Dermatol., 154(5), pp. 592-595, May 2018.;;Tzartos et al, Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis, Am. J. Pathol., 172, pp. 146-155, 2008.;;Van Vollenhoven et al, Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study, Lancet, 392, pp. 1330-1339, 2018.;;Vargas-Rojas et al, Increase of Th17 cells in peripheral blood of patients with chronic obstructive pulmonary disease, Respir. Med., 105(11), pp. 1648-1654, 2011.;;Wen et al, Interleukin-17 Expression Positively Correlates with Disease Severity of Lupus Nephritis by Increasing Anti-Double-Stranded DNA Antibody Production in a Lupus Model Induced by Activated Lymphocyte Derived DNA, PLoS One., 8, e58161, 2013.;;Wendling et al, Serum IL-17, BMP-7, and bone turnover markers in patients with ankylosing spondylitis, Joint Bone Spine. 74, pp. 304-305, 2007.;;Willing et al, Production of IL-17 by MAIT Cells Is Increased in Multiple Sclerosis and Is Associated with IL-7 Receptor Expression, J. Immunol., 200(3), pp. 974-982, 2018.;;Wong et al, Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity, Clin. Immunol., 127(3), pp. 385-393, 2008.;;Wong et al, Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus, Lupus, 9(8), pp. 589-593, 2000.;;Xing et al, Elevated Th17 cells are accompanied by FoxP3+ Treg cells decrease in patients with lupus nephritis, Rheumatol. Int., 32(4), pp. 949-958, 2012.;;Zhang et al, Increased Frequencies of Th22 Cells as well as Th17 Cells in the Peripheral Blood of Patients with Ankylosing Spondylitis and Rheumatoid Arthritis, PLoS One, 7(4), e31000, 2012.;;Zhang et al, Suppression of experimental autoimmune uveoretinitis by Anti-IL-17 antibody, Curr. Eye Res. 34(4), pp. 297-303, Apr. 2009.;;Zhao et al, Increased serum interleukin 17 in patients with systemic lupus erythematosus, Mol. Biol. Rep., 37(1), pp. 81-85, 2010.;;International Search Report and Written Opinion for Corresponding Application No. PCT/US2021/029641, dated Jul. 2, 2021.;;HitGen, “HitGen presents new IL-17RA antagonists”, BioWorld Science, Immunomodulatin Agents, Dec. 9, 2019.",ACTIVE
127,EP,B1,EP 3807251 B1,119-751-099-010-922,2022-09-07,2022,EP 19758804 A,2019-06-17,US 201862686323 P;;IB 2019055045 W,2018-06-18,PHENYL AND PYRIDINYL SUBSTITUTED IMIDAZOLES AS MODULATORS OF RORYT,,JANSSEN PHARMACEUTICA NV,MARTIN CONNOR L;;FENNEMA ELIZABETH G;;KUMMER DAVID A;;NISHIMURA RACHEL T;;TANIS VIRGINIA M;;WOODS CRAIG R;;FOURIE ANNE M;;XUE XIAOHUA;;GOLDBERG STEVEN,,https://lens.org/119-751-099-010-922,Granted Patent,yes,3,0,10,10,0,C07D233/66;;C07D401/04;;A61P29/00;;C07D233/90;;C07D401/04,C07D233/66;;A61K31/4178;;A61P29/00;;C07D401/04,,0,0,,,,ACTIVE
128,AU,A1,AU 2021/313136 A1,174-811-801-759-64X,2023-03-02,2023,AU 2021/313136 A,2021-07-19,US 202063054089 P;;US 202163193535 P;;US 2021/0042254 W,2020-07-20,Particles and methods of assaying,"Disclosed herein are particles and methods of using said particles in assays for detection of biomolecules in a sample. Various methods of the present disclosure utilize particles for biomolecule adsorption. In some aspects, the present disclosure provides methods which utilize multiple particle concentrations to differentially fractionate biological samples. In further aspects, the present disclosure provides methods which utilize low particle concentrations to enhance adsorbed biomolecule diversity.",SEER INC,FAROKHZAD OMID C;;STOLARCZYK CRAIG;;BLUME JOHN E;;ZHAO XIAOYAN;;GOLDBERG MARTIN;;FIGA MICHAEL;;SIDDIQUI ASIM;;HORNBURG DANIEL;;HARRIS DAMIAN;;MA PHILIP;;PLATT THEODORE;;ROSHDIFERDOSI SHADI,,https://lens.org/174-811-801-759-64X,Patent Application,no,0,0,9,9,0,G01N33/54333;;G01N33/6848;;G16B40/00;;B82Y30/00;;G01N33/54333;;G16B40/00;;G01N33/6848;;B82Y30/00;;G01N33/54333;;G01N33/54393;;G01N33/6848;;G16B40/00;;B82Y30/00;;G01N33/6848;;G01N2458/30,C12Q1/32;;C07D277/68;;C12Q1/66,,0,0,,,,PENDING
129,US,A1,US 2002/0149956 A1,108-428-971-001-940,2002-10-17,2002,US 83267701 A,2001-04-11,US 83267701 A,2001-04-11,Conversion of single phase to multiple phase alternating current,"
   A system for controlling multiple vehicle includes a twelve volt (12V)/forty-two volt (42V) battery power distribution system that provides direct current. The system converts single phase alternating current to multiple phase alternating current to simultaneously power multiple vehicle systems. A single pulse width modulation generator converts the direct current from the 12V/42V battery power distribution system to alternating current. This provides one power supply path of alternating current, which has a first phase. A splitter device splits the one power supply path of alternating current into three power paths. A lead/lag circuit is used to shift the alternating current of the second path to a second phase different than the first phase of the first power supply path. A second lead/lag circuit for shifts the alternating current of the third path to a third phase different than the first phase or the second phase. This creates a three-phase alternating current power from a single direct current source. The three-phase alternating current is used to power a plurality of induction motors that operate multiple vehicle systems. 
",MERITOR LIGHT VEHICLE TECH,FOWLER CRAIG RAE;;KRAMER DENNIS A;;QUERE JEROME;;FIN ENRICO;;CHENE GEORGE;;CHIU STEPHEN;;GARRIDO PASCAL;;GOLDBERG IRA B;;HOPSON CHARLES;;BARRY DAVID M;;ROGOVIN DAN,MERITOR LIGHT VEHICLE TECHNOLOGY L.L.C (2000-07-07),https://lens.org/108-428-971-001-940,Patent Application,yes,0,2,4,4,0,H02M5/14;;H02M5/14,H02M5/14,363/148,0,0,,,,EXPIRED
130,US,B2,US 6831849 B2,119-415-781-879-433,2004-12-14,2004,US 83267701 A,2001-04-11,US 83267701 A,2001-04-11,Conversion of single phase to multiple phase alternating current,"
    A system for controlling multiple vehicle includes a twelve volt (12V)/forty-two volt (42V) battery power distribution system that provides direct current. The system converts single phase alternating current to multiple phase alternating current to simultaneously power multiple vehicle systems. A single pulse width modulation generator converts the direct current from the 12V/42V battery power distribution system to alternating current. This provides one power supply path of alternating current, which has a first phase. A splitter device splits the one power supply path of alternating current into three power paths. A lead/lag circuit is used to shift the alternating current of the second path to a second phase different than the first phase of the first power supply path. A second lead/lag circuit for shifts the alternating current of the third path to a third phase different than the first phase or the second phase. This creates a three-phase alternating current power from a single direct current source. The three-phase alternating current is used to power a plurality of induction motors that operate multiple vehicle systems. 
",MERITOR LIGHT VEHICLE TECH,FOWLER CRAIG RAE;;KRAMER DENNIS A;;QUERE JEROME;;FIN ENRICO;;CHENE GEORGE;;CHIU STEPHEN;;GARRIDO PASCAL;;GOLDBERG IRA B;;HOPSON CHARLES;;BARRY DAVID M;;ROGOVIN DAN,MERITOR LIGHT VEHICLE TECHNOLOGY L.L.C (2000-07-07),https://lens.org/119-415-781-879-433,Granted Patent,yes,13,6,4,4,0,H02M5/14;;H02M5/14,H02M5/14,363/148;;363/36,0,0,,,,EXPIRED
131,US,B2,US 6538408 B2,192-732-959-934-046,2003-03-25,2003,US 83689801 A,2001-04-17,US 83689801 A,2001-04-17,Controls to incorporate three-phase motors into vehicles,"
    A plurality of motors for use in driving accessories on a vehicle, are each powered by three-phase current. A single controller controls the supply three-phase current to the plurality of motors. In another aspect of the invention, pseudothree-phase current is created from a direct current voltage source. A chopping circuit chops the voltage into a plurality of pulses, and a phase shift circuit then creates phase-shifted power signals from those pulses. The present invention thus enables the use of three-phase alternating current motors on a vehicle to drive accessories. This reduces the cost and size of the required motors. 
",MERITOR LIGHT VEHICLE TECH,FOWLER CRAIG RAE;;KRAMER DENNIS A;;QUERE JEROME;;FIN ENRICO;;CHENE GEORGE;;CHIU STEPHEN;;GARRIDO PASCAL;;GOLDBERG IRA B;;HOPSON CHARLES;;BARRY DAVID M;;ROGOVIN DAN,,https://lens.org/192-732-959-934-046,Granted Patent,yes,12,4,7,7,0,B60R16/03;;B60R16/03;;H02M7/48;;H02M7/48;;H02J2207/20;;H02J2207/20;;H02J2310/46,B60R16/02;;H02J7/00;;H02M7/48,318/498;;318/85;;318/105,0,0,,,,EXPIRED
132,US,A1,US 2002/0149333 A1,129-903-741-257-117,2002-10-17,2002,US 83316401 A,2001-04-11,US 83316401 A,2001-04-11,AC motors for driving vehicle closures,"
   An AC motor is utilized to drive a closure on a vehicle. The use of the AC motor provides valuable benefits with regard to cost and size. Further, a three-phase AC motor may be utilized, and the pulses in its power supply monitored to determine an obstruction in the path of the closure. Frequency control may also be utilized to provide optimum control of the drive of the component at both start-up and stop. 
",MERITOR LIGHT VEHICLE TECH,FOWLER CRAIG RAE;;KRAMER DENNIS A;;QUERE JEROME;;FIN ENRICO;;CHENE GEORGE;;CHIU STEPHEN;;GARRIDO PASCAL;;GOLDBERG IRA B;;HOPSON CHARLES;;BARRY DAVID M;;ROGOVIN DAN,INTEVA PRODUCTS USA LLC (2010-12-16);;MERITOR LIGHT VEHICLE TECHNOLOGY LLC (2002-07-07);;INTEVA PRODUCTS LLC (2011-01-27),https://lens.org/129-903-741-257-117,Patent Application,yes,0,3,4,4,0,H02H7/0851;;E05Y2900/542;;E05Y2900/55;;E05F15/41;;H02H7/0851;;E05Y2900/542;;E05Y2900/55;;E05F15/41,E05F15/00;;H02H7/085,318/445,0,0,,,,EXPIRED
133,US,B2,US 6538400 B2,107-557-869-361-59X,2003-03-25,2003,US 85077101 A,2001-05-08,US 85077101 A,2001-05-08,Control system for an electric motor,"
    An apparatus for controlling multiple vehicle systems includes a single power supply that provides a direct current source. The power supply is comprised of a thirty-six volt (36 V) battery power distribution system. A converter is electrically connected to the power supply to convert direct current to alternating current. A plurality of induction motors are used to operate various vehicle systems. The motors receive alternating current via electrical connections between the converter and the motors. A central processor is connected to relays sending power to each of the motors and provides control signals to the motors based on input from control members used to activate each of the various vehicle systems. At least one sensor is associated with each of the motors to monitor voltage or current of the respective motor and to generate a diagnostic signal that is sent to the processor. The processor generates a warning signal when any of the diagnostic signals indicates that voltage within the respective motor is outside a predetermined range. A piezoelectric material is associated with each of the motors to provide an internal control signal for the motor. The piezoelectric material can be used to control acceleration or deceleration of the motor based on the rotational force of a rotor within the motor or can be use to activate an auxiliary winding in the motor based on mechanical input to the respective controller. 
",MERITOR LIGHT VEHICLE TECH,FOWLER CRAIG RAE;;QUERE JEROME;;KRAMER DENNIS A;;FIN ENRICO;;CHENE GEORGE;;GOLDBERG IRA B;;CHIU STEPHEN;;HOPSON CHARLES;;GARRIDO PASCAL;;BARRY DAVID M;;ROGOVIN DAN,MERITOR LIGHT VEHICLE TECHNOLOGY L.L.C (2000-01-26),https://lens.org/107-557-869-361-59X,Granted Patent,yes,10,12,3,3,0,H02K11/33;;H02K11/35;;H02K11/35;;H02K11/33,H02K11/00,318/34;;318/139;;318/727;;318/798;;318/801;;318/805;;180/65.1;;180/65.3;;180/65.8,0,0,,,,EXPIRED
134,US,A1,US 2002/0149339 A1,132-019-207-319-358,2002-10-17,2002,US 83689801 A,2001-04-17,US 83689801 A,2001-04-17,Controls to incorporate three-phase motors into vehicles,"
   A plurality of motors for use in driving accessories on a vehicle, are each powered by three-phase current. A single controller controls the supply three-phase current to the plurality of motors. In another aspect of the invention, pseudothree-phase current is created from a direct current voltage source. A chopping circuit chops the voltage into a plurality of pulses, and a phase shift circuit then creates phase-shifted power signals from those pulses. The present invention thus enables the use of three-phase alternating current motors on a vehicle to drive accessories. This reduces the cost and size of the required motors. 
",MERITOR LIGHT VEHICLE TECH,FOWLER CRAIG RAE;;KRAMER DENNIS A;;QUERE JEROME;;FIN ENRICO;;CHENE GEORGE;;CHIU STEPHEN;;GARRIDO PASCAL;;GOLDBERG IRA B;;HOPSON CHARLES;;BARRY DAVID M;;ROGOVIN DAN,,https://lens.org/132-019-207-319-358,Patent Application,yes,0,0,7,7,0,B60R16/03;;B60R16/03;;H02M7/48;;H02M7/48;;H02J2207/20;;H02J2207/20;;H02J2310/46,B60R16/02;;H02J7/00;;H02M7/48,318/727,0,0,,,,EXPIRED
135,KR,A,KR 20230077717 A,091-241-378-326-298,2023-06-01,2023,KR 20237005731 A,2021-07-19,US 202063054089 P;;US 202163193535 P;;US 2021/0042254 W,2020-07-20,입자 및 검정 방법,"샘플 내 생체분자의 검출을 위한 검정에서 입자 및 상기 입자를 사용하는 방법이 본원에 개시된다. 본 개시내용의 다양한 방법은 생체분자 흡착을 위해 입자를 사용한다. 일부 측면에서, 본 개시내용은 생물학적 샘플을 차등적으로 분류하기 위해 다중 입자 농도를 이용하는 방법을 제공한다. 추가 측면에서, 본 개시내용은 흡착된 생체분자 다양성을 향상시키기 위해 낮은 입자 농도를 이용하는 방법을 제공한다.",SEER INC,FAROKHZAD OMID C;;STOLARCZYK CRAIG;;BLUME JOHN E;;ZHAO XIAOYAN;;GOLDBERG MARTIN;;FIGA MICHAEL;;SIDDIQUI ASIM;;HORNBURG DANIEL;;HARRIS DAMIAN;;MA PHILIP;;PLATT THEODORE;;ROSHDIFERDOSI SHADI,,https://lens.org/091-241-378-326-298,Patent Application,no,0,0,9,9,0,G01N33/54333;;G01N33/6848;;G16B40/00;;B82Y30/00;;G01N33/54333;;G16B40/00;;G01N33/6848;;B82Y30/00;;G01N33/54333;;G01N33/54393;;G01N33/6848;;G16B40/00;;B82Y30/00;;G01N33/6848;;G01N2458/30,G01N33/543;;B82Y30/00;;G01N33/68;;G16B40/00,,0,0,,,,PENDING
136,US,A1,US 2002/0149291 A1,025-547-301-710-687,2002-10-17,2002,US 83689201 A,2001-04-17,US 83689201 A,2001-04-17,Straight wire armature,"
   In the disclosed embodiment of this invention, sets of straight wire bundles are molded or otherwise encased about a cylindrical rotor casing. The straight wire bundles lie parallel to the axis of the cylindrical rotor casing. This process is an alternative to a traditional type of electric motor armature which uses a wire that is coiled around the cylindrical rotor casing. Since the wire bundles are straight and not pulled from a single wire roll, breaking and stretching of the wire is greatly reduced. The straight wire bundles are connected at their ends using a circuit cap to form a complete electrical circuit. 
",MERITOR LIGHT VEHICLE TECH,HOPSON CHARLES;;FOWLER CRAIG RAE;;CHIU STEPHEN;;QUERE JEROME;;KRAMER DENNIS A;;CHENE GEORGE;;GARRIDO PASCAL;;FIN ENRICO;;GOLDBERG IRA B;;BARRY DAVID M;;ROGOVIN DAN,MERITOR LIGHT VEHICLE TECHNOLOGY L.L.C (2001-02-14),https://lens.org/025-547-301-710-687,Patent Application,yes,14,0,3,3,0,H02K3/12;;H02K3/12,H02K3/12,31027,0,0,,,,DISCONTINUED
137,CA,A1,CA 3186415 A1,038-121-777-642-791,2022-01-27,2022,CA 3186415 A,2021-07-19,US 202063054089 P;;US 202163193535 P;;US 2021/0042254 W,2020-07-20,PARTICLES AND METHODS OF ASSAYING,"Disclosed herein are particles and methods of using said particles in assays for detection of biomolecules in a sample. Various methods of the present disclosure utilize particles for biomolecule adsorption. In some aspects, the present disclosure provides methods which utilize multiple particle concentrations to differentially fractionate biological samples. In further aspects, the present disclosure provides methods which utilize low particle concentrations to enhance adsorbed biomolecule diversity.",SEER INC,FAROKHZAD OMID C;;STOLARCZYK CRAIG;;BLUME JOHN E;;ZHAO XIAOYAN;;GOLDBERG MARTIN;;FIGA MICHAEL;;SIDDIQUI ASIM;;HORNBURG DANIEL;;HARRIS DAMIAN;;MA PHILIP;;PLATT THEODORE;;ROSHDIFERDOSI SHADI,,https://lens.org/038-121-777-642-791,Patent Application,no,0,0,9,9,0,G01N33/54333;;G01N33/6848;;G16B40/00;;B82Y30/00;;G01N33/54333;;G16B40/00;;G01N33/6848;;B82Y30/00;;G01N33/54333;;G01N33/54393;;G01N33/6848;;G16B40/00;;B82Y30/00;;G01N33/6848;;G01N2458/30,C07D277/68;;C12Q1/32;;C12Q1/66,,0,0,,,,PENDING
138,US,A1,US 2002/0149280 A1,024-577-731-013-727,2002-10-17,2002,US 83316501 A,2001-04-11,US 83316501 A,2001-04-11,Solid body induction motor for vehicle applications,"
   A method of forming a relatively low cost motor provides a motor rotor and/or stator which has a generally solid body. The core of the body is formed of a less conductive material, and a more conductive material is at circumferentially spaced locations on the core. In one embodiment, the conductive material and the less conductive material are co-extruded. In a second embodiment, the core material is formed by powdered metal technology, and the conductive material is deposited onto the core. 
",MERITOR LIGHT VEHICLE TECH,FOWLER CRAIG RAE;;KRAMER DENNIS A;;QUERE JEROME;;FIN ENRICO;;CHENE GEORGE;;CHIU STEPHEN;;GARRIDO PASCAL;;GOLDBERG IRA B;;HOPSON CHARLES;;BARRY DAVID M;;ROGOVIN DAN,MERITOR LIGHT VEHICLE TECHNOLOGY LLC (2000-07-07),https://lens.org/024-577-731-013-727,Patent Application,yes,14,0,3,3,0,H02K1/02;;H02K3/02;;H02K15/00;;H02K15/02;;H02K15/02;;H02K3/02;;H02K15/00;;H02K1/02,H02K1/02;;H02K3/02;;H02K15/00;;H02K15/02,310/166;;310/216,0,0,,,,DISCONTINUED
139,US,A1,US 2023/0324401 A1,107-097-874-161-045,2023-10-12,2023,US 202118006142 A,2021-07-19,US 202118006142 A;;US 202163193535 P;;US 202063054089 P;;US 2021/0042254 W,2020-07-20,PARTICLES AND METHODS OF ASSAYING,"Disclosed herein are particles and methods of using said particles in assays for detection of biomolecules in a sample. Various methods of the present disclosure utilize particles for biomolecule adsorption. In some aspects, the present disclosure provides methods which utilize multiple particle concentrations to differentially fractionate biological samples. In further aspects, the present disclosure provides methods which utilize low particle concentrations to enhance adsorbed biomolecule diversity.",SEER INC,FAROKHZAD OMID C;;STOLARCZYK CRAIG;;BLUME JOHN E;;ZHAO XIAOYAN;;GOLDBERG MARTIN;;FIGA MICHAEL;;SIDDIQUI ASIM;;HORNBURG DANIEL;;HARRIS DAMIAN;;MA PHILIP;;PLATT THEODORE;;ROSHDIFERDOSI SHADI,SEER INC (2022-08-30),https://lens.org/107-097-874-161-045,Patent Application,yes,0,0,9,9,0,G01N33/54333;;G01N33/6848;;G16B40/00;;B82Y30/00;;G01N33/54333;;G16B40/00;;G01N33/6848;;B82Y30/00;;G01N33/54333;;G01N33/54393;;G01N33/6848;;G16B40/00;;B82Y30/00;;G01N33/6848;;G01N2458/30,G01N33/68,,0,0,,,,PENDING
140,EP,A1,EP 4182474 A1,117-091-518-745-787,2023-05-24,2023,EP 21847432 A,2021-07-19,US 202063054089 P;;US 202163193535 P;;US 2021/0042254 W,2020-07-20,PARTICLES AND METHODS OF ASSAYING,,SEER INC,FAROKHZAD OMID C;;STOLARCZYK CRAIG;;BLUME JOHN E;;ZHAO XIAOYAN;;GOLDBERG MARTIN;;FIGA MICHAEL;;SIDDIQUI ASIM;;HORNBURG DANIEL;;HARRIS DAMIAN;;MA PHILIP;;PLATT THEODORE;;ROSHDIFERDOSI SHADI,,https://lens.org/117-091-518-745-787,Patent Application,yes,0,0,9,9,0,G01N33/54333;;G01N33/6848;;G16B40/00;;B82Y30/00;;G01N33/54333;;G16B40/00;;G01N33/6848;;B82Y30/00;;G01N33/54333;;G01N33/54393;;G01N33/6848;;G16B40/00;;B82Y30/00;;G01N33/6848;;G01N2458/30,C12Q1/32;;C07D277/68;;C12Q1/66,,0,0,,,,PENDING
141,US,A1,US 2002/0167286 A1,059-615-871-877-169,2002-11-14,2002,US 85077101 A,2001-05-08,US 85077101 A,2001-05-08,Control system for an electric motor,"
   An apparatus for controlling multiple vehicle systems includes a single power supply that provides a direct current source. The power supply is comprised of a thirty-six volt (36 V) battery power distribution system. A converter is electrically connected to the power supply to convert direct current to alternating current. A plurality of induction motors are used to operate various vehicle systems. The motors receive alternating current via electrical connections between the converter and the motors. A central processor is connected to relays sending power to each of the motors and provides control signals to the motors based on input from control members used to activate each of the various vehicle systems. At least one sensor is associated with each of the motors to monitor voltage or current of the respective motor and to generate a diagnostic signal that is sent to the processor. The processor generates a warning signal when any of the diagnostic signals indicates that voltage within the respective motor is outside a predetermined range. A piezoelectric material is associated with each of the motors to provide an internal control signal for the motor. The piezoelectric material can be used to control acceleration or deceleration of the motor based on the rotational force of a rotor within the motor or can be use to activate an auxiliary winding in the motor based on mechanical input to the respective controller. 
",MERITOR LIGHT VEHICLE TECH,FOWLER CRAIG RAE;;QUERE JEROME;;KRAMER DENNIS A;;FIN ENRICO;;CHENE GEORGE;;GOLDBERG IRA B;;CHIU STEPHEN;;HOPSON CHARLES;;GARRIDO PASAL;;BARRY DAVID M;;ROGOVIN DAN,MERITOR LIGHT VEHICLE TECHNOLOGY L.L.C (2000-01-26),https://lens.org/059-615-871-877-169,Patent Application,yes,0,4,3,3,0,H02K11/33;;H02K11/35;;H02K11/35;;H02K11/33,H02K11/00,318/34,0,0,,,,EXPIRED
142,WO,A1,WO 2022/020272 A1,165-439-002-604-372,2022-01-27,2022,US 2021/0042254 W,2021-07-19,US 202063054089 P;;US 202163193535 P,2020-07-20,PARTICLES AND METHODS OF ASSAYING,"Disclosed herein are particles and methods of using said particles in assays for detection of biomolecules in a sample. Various methods of the present disclosure utilize particles for biomolecule adsorption. In some aspects, the present disclosure provides methods which utilize multiple particle concentrations to differentially fractionate biological samples. In further aspects, the present disclosure provides methods which utilize low particle concentrations to enhance adsorbed biomolecule diversity.",SEER INC,FAROKHZAD OMID C;;STOLARCZYK CRAIG;;BLUME JOHN E;;ZHAO XIAOYAN;;GOLDBERG MARTIN;;FIGA MICHAEL;;SIDDIQUI ASIM;;HORNBURG DANIEL;;HARRIS DAMIAN;;MA PHILIP;;PLATT THEODORE;;ROSHDIFERDOSI SHADI,,https://lens.org/165-439-002-604-372,Patent Application,yes,4,7,9,9,0,G01N33/54333;;G01N33/6848;;G16B40/00;;B82Y30/00;;G01N33/54333;;G16B40/00;;G01N33/6848;;B82Y30/00;;G01N33/54333;;G01N33/54393;;G01N33/6848;;G16B40/00;;B82Y30/00;;G01N33/6848;;G01N2458/30,C12Q1/32;;C07D277/68;;C12Q1/66,,0,0,,,,PENDING
143,US,B2,US 6614200 B2,088-803-477-525-261,2003-09-02,2003,US 83316401 A,2001-04-11,US 83316401 A,2001-04-11,AC motors for driving vehicle closures,"
    An AC motor is utilized to drive a closure on a vehicle. The use of the AC motor provides valuable benefits with regard to cost and size. Further, a three-phase AC motor may be utilized, and the pulses in its power supply monitored to determine an obstruction in the path of the closure. Frequency control may also be utilized to provide optimum control of the drive of the component at both start-up and stop. 
",MERITOR LIGHT VEHICLE TECH,FOWLER CRAIG RAE;;KRAMER DENNIS A;;QUERE JEROME;;FIN ENRICO;;CHENE GEORGE;;CHIU STEPHEN;;GARRIDO PASCAL;;GOLDBERG IRA B;;HOPSON CHARLES;;BARRY DAVID M;;ROGOVIN DAN,INTEVA PRODUCTS USA LLC (2010-12-16);;MERITOR LIGHT VEHICLE TECHNOLOGY LLC (2002-07-07);;INTEVA PRODUCTS LLC (2011-01-27),https://lens.org/088-803-477-525-261,Granted Patent,yes,3,21,4,4,0,H02H7/0851;;E05Y2900/542;;E05Y2900/55;;E05F15/41;;H02H7/0851;;E05Y2900/542;;E05Y2900/55;;E05F15/41,E05F15/00;;H02H7/085,318445;;318287;;318286;;318280;;318469;;318461;;318266,0,0,,,,EXPIRED
144,CN,A,CN 116234925 A,009-466-965-978-614,2023-06-06,2023,CN 202180064081 A,2021-07-19,US 202063054089 P;;US 202163193535 P;;US 2021/0042254 W,2020-07-20,PARTICLES AND ASSAY METHODS,"Disclosed herein are particles and methods of using the particles in assays for detecting biomolecules in a sample. Various methods of the present disclosure utilize particles for biomolecule adsorption. In some aspects, the present disclosure provides methods for differentially fractionating a biological sample using multiple particle concentrations. In further aspects, the present disclosure provides methods for utilizing low particle concentrations to enhance the diversity of adsorbed biomolecules.",SEEL CORP,FAROHAZAD OMID C;;STOLARCZYK CRAIG;;BLUME JOHN E;;ZHAO XIAOYAN;;GOLDBERG MARTIN;;FIGA MICHAEL;;SIDDIQUI ASIM;;HOHNBERGER DANIEL;;HARRIS DAMIAN;;MA PHILIP;;PLATT THEODORE;;ROSHDI FILDOSSI SHADI,,https://lens.org/009-466-965-978-614,Patent Application,no,0,0,9,9,0,G01N33/54333;;G01N33/6848;;G16B40/00;;B82Y30/00;;G01N33/54333;;G16B40/00;;G01N33/6848;;B82Y30/00;;G01N33/54333;;G01N33/54393;;G01N33/6848;;G16B40/00;;B82Y30/00;;G01N33/6848;;G01N2458/30,C12Q1/66,,0,0,,,,PENDING
145,US,A1,US 2019/0382349 A1,133-285-418-867-387,2019-12-19,2019,US 201916442837 A,2019-06-17,US 201916442837 A;;US 201862686308 P,2018-06-18,PHENYL SUBSTITUTED PYRAZOLES AS MODULATORS OF RORgT,"The present invention comprises compounds of Formula I. wherein: R 1 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and Q are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-γ-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.",JANSSEN PHARMACEUTICA NV,GOLDBERG STEVEN;;MARTIN CONNOR L;;FENNEMA ELIZABETH G;;KUMMER DAVID A;;NISHIMURA RACHEL T;;WOODS CRAIG R;;WOLIN RONALD L;;JONES WILLIAM M;;FOURIE ANNE M;;XUE XIAOHUA,JANSSEN PHARMACEUTICA NV (2020-01-14),https://lens.org/133-285-418-867-387,Patent Application,yes,0,5,7,7,4,A61P29/00;;C07D231/14;;C07D231/14;;C07D401/12;;C07D403/10;;C07D405/12;;C07D405/12,C07D231/14;;C07D401/12;;C07D403/10;;C07D405/12,,0,0,,,,ACTIVE
146,WO,A1,WO 2019/243999 A1,151-082-909-296-200,2019-12-26,2019,IB 2019055043 W,2019-06-17,US 201862686308 P,2018-06-18,PHENYL SUBSTITUTED PYRAZOLES AS MODULATORS OF RORYT,"The present invention comprises compounds of Formula (I). wherein: R 1 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and Q are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-y-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating RORĻγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).",JANSSEN PHARMACEUTICA NV;;GOLDBERG STEVEN,GOLDBERG STEVEN;;MARTIN CONNOR L;;FENNEMA ELIZABETH G;;KUMMER DAVID A;;NISHIMURA RACHEL T;;WOODS CRAIG R;;WOLIN RONALD L;;JONES WILLIAM M;;FOURIE ANNE M;;XUE XIAOHUA,,https://lens.org/151-082-909-296-200,Patent Application,yes,3,0,7,7,4,C07D231/14;;C07D405/12;;A61P29/00;;C07D231/14;;C07D401/12;;C07D403/10;;C07D405/12,C07D231/14;;A61K31/415;;A61P29/00;;C07D405/12,,31,29,068-508-663-743-396;;020-545-279-619-551;;078-205-757-883-386;;064-399-651-040-903;;016-505-509-019-957;;014-408-820-938-035;;066-119-584-271-19X;;035-586-215-470-490;;030-303-530-555-166;;039-460-067-637-00X;;002-405-354-697-844;;078-731-621-499-369;;088-727-134-679-160;;049-931-466-317-688;;118-307-749-079-773;;006-384-711-859-473;;048-384-949-179-543;;028-713-636-085-561;;004-514-663-069-206;;011-663-094-062-663;;156-601-101-421-818;;042-371-686-427-160;;095-361-043-889-533;;000-649-437-049-891;;018-908-523-184-712;;093-144-517-257-295;;180-631-728-571-083;;096-841-656-118-220;;077-295-491-167-117,10.1146/annurev.immunol.021908.132710;;19132915;;15485625;;10.1016/j.immuni.2004.08.018;;14984588;;10.1111/j.1440-1711.2004.01212.x;;10.1038/nri1807;;16557264;;10.1016/j.it.2005.10.003;;16290228;;16990136;;10.1016/j.cell.2006.07.035;;12610626;;10.1038/nature01355;;pmc2212798;;10.1084/jem.20041257;;15657292;;16670770;;pmc1451201;;10.1172/jci21404;;20956338;;pmc3776381;;10.4049/jimmunol.1001538;;pmc3582833;;23174342;;10.1016/j.biopsych.2012.09.021;;10.1016/j.psychres.2010.10.029;;21129782;;25904554;;pmc4468634;;10.1124/mol.114.097485;;21853531;;pmc3377107;;10.1002/emmm.201100172;;12814161;;10.1053/rmed.2003.1507;;10.1136/gut.52.1.65;;pmc1773503;;12477762;;11984595;;10.1038/nm0502-500;;10.1016/j.jaci.2012.04.024;;pmc3470466;;22677045;;pmc2852824;;10.3748/wjg.v16.i14.1753;;20380008;;10.1038/gene.2008.16;;18368064;;20875338;;20453841;;10.1038/ng.583;;21747375;;10.1038/nbt.1906;;22455412;;10.1056/nejmoa1109017;;22455413;;10.1056/nejmoa1109997;;20926833;;10.1126/scitranslmed.3001107;;10.1351/pac197645010011;;10.1002/anie.198205671;;10.1002/0471220574,"KORN, T.E. BETTELLI ET AL.: ""IL-17 and Thl7 Cells"", ANNU REV IMMUNOL, vol. 27, 2009, pages 485 - 517;;KOLLS, J. K.A. LINDEN: ""Interleukin-17 family members and inflammation"", IMMUNITY, vol. 21, no. 4, 2004, pages 467 - 76, XP001205649, doi:10.1016/j.immuni.2004.08.018;;STAMP, L. K.M. J. JAMES ET AL.: ""Interleukin-17: the missing link between T-cell accumulation and effector cell actions in rheumatoid arthritis"", IMMUNOL CELL BIOL, vol. 82, no. 1, 2004, pages 1 - 9, XP009092747, doi:10.1111/j.1440-1711.2004.01212.x;;DONG, C.: ""Diversification of T-helper-cell lineages: finding the family root of IL-17-producing cells"", NAT REV IMMUNOL, vol. 6, no. 4, 2006, pages 329 - 33;;MCKENZIE, B. S.R. A. KASTELEIN ET AL.: ""Understanding the IL-23-IL-17 immune pathway"", TRENDS IMMUNOL, vol. 27, no. 1, 2006, pages 17 - 23, XP028058535, doi:10.1016/j.it.2005.10.003;;IVANOV, IIB. S. MCKENZIE ET AL.: ""The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells"", CELL, vol. 126, no. 6, 2006, pages 1121 - 33, XP008091324, doi:10.1016/j.cell.2006.07.035;;CUA, D. J.J. SHERLOCK ET AL.: ""Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain"", NATURE, vol. 421, no. 6924, 2003, pages 744 - 8, XP002971969, doi:10.1038/nature01355;;LANGRISH, C. L.Y. CHEN ET AL.: ""IL-23 drives a pathogenic T cell population that induces autoimmune inflammation"", J EXP MED, vol. 201, no. 2, 2005, pages 233 - 40, XP001206021, doi:10.1084/jem.20041257;;YEN, D.J. CHEUNG ET AL.: ""IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6"", J CLIN INVEST, vol. 116, no. 5, 2006, pages 1310 - 6, XP009127727, doi:10.1172/JCI21404;;TONEL, G.C. CONRAD ET AL.: ""Cutting edge: A critical functional role for IL-23 in psoriasis"", J IMMUNOL, vol. 185, no. 10, pages 5688 - 91, XP055203326, doi:10.4049/jimmunol.1001538;;BEUREL, E.HARRINGTON, L. E.JOPE, R. S.: ""Inflammatory T helper 17 cells promote depression-like behavior in mice"", BIOL PSYCHIATRY, vol. 73, no. 7, 2013, pages 622 - 30, XP028997121, doi:10.1016/j.biopsych.2012.09.021;;CHEN, Y. ET AL.: ""Emerging tendency towards autoimmune process in major depressive patients: A novel insight from Thl7 cells"", PSYCHIATRY RESEARCH, vol. 188, no. 2, 2011, pages 224 - 230;;CHANG, M. R. ET AL.: ""Antiobesity Effect of a Small Molecule Repressor of RORy"", MOL PHARMACOL., vol. 88, no. 1, 2015, pages 48 - 56;;MEISSBURGER, B. ET AL.: ""Adipogenesis and insulin sensitivity in obesity are regulated by retinoid-related orphan receptor gamma"", EMBO MOL MED., vol. 3, no. 11, 2011, pages 637 - 651;;BARCZYK, A.W. PIERZCHALA ET AL.: ""Interleukin-17 in sputum correlates with airway hyperresponsiveness to methacholine"", RESPIR MED, vol. 97, no. 6, 2003, pages 726 - 33;;FUJINO, S.A. ANDOH ET AL.: ""Increased expression of interleukin 17 in inflammatory bowel disease"", GUT, vol. 52, no. 1, 2003, pages 65 - 70;;LOCK, C.G. HERMANS ET AL.: ""Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis"", NAT MED, vol. 8, no. 5, 2002, pages 500 - 8, XP002542559, doi:10.1038/nm0502-500;;KRUEGER, J. G.S. FRETZIN ET AL.: ""IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis"", J ALLERGY CLIN IMMUNOL, vol. 130, no. 1, pages 145 - 154 e9;;GAZOULI, M.I. PACHOULA ET AL.: ""NOD2/CARD15, ATG16L1 and IL23R gene polymorphisms and childhood-onset of Crohn's disease"", WORLD J GASTROENTEROL, vol. 16, no. 14, pages 1753 - 8;;NUNEZ, C.B. DEMA ET AL.: ""IL23R: a susceptibility locus for celiac disease and multiple sclerosis?"", GENES IMMUN, vol. 9, no. 4, 2008, pages 289 - 93;;BOWES, J.A. BARTON: ""The genetics of psoriatic arthritis: lessons from genome-wide association studies"", DISCOV MED, vol. 10, no. 52, pages 177 - 83;;KOCHI, Y.Y. OKADA ET AL.: ""A regulatory variant in CCR6 is associated with rheumatoid arthritis susceptibility"", NAT GENET, vol. 42, no. 6, pages 515 - 9, XP055019443, doi:10.1038/ng.583;;GARBER K.: ""Psoriasis: from bed to bench and bac"", NAT BIOTECH, vol. 29, 2011, pages 563 - 566, XP055307288, doi:10.1038/nbt.1906;;PAPP, K. A.: ""Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis"", N ENGL J MED, vol. 366, no. 13, 2012, pages 1181 - 9, XP002726554, doi:10.1056/NEJMoa1109017;;LEONARDI, C.R. MATHESON ET AL.: ""Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis"", N ENGL J MED, vol. 366, no. 13, pages 1190 - 9, XP002681513, doi:10.1056/NEJMoa1109997;;HUEBER, W.PATEL, D.D.DRYJA, T.WRIGHT, A.M.KOROLEVA, I.BRUIN, G.ANTONI, C.DRAELOS, Z.GOLD, M.H.DUREZ, P.: ""Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis"", SCI TRANSL MED, vol. 2, 2010, pages 5272;;""Design of Prodrugs"", 1985, ELSEVIER;;PURE & APPL. CHEM., vol. 45, 1976, pages 11 - 30;;ANGEW. CHEM. INT. ED. ENGL., vol. 21, 1982, pages 567 - 583;;""Protective Groups in Organic Chemistry"", 1973, PLENUM PRESS;;T.W. GREENEP.G.M. WUTS: ""Protective Groups in Organic Synthesis"", 1991, JOHN WILEY & SONS",PENDING
147,CA,A1,CA 3103929 A1,073-095-780-737-292,2019-12-26,2019,CA 3103929 A,2019-06-17,US 201862686308 P;;IB 2019055043 W,2018-06-18,PHENYL SUBSTITUTED PYRAZOLES AS MODULATORS OF RORYT,"The present invention comprises compounds of Formula (I). wherein: R1, R3, R4, R5, R6, R7, R8, and Q are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-y-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating RORL?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).",JANSSEN PHARMACEUTICA NV,GOLDBERG STEVEN;;MARTIN CONNOR L;;FENNEMA ELIZABETH G;;KUMMER DAVID A;;NISHIMURA RACHEL T;;WOODS CRAIG R;;WOLIN RONALD L;;JONES WILLIAM M;;FOURIE ANNE M;;XUE XIAOHUA,,https://lens.org/073-095-780-737-292,Patent Application,no,0,0,7,7,4,C07D231/14;;C07D405/12;;A61P29/00;;C07D231/14;;C07D401/12;;C07D403/10;;C07D405/12,C07D231/14;;A61K31/415;;A61P29/00;;C07D405/12,,0,0,,,,PENDING
148,US,B2,US 10975037 B2,199-815-073-737-981,2021-04-13,2021,US 201916442837 A,2019-06-17,US 201916442837 A;;US 201862686308 P,2018-06-18,Phenyl substituted pyrazoles as modulators of RORγt,"The present invention comprises compounds of Formula I. wherein: R 1 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and Q are defined in the specification. The invention also comprises a method of treating or ameliorating a ROR-γ-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.",JANSSEN PHARMACEUTICA NV,GOLDBERG STEVEN;;MARTIN CONNOR L;;FENNEMA ELIZABETH G;;KUMMER DAVID A;;NISHIMURA RACHEL T;;WOODS CRAIG R;;WOLIN RONALD L;;JONES WILLIAM M;;FOURIE ANNE M;;XUE XIAOHUA,JANSSEN PHARMACEUTICA NV (2020-01-14),https://lens.org/199-815-073-737-981,Granted Patent,yes,70,0,7,7,4,A61P29/00;;C07D231/14;;C07D231/14;;C07D401/12;;C07D403/10;;C07D405/12;;C07D405/12,C07D231/14;;C07D401/12;;C07D403/10;;C07D405/12,,75,50,096-841-656-118-220;;118-307-749-079-773;;002-405-354-697-844;;156-601-101-421-818;;007-924-207-867-846;;078-731-621-499-369;;021-032-916-096-988;;066-119-584-271-19X;;021-966-133-884-768;;064-399-651-040-903;;068-503-038-383-863;;000-951-373-751-063;;065-682-394-873-532;;006-384-711-859-473;;095-361-043-889-533;;004-514-663-069-206;;015-723-750-303-611;;093-144-517-257-295;;014-408-820-938-035;;060-797-640-900-566;;042-371-686-427-160;;020-545-279-619-551;;068-508-663-743-396;;028-713-636-085-561;;093-884-198-693-922;;035-586-215-470-490;;018-908-523-184-712;;039-642-981-580-110;;048-384-949-179-543;;026-128-338-578-202;;016-505-509-019-957;;106-524-118-716-284;;049-931-466-317-688;;011-663-094-062-663;;093-649-439-334-809;;000-649-437-049-891;;180-631-728-571-083;;058-874-856-370-984;;078-205-757-883-386;;039-460-067-637-00X;;098-868-304-673-40X;;102-770-086-354-044;;011-549-952-564-856;;044-653-508-978-443;;030-303-530-555-166;;057-603-192-746-115;;023-187-898-049-000;;011-872-379-895-774;;041-951-775-835-195;;002-380-530-828-658,10.1002/anie.198205671;;12814161;;10.1053/rmed.2003.1507;;pmc3582833;;23174342;;10.1016/j.biopsych.2012.09.021;;20875338;;pmc4474185;;10.1002/art.38272;;24574218;;10.1016/j.psychres.2010.10.029;;21129782;;10.1002/0471264180.or028.02;;12610626;;10.1038/nature01355;;21920821;;10.1016/j.clim.2011.08.005;;10.1038/nri1807;;16557264;;24502334;;10.1021/jm401901d;;10.1056/nejmoa1602773;;27959607;;10.18103/mra.v0i4.334;;10.1136/gut.52.1.65;;pmc1773503;;12477762;;21747375;;10.1038/nbt.1906;;pmc2852824;;10.3748/wjg.v16.i14.1753;;20380008;;29192397;;10.1007/s40273-017-0593-2;;20926833;;10.1126/scitranslmed.3001107;;16990136;;10.1016/j.cell.2006.07.035;;10.1111/cei.12670;;26080615;;pmc4687521;;20453841;;10.1038/ng.583;;15485625;;10.1016/j.immuni.2004.08.018;;10.1146/annurev.immunol.021908.132710;;19132915;;10.1016/j.jaci.2012.04.024;;pmc3470466;;22677045;;pmc2812071;;10.1124/mol.109.060905;;19887649;;pmc2212798;;10.1084/jem.20041257;;15657292;;22455413;;10.1056/nejmoa1109997;;10.1002/chin.200930099;;11984595;;10.1038/nm0502-500;;10.1021/bi048135v;;15794662;;10.1016/j.it.2005.10.003;;16290228;;24918373;;10.1056/nejmoa1315231;;21853531;;pmc3377107;;10.1002/emmm.201100172;;10.1038/gene.2008.16;;18368064;;10.1089/108705701753364922;;10.1177/108705710100600609;;11788061;;22455412;;10.1056/nejmoa1109017;;10.1351/pac197645010011;;23075178;;10.1056/nejmoa1203572;;14984588;;10.1111/j.1440-1711.2004.01212.x;;20956338;;pmc3776381;;10.4049/jimmunol.1001538;;10.1002/eji.201546095;;27019190;;10.1517/14712598.2014.890587;;24555741;;10.1016/j.tips.2014.07.006;;25131183;;10.1155/2016/6470364;;26941484;;pmc4749797;;16670770;;pmc1451201;;10.1172/jci21404;;10.1021/ol1019597;;20866102;;10.18632/oncotarget.12673;;27750219;;pmc5352448;;10.1371/journal.pone.0188391;;29155882;;pmc5695821;;22949321;;10.1002/eji.201242740;;pmc3609417;;24792721;;10.1016/j.drudis.2014.04.012,"Angew. Chem. Int. Ed. Engl. 1982, 21, 567-583.;;Barczyk, A., W. Pierzchala, et al. (2003). “Interleukin-17 in sputum correlates with airway hyperresponsiveness to methacholine.” Respir Med 97(6): 726-33.;;Beurel, E., Harrington, L. E., Jope, R. S. (2013) “Inflammatory T helper 17 cells promote depression-like behavior in mice.” Biol Psychiatry 73(7): 622-30.;;Bimekizumab demonstrates impressive joint and skin responses for psoriatic arthritis patients. Dec. 20, 2017. https://www.ucb.com/stories-media/Press-Releases/article/Bimekizumab-demonstrates-impressive-joint-and-skin-responses-for-psoriatic-arthritis-patients-nbsp.;;Bowes, J. and A. Barton “The genetics of psoriatic arthritis: lessons from genome-wide association studies.” Discov Med 10(52): 177-83 (2010).;;Chang M, “Pharmacologic Repression of Retinoic Acid Receptor—Related Orphan Nuclear Receptor □ Is Therapeutic in the Collagen-Induced Arthritis Experimental Model”, Arthritis & Rheumatology (2014), 66(3), 579-588.;;Chang, M. R. et al. (2015) “Antiobesity Effect of a Small Molecule Repressor of RORγ.” Mol Pharmacol. 88(1): 48-56.;;Chen, Y., et al. (2011). “Emerging tendency towards autoimmune process in major depressive patients: A novel insight from Th17 cells.” Psychiatry Research 188(2): 224-230.;;Cheng, Chia-Chung et al., The Friedlander synthesis of quinolines, Organic Reactions, 1982, 28, pp. 37-201.;;Cua, D. J., J. Sherlock, et al. (2003). “Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain.” Nature 421(6924): 744-8.;;De Wit et al., , RORγt inhibitors suppress TH17 responses in inflammatory arthritis and inflammatory bowel disease. Journal of Allergy and Clinical Immunology, vol. 137 , Issue 3, (2016), 960-963.;;Dolff S et al., Disturbed Th1, Th2, Th17 and T-reg balance in patients with systemic lupus erythematosus, Clinical Immunology 141(2):197-204 ⋅ Aug. 2011.;;Dong, C. (2006). “Diversification of T-helper-cell lineages: finding the family root of IL-17-producing cells.” Nat Rev Immunol 6(4): 329-33.;;Fauber et al., J. Med. Chem. 2014, 57, 5871-5892.;;Feagan BG, et al. Ustekinumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2016;375(20):1946-60.;;Fitzpatrick, Leo Robert. Ror-gamma T inhibition as a Pharmacological Approach for Inflammatory Bowel Disease. Medical Research Archives, [S.1.], v. 2, n. 2, Aug. 2015.;;Fujino, S., A. Andoh, et al. (2003). “Increased expression of interleukin 17 in inflammatory bowel disease.” Gut 52(1): 65-70.;;Garber K. (2011). “Psoriasis: from bed to bench and back” Nat Biotech 29, 563-566.;;Gazouli, M., I. Pachoula, et al. “NOD2/CARD15, ATG16L1 and IL23R gene polymorphisms and childhood-onset of Crohn's disease.” World J Gastroenterol 16(14): 1753-8 (2010).;;Hodgson et al., Ustekinumab for Treating Moderately to Severely Active Crohn's Disease after Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics (2018) 36:4, 387-398.;;Hueber, W., Patel, D.D., Dryja, T., Wright, A.M., Koroleva, I., Bruin, G., Antoni, C., Draelos, Z., Gold, M.H., Durez, P., Tak, P.P., Gomez-Reino, J.J., Foster, C.S., Kim, R.Y., Samson, C.M., Falk, N.S., Chu, D.S., Callanan, D., Nguyen, Q.D., Rose, K., Haider, A., Di Padova, F. (2010) Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2, 5272.;;Innovimmune: ROR Gamma Inhibitor (INV-17) Tested in Lupus Model. 2015 Eular Congress News. https://static1.squarespace.com/static/577aff0015d5db17f97d2d57/t/584f44f9725e254d6b032644/1481590043630/150611_INV-17+Lupus+Thursday_EULAR_2015+small+size.pdf.;;Ivanov, II, B. S. McKenzie, et al. (2006). “The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+T helper cells.” Cell 126(6): 1121-33.;;Jethwa H at al., The interleukin (IL)-23/IL-17 axis in ankylosing spondylitis: new advances and potentials for treatment, Clinical and Experimental Immunology, 2015, 183: 30-36.;;Kochi, Y., Y. Okada, et al. (2010) “A regulatory variant in CCR6 is associated with rheumatoid arthritis susceptibility.” Nat Genet 42(6): 515-9.;;Kolls, J. K. and A. Linden (2004). “Interleukin-17 family members and inflammation.” Immunity 21(4): 467-76.;;Korn, T., E. Bettelli, et al. (2009). “IL-17 and Th17 Cells.” Annu Rev Immunol 27: 485-517.;;Krueger, J. G., S. Fretzin, et al. “IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis.” J Allergy Clin Immunol 130(1):145-154 e9 (2012).;;Kumar N, “The Benzenesulfoamide T0901317 [N-(2,2,2-Trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-benzenesulfonamide] Is a Novel Retinoic Acid Receptor-Related Orphan Receptor-□/□ Inverse Agonist”, Molecular Pharmacology (2010), 77(2), 228-236.;;Langrish, C. L., Y. Chen, et al. (2005). “IL-23 drives a pathogenic T cell population that induces autoimmune inflammation.” J Exp Med 201(2): 233-40.;;Leonardi, C., R. Matheson, et al. “Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis.” N Engl J Med 366(13): 1190-9 (2012).;;Liegault, et al., “Establishment of Broadly Applicable reaction condisions for the Palladium-Catalyzed Direct Arylation of Heteroatom-Containing Aromatic Compounds”, The Journal of Organic Chemistry, (2009), vol. 74, No. 5, 6, pp. 1826-1834.;;Lock, C., G. Hermans, et al. (2002). “Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis.” Nat Med 8(5): 500-8.;;Matulis, D., Kranz, J. K., Salemme, F. R., and Todd, M. J. (2005) Thermodynamic stability of carbonic anhydrase: measurements of binding affinity and stoichiometry using ThermoFluor. Biochemistry 44, 5258-66.;;McGinley et al., (2018) Th17 cells, γδ T cells and their interplay in EAE and multiple sclerosis. Journal of Autoimmunity 87, 97-108.;;McKenzie, B. S., R. A. Kastelein, et al. (2006). “Understanding the IL-23-IL-17 immune pathway.” Trends Immunol 27(1): 17-23.;;Mease, P. J. et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis, The New England Journal of Medicine 370, 2295-2306 (2014).;;Meissburger, B. et al. (2011) “Adipogenesis and insulin sensitivity in obesity are regulated by retinoid-related orphan receptor gamma.” EMBO Mol Med. 3(11): 637-651.;;Nunez, C., B. Dema, et al. (2008). “IL23R: a susceptibility locus for celiac disease and multiple sclerosis?” Genes Immun 9(4): 289-93.;;Pantoliano, M. W., Petrella, E. C., Kwasnoski, J. D., Lobanov, V. S., Myslik, J., Graf, E., Carver, T., Asel, E., Springer, B. A., Lane, P., and Salemme, F. R. (2001) High-density miniaturized thermal shift assays as a general strategy for drug discovery. J Biomol Screen 6, 429-40.;;Papp, K. A., “Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.” N Engl J Med 2012 366(13): 1181-9.;;Poddhubnyy et al., Ann Rheum Dis 2014;0:1-7.;;Pure & Appl. Chem. 45, 1976, 11-30.;;Qian et al., Clin. Invest. (2012) 2(4), 417-421.;;Registry(STN)[online], [Search Date: May 13, 2019]CAS Registration No. 791058-42-9,263386-02-3.;;Sandborn WJ et al. Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease N Engl J Med 2012; 367:1519-1528.;;Silva MJ et al, Glucocorticoid Resistant Asthma: The Potential Contribution of IL-17. Biomark J. 2016, 1:6.;;Stamp, L. K., M. J. James, et al. (2004). “Interleukin-17: the missing link between T-cell accumulation and effector cell actions in rheumatoid arthritis” Immunol Cell Biol 82(1): 1-9.;;Tonel, G., C. Conrad, et al. “Cutting edge: A critical functional role for IL-23 in psoriasis.” J Immunol 185(10): 5688-91 (2010).;;Wang X, Wei Y, Xiao H, et al. A novel IL-23p19/Ebi3 (IL-39) cytokine mediates inflammation in Lupus-like mice. Eur J Immunol. 2016;46(6):1343-1350.;;Weitz JE et al., Ustekinumab: Targeting the IL-17 Pathway to Improve Outcomes in Psoriatic Arthritis. Expert Opin Biol Ther 2104 14, 515-526.;;Withers DR, et al. Transient inhibition of ROR-γt therapeutically limits intestinal inflammation by reducing TH17 cells and preserving group 3 innate lymphoid cells Nature Medicine 2016, 22, 319.;;Yang et al., Trends in Pharmacological Sciences, Oct. 2014, vol. 35, No. 10, 493-500.;;Yang X et al. Does IL-17 Respond to the Disordered Lung Microbiome and Contribute to the Neutrophilic Phenotype in Asthma? Mediators of Inflammation. vol. 2016 (2016), Article ID 6470364, pp. 1-7.;;Yao, et al, “Preparation Method of N-butyl-5-phenylthiazole-4-Formamide Derivative Via Coupling Reaction Under Catalysis of Copper Catalyst”, Database accession No. 2014:924023.;;Yen, D., J. Cheung, et al. (2006). “IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6.” J Clin Invest 116(5): 1310-6.;;Zhang, et al., “Decarboxylative Cross-Coupling of Azoyl Carboxylic Acids with Aryl Halides”, Organic Letters, (2010) vol. 12, No. 21, pp. 4745-47457.;;PCT/US2015/058193, Written Opinion dated Jan. 26, 2016.;;PCT/US2015/058198, Written Opinion dated Jan. 21, 2016.;;PCT/US2015/058200, Written Opinion dated Jan. 27, 2016.;;PCT/US2015/058193, International Search Report, dated Jan. 26, 2016.;;PCT/US2015/058198, International Search Report, dated Jan. 21, 2016.;;PCT/US2015/058200, International Search Report, dated Jan. 27, 2016.;;PCT/US2017/029531, International Search Report, dated Sep. 15, 2017.;;PCT/US2017/029531, International Preliminary Report on Patentability, dated Oct. 30, 2018.;;PCT/IB2019/055043, International Search Report, dated Sep. 30, 2019.;;PCT/IB2019/055045, International Search Report, dated Sep. 30, 2019.;;PCT/IB2019/055046, International Search Report, dated Oct. 4, 2019.;;PCT/IB2019/055048, International Search Report, dated Sep. 27, 2019.;;Eastman; Oncotarget. 2017, 8, 8854-8866. DOI: 10.18632/oncotarget.12673 (Year: 2017).;;Guendisch; PLoS ONE 2017, 12, e0188391. DOI: 10.1371/journal.pone.0188391 (Year: 2017).;;Huh; Eur. J. Immunol. 2012. 42, 2232-2237. DOI: 10.1002/eji.201242740 (Year: 2012).;;Isono; Drug Discovery Today, 2014, 19, 1205-1211. DOI: 10.1016/j.drudis.2014.04.012 (Year: 2014).;;Kiaei; Basic Clin Neurosci. 2013, 4, 3-4. URL: http://bcn.iums.ac.ir/article-1-307-en.html (Year: 2013).;;Xue; Scientific Reports 2016, 6, Article No. 37977. DOI: 10.1038/srep37977 (Year: 2016).",ACTIVE
149,EP,A1,EP 3790865 A1,036-609-329-523-023,2021-03-17,2021,EP 19759038 A,2019-06-17,US 201862686308 P;;IB 2019055043 W,2018-06-18,PHENYL SUBSTITUTED PYRAZOLES AS MODULATORS OF RORYT,,JANSSEN PHARMACEUTICA NV,MARTIN CONNOR L;;FENNEMA ELIZABETH G;;KUMMER DAVID A;;NISHIMURA RACHEL T;;WOODS CRAIG R;;WOLIN RONALD L;;JONES WILLIAM M;;FOURIE ANNE M;;XUE XIAOHUA;;GOLDBERG STEVEN,,https://lens.org/036-609-329-523-023,Patent Application,yes,0,0,7,7,0,A61P29/00;;C07D231/14;;C07D231/14;;C07D401/12;;C07D403/10;;C07D405/12;;C07D405/12,C07D231/14;;A61K31/415;;A61P29/00;;C07D405/12,,1,0,,,See references of WO 2019243999A1,DISCONTINUED
150,CN,A,CN 112566901 A,162-375-285-831-620,2021-03-26,2021,CN 201980054161 A,2019-06-17,US 201862686308 P;;IB 2019055043 W,2018-06-18,PHENYL SUBSTITUTED PYRAZOLES AS MODULATORS OF RORYT,"The present invention comprises compounds of Formula (I). wherein: R1, R3, R4, R5, R6, R7, R8, and Q are defined in the specification. The invention also comprises a method of treating or amelioratinga ROR-y-t mediated syndrome, disorder or disease, including wherein the syndrome, disorder or disease is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, and psoriasis. The invention also comprises a method of modulating ROR Gamma t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).",JANSSEN PHARMACEUTICA NV,GOLDBERG STEVEN;;MARTIN CONNOR L;;FENNEMA ELIZABETH G;;KUMMER DAVID A;;NISHIMURA RACHEL T;;WOODS CRAIG R;;WOLIN RONALD L;;JONES WILLIAM M;;FOURIE ANNE M;;XUE XIAOHUA,,https://lens.org/162-375-285-831-620,Patent Application,no,5,1,7,7,0,C07D231/14;;C07D405/12;;A61P29/00;;C07D231/14;;C07D401/12;;C07D403/10;;C07D405/12,C07D231/14;;A61K31/415;;A61P29/00;;C07D405/12,,1,0,,,"王静静 等: ""白介素-17A与白介素-17C在炎症性疾病中的研究进展"", 中国免疫学杂志, vol. 31, no. 11, pages 1441 - 1446",PENDING
151,EP,A1,EP 2276731 A1,079-939-273-850-659,2011-01-26,2011,EP 09730594 A,2009-04-08,US 2009/0039850 W;;US 4341608 P,2008-04-09,2-SULFONYLAMINO-4-HETEROARYL BUTYRAMIDE ANTAGONISTS OF CCR10,,BOEHRINGER INGELHEIM INT;;BOEHRINGER INGELHEIM PHARMA,ABEYWARDANE ASITHA;;COGAN DEREK;;CHOI YOUNGGI;;GAO DONGHONG A;;GOLDBERG DANIEL R;;HEIM-RIETHER ALEXANDER;;MILLER CRAIG ANDREW;;RAMSDEN PHILIP DEAN;;SMITH KEENAN LANA LOUISE;;SNOW ROGER JOHN;;YU YANG,,https://lens.org/079-939-273-850-659,Patent Application,yes,0,0,7,7,0,C07D207/34;;C07D211/16;;C07D403/12;;C07D513/04;;A61P11/06;;A61P17/00;;A61P25/28;;A61P29/00;;A61P35/00;;A61P37/08;;A61P43/00;;C07D211/16;;C07D207/34;;C07D513/04;;C07D403/12,C07D207/34;;A61K31/439;;A61P25/28;;C07D211/16;;C07D403/12;;C07D513/04,,0,0,,,,DISCONTINUED
152,EC,A,EC SP22091485 A,131-113-634-852-08X,2022-12-30,2022,EC DI202291485 A,2022-11-29,US 202063017682 P,2020-04-30,IMIDAZOLPIRIDAZINAS COMO MODULADORES DE IL-17,"La presente solicitud describe compuestos que tienen la siguiente fórmula: (I), o sales farmacéuticamente aceptables de estos, en donde R1, R2, R3, R4 y R5 se definen en la especificación, así como métodos para elaborar y usar los compuestos descritos en la presente descripción para tratar o mejorar un síndrome, trastorno y/o enfermedad mediada por la IL-17.",JANSSEN PHARMACEUTICA NV,KUMMER DAVID;;ROVIRA ALEXANDER;;BEHENNA DOUGLAS;;GOLDBERG STEVEN;;TANIS VIRGINIA;;MEDUNA STEVEN;;DECKHUT CHARLOTTE;;MARTIN CONNOR;;LOSKOT STEVEN;;XUE XIAOHUA;;KEITH JOHN;;WOODS CRAIG;;RHORER TIMOTHY;;MCCARVER STEFAN;;VALDES ALEXANDER,,https://lens.org/131-113-634-852-08X,Patent Application,no,0,0,21,21,0,A61P11/00;;C07D487/04;;A61P11/00;;C07D487/04;;C07D487/04;;A61K31/519;;A61K31/5025;;A61P29/00;;A61P17/06;;A61P19/02;;A61P11/06;;C07D487/04,C07D487/04;;A61K31/5025;;A61P11/00,,0,0,,,,PENDING
153,AU,A1,AU 2021/264528 A1,180-008-534-835-998,2023-01-19,2023,AU 2021/264528 A,2021-04-28,US 202063017682 P;;US 2021/0029641 W,2020-04-30,Imidazopyridazines as modulators of IL-17,"The present application discloses compounds having the following formula: (I), or pharmaceutically acceptable salts thereof, wherein R",JANSSEN PHARMACEUTICA NV,BEHENNA DOUGLAS;;DECKHUT CHARLOTTE;;ROVIRA ALEXANDER;;GOLDBERG STEVEN;;KUMMER DAVID;;KEITH JOHN;;WOODS CRAIG;;RHORER TIMOTHY;;TANIS VIRGINIA;;MARTIN CONNOR;;MEDUNA STEVEN;;MCCARVER STEFAN;;VALDES ALEXANDER;;LOSKOT STEVEN;;XUE XIAOHUA,,https://lens.org/180-008-534-835-998,Patent Application,no,0,0,21,21,0,A61P11/00;;C07D487/04;;A61P11/00;;C07D487/04;;C07D487/04;;A61K31/519;;A61K31/5025;;A61P29/00;;A61P17/06;;A61P19/02;;A61P11/06;;C07D487/04,C07D487/04;;A61K31/5025;;A61P11/00,,0,0,,,,PENDING
154,CL,A1,CL 2022002989 A1,067-336-935-279-669,2023-04-28,2023,CL 2022002989 A,2022-10-27,US 202163017682 P,2021-04-30,Imidazopiridazinas como moduladores de il-17.,"La presente solicitud describe compuestos que tienen la siguiente fórmula: (I), o sales farmacéuticamente aceptables de estos, en donde R1 , R2 , R3 , R4 y R5 se definen en la especificación, así como métodos para elaborar y usar los compuestos descritos en la presente descripción para tratar o mejorar un síndrome, trastorno y/o enfermedad mediada por la IL-17.",JANSSEN PHARMACEUTICA NV,TANIS VIRGINIA;;GOLDBERG STEVEN;;XUE XIAOHUA;;KEITH JOHN;;BEHENNA DOUGLAS;;DECKHUT CHARLOTTE;;ROVIRA ALEXANDER;;KUMMER DAVID;;WOODS CRAIG;;RHORER TIMOTHY;;MARTIN CONNOR;;MEDUNA STEVEN;;MCCARVER STEFAN;;VALDES ALEXANDER;;LOSKOT STEVEN,,https://lens.org/067-336-935-279-669,Patent Application,no,0,0,1,1,0,,A61K31/5025;;A61P11/00;;C07D487/04,,0,0,,,,PENDING
155,WO,A1,WO 2023/049888 A1,037-857-405-380-925,2023-03-30,2023,US 2022/0077003 W,2022-09-26,US 202163248569 P,2021-09-27,BENZIMIDAZOLES AS MODULATORS OF IL-17,"The present application discloses compounds of Formula (I): (I), or pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , and R 4 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.",JANSSEN PHARMACEUTICA NV,DECKHUT CHARLOTTE;;BEHENNA DOUGLAS;;BEMBENEK SCOTT;;GOLDBERG STEVEN;;JACKSON PAUL;;KEITH JOHN;;LOSKOT STEVEN;;MARTIN CONNOR;;MCCARVER STEFAN;;MEDUNA STEVEN;;RHORER TIMOTHY;;SHIH AMY;;TANIS VIRGINIA;;WOODS CRAIG;;XUE XIAOHUA,,https://lens.org/037-857-405-380-925,Patent Application,yes,2,0,1,1,2,C07D413/12;;C07D403/12;;C07D405/14;;C07D413/14;;C07D417/12;;C07D409/12;;C07D487/04;;C07D235/14;;A61P29/00;;A61P19/02;;A61P17/06,A61P17/06;;A61K31/4184;;A61K31/4192;;A61K31/4196;;A61K31/4245;;A61P19/02;;A61P29/00;;C07D235/14;;C07D403/12;;C07D405/14;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D487/04,,73,54,054-802-024-202-015;;058-789-884-920-166;;136-423-172-061-579;;027-089-613-263-553;;025-952-159-780-367;;033-396-476-290-463;;042-652-742-080-407;;048-539-201-653-261;;078-205-757-883-386;;143-102-097-264-216;;013-724-187-099-739;;029-486-145-073-303;;055-333-219-420-597;;010-579-552-237-152;;105-951-486-462-687;;017-862-476-027-388;;023-332-188-728-162;;037-994-008-331-813;;017-399-513-974-156;;034-225-124-078-880;;038-941-857-044-672;;000-741-398-771-460;;021-252-678-469-447;;068-332-664-903-404;;048-496-134-706-820;;149-506-609-878-449;;020-676-452-752-488;;009-483-825-408-761;;000-339-990-213-470;;008-027-654-197-334;;025-108-977-939-014;;084-764-362-530-285;;104-840-740-454-175;;061-479-402-388-686;;012-297-050-482-286;;003-280-341-006-389;;047-632-501-021-733;;147-839-336-026-699;;023-034-514-079-124;;030-484-724-366-406;;034-017-376-658-324;;020-760-468-731-878;;048-343-961-635-600;;002-124-596-251-49X;;034-596-672-073-434;;094-824-941-012-161;;041-043-878-985-539;;053-984-061-730-021;;088-960-339-875-350;;087-285-135-148-968;;180-631-728-571-083;;096-841-656-118-220;;077-295-491-167-117;;007-448-039-571-717,19575028;;pmc2821718;;10.1038/nri2586;;28254169;;10.1016/j.it.2017.01.006;;pmc5411326;;28887948;;10.1016/j.jaci.2017.07.004;;pmc5600287;;10.1007/s12016-018-8702-3;;pmc6244934;;30109481;;pmc4346500;;10.1038/nrrheum.2014.198;;25422000;;24470327;;10.1002/art.38376;;pmc4158887;;10.2217/cer-2018-0141;;30806520;;10.1007/s40744-018-0106-6;;29605841;;pmc5935619;;14984588;;10.1111/j.1440-1711.2004.01212.x;;10.1016/j.jbspin.2006.11.005;;17369068;;10.1002/art.24568;;19479869;;22485125;;10.1371/journal.pone.0031000;;pmc3317658;;25288779;;10.1093/rheumatology/keu382;;pmc3218910;;10.1186/ar3370;;21689402;;29945918;;10.1136/annrheumdis-2018-213328;;pmc6104676;;10.3410/f.733519001.793552052;;21641076;;10.1016/j.jaad.2010.07.010;;10.1111/bjd.14075;;26282467;;10.1016/j.jid.2017.05.033;;28652108;;pmc6128497;;29617527;;10.1001/jamadermatol.2018.0141;;30801662;;10.1111/bjd.17822;;pmc4227922;;10.1038/jid.2014.263;;24945093;;30219389;;10.1016/j.jaut.2018.09.003;;18432274;;10.1038/jid.2008.111;;10.1111/exd.13112;;27304428;;pmc5502835;;26804758;;10.1016/j.autrev.2016.01.004;;pmc4769658;;pmc4470702;;10.1111/pcmr.12284;;24935676;;10335518;;10.1191/135245899678847275;;10.1177/135245859900500206;;pmc2189615;;18156204;;10.2353/ajpath.2008.070690;;10.4049/jimmunol.1701213;;29298833;;27142710;;10.1007/s00415-016-8128-x;;10.1067/mai.2003.1557;;12789232;;11544464;;10.1067/mai.2001.117929;;10.1016/j.rmed.2011.05.017;;21763119;;10.1172/jci121087;;pmc6307967;;30383540;;23957503;;pmc5569243;;10.3109/09273948.2013.815786;;10.1016/j.ajo.2011.01.031;;21570674;;10.1080/02713680902741696;;19373578;;10.1016/j.ophtha.2012.09.040;;23290985;;25638011;;10.1016/j.ophtha.2014.12.033;;22207110;;pmc3560674;;10.12659/msm.882204;;26293646;;10.1038/leu.2015.228;;pmc4740263;;11035433;;10.1191/096120300678828703;;18373953;;10.1016/j.clim.2008.01.019;;19347604;;10.1007/s11033-009-9533-3;;10.1007/s10875-009-9365-x;;20107878;;21243492;;10.1007/s00296-010-1771-0;;10.1007/s10067-010-1510-7;;20563617;;23472149;;pmc3589375;;10.1371/journal.pone.0058161;;10.1016/s0140-6736(18)32167-6;;30249507;;30874446;;10.1080/1744666x.2019.1593141;;10.1351/pac197645010011;;10.1002/anie.198205671;;10.1002/0471220574;;10.5152/eurjrheum.2019.19057;;31364979;;pmc6668637,"GAFFEN, S.: ""Structure and signaling in the IL-17 receptor family"", NAT. REV. IMMUNOL., vol. 9, 2009, pages 556 - 567;;AMATYA N. ET AL., TRENDS IN IMMUNOLOGY, vol. 38, 2017, pages 310 - 322;;HAWKES ET AL.: ""Psoriasis Pathogenesis and the Development of Novel, Targeted Immune Therapies"", J ALLERGY CLIN IMMUNOL, vol. 140, no. 3, 2017, pages 645 - 653, XP085165342, DOI: 10.1016/j.jaci.2017.07.004;;BLAUVELT A.CHIRICOZZI A.: ""The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis"", CLIN REV ALLERGY IMMUNOL, vol. 55, no. 3, 2018, pages 379 - 390, XP036632999, DOI: 10.1007/s12016-018-8702-3;;ADAMOPOULOS I.MELLINS E., NATURE REVIEWS RHEUMATOLOGY, vol. 11, 2015, pages 189 - 94;;MENON B. ET AL., ARTHRITIS & RHEUMATOLOGY, vol. 66, 2014, pages 1272 - 81;;MEASE P. ET AL., EUR. J. RHEUMATOL., vol. 6, no. 3, 1 July 2019 (2019-07-01), pages 113 - 121;;STRAND V. ET AL., J. COMP. EFF. RES., vol. 8, no. 7, 2019, pages 497 - 510;;NASH P. ET AL., RHEUMATOL. THER., vol. 5, no. 1, 2018, pages 99 - 122;;MEASE, P. ET AL., ANN RHEUM DISS, vol. 79, 2020, pages 123 - 131;;STAMP, L. ET AL., IMMUNOL. CELL BIOL., vol. 82, no. 1, 2004, pages 1 - 9;;WENDLING D. ET AL., JOINT BONE SPINE, vol. 74, 2007, pages 304 - 305;;SHEN H. ET AL., ARTHRITIS RHEUM, vol. 60, no. 6, 2009, pages 1647 - 56;;ZHANG L. ET AL., PLOS ONE, vol. 7, no. 4, 2012, pages e31000;;JANSEN D. ET AL., RHEUMATOLOGY (OXFORD, vol. 54, no. 4, April 2015 (2015-04-01), pages 728 - 735;;APPEL H. ET AL., ARTHRITIS RES. THER., vol. 13, no. 3, 2011, pages R95;;DEODHAR A. ET AL., ARTHRITIS RHEUMATOL, vol. 71, no. 2, 2019, pages 258 - 270;;BAETEN D. ET AL., ANN. RHEUM. DIS., vol. 77, no. 9, 2018, pages 1295 - 1302;;SCHLAPBACH C. ET AL., J. AM. ACAD. DERMATOL., vol. 65, no. 4, 2011, pages 790;;KELLY G. ET AL., BRITISH J. DERMATOL., vol. 173, no. 6, 2015, pages 1431 - 9;;MORAN B. ET AL., J. INVEST. DERMATOL., vol. 137, no. 11, 2017, pages 2389;;THOMI R. ET AL., JAMA DERMATOL, vol. 154, no. 5, 2018, pages 592;;PRUSSICK L. ET AL., BRITISH J. DERMATOL., vol. 181, no. 3, September 2019 (2019-09-01), pages 609 - 611;;LE JAN S. ET AL., J. INVEST. DERMATOL., vol. 134, no. 12, 2014, pages 2908 - 2917;;CHAKIEVSKA L., J AUTOIMMUN., vol. 96, 2019, pages 104 - 112;;CHAKIEVSKA L., J AUTOIMMUN, vol. 96, 2019, pages 104 - 112;;KOGA C. ET AL., J. INVEST. DERMATOL., vol. 128, 2008, pages 2625 - 2630;;KHATTRI S. ET AL., EXP. DERMATOL., vol. 26, no. 1, January 2017 (2017-01-01), pages 28 - 35;;SINGH R. ET AL., AUTOIMMUN. REV, vol. 15, no. 4, April 2016 (2016-04-01), pages 397 - 404;;EBY J. ET AL., PIGMENT CELL & MELANOMA RES, vol. 27, no. 6, November 2014 (2014-11-01), pages 1075 - 85;;LOCK, C. ET AL., NAT. MED., vol. 8, 2002, pages 500 - 5085;;MATUSEVICIUS, D. ET AL., MULT. SCLER., vol. 5, 1999, pages 101 - 104;;TZARTOS, J. ET AL., AM. J. PATHOL., vol. 172, 2008, pages 146 - 155;;WILLING A. ET AL., J. IMMUNOL., vol. 200, no. 3, 2018, pages 974 - 982;;NEUROIMMUNOL, vol. 332, 2019, pages 147 - 154;;HAVRDOVA, E. ET AL., J. NEUROL., vol. 263, 2016, pages 1287 - 1295;;CHAKIR J. ET AL., J. ALLERGY CLIN. IMMUNOL., vol. 111, no. 6, 2003, pages 1293 - 8;;MOLET S. ET AL., J. ALLERGY CLIN. IMMUNOL., vol. 108, no. 3, 2001, pages 430 - 8;;CAMARGO LDN. ET AL., FRONT IMMUNOL, vol. 8, 2018, pages 1835;;DOS SANTOS T. ET AL., FRONT. PHYSIOL., vol. 5, no. 9, 2018, pages 1183;;VARGAS-ROJAS M. ET AL., RESPIR. MED., vol. 105, no. 11, November 2011 (2011-11-01), pages 1648 - 54;;CHRISTENSON S. ET AL., J. CLIN. INVEST., vol. 129, no. 1, 2019, pages 169 - 181;;CHEN Y. ET AL., PLOS ONE, vol. 6, 2011, pages el8139;;EL-ASRAR A. ET AL., CLIN. IMMUNOL., vol. 141, no. 2, 2011, pages 197 - 204;;JAWAD S. ET AL., OCUL. IMMUNOL. INFLAMM., vol. 21, no. 6, 2013, pages 434 - 9;;KUIPER J. ET AL., AM. J. OPHTHALMOL., vol. 152, no. 2, 2011, pages 177 - 182;;ZHANG R. ET AL., CURR. EYE RES., vol. 34, no. 4, April 2009 (2009-04-01), pages 297 - 303;;DICK A. ET AL., OPHTHALMOLOGY, vol. 120, no. 4, 2013, pages 777 - 87;;LETKO E. ET AL., OPHTHALMOLOGY, vol. 122, no. 5, 2015, pages 939 - 948;;MUGHEDDU C. ET AL., DERMATOL. THER., vol. 30, no. 5, September 2017 (2017-09-01), pages el2527;;LEMANCEWICZ D. ET AL., MED. SCI. MONIT., vol. 18, no. 1, 2012, pages BR54 - BR59;;PRABHALA R. ET AL., LEUKEMIA, vol. 30, no. 2, February 2016 (2016-02-01), pages 379 - 389;;WONG C. ET AL., LUPUS, vol. 9, no. 8, 2000, pages 589 - 593;;WONG C. ET AL., CLINICAL IMMUNOLOGY, vol. 127, no. 3, 2008, pages 385 - 393;;ZHAO X-F. ET AL., MOL. BIOL. REP., vol. 37, no. 1, January 2010 (2010-01-01), pages 81 - 5;;CHEN X. ET AL., J. CLIN. IMMUNOL., vol. 30, no. 2, March 2010 (2010-03-01), pages 221 - 5;;XING Q. ET AL., RHEUMATOL. INT., vol. 32, no. 4, April 2012 (2012-04-01), pages 949 - 58;;MA J. ET AL., CLIN. RHEUMATOL., vol. 29, no. 11, 2010, pages 1251 - 1258;;WEN, Z. ET AL., PLOS ONE, vol. 8, 2013, pages e58161;;VAN VOLLENHOVEN R. ET AL., LANCET, vol. 392, 2018, pages 1330 - 39;;KOGA T. ET AL., EXPERT REV. CLIN. IMMUNOL., vol. 15, no. 6, 2019, pages 629 - 637;;""GenBank"", Database accession no. NM_002190.3;;PURE & APPL. CHEM., vol. 45, 1976, pages 11 - 30;;ANGEW. CHEM., vol. 21, 1982, pages 567 - 583;;""Protective Groups in Organic Chemistry"", 1973, PLENUM PRESS;;T.W. GREENEP.G.M. WUTS: ""Protective Groups in Organic Synthesis"", 1991, JOHN WILEY & SONS;;HAWKES ET AL.: ""Psoriasis Pathogenesis and the Development of Novel, Targeted Immune Therapies"", J ALLERGY CLIN IMMUNOL., vol. 140, no. 3, 2017, pages 645 - 653, XP085165342, DOI: 10.1016/j.jaci.2017.07.004;;MEASE P. ET AL., EUR. J. RHEUMATOL., vol. 6, no. 3, 1 July 2018 (2018-07-01), pages 113 - 121;;ROBERT ET AL., FRONT. MED., 14 January 2019 (2019-01-14);;KELLY G. ET AL., BRITISH J. DERMATOL., vol. 173, no. 6, December 2015 (2015-12-01), pages 1431 - 9;;SETIADI AF ET AL., J NEUROIMMUNOL., vol. 15, no. 332, 2019, pages 147 - 154;;CAMARGO LDN. ET AL., FRONT IMMUNOL., vol. 8, 2018, pages 1835;;""Remington's Pharmaceutical Sciences"", 1985, MACK PUBLISHING COMPANY",PENDING
156,US,B2,US 8586748 B2,015-712-115-630-425,2013-11-19,2013,US 93700609 A,2009-04-08,US 93700609 A;;US 4341608 P;;US 2009/0039850 W,2008-04-09,2-sulfonylamino-4-heteroaryl butyramide antagonists of CCR10,"This invention relates to a compound of formula (I) and the pharmaceutically acceptable salts thereof wherein R 1 , R 2 , R 4 . Ar and Het are as defined herein. The invention also relates to methods of using the compound of formula (I) to treat a diseases and disorders that are mediated or sustained through the activity of CCR10.",ABEYWARDANE ASITHA;;COGAN DEREK;;CHOI YOUNGGI;;GAO DONGHONG A;;GOLDBERG DANIEL R;;HEIM-RIETHER ALEXANDER;;MILLER CRAIG ANDREW;;RAMSDEN PHILIP DEAN;;SMITH KEENAN LANA LOUISE;;SNOW ROGER JOHN;;YU YANG;;BOEHRINGER INGELHEIM INT,ABEYWARDANE ASITHA;;COGAN DEREK;;CHOI YOUNGGI;;GAO DONGHONG A;;GOLDBERG DANIEL R;;HEIM-RIETHER ALEXANDER;;MILLER CRAIG ANDREW;;RAMSDEN PHILIP DEAN;;SMITH KEENAN LANA LOUISE;;SNOW ROGER JOHN;;YU YANG,BOEHRINGER INGELHEIM INTERNATIONAL GMBH (2011-01-05),https://lens.org/015-712-115-630-425,Granted Patent,yes,5,1,7,7,0,C07D207/34;;C07D211/16;;C07D403/12;;C07D513/04;;A61P11/06;;A61P17/00;;A61P25/28;;A61P29/00;;A61P35/00;;A61P37/08;;A61P43/00;;C07D211/16;;C07D207/34;;C07D513/04;;C07D403/12,C07D401/12;;A61K31/454;;C07D401/14,546/208;;546/211;;514/326,3,1,033-630-923-318-601,10.1007/s00109-005-0637-5;;15827759,"Quinones et. al. ""The complex role of the chemokine receptor CCR2 in collagen-induced arthritis: implications for therapeutic targeting of CCR2 in rheumatoid arthritis"" Journal of Molecular Medicine 2005 83: 672-681.;;Wagner et al.; Syntheses von 4-(4-Amidino-phenyl)-2-arylsulfonylaminobuttersaeureamiden; Die Pharmazie; vol. 37; No. 1; Jan. 1, 1982; pp. 13-16.;;International Search Report for corresponding PCT/US2009/039850; date of mailing Sep. 24, 2009.",ACTIVE
157,PE,A1,PE 20230469 A1,195-515-090-167-052,2023-03-14,2023,PE 2022002520 A,2021-04-28,US 202063017682 P;;US 2021/0029641 W,2020-04-30,IMIDAZOPIRIDAZINAS COMO MODULADORES DE IL-17,"La presente invencion se refiere a un compuesto de formula I, donde: R1 es alquilo C1-C6, -alquilo C0-C6-cicloalquilo C3-C6 o heterociclo de 5 a 6 miembros que tiene 1 a 2 atomos de nitrogeno, donde el alquilo C1-C6 esta opcionalmente sustituido con uno a seis grupos R1a, el alquiloC-0-C2.cicloalquilo C3-C6 esta opcionalmente sustituido con uno a seis grupos R1b y el heterociclo de 5 a 6 miembros esta opcionalmente sustituido con tres grupos R1c ; R2 es H, cicloalquilo C3-C5 o alquilo C1-C4, en donde alquilo C1-C4 esta opcionalmente sustituido con uno a seis grupos R2a; R1a, R1b y R2a son independientemente fluor, CN, OH, entre otros; R1c es independientemente OCH3, OCF3, entre otros; R3 es alquilo C0-C1-cicloalquilo C3-C6, entre otros; R4 es cicloalquilo C3-C6, fenilo o heteroarilo de 5 a 6 miembros que tiene 1 a 4 heteroatomos seleccionados de N, O y S; R5 es hidrogeno o halogeno; en donde cuando R4 es 1,2,4-triazolilo, entonces R4 es un heteroarilo de 6 miembros sustituidos que no se encuentra en la posicion para. Son compuestos especificos los compuestos de formula i), ii), entre otros. Tambien se refiere a una composicion farmaceutica. Dichos compuestos son imidazopiridazinas que modulan la interleucina-17A (IL-17A), siendo utiles en el tratamiento de enfermedades inflamatorias mediadas por la IL-17A.",JANSSEN PHARMACEUTICA NV,BEHENNA DOUGLAS;;DECKHUT CHARLOTTE;;ROVIRA ALEXANDER;;GOLDBERG STEVEN;;KUMMER DAVID;;KEITH JOHN;;WOODS CRAIG;;RHORER TIMOTHY;;TANIS VIRGINIA;;MARTIN CONNOR;;MEDUNA STEVEN;;MCCARVER STEFAN;;VALDES ALEXANDER;;LOSKOT STEVEN;;XUE XIAOHUA,,https://lens.org/195-515-090-167-052,Patent Application,no,0,0,21,21,0,A61P11/00;;C07D487/04;;A61P11/00;;C07D487/04;;C07D487/04;;A61K31/519;;A61K31/5025;;A61P29/00;;A61P17/06;;A61P19/02;;A61P11/06;;C07D487/04,C07D487/04;;A61K31/5025;;A61P11/00,,0,0,,,,PENDING
158,BR,A2,BR 112022021962 A2,062-434-870-873-778,2023-03-28,2023,BR 112022021962 A,2021-04-28,US 2021/0029641 W;;US 202063017682 P,2020-04-30,IMIDAZOPIRIDAZINAS COMO MODULADORES DE IL-17,"IMIDAZOPIRIDAZINAS COMO MODULADORES. A presente invenção refere-se a compostos que têm a seguinte fórmula: (I), ou sais farmaceuticamente aceitáveis dos mesmos, em que R1, R2, R3, R4 e R5 são definidos no relatório descritivo, bem como métodos de preparo e uso dos compostos divulgados na presente invenção para tratar ou melhorar uma síndrome, distúrbio e/ou doença mediada por IL-17.",JANSSEN PHARMACEUTICA NV,DOUGLAS BEHENNA;;CHARLOTTE DECKHUT;;ALEXANDER ROVIRA;;STEVEN GOLDBERG;;DAVID KUMMER;;JOHN KEITH;;CRAIG WOODS;;TIMOTHY RHORER;;VIRGINIA TANIS;;CONNOR MARTIN;;STEVEN MEDUNA;;STEFAN MCCARVER;;ALEXANDER VALDES;;STEVEN LOSKOT;;XIAOHUA XUE,,https://lens.org/062-434-870-873-778,Patent Application,no,0,0,21,21,0,A61P11/00;;C07D487/04;;A61P11/00;;C07D487/04;;C07D487/04;;A61K31/519;;A61K31/5025;;A61P29/00;;A61P17/06;;A61P19/02;;A61P11/06;;C07D487/04,C07D487/04;;A61K31/5025;;A61P11/00,,0,0,,,,PENDING
159,CA,A1,CA 2720613 A1,161-103-186-861-95X,2009-10-15,2009,CA 2720613 A,2009-04-08,US 4341608 P;;US 2009/0039850 W,2008-04-09,2-SULFONYLAMINO-4-HETEROARYL BUTYRAMIDE ANTAGONISTS OF CCR10,"This invention relates to a compound of formula (I) and the pharmaceutically acceptable salts thereof wherein R1, R2, R4. Ar and Het are as defined herein. The invention also relates to methods of using the compound of formula (I) to treat a diseases and disorders that are mediated or sustained through the activity of CCR10.",BOEHRINGER INGELHEIM INT,ABEYWARDANE ASITHA;;COGAN DEREK;;CHOI YOUNGGI;;GAO DONGHONG A;;GOLDBERG DANIEL R;;HEIM-RIETHER ALEXANDER;;MILLER CRAIG ANDREW;;RAMSDEN PHILIP DEAN;;SMITH KEENAN LANA LOUISE;;SNOW ROGER JOHN;;YU YANG,,https://lens.org/161-103-186-861-95X,Patent Application,no,0,0,7,7,0,C07D207/34;;C07D211/16;;C07D403/12;;C07D513/04;;A61P11/06;;A61P17/00;;A61P25/28;;A61P29/00;;A61P35/00;;A61P37/08;;A61P43/00;;C07D211/16;;C07D207/34;;C07D513/04;;C07D403/12,C07D207/34;;A61K31/439;;A61P25/28;;C07D211/16;;C07D403/12;;C07D513/04,,0,0,,,,DISCONTINUED
160,WO,A1,WO 2021/222404 A1,176-313-446-645-314,2021-11-04,2021,US 2021/0029641 W,2021-04-28,US 202063017682 P,2020-04-30,IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17,"The present application discloses compounds having the following formula: (I), or pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , R 4 and R 5 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.",JANSSEN BIOTECH INC;;BEHENNA DOUGLAS;;DECKHUT CHARLOTTE;;ROVIRA ALEXANDER,BEHENNA DOUGLAS;;DECKHUT CHARLOTTE;;ROVIRA ALEXANDER;;GOLDBERG STEVEN;;KUMMER DAVID;;KEITH JOHN;;WOODS CRAIG;;RHORER TIMOTHY;;TANIS VIRGINIA;;MARTIN CONNOR;;MEDUNA STEVEN;;MCCARVER STEFAN;;VALDES ALEXANDER;;LOSKOT STEVEN;;XUE XIAOHUA,,https://lens.org/176-313-446-645-314,Patent Application,yes,3,6,21,21,2,A61P11/00;;C07D487/04;;A61P11/00;;C07D487/04;;C07D487/04;;A61K31/519;;A61K31/5025;;A61P29/00;;A61P17/06;;A61P19/02;;A61P11/06;;C07D487/04,C07D487/04;;A61K31/5025;;A61P11/00,,69,57,054-802-024-202-015;;058-789-884-920-166;;136-423-172-061-579;;027-089-613-263-553;;025-952-159-780-367;;033-396-476-290-463;;042-652-742-080-407;;048-539-201-653-261;;078-205-757-883-386;;143-102-097-264-216;;013-724-187-099-739;;029-486-145-073-303;;055-333-219-420-597;;010-579-552-237-152;;105-951-486-462-687;;017-862-476-027-388;;037-994-008-331-813;;017-399-513-974-156;;034-225-124-078-880;;038-941-857-044-672;;000-741-398-771-460;;021-252-678-469-447;;068-332-664-903-404;;048-496-134-706-820;;149-506-609-878-449;;048-384-949-179-543;;020-676-452-752-488;;009-483-825-408-761;;000-339-990-213-470;;004-860-868-419-945;;008-027-654-197-334;;025-108-977-939-014;;084-764-362-530-285;;017-998-842-042-637;;104-840-740-454-175;;061-479-402-388-686;;009-864-444-828-040;;012-297-050-482-286;;003-280-341-006-389;;047-632-501-021-733;;147-839-336-026-699;;023-034-514-079-124;;030-484-724-366-406;;034-017-376-658-324;;020-760-468-731-878;;048-343-961-635-600;;002-124-596-251-49X;;034-596-672-073-434;;094-824-941-012-161;;041-043-878-985-539;;053-984-061-730-021;;088-960-339-875-350;;087-285-135-148-968;;180-631-728-571-083;;096-841-656-118-220;;077-295-491-167-117;;000-478-646-057-608,19575028;;pmc2821718;;10.1038/nri2586;;28254169;;10.1016/j.it.2017.01.006;;pmc5411326;;28887948;;10.1016/j.jaci.2017.07.004;;pmc5600287;;10.1007/s12016-018-8702-3;;pmc6244934;;30109481;;pmc4346500;;10.1038/nrrheum.2014.198;;25422000;;24470327;;10.1002/art.38376;;pmc4158887;;10.2217/cer-2018-0141;;30806520;;10.1007/s40744-018-0106-6;;29605841;;pmc5935619;;14984588;;10.1111/j.1440-1711.2004.01212.x;;10.1016/j.jbspin.2006.11.005;;17369068;;10.1002/art.24568;;19479869;;22485125;;10.1371/journal.pone.0031000;;pmc3317658;;25288779;;10.1093/rheumatology/keu382;;pmc3218910;;10.1186/ar3370;;21689402;;29945918;;10.1136/annrheumdis-2018-213328;;pmc6104676;;10.3410/f.733519001.793552052;;21641076;;10.1016/j.jaad.2010.07.010;;10.1016/j.jid.2017.05.033;;28652108;;pmc6128497;;29617527;;10.1001/jamadermatol.2018.0141;;30801662;;10.1111/bjd.17822;;pmc4227922;;10.1038/jid.2014.263;;24945093;;30219389;;10.1016/j.jaut.2018.09.003;;18432274;;10.1038/jid.2008.111;;10.1111/exd.13112;;27304428;;pmc5502835;;26804758;;10.1016/j.autrev.2016.01.004;;pmc4769658;;pmc4470702;;10.1111/pcmr.12284;;24935676;;11984595;;10.1038/nm0502-500;;10335518;;10.1191/135245899678847275;;10.1177/135245859900500206;;pmc2189615;;18156204;;10.2353/ajpath.2008.070690;;10.4049/jimmunol.1701213;;29298833;;10.1016/j.jneuroim.2019.04.011;;31034962;;27142710;;10.1007/s00415-016-8128-x;;10.1067/mai.2003.1557;;12789232;;11544464;;10.1067/mai.2001.117929;;30233389;;10.3389/fphys.2018.01183;;pmc6134017;;10.1016/j.rmed.2011.05.017;;21763119;;10.1172/jci121087;;pmc6307967;;30383540;;pmc3068165;;21479174;;10.1371/journal.pone.0018139;;23957503;;pmc5569243;;10.3109/09273948.2013.815786;;10.1016/j.ajo.2011.01.031;;21570674;;10.1080/02713680902741696;;19373578;;10.1016/j.ophtha.2012.09.040;;23290985;;25638011;;10.1016/j.ophtha.2014.12.033;;22207110;;pmc3560674;;10.12659/msm.882204;;26293646;;10.1038/leu.2015.228;;pmc4740263;;11035433;;10.1191/096120300678828703;;18373953;;10.1016/j.clim.2008.01.019;;19347604;;10.1007/s11033-009-9533-3;;10.1007/s10875-009-9365-x;;20107878;;21243492;;10.1007/s00296-010-1771-0;;10.1007/s10067-010-1510-7;;20563617;;23472149;;pmc3589375;;10.1371/journal.pone.0058161;;10.1016/s0140-6736(18)32167-6;;30249507;;30874446;;10.1080/1744666x.2019.1593141;;10.1351/pac197645010011;;10.1002/anie.198205671;;10.1002/0471220574;;10.1055/s-1979-28898,"GAFFEN, S: ""Structure and signaling in the IL-17 receptor family"", NAT. REV. IMMUNOL., vol. 9, 2009, pages 556 - 567;;AMATYAN ET AL., TRENDS IN IMMUNOLOGY, vol. 38, 2017, pages 310 - 322;;HAWKES ET AL.: ""Psoriasis Pathogenesis and the Development of Novel, Targeted Immune Therapies"", J ALLERGY CLIN IMMUNOL, vol. 140, no. 3, 2017, pages 645 - 653, XP085165342, DOI: 10.1016/j.jaci.2017.07.004;;BLAUVELT ACHIRICOZZI A: ""The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis"", CLIN REV ALLERGY IMMUNOL, vol. 55, no. 3, 2018, pages 379 - 390, XP036632999, DOI: 10.1007/s12016-018-8702-3;;ADAMOPOULOS IMELLINS E, NATURE REVIEWS RHEUMATOLOGY, vol. 11, 2015, pages 189 - 94;;MENON B ET AL., ARTHRITIS & RHEUMATOLOGY, vol. 66, 2014, pages 1272 - 81;;MEASE P ET AL., EUR. J. RHEUMATOL., vol. 6, no. 3, 1 July 2019 (2019-07-01), pages 113 - 121;;STRAND V ET AL., J. COMP. EFF. RES., vol. 8, no. 7, 2019, pages 497 - 510;;NASH P ET AL., RHEUMATOL. THER., vol. 5, no. 1, 2018, pages 99 - 122;;MEASE, P ET AL., ANN RHEUM DISS, vol. 79, 2020, pages 123 - 131;;STAMP, L ET AL., IMMUNOL. CELL BIOL., vol. 82, no. 1, 2004, pages 1 - 9;;ROBERT M.MIOSSEC P., FRONT. MED., vol. 5, 2019, pages 364;;WENDLING D ET AL., JOINT BONE SPINE, vol. 74, 2007, pages 304 - 305;;SHEN H ET AL., ARTHRITIS RHEUM, vol. 60, no. 6, 2009, pages 1647 - 56;;ZHANG L ET AL., PLOS ONE, vol. 7, no. 4, 2012, pages e31000;;JANSEN D ET AL., RHEUMATOLOGY (OXFORD, vol. 54, no. 4, April 2015 (2015-04-01), pages 728 - 735;;APPEL H ET AL., ARTHRITIS RES. THER., vol. 13, no. 3, 2011, pages R95;;DEODHAR A ET AL., ARTHRITIS RHEUMATOL., vol. 71, no. 2, 2019, pages 258 - 270;;BAETEN D ET AL., ANN. RHEUM. DIS., vol. 77, no. 9, 2018, pages 1295 - 1302;;SCHLAPBACH C ET AL., J. AM. ACAD. DERMATOL., vol. 65, no. 4, 2011, pages 790;;KELLY G ET AL., BRITISH J. DERMATOL., vol. 173, no. 6, December 2015 (2015-12-01), pages 1431 - 9;;MORAN B ET AL., J. INVEST. DERMATOL., vol. 137, no. 11, 2017, pages 2389;;THOMI R ET AL., JAMA DERMATOL, vol. 154, no. 5, 2018, pages 592;;PRUSSICK L ET AL., BRITISH J. DERMATOL., vol. 181, no. 3, September 2019 (2019-09-01), pages 609 - 611;;LE JAN S ET AL., J. INVEST. DERMATOL., vol. 134, no. 12, 2014, pages 2908 - 2917;;CHAKIEVSKA L, J AUTOIMMUN., vol. 96, 2019, pages 104 - 112;;CHAKIEVSKA L, J AUTOIMMUN, vol. 96, 2019, pages 104 - 112;;KOGA C ET AL., J. INVEST. DERMATOL., vol. 128, 2008, pages 2625 - 2630;;KHATTRI S ET AL., EXP. DERMATOL., vol. 26, no. 1, January 2017 (2017-01-01), pages 28 - 35;;SINGH R ET AL., AUTOIMMUN. REV, vol. 15, no. 4, April 2016 (2016-04-01), pages 397 - 404;;EBY J ET AL., PIGMENT CELL & MELANOMA RES, vol. 27, no. 6, November 2014 (2014-11-01), pages 1075 - 85;;LOCK, C ET AL., NAT. MED., vol. 8, 2002, pages 500 - 508;;MATUSEVICIUS, D ET AL., MULT. SCLER., vol. 5, 1999, pages 101 - 104;;TZARTOS, J ET AL., AM. J. PATHOL., vol. 172, 2008, pages 146 - 155;;WILLING A ET AL., J. IMMUNOL., vol. 200, no. 3, 2018, pages 974 - 982;;SETIADI AF ET AL., J NEUROIMMUNOL., vol. 332, 2019, pages 147 - 154;;HAVRDOVA, E ET AL., J. NEUROL., vol. 263, 2016, pages 1287 - 1295;;CHAKIR J ET AL., J. ALLERGY CLIN. IMMUNOL., vol. 111, no. 6, 2003, pages 1293 - 8;;MOLET S ET AL., J. ALLERGY CLIN. IMMUNOL., vol. 108, no. 3, 2001, pages 430 - 8;;CAMARGO LDN ET AL., FRONT IMMUNOL, vol. 8, 2018, pages 1835;;DOS SANTOS T ET AL., FRONT. PHYSIOL., vol. 9, 2018, pages 1183;;VARGAS-ROJAS M ET AL., RESPIR. MED., vol. 105, no. 11, November 2011 (2011-11-01), pages 1648 - 54;;CHRISTENSON S ET AL., J. CLIN. INVEST., vol. 129, no. 1, 2019, pages 169 - 181;;CHEN Y ET AL., PLOS ONE, vol. 6, 2011, pages e18139;;EL-ASRAR A ET AL., CLIN. IMMUNOL., vol. 141, no. 2, 2011, pages 197 - 204;;JAWAD S ET AL., OCUL. IMMUNOL. INFLAMM., vol. 21, no. 6, 2013, pages 434 - 9;;KUIPER J ET AL., AM. J. OPHTHALMOL., vol. 152, no. 2, 2011, pages 177 - 182;;ZHANG R ET AL., CURR. EYE RES., vol. 34, no. 4, April 2009 (2009-04-01), pages 297 - 303;;DICK A ET AL., OPHTHALMOLOGY, vol. 120, no. 4, 2013, pages 777 - 87;;LETKO E ET AL., OPHTHALMOLOGY, vol. 122, no. 5, 2015, pages 939 - 948;;MUGHEDDU C ET AL., DERMATOL. THER., vol. 30, no. 5, September 2017 (2017-09-01), pages e12527;;LEMANCEWICZ D ET AL., MED. SCI. MONIT., vol. 18, no. 1, 2012, pages BR54 - BR59;;PRABHALA R ET AL., LEUKEMIA, vol. 30, no. 2, February 2016 (2016-02-01), pages 379 - 389;;WONG C ET AL., LUPUS, vol. 9, no. 8, 2000, pages 589 - 593;;WONG C ET AL., CLINICAL IMMUNOLOGY, vol. 127, no. 3, 2008, pages 385 - 393;;ZHAO X-F ET AL., MOL. BIOL. REP., vol. 37, no. 1, January 2010 (2010-01-01), pages 81 - 5;;CHEN X ET AL., J. CLIN. IMMUNOL., vol. 30, no. 2, March 2010 (2010-03-01), pages 221 - 5;;XING Q ET AL., RHEUMATOL. INT., vol. 32, no. 4, April 2012 (2012-04-01), pages 949 - 58;;MA J ET AL., CLIN. RHEUMATOL., vol. 29, no. 11, 2010, pages 1251 - 1258;;WEN, Z ET AL., PLOS ONE, vol. 8, 2013, pages e58161;;VAN VOLLENHOVEN R ET AL., LANCET, vol. 392, 2018, pages 1330 - 39;;KOGA T ET AL., EXPERT REV. CLIN. IMMUNOL., vol. 15, no. 6, 2019, pages 629 - 637;;""GenBank"", Database accession no. NM 002190.3;;PURE & APPL. CHEM., vol. 45, 1976, pages 11 - 30;;ANGEW. CHEM. INT. ED. ENGL., vol. 21, 1982, pages 567 - 583;;""Protective Groups in Organic Chemistry"", 1973, PLENUM PRESS;;T.W. GREENEP.G.M. WUTS: ""Protective Groups in Organic Synthesis"", 1991, JOHN WILEY & SONS;;POLLET, P.GELIN, S.: ""Tetronic Acids and Derivatives; Part VI. A Convenient Synthesis of New 4-Oxo-2-phenyl-2H-4,6-dihydrofuro[3,4-d]triazole and 4-Oxo-4,6-dihydrofuro[3,4-c]furazan Systems"", SYNTHESIS, vol. 12, 1979, pages 977;;DE BOER, TH. J.BACKER, H. J., ORG. SYNTH., vol. 36, 1956, pages 16",PENDING
161,CO,A2,CO 2022017072 A2,166-395-126-604-790,2022-12-09,2022,CO 2022017072 A,2022-11-29,US 2021/0029641 W;;US 202063017682 P,2020-04-30,Imidazopiridazinas como moduladores de il-17,"La presente solicitud describe compuestos que tienen la siguiente fórmula: (I), o sales farmacéuticamente aceptables de estos, en donde R1, R2, R3, R4 y R5 se definen en la especificación, así como métodos para elaborar y usar los compuestos descritos en la presente descripción para tratar o mejorar un síndrome, trastorno y/o enfermedad mediada por la IL-17.",JANSSEN PHARMACEUTICA NV,BEHENNA DOUGLAS;;DECKHUT CHARLOTTE;;ROVIRA ALEXANDER;;GOLDBERG STEVEN;;KUMMER DAVID;;KEITH JOHN;;WOODS CRAIG;;RHORER TIMOTHY;;TANIS VIRGINIA;;MARTIN CONNOR;;MEDUNA STEVEN;;MCCARVER STEFAN;;VALDES ALEXANDER;;LOSKOT STEVEN;;XUE XIAOHUA,,https://lens.org/166-395-126-604-790,Patent Application,no,0,0,21,21,0,A61P11/00;;C07D487/04;;A61P11/00;;C07D487/04;;C07D487/04;;A61K31/519;;A61K31/5025;;A61P29/00;;A61P17/06;;A61P19/02;;A61P11/06;;C07D487/04,C07D487/04;;A61K31/5025;;A61P11/00,,0,0,,,,PENDING
162,CA,A1,CA 3181676 A1,194-254-316-142-415,2021-11-04,2021,CA 3181676 A,2021-04-28,US 202063017682 P;;US 2021/0029641 W,2020-04-30,IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17,"The present application discloses compounds having the following formula: (I), or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.",JANSSEN PHARMACEUTICA NV,BEHENNA DOUGLAS;;DECKHUT CHARLOTTE;;ROVIRA ALEXANDER;;GOLDBERG STEVEN;;KUMMER DAVID;;KEITH JOHN;;WOODS CRAIG;;RHORER TIMOTHY;;TANIS VIRGINIA;;MARTIN CONNOR;;MEDUNA STEVEN;;MCCARVER STEFAN;;VALDES ALEXANDER;;LOSKOT STEVEN;;XUE XIAOHUA,,https://lens.org/194-254-316-142-415,Patent Application,no,0,0,21,21,2,A61P11/00;;C07D487/04;;A61P11/00;;C07D487/04;;C07D487/04;;A61K31/519;;A61K31/5025;;A61P29/00;;A61P17/06;;A61P19/02;;A61P11/06;;C07D487/04,A61K31/5025;;A61P11/00;;C07D487/04,,0,0,,,,PENDING
163,US,A1,US 2011/0275800 A1,096-971-173-731-464,2011-11-10,2011,US 93700609 A,2009-04-08,US 93700609 A;;US 4341608 P;;US 2009/0039850 W,2008-04-09,2-SULFONYLAMINO-4-HETEROARYL BUTYRAMIDE ANTAGONISTS OF CCR10,"This invention relates to a compound of formula (I) and the pharmaceutically acceptable salts thereof wherein R 1 , R 2 , R 4 . Ar and Het are as defined herein. The invention also relates to methods of using the compound of formula (I) to treat a diseases and disorders that are mediated or sustained through the activity of CCR 10 .",BOEHRINGER INGELHEIM INT,ABEYWARDANE ASITHA;;COGAN DEREK;;CHOI YOUNGGI;;GAO DONGHONG A;;GOLDBERG DANIEL R;;HEIM-RIETHER ALEXANDER;;MILLER CRAIG ANDREW;;RAMSDEN PHILIP DEAN;;SMITH KEENAN LANA LOUISE;;SNOW ROGER JOHN;;YU YANG,BOEHRINGER INGELHEIM INTERNATIONAL GMBH (2011-01-05),https://lens.org/096-971-173-731-464,Patent Application,yes,0,2,7,7,0,C07D207/34;;C07D211/16;;C07D403/12;;C07D513/04;;A61P11/06;;A61P17/00;;A61P25/28;;A61P29/00;;A61P35/00;;A61P37/08;;A61P43/00;;C07D211/16;;C07D207/34;;C07D513/04;;C07D403/12,C07D249/04;;C07D403/14;;C07D401/06;;C07D401/14;;C07D405/14,540/575;;546/196;;546/201;;546/211;;546/210;;548/255;;546/146,0,0,,,,ACTIVE
164,KR,A,KR 20230019507 A,023-155-015-615-763,2023-02-08,2023,KR 20227041943 A,2021-04-28,US 202063017682 P;;US 2021/0029641 W,2020-04-30,IL-17의 조절제로서의 이미다조피리다진,"본 출원은 하기 화학식 I을 갖는 화합물 또는 이의 약제학적으로 허용되는 염(상기 식에서, R1, R2, R3, R4 및 R5는 본 명세서에 정의됨)뿐만 아니라, IL-17 매개 증후군, 장애 및/또는 질병을 치료 또는 개선하기 위한 본 명세서에 개시된 화합물의 제조 및 사용 방법을 개시한다. JPEGpct02298.jpg4463",JANSSEN PHARMACEUTICA NV,BEHENNA DOUGLAS;;DECKHUT CHARLOTTE;;ROVIRA ALEXANDER;;GOLDBERG STEVEN;;KUMMER DAVID;;KEITH JOHN;;WOODS CRAIG;;RHORER TIMOTHY;;TANIS VIRGINIA;;MARTIN CONNOR;;MEDUNA STEVEN;;MCCARVER STEFAN;;VALDES ALEXANDER;;LOSKOT STEVEN;;XUE XIAOHUA,,https://lens.org/023-155-015-615-763,Patent Application,no,0,0,21,21,0,A61P11/00;;C07D487/04;;A61P11/00;;C07D487/04;;C07D487/04;;A61K31/519;;A61K31/5025;;A61P29/00;;A61P17/06;;A61P19/02;;A61P11/06;;C07D487/04,C07D487/04;;A61K31/5025;;A61K31/519;;A61P11/06;;A61P17/06;;A61P19/02;;A61P29/00,,0,0,,,,PENDING
165,WO,A1,WO 2009/126675 A1,018-073-200-936-526,2009-10-15,2009,US 2009/0039850 W,2009-04-08,US 4341608 P,2008-04-09,2-SULFONYLAMINO-4-HETEROARYL BUTYRAMIDE ANTAGONISTS OF CCR10,"This invention relates to a compound of formula (I) and the pharmaceutically acceptable salts thereof wherein R 1 , R 2 , R 4 . Ar and Het are as defined herein. The invention also relates to methods of using the compound of formula (I) to treat a diseases and disorders that are mediated or sustained through the activity of CCR10.",BOEHRINGER INGELHEIM INT;;BOEHRINGER INGELHEIM PHARMA;;ABEYWARDANE ASITHA;;COGAN DEREK;;CHOI YOUNGGI;;GAO DONGHONG A;;GOLDBERG DANIEL R;;HEIM-RIETHER ALEXANDER;;MILLER CRAIG ANDREW;;RAMSDEN PHILIP DEAN;;SMITH KEENAN LANA LOUISE;;SNOW ROGER JOHN;;YU YANG,ABEYWARDANE ASITHA;;COGAN DEREK;;CHOI YOUNGGI;;GAO DONGHONG A;;GOLDBERG DANIEL R;;HEIM-RIETHER ALEXANDER;;MILLER CRAIG ANDREW;;RAMSDEN PHILIP DEAN;;SMITH KEENAN LANA LOUISE;;SNOW ROGER JOHN;;YU YANG,,https://lens.org/018-073-200-936-526,Patent Application,yes,1,5,7,7,0,C07D207/34;;C07D211/16;;C07D403/12;;C07D513/04;;A61P11/06;;A61P17/00;;A61P25/28;;A61P29/00;;A61P35/00;;A61P37/08;;A61P43/00;;C07D211/16;;C07D207/34;;C07D513/04;;C07D403/12,C07D207/34;;A61K31/439;;A61P25/28;;C07D211/16;;C07D403/12;;C07D513/04,,1,0,,,"WAGNER G ET AL: ""Synthese von 4-(4-Amidino- phenyl)-2-arylsulfonylaminobuttersäureamiden"", DIE PHARMAZIE, GOVI VERLAG, ESCHBORN, DE, vol. 37, no. 1, 1 January 1982 (1982-01-01), pages 13 - 16, XP002540948",PENDING
166,EP,A1,EP 4143195 A1,022-584-318-888-098,2023-03-08,2023,EP 21729078 A,2021-04-28,US 202063017682 P;;US 2021/0029641 W,2020-04-30,IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17,,JANSSEN PHARMACEUTICA NV,BEHENNA DOUGLAS;;DECKHUT CHARLOTTE;;ROVIRA ALEXANDER;;GOLDBERG STEVEN;;KUMMER DAVID;;KEITH JOHN;;WOODS CRAIG;;RHORER TIMOTHY;;TANIS VIRGINIA;;MARTIN CONNOR;;MEDUNA STEVEN;;MCCARVER STEFAN;;VALDES ALEXANDER;;LOSKOT STEVEN;;XUE XIAOHUA,,https://lens.org/022-584-318-888-098,Patent Application,yes,0,0,21,21,0,A61P11/00;;C07D487/04;;A61P11/00;;C07D487/04;;C07D487/04;;A61K31/519;;A61K31/5025;;A61P29/00;;A61P17/06;;A61P19/02;;A61P11/06;;C07D487/04,C07D487/04;;A61K31/5025;;A61P11/00,,0,0,,,,PENDING
167,MX,A,MX 2022013647 A,150-902-512-342-381,2023-02-01,2023,MX 2022013647 A,2021-04-28,US 202063017682 P;;US 2021/0029641 W,2020-04-30,IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17.,"The present application discloses compounds having the following formula: (I), or pharmaceutically acceptable salts thereof, wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.",JANSSEN PHARMACEUTICA NV,KUMMER DAVID;;TANIS VIRGINIA;;GOLDBERG STEVEN;;KEITH JOHN;;XUE XIAOHUA;;MARTIN CONNOR;;BEHENNA DOUGLAS;;DECKHUT CHARLOTTE;;ROVIRA ALEXANDER;;WOODS CRAIG;;RHORER TIMOTHY;;MEDUNA STEVEN;;MCCARVER STEFAN;;VALDES ALEXANDER;;LOSKOT STEVEN,,https://lens.org/150-902-512-342-381,Patent Application,no,0,0,21,21,0,A61P11/00;;C07D487/04;;A61P11/00;;C07D487/04;;C07D487/04;;A61K31/519;;A61K31/5025;;A61P29/00;;A61P17/06;;A61P19/02;;A61P11/06;;C07D487/04,A61P11/00;;A61K31/5025;;C07D487/04,,0,0,,,,PENDING
168,UY,A,UY 39188 A,162-465-987-173-940,2021-10-29,2021,UY 39188 A,2021-04-28,US 202063017682 P,2020-04-30,IMIDAZOPIRIDAZINAS COMO MODULADORES DE IL-17,"La presente solicitud divulga compuestos que tienen la siguiente fórmula: o sales aceptables desde el punto farmacéutico de esta, en donde R1, R2, R3, R4 y R5 se definen en la memoria descriptiva, así como métodos para elaboración y uso de los compuestos divulgados en la presente para tratar o mejorar un síndrome, trastorno y/o enfermedad mediado por IL-17.",JANSSEN BIOTECH INC,GOLDBERG STEVEN;;KUMMER DAVID;;KEITH JOHN J;;WOODS CRAIG;;RHORER TIMOTHY;;TANIS VIRGINIA;;MARTIN CONNOR;;MEDUNA STEVEN;;MCCARVER STEFAN;;VALDES ALEXANDER;;LOSKOT STEVEN;;BEHENNA DOUGLAS;;ROVIRA ALEXANDER;;CHARLOTTE DECKHUT;;XUE XIAOHUA,,https://lens.org/162-465-987-173-940,Patent Application,no,0,0,21,21,0,A61P11/00;;C07D487/04;;A61P11/00;;C07D487/04;;C07D487/04;;A61K31/519;;A61K31/5025;;A61P29/00;;A61P17/06;;A61P19/02;;A61P11/06;;C07D487/04,A61P11/00;;A61K31/5025;;A61P17/06;;A61P19/02;;A61P37/00;;C07D231/14;;C07D249/04;;C07D261/10;;C07D401/12;;C07D403/12;;C07D487/04,,0,0,,,,PENDING
169,AR,A1,AR 121959 A1,193-649-965-303-91X,2022-07-27,2022,AR P210101149 A,2021-04-28,US 202063017682 P,2020-04-30,IMIDAZOPIRIDAZINAS COMO MODULADORES DE IL-17,"La presente solicitud divulga compuestos que tienen la siguiente fórmula (1), o sales farmacéuticamente aceptables de los mismos, en donde R¹, R², R³, R⁴ y R⁵ han sido definidos en la memoria, así como métodos de elaboración y uso de los compuestos descriptos para tratar o mejorar un síndrome, trastorno y/o enfermedad mediada por IL-17. Reivindicación 1: Un compuesto de la fórmula (1), o una sal farmacéuticamente aceptable del mismo, en donde: R¹ es alquilo-C₍₁₋₆₎, alquilo-C₍₀₋₂₎cicloalquilo-C₍₃₋₆₎, o un heterociclilo de 5 a 6 miembros que tiene 1 a 2 átomos de nitrógeno; en donde el alquilo-C₍₁₋₆₎ es insustituido o sustituido con uno a seis grupos R¹ᵃ; en donde el alquilo-C₍₀₋₂₎cicloalquilo-C₍₃₋₆₎ es insustituido o sustituido con uno a seis grupos R¹ᵇ; y en donde el heterociclilo de 5 a 6 miembros es insustituido o sustituido con uno a tres grupos R¹ᶜ; R² es H, cicloalquilo-C₍₃₋₅₎, o alquilo-C₍₁₋₄₎; en donde el alquilo-C₍₁₋₄₎ es insustituido o sustituido con uno a seis grupos R²ᵃ; R¹ᵃ, R¹ᵇ y R²ᵃ son respectiva e independientemente flúor, cicloalquilo-C₍₃₋₅₎, -CN, -OH, O-alquilo-C₍₁₋₃₎ u O-cicloalquilo-C₍₃₋₄₎, en donde los grupos O-alquilo-C₍₁₋₃₎ y O-cicloalquilo-C₍₃₋₄₎ son insustituidos o sustituidos con uno a tres átomos de flúor; cada R¹ᶜ es independientemente -OCH₃, -OCF₃, -OCHF₂, o alquilo-C₍₁₋₄₎ que es insustituido o sustituido con uno a seis átomos de flúor; R³ es alquilo-C₍₀₋₁₎cicloalquilo-C₍₃₋₆₎, alquilo-C₍₃₋₆₎ o alquilo-C₍₁₋₂₎O-alquilo-C₍₁₋₃₎, en donde el alquilo-C₍₀₋₁₎cicloalquilo-C₍₃₋₆₎, alquilo-C₍₃₋₆₎ y alquilo-C₍₁₋₂₎O-alquilo-C₍₁₋₃₎ son insustituidos o sustituidos con uno a cinco grupos R³ᵃ cada uno independientemente seleccionado entre flúor, -CH₃ -CHF₂, -CF₃, OH y =O; R⁴ es cicloalquilo-C₍₃₋₆₎, fenilo, o un heteroarilo de 5 a 6 miembros que tiene 1 a 4 heteroátomos seleccionados entre N, O, y S; en donde el cicloalquilo-C₍₃₋₆₎ es insustituido o sustituido con uno a tres grupos R⁴ᵃ cada uno independientemente seleccionado entre halógeno, O-alquilo-C₍₁₋₃₎, y alquilo-C₍₁₋₄₎ en donde el O-alquilo-C₍₁₋₃₎, y alquilo-C₍₁₋₄₎ son insustituidos o sustituidos con uno a tres átomos de flúor; alternativamente, dos grupos R⁴ᵃ unidos al mismo átomo de carbono pueden combinarse con el átomo al cual están unidos para formar un cicloalquilo C₍₃₋₆₎; en donde el fenilo es insustituido o sustituido con uno a tres grupos R⁴ᵇ cada uno independientemente seleccionado entre halógeno, -CN, alquilo-C₍₀₋₂₎cicloalquilo-C₍₃₋₄₎, O-alquilo-C₍₀₋₂₎cicloalquilo-C₍₃₋₄₎, O-alquilo-C₍₁₋₃₎, alquilo-C₍₁₋₄₎ y un heterociclilo de 3 a 6 miembros que tiene 1 a 2 heteroátomos seleccionados entre N y O, en donde el O-alquilo-C₍₁₋₃₎, alquilo-C₍₀₋₂₎cicloalquilo-C₍₃₋₄₎ y alquilo-C₍₁₋₄₎ son insustituidos o sustituidos con uno a tres átomos de flúor, y en donde el heterociclilo es insustituido o sustituido con 1 oxo; en donde el heteroarilo de 5 a 6 miembros es insustituido o sustituido con uno o dos grupos R⁴ᶜ; cada R⁴ᶜ es independientemente halógeno, -CN, -OH, -N(R⁴ᶜ¹)(R⁴ᶜ²), alquilo-C₍₀₋₂₎cicloalquilo-C₍₃₋₆₎, O-alquilo-C₍₀₋₂₎cicloalquilo-C₍₃₋₄₎, alquilo-C₍₁₋₄₎, O-alquilo-C₍₁₋₃₎, o un heterociclilo de 3 a 6 miembros que tiene 1 a 2 heteroátomos seleccionados entre N y O, en donde los grupos alquilo-C₍₀₋₂₎cicloalquilo-C₍₃₋₆₎, alquilo-C₍₁₋₄₎, O-alquilo-C₍₁₋₃₎ y heterociclilo son insustituidos o sustituidos con uno a seis grupos R⁴ᵈ; alternativamente, dos grupos R⁴ᶜ unidos a los átomos anulares adyacentes pueden combinarse para formar un cicloalquilo-C₍₄₋₆₎; cada R⁴ᵈ es independientemente flúor, -CN, -OH, oxo, alquilo-C₍₁₋₃₎, O-alquilo-C₍₁₋₃₎, O-cicloalquilo-C₍₃₋₄₎, alquilo-C₍₀₋₂₎-N(R⁴ᵈ¹)(R⁴ᵈ²), alquilo-C₍₀₋₂₎-N(alquilo-C₍₁₋₄₎)C(O)(alquilo-C₍₁₋₄₎) o un heterociclilo de 3 a 6 miembros que tiene 1 a 2 heteroátomos seleccionados entre N y O, en donde los grupos el alquilo-C₍₁₋₃₎, O-alquilo-C₍₁₋₃₎, O-cicloalquilo-C₍₃₋₄₎ y heterociclilo son insustituidos o sustituidos con uno a tres átomos de flúor; R⁴ᶜ¹, R⁴ᶜ², R⁴ᵈ¹ y R⁴ᵈ² son respectiva e independientemente H o -alquilo-C₍₁₋₃₎, en donde el alquilo-C₍₁₋₃₎ es insustituido o sustituido con uno a seis grupos seleccionados entre flúor y cloro; alternativamente R⁴ᵈ¹ y R⁴ᵈ² se pueden combinar con el átomo al cual están unidos para formar un heterociclilo de 3 a 6 miembros que tiene 1 a 3 heteroátomos seleccionados entre N, O y S, en donde el heterociclilo es insustituido o sustituido con 1 a 4 átomos de flúor; y R⁵ es hidrógeno o halógeno; en donde cuando R⁴ es 1,2,4-triazolilo, luego R⁴ es un resto de fórmula (2) ó (3), y cuando R⁴ es un heteroarilo de 6 miembros sustituido, el heteroarilo sustituido es insustituido en la posición -para.",JANSSEN BIOTECH INC,GOLDBERG STEVEN;;KUMMER DAVID;;KEITH JOHN J;;WOODS CRAIG;;RHORER TIMOTHY;;TANIS VIRGINIA;;CONNOR MARTIN;;MEDUNA STEVEN;;MCARVER STEFAN;;VALDES ALEXANDER;;LOSKOT STEVEN;;BEHENNA DOUGLAS;;ROVIRA ALEXANDER;;DECKHUT CHARLOTTE;;XUE XIAOHUA,,https://lens.org/193-649-965-303-91X,Patent Application,no,0,0,21,21,0,A61P11/00;;C07D487/04;;A61P11/00;;C07D487/04;;C07D487/04;;A61K31/519;;A61K31/5025;;A61P29/00;;A61P17/06;;A61P19/02;;A61P11/06;;C07D487/04,C07D487/04;;A61K31/5025;;A61P11/00,,0,0,,,,PENDING
170,US,A1,US 2022/0402922 A1,193-997-547-355-62X,2022-12-22,2022,US 202117242512 A,2021-04-28,US 202117242512 A;;US 202063017682 P,2020-04-30,IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17,"The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , R 4 and R 5 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.",JANSSEN BIOTECH INC,GOLDBERG STEVEN;;KUMMER DAVID;;KEITH JOHN;;WOODS CRAIG;;RHORER TIMOTHY;;TANIS VIRGINIA M;;MARTIN CONNOR;;MEDUNA STEVEN;;MCCARVER STEFAN;;VALDES ALEXANDER;;LOSKOT STEVEN;;BEHENNA DOUGLAS;;ROVIRA ALEXANDER;;DECKHUT CHARLOTTE;;XUE XIAOHUA,CILAG AG (2021-02-09);;JANSSEN RESEARCH & DEVELOPMENT LLC (2021-02-02);;JANSSEN PHARMACEUTICA NV (2021-07-21);;JANSSEN BIOTECH INC (2021-10-07),https://lens.org/193-997-547-355-62X,Patent Application,yes,0,0,21,21,2,A61P11/00;;C07D487/04;;A61P11/00;;C07D487/04;;C07D487/04;;A61K31/519;;A61K31/5025;;A61P29/00;;A61P17/06;;A61P19/02;;A61P11/06;;C07D487/04,C07D487/04,,0,0,,,,ACTIVE
171,TW,A,TW 202208367 A,190-741-861-553-298,2022-03-01,2022,TW 110115268 A,2021-04-28,US 202063017682 P,2020-04-30,Imidazopyridazines as modulators of IL-17,"The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.",JANSSEN PHARMACEUTICA NV,GOLDBERG STEVEN;;KUMMER DAVID;;KEITH JOHN J;;WOODS CRAIG;;RHORER TIMOTHY;;TANIS VIRGINIA;;MARTIN CONNOR;;MEDUNA STEVEN;;MCCARVER STEFAN;;VALDES ALEXANDER;;LOSKOT STEVEN;;BEHENNA DOUGLAS;;ROVIRA ALEXANDER;;DECKHUT CHARLOTTE;;XUE XIAOHUA,,https://lens.org/190-741-861-553-298,Patent of Addition,no,0,0,21,21,0,A61P11/00;;C07D487/04;;A61P11/00;;C07D487/04;;C07D487/04;;A61K31/519;;A61K31/5025;;A61P29/00;;A61P17/06;;A61P19/02;;A61P11/06;;C07D487/04,C07D487/04;;A61K31/5025;;A61P29/00,,0,0,,,,PENDING
172,US,A1,US 2023/0357254 A1,177-648-840-585-314,2023-11-09,2023,US 202318297268 A,2023-04-07,US 202318297268 A;;US 202117242512 A;;US 202063017682 P,2020-04-30,IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17,"The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , R 4 and R 5 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.",JANSSEN PHARMACEUTICA NV,GOLDBERG STEVEN;;KUMMER DAVID;;KEITH JOHN;;WOODS CRAIG;;RHORER TIMOTHY;;TANIS VIRGINIA M;;MARTIN CONNOR;;MEDUNA STEVEN;;MCCARVER STEFAN;;VALDES ALEXANDER;;LOSKOT STEVEN;;BEHENNA DOUGLAS;;ROVIRA ALEXANDER;;DECKHUT CHARLOTTE;;XUE XIAOHUA,CILAG AG (2021-02-09);;JANSSEN RESEARCH & DEVELOPMENT LLC (2021-10-07);;JANSSEN PHARMACEUTICA NV (2021-07-21);;JANSSEN BIOTECH INC (2021-02-17),https://lens.org/177-648-840-585-314,Patent Application,yes,3,0,21,21,0,A61P11/00;;C07D487/04;;A61P11/00;;C07D487/04;;C07D487/04;;A61K31/519;;A61K31/5025;;A61P29/00;;A61P17/06;;A61P19/02;;A61P11/06;;C07D487/04,C07D487/04,,0,0,,,,PENDING
173,NZ,A,NZ 706775 A,123-714-041-960-601,2018-10-26,2018,NZ 70677513 A,2013-10-15,US 2013/0065013 W;;US 201261714419 P;;US 201261725528 P;;US 201361782257 P,2012-10-16,Methylene linked quinolinyl modulators of ror-gamma-t,"The present invention comprises compounds of Formula (I), wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.",JANSSEN PHARMACEUTICA NV,LEONARD KRISTI;;BARBAY KENT;;EDWARDS JAMES;;KREUTTER KEVIN;;KUMMER DAVID;;MAHAROOF UMAR;;NISHIMURA RACHEL;;URBANSKI MAUD;;VENKATESAN HARIHARAN;;WANG AIHUA;;WOLIN RONALD;;WOODS CRAIG;;PIERCE JOAN;;GOLDBERG STEVEN;;FOURIE ANNE;;XUE XIAOHUA,,https://lens.org/123-714-041-960-601,Patent Application,no,0,0,49,50,0,C07D413/14;;C07D401/06;;A61K31/4709;;C07D401/14;;C07D417/14;;C07D409/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P37/00;;A61P37/02;;C07D401/06;;A61K31/4709;;A61K45/06;;C07D401/14;;C07D417/14;;C07D409/14;;C07D413/14,C07D401/14;;A61K31/4709;;A61P29/00;;C07D401/06;;C07D409/14;;C07D413/14;;C07D417/14,,0,0,,,,DISCONTINUED
174,HU,T2,HU E035335 T2,000-746-748-026-632,2018-05-02,2018,HU E13786564 A,2013-10-15,US 201261714419 P;;US 201261725528 P;;US 201361782257 P,2012-10-16,METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T,,JANSSEN PHARMACEUTICA NV,LEONARD KRISTI;;BARBAY KENT;;EDWARDS JAMES;;KREUTTER KEVIN;;KUMMER DAVID;;MAHAROOF UMAR;;NISHIMURA RACHEL;;URBANSKI MAUD;;VENKATESAN HARIHARAN;;WANG AIHUA;;WOLIN RONALD;;WOODS CRAIG;;PIERCE JOAN;;GOLDBERG STEVEN;;FOURIE ANNE;;XUE XIAOHUA,,https://lens.org/000-746-748-026-632,Amended Patent,no,0,0,49,50,0,C07D413/14;;C07D401/06;;A61K31/4709;;C07D401/14;;C07D417/14;;C07D409/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P37/00;;A61P37/02;;C07D401/06;;A61K31/4709;;A61K45/06;;C07D401/14;;C07D417/14;;C07D409/14;;C07D413/14,A61P29/00,,0,0,,,,PENDING
175,NO,L,NO 20024055 L,087-706-649-592-305,2002-10-24,2002,NO 20024055 A,2002-08-26,US 74801000 A;;US 0146812 W,2000-12-27,Interaktiv sökeprosess for produktforespörsler,,USDAHLIN RONALD SCOTT,COOLEY JR WALTER H;;TRAINA GARY JAMES;;WELLS JULIE SUZANNE;;CAGLEY GEORGE DAVID;;KHINDA MANJEET KAUR;;VILLAGOMEZ ROGER CHARLENE ECLA;;IKEMOTO FRED MASATO;;STOTTS WAYNE ALLEN;;SWAIN STEPHEN ARTHUR;;TETIRICK CRAIG WESLEY;;PHILLIPS COLIN TERRY;;COX DONNA MARIE;;OSE LESLIE JEAN;;LEIGHTY CRAIG ERNEST;;PANETTA THOMAS STEVEN;;GOLDBERG CRAIG SCOTT;;WONG CAROLYN ELIZABETH;;SCHUSTER ROBERT MERLE;;CORY RICHARD LANCE;;DULEY SR JAMES MICHAEL,,https://lens.org/087-706-649-592-305,Abstract,no,0,0,13,13,0,G06Q10/087;;G06Q10/0875;;G06Q10/087;;G06Q10/0875;;Y10S707/99933,G21C17/00;;G06F17/30;;G06Q10/08,,0,0,,,,DISCONTINUED
176,EP,A2,EP 1348179 A2,131-181-377-502-410,2003-10-01,2003,EP 01990872 A,2001-12-03,US 0146812 W;;US 74801000 A,2000-12-27,INTERACTIVE SEARCH PROCESS FOR PRODUCT INQUIRIES,,GEN ELECTRIC,"COOLEY, WALTER, H., JR.;;TRAINA, GARY, JAMES;;WELLS, JULIE, SUZANNE;;CAGLEY, GEORGE, DAVID;;KHINDA, MANJEET, KAUR;;VILLAGOMEZ ROGER, CHARLENE, ECLAVEA;;IKEMOTO, FRED, MASATO;;STOTTS, WAYNE, ALLEN;;SWAIN, STEPHEN, ARTHUR;;TETIRICK, CRAIG, WESLEY;;PHILLIPS, COLIN, TERRY;;COX, DONNA, MARIE;;OSE, LESLIE, JEAN;;LEIGHTY, CRAIG, ERNEST;;PANETTA, THOMAS, STEVEN;;GOLDBERG, CRAIG, SCOTT;;WONG, CAROLYN, ELIZABETH;;SCHUSTER, ROBERT, MERLE;;CORY, RICHARD, LANCE;;GAY, JAMES, STEPHENS",,https://lens.org/131-181-377-502-410,Patent Application,yes,0,0,13,13,0,G06Q10/087;;G06Q10/0875;;G06Q10/087;;G06Q10/0875;;Y10S707/99933,G21C17/00;;G06F17/30;;G06Q10/08,,0,0,,,,DISCONTINUED
177,NO,D0,NO 20024055 D0,034-306-649-679-317,2002-08-26,2002,NO 20024055 A,2002-08-26,US 74801000 A;;US 0146812 W,2000-12-27,Interaktiv sökeprosess for produktforespörsler,,USDAHLIN RONALD SCOTT,COOLEY JR WALTER H;;TRAINA GARY JAMES;;WELLS JULIE SUZANNE;;CAGLEY GEORGE DAVID;;KHINDA MANJEET KAUR;;VILLAGOMEZ ROGER CHARLENE ECLA;;IKEMOTO FRED MASATO;;STOTTS WAYNE ALLEN;;SWAIN STEPHEN ARTHUR;;TETIRICK CRAIG WESLEY;;PHILLIPS COLIN TERRY;;COX DONNA MARIE;;OSE LESLIE JEAN;;LEIGHTY CRAIG ERNEST;;PANETTA THOMAS STEVEN;;GOLDBERG CRAIG SCOTT;;WONG CAROLYN ELIZABETH;;SCHUSTER ROBERT MERLE;;CORY RICHARD LANCE;;DULEY SR JAMES MICHAEL,,https://lens.org/034-306-649-679-317,Patent Application,no,0,0,13,13,0,G06Q10/087;;G06Q10/0875;;G06Q10/087;;G06Q10/0875;;Y10S707/99933,G21C17/00;;G06F17/30;;G06Q10/08,,0,0,,,,DISCONTINUED
178,WO,A1,WO 2023/049885 A1,068-511-032-611-765,2023-03-30,2023,US 2022/0076999 W,2022-09-26,US 202163248561 P;;US 202163273395 P,2021-09-27,BENZIMIDAZOLE AND AZABENZIMIDAZOLE IL-17 INHIBITOR COMPOUNDS,"The present application discloses compounds having the following formula (I): or pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , R 4 , and X are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.",JANSSEN PHARMACEUTICA NV,GOLDBERG STEVEN D;;BEHENNA DOUGLAS C;;LOSKOT STEVEN A;;MCCARVER STEFAN J;;RHORER TIMOTHY B;;SONG KRISTEN G;;VALDES ALEXANDER E;;WOODS CRAIG R;;XUE XIAOHUA;;SHIREMAN BROCK T;;TANIS VIRGINIA M;;GORDON DEANE,,https://lens.org/068-511-032-611-765,Patent Application,yes,3,0,1,1,2,C07D405/14;;C07D471/04;;C07D403/14;;A61P29/00,C07D403/14;;A61K31/437;;A61P29/00;;C07D405/14;;C07D471/04,,66,53,054-802-024-202-015;;058-789-884-920-166;;136-423-172-061-579;;027-089-613-263-553;;025-952-159-780-367;;033-396-476-290-463;;042-652-742-080-407;;048-539-201-653-261;;078-205-757-883-386;;143-102-097-264-216;;013-724-187-099-739;;029-486-145-073-303;;055-333-219-420-597;;010-579-552-237-152;;105-951-486-462-687;;037-994-008-331-813;;017-399-513-974-156;;038-941-857-044-672;;000-741-398-771-460;;021-252-678-469-447;;068-332-664-903-404;;048-496-134-706-820;;149-506-609-878-449;;048-384-949-179-543;;020-676-452-752-488;;009-483-825-408-761;;000-339-990-213-470;;004-860-868-419-945;;008-027-654-197-334;;025-108-977-939-014;;084-764-362-530-285;;017-998-842-042-637;;104-840-740-454-175;;061-479-402-388-686;;012-297-050-482-286;;003-280-341-006-389;;047-632-501-021-733;;147-839-336-026-699;;023-034-514-079-124;;030-484-724-366-406;;034-017-376-658-324;;020-760-468-731-878;;048-343-961-635-600;;002-124-596-251-49X;;034-596-672-073-434;;094-824-941-012-161;;041-043-878-985-539;;053-984-061-730-021;;088-960-339-875-350;;087-285-135-148-968;;180-631-728-571-083;;096-841-656-118-220;;077-295-491-167-117,19575028;;pmc2821718;;10.1038/nri2586;;28254169;;10.1016/j.it.2017.01.006;;pmc5411326;;28887948;;10.1016/j.jaci.2017.07.004;;pmc5600287;;10.1007/s12016-018-8702-3;;pmc6244934;;30109481;;pmc4346500;;10.1038/nrrheum.2014.198;;25422000;;24470327;;10.1002/art.38376;;pmc4158887;;10.2217/cer-2018-0141;;30806520;;10.1007/s40744-018-0106-6;;29605841;;pmc5935619;;14984588;;10.1111/j.1440-1711.2004.01212.x;;10.1016/j.jbspin.2006.11.005;;17369068;;10.1002/art.24568;;19479869;;22485125;;10.1371/journal.pone.0031000;;pmc3317658;;25288779;;10.1093/rheumatology/keu382;;pmc3218910;;10.1186/ar3370;;21689402;;29945918;;10.1136/annrheumdis-2018-213328;;pmc6104676;;10.3410/f.733519001.793552052;;10.1016/j.jid.2017.05.033;;28652108;;pmc6128497;;29617527;;10.1001/jamadermatol.2018.0141;;pmc4227922;;10.1038/jid.2014.263;;24945093;;30219389;;10.1016/j.jaut.2018.09.003;;18432274;;10.1038/jid.2008.111;;10.1111/exd.13112;;27304428;;pmc5502835;;26804758;;10.1016/j.autrev.2016.01.004;;pmc4769658;;pmc4470702;;10.1111/pcmr.12284;;24935676;;11984595;;10.1038/nm0502-500;;10335518;;10.1191/135245899678847275;;10.1177/135245859900500206;;pmc2189615;;18156204;;10.2353/ajpath.2008.070690;;10.4049/jimmunol.1701213;;29298833;;10.1016/j.jneuroim.2019.04.011;;31034962;;27142710;;10.1007/s00415-016-8128-x;;10.1067/mai.2003.1557;;12789232;;11544464;;10.1067/mai.2001.117929;;30233389;;10.3389/fphys.2018.01183;;pmc6134017;;10.1016/j.rmed.2011.05.017;;21763119;;10.1172/jci121087;;pmc6307967;;30383540;;23957503;;pmc5569243;;10.3109/09273948.2013.815786;;10.1016/j.ajo.2011.01.031;;21570674;;10.1080/02713680902741696;;19373578;;10.1016/j.ophtha.2012.09.040;;23290985;;25638011;;10.1016/j.ophtha.2014.12.033;;22207110;;pmc3560674;;10.12659/msm.882204;;26293646;;10.1038/leu.2015.228;;pmc4740263;;11035433;;10.1191/096120300678828703;;18373953;;10.1016/j.clim.2008.01.019;;19347604;;10.1007/s11033-009-9533-3;;10.1007/s10875-009-9365-x;;20107878;;21243492;;10.1007/s00296-010-1771-0;;10.1007/s10067-010-1510-7;;20563617;;23472149;;pmc3589375;;10.1371/journal.pone.0058161;;10.1016/s0140-6736(18)32167-6;;30249507;;30874446;;10.1080/1744666x.2019.1593141;;10.1351/pac197645010011;;10.1002/anie.198205671;;10.1002/0471220574,"GAFFEN, S: ""Structure and signaling in the IL-17 receptor family"", NAT. REV. IMMUNOL., vol. 9, 2009, pages 556 - 567;;AMATYA N, TRENDS IN IMMUNOLOGY, vol. 38, 2017, pages 310 - 322;;HAWKES ET AL.: ""Psoriasis Pathogenesis and the Development of Novel, Targeted Immune Therapies"", J ALLERGY CLIN IMMUNOL, vol. 140, no. 3, 2017, pages 645 - 653, XP085165342, DOI: 10.1016/j.jaci.2017.07.004;;BLAUVELT ACHIRICOZZI A: ""The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis"", CLIN REV ALLERGY IMMUNOL, vol. 55, no. 3, 2018, pages 379 - 390, XP036632999, DOI: 10.1007/s12016-018-8702-3;;ADAMOPOULOS IMELLINS E, NATURE REVIEWS RHEUMATOLOGY, vol. 11, 2015, pages 189 - 94;;MENON B ET AL., ARTHRITIS & RHEUMATOLOGY, vol. 66, 2014, pages 1272 - 81;;MEASE P ET AL., EUR. J. RHEUMATOL., vol. 6, no. 3, 1 July 2019 (2019-07-01), pages 113 - 121;;STRAND V ET AL., J. COMP. EFF. RES., vol. 8, no. 7, 2019, pages 497 - 510;;NASH P ET AL., RHEUMATOL. THER., vol. 5, no. 1, 2018, pages 99 - 122;;MEASE, P ET AL., ANN RHEUM DISS, vol. 79, 2020, pages 123 - 131;;STAMP, L ET AL.: ""The recognition of IL-17 as a pro-inflammatory T cell derived cytokine, and its abundance within rheumatoid joints, provides the strongest candidate mechanism to date through which T cells can capture and localize macrophage effector functions in rheumatoid arthritis"", IMMUNOL. CELL BIOL., vol. 82, no. 1, 2004, pages 1 - 9;;WENDLING D ET AL., JOINT BONE SPINE, vol. 74, 2007, pages 304 - 305;;SHEN H ET AL., ARTHRITIS RHEUM, vol. 60, no. 6, 2009, pages 1647 - 56;;ZHANG L ET AL., PLOS ONE, vol. 7, no. 4, 2012, pages e31000;;JANSEN D ET AL., RHEUMATOLOGY (OXFORD, vol. 54, no. 4, April 2015 (2015-04-01), pages 728 - 735;;APPEL H ET AL., ARTHRITIS RES. THER., vol. 13, no. 3, 2011, pages R95;;DEODHAR A ET AL., ARTHRITIS RHEUMATOL, vol. 71, no. 2, 2019, pages 258 - 270;;BAETEND ET AL., ANN. RHEUM. DIS, vol. 77, no. 9, 2018, pages 1295 - 1302;;SCHLAPBACH C ET AL., J., vol. 65, no. 4, 2011, pages 790;;KELLY G ET AL., BRITISH J. DERMATOL., vol. 173, no. 6, December 2015 (2015-12-01), pages 1431 - 9;;MORANB ET AL., J. INVEST. DERMATOL., vol. 137, no. 11, 2017, pages 2389;;THOMI R ET AL., JAMA DERMATOL, vol. 154, no. 5, 2018, pages 592;;PRUSSICK L ET AL., BRITISH J, vol. 181, no. 3, September 2019 (2019-09-01), pages 609 - 611;;LE JAN S ET AL., J. INVEST. DERMATOL., vol. 134, no. 12, 2014, pages 2908 - 2917;;CHAKIEVSKA L, J AUTOIMMUN., vol. 96, 2019, pages 104 - 112;;CHAKIEVSKA L, J AUTOIMMUN, vol. 96, 2019, pages 104 - 112;;KOGA C ET AL., J. INVEST. DERMATOL., vol. 128, 2008, pages 2625 - 2630;;KHATTRI S ET AL., EXP. DERMATOL., vol. 26, no. 1, January 2017 (2017-01-01), pages 28 - 35;;SINGH R ET AL., AUTOIMMUN. REV, vol. 15, no. 4, April 2016 (2016-04-01), pages 397 - 404;;EBY J ET AL., PIGMENT CELL & MELANOMA RES, vol. 27, no. 6, November 2014 (2014-11-01), pages 1075 - 85;;LOCK, C ET AL., NAT. MED., vol. 8, 2002, pages 500 - 508;;MATUSEVICIUS, D. ET AL., MULT. SCLER, vol. 5, 1999, pages 101 - 104;;TZARTOS, J ET AL., AM. J. PATHOL., vol. 172, 2008, pages 146 - 155;;WILLING A ET AL., J. IMMUNOL., vol. 200, no. 3, 2018, pages 974 - 982;;SETIADI AF ET AL., J NEUROIMMUNOL, vol. 332, 2019, pages 147 - 154;;HAVRDOVA, E ET AL., J. NEUROL., vol. 263, 2016, pages 1287 - 1295;;CHAKIR J ET AL., J. ALLERGY CLIN. IMMUNOL., vol. 111, no. 6, 2003, pages 1293 - 8;;MOLET S ET AL., J. ALLERGY CLIN. IMMUNOL., vol. 108, no. 3, 2001, pages 430 - 8;;CAMARGO LDN ET AL., FRONT IMMUNOL, vol. 8, 2018, pages 1835;;DOS SANTOS T ET AL., FRONT. PHYSIOL, vol. 9, 2018, pages 1183;;VARGAS-ROJAS M ET AL., RESPIR. MED., vol. 105, no. 11, November 2011 (2011-11-01), pages 1648 - 54;;CHRISTENSON S ET AL., J. CLIN. INVEST., vol. 129, no. 1, 2019, pages 169 - 181;;CHEN Y ET AL., PLOS ONE, vol. 6, 2011, pages el8139;;EL-ASRAR A ET AL., CLIN. IMMUNOL., vol. 141, no. 2, 2011, pages 197 - 204;;JAWAD S ET AL., OCUL. IMMUNOL. INFLAMM., vol. 21, no. 6, 2013, pages 434 - 9;;KUIPER J ET AL., AM. J. OPHTHALMOL., vol. 152, no. 2, 2011, pages 177 - 182;;ZHANG R ET AL., CURR. EYE RES., vol. 34, no. 4, April 2009 (2009-04-01), pages 297 - 303;;DICK A ET AL., OPHTHALMOLOGY, vol. 120, no. 4, 2013, pages 777 - 87;;LETKO E ET AL., OPHTHALMOLOGY, vol. 122, no. 5, 2015, pages 939 - 948;;MUGHEDDU C ET AL., DERMATOL. THER., vol. 30, no. 5, September 2017 (2017-09-01), pages el2527;;LEMANCEWICZ D ET AL., MED. SCI. MONIT., vol. 18, no. 1, 2012, pages BR54 - BR59;;PRABHALA R ET AL., LEUKEMIA, vol. 30, no. 2, February 2016 (2016-02-01), pages 379 - 389;;WONG C ET AL., LUPUS, vol. 9, no. 8, 2000, pages 589 - 593;;WONG C ET AL., CLINICAL IMMUNOLOGY, vol. 127, no. 3, 2008, pages 385 - 393;;ZHAO X-F. ET AL., MOL. BIOL. REP., vol. 37, no. 1, January 2010 (2010-01-01), pages 81 - 5;;CHEN X ET AL., J. CLIN. IMMUNOL., vol. 30, no. 2, March 2010 (2010-03-01), pages 221 - 5;;XING Q ET AL., RHEUMATOL. INT., vol. 32, no. 4, April 2012 (2012-04-01), pages 949 - 58;;MA J ET AL., CLIN. RHEUMATOL., vol. 29, no. 11, 2010, pages 1251 - 1258;;WEN, Z ET AL., PLOS ONE, vol. 8, 2013, pages e58161;;VAN VOLLENHOVEN R ET AL., LANCET, vol. 392, 2018, pages 1330 - 39;;KOGA T ET AL., EXPERT REV. CLIN. IMMUNOL., vol. 15, no. 6, 2019, pages 629 - 637;;""GenBank"", Database accession no. NM_002190.3;;PURE & APPL. CHEM., vol. 45, 1976, pages 11 - 30;;ANGEW. CHEM. INT. ED. ENGL., vol. 21, 1982, pages 567 - 583;;""Protective Groups in Organic Chemistry"", 1973, PLENUM PRESS;;T.W. GREENEP.G.M. WUTS: ""Protective Groups in Organic Synthesis"", 1991, JOHN WILEY & SONS",PENDING
179,US,A1,US 2002/0082958 A1,114-958-398-181-816,2002-06-27,2002,US 74801000 A,2000-12-27,US 74801000 A,2000-12-27,Interactive search process for product inquiries,"
   A business process utilizes computer software and electronic customer/supplier connections to supply information, receive requests for quotation, supply quotations, receive purchase orders, and perform commercial and technical functions associated with delivery of such purchase orders or quotations with respect to environment and use specific products. Such products require customer or plant application unique technical evaluation and/or commercial processing to ensure applicability to a specific customer application. The system provides a vehicle to search for parts requiring such technical review encompassing anticipated product use. 
",COOLEY WALTER HENING;;TRAINA GARY JAMES;;WELLS JULIE SUZANNE;;CAGLEY GEORGE DAVID;;KHINDA MANJEET KAUR;;ROGER CHARLENE ECLAVEA VILLAGOMEZ;;IKEMOTO FRED MASATO;;STOTTS WAYNE ALLEN;;SWAIN STEPHEN ARTHUR;;TETIRICK CRAIG WESLEY;;PHILLIPS COLIN TERRY;;COX DONNA MARIE;;OSE LESLIE JEAN;;LEIGHTY CRAIG ERNEST;;PANETTA THOMAS S.;;GOLDBERG CRAIG SCOTT;;WONG CAROLYN ELIZABETH;;SCHUSTER ROBERT MERLE;;CORY RICHARD LANCE;;DULEY JAMES MICHAEL;;GAY JAMES STEPHENS;;DAHLIN RONALD SCOTT;;SHOCKLEY CAROLYN R.,COOLEY WALTER HENING;;TRAINA GARY JAMES;;WELLS JULIE SUZANNE;;CAGLEY GEORGE DAVID;;KHINDA MANJEET KAUR;;ROGER CHARLENE ECLAVEA VILLAGO;;IKEMOTO FRED MASATO;;STOTTS WAYNE ALLEN;;SWAIN STEPHEN ARTHUR;;TETIRICK CRAIG WESLEY;;PHILLIPS COLIN TERRY;;COX DONNA MARIE;;OSE LESLIE JEAN;;LEIGHTY CRAIG ERNEST;;PANETTA THOMAS S;;GOLDBERG CRAIG SCOTT;;WONG CAROLYN ELIZABETH;;SCHUSTER ROBERT MERLE;;CORY RICHARD LANCE;;DULEY JAMES MICHAEL;;GAY JAMES STEPHENS;;DAHLIN RONALD SCOTT;;SHOCKLEY CAROLYN R,GENERAL ELECTRIC COMPANY (2000-12-07),https://lens.org/114-958-398-181-816,Patent Application,yes,6,12,13,13,0,G06Q10/087;;G06Q10/0875;;G06Q10/087;;G06Q10/0875;;Y10S707/99933,G21C17/00;;G06F17/30;;G06Q10/08,705/29,0,0,,,,EXPIRED
180,CY,T1,CY 1119234 T1,187-920-498-416-082,2018-02-14,2018,CY 171100793 T,2017-07-25,US 201261714419 P;;US 201261725528 P;;US 201361782257 P;;US 2013/0065013 W,2012-10-16,ΜΕΘΥΛΕΝΟ ΣΥΝΔΕΔΕΜΕΝΟΙ ΚΙΝΟΛΙΝΥΛ ΡΥΘΜΙΣΤΕΣ ΤΟΥ ROR-ΓΑΜΜΑ-Τ,"Η παρούσα εφεύρεση περιλαμβάνει ενώσεις του Τύπου (I), όπου: R1, R2, R3, R4, R5, R6, R7, R8 και R9 ορίζονται στην προδιαγραφή. Η εφεύρεση επίσης περιλαμβάνει μέθοδο θεραπείας ή βελτίωσης συνδρόμου, διαταραχής ή ασθένειας, όπου το εν λόγω σύνδρομο, διαταραχή ή ασθένεια είναι ρευματοειδής αρθρίτιδα ή ψωρίαση. Η εφεύρεση περιλαμβάνει επίσης μέθοδο ρύθμισης δραστικότητας RORγt σε ένα θηλαστικό με χορήγηση μιας θεραπευτικώς αποτελεσματικής ποσότητας τουλάχιστον μιας ένωσης της αξίωσης 1.",JANSSEN PHARMACEUTICA NV,LEONARD KRISTI A;;BARBAY KENT;;EDWARDS JAMES P;;KREUTTER KEVIN D;;KUMMER DAVID A;;MAHAROOF UMAR;;NISHIMURA RACHEL;;URBANSKI MAUD;;VENKATESAN HARIHARAN;;WANG AIHUA;;WOLIN RONALD L;;WOODS CRAIG R;;PIERCE JOAN;;GOLDBERG STEVEN;;FOURIE ANNE;;XUE XIAOHUA,,https://lens.org/187-920-498-416-082,Granted Patent,no,0,0,49,50,0,C07D413/14;;C07D401/06;;A61K31/4709;;C07D401/14;;C07D417/14;;C07D409/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P37/00;;A61P37/02;;C07D401/06;;A61K31/4709;;A61K45/06;;C07D401/14;;C07D417/14;;C07D409/14;;C07D413/14,C07D401/14;;A61K31/4709;;A61P29/00;;C07D401/06;;C07D409/14;;C07D413/14;;C07D417/14,,0,0,,,,ACTIVE
181,HK,A1,HK 1213248 A1,181-700-409-657-069,2016-06-30,2016,HK 16101098 A,2016-02-01,US 2013/0065013 W;;US 201261714419 P;;US 201261725528 P;;US 201361782257 P,2012-10-16,METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T ROR--T,,JANSSEN PHARMACEUTICA NV,LEONARD KRISTI A;;BARBAY KENT;;EDWARDS JAMES P;;KREUTTER KEVIN D;;KUMMER DAVID A;;MAHAROOF UMAR;;NISHIMURA RACHEL;;URBANSKI MAUD;;VENKATESAN HARIHARAN;;WANG AIHUA;;WOLIN RONALD L;;WOODS CRAIG R;;PIERCE JOAN;;GOLDBERG STEVEN;;FOURIE ANNE;;XUE XIAOHUA,,https://lens.org/181-700-409-657-069,Patent Application,no,0,0,49,50,0,C07D413/14;;C07D401/06;;A61K31/4709;;C07D401/14;;C07D417/14;;C07D409/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P37/00;;A61P37/02;;C07D401/06;;A61K31/4709;;A61K45/06;;C07D401/14;;C07D417/14;;C07D409/14;;C07D413/14,C07D/;;A61K/;;A61P/,,0,0,,,,DISCONTINUED
182,CA,A1,CA 2888210 A1,017-966-397-284-26X,2014-04-24,2014,CA 2888210 A,2013-10-15,US 201261714419 P;;US 201261725528 P;;US 201361782257 P;;US 2013/0065013 W,2012-10-16,METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T,"The present invention comprises compounds of Formula (I), wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.",JANSSEN PHARMACEUTICA NV,LEONARD KRISTI A;;BARBAY KENT;;EDWARDS JAMES P;;KREUTTER KEVIN D;;KUMMER DAVID A;;MAHAROOF UMAR;;NISHIMURA RACHEL;;URBANSKI MAUD;;VENKATESAN HARIHARAN;;WANG AIHUA;;WOLIN RONALD L;;WOODS CRAIG R;;PIERCE JOAN;;GOLDBERG STEVEN;;FOURIE ANNE;;XUE XIAOHUA,,https://lens.org/017-966-397-284-26X,Patent Application,no,0,0,49,50,9,C07D413/14;;C07D401/06;;A61K31/4709;;C07D401/14;;C07D417/14;;C07D409/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P37/00;;A61P37/02;;C07D401/06;;A61K31/4709;;A61K45/06;;C07D401/14;;C07D417/14;;C07D409/14;;C07D413/14,C07D401/14;;A61K31/4709;;A61P29/00;;C07D401/06;;C07D409/14;;C07D413/14;;C07D417/14,,0,0,,,,ACTIVE
183,PH,A1,PH 12015500817 A1,065-459-012-289-989,2015-06-08,2015,PH 12015500817 A,2015-04-14,US 201361782257 P;;US 201261725528 P;;US 201261714419 P;;US 2013/0065013 W,2012-10-16,METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T,"The present invention comprises compounds of Formula (I), wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.",JANSSEN PHARMACEUTICA NV,LEONARD KRISTI A;;KENT BARBAY;;EDWARDS JAMES P;;KREUTTER KEVIN D;;KUMMER DAVID A;;UMAR MAHAROOF;;RACHEL NISHIMURA;;MAUD URBANSKI;;HARIHARAN VENKATESAN;;AIHUA WANG;;WOLIN RONALD L;;WOODS CRAIG R;;JOAN PIERCE;;STEVEN GOLDBERG;;ANNE FOURIE;;XIAOHUA XUE,,https://lens.org/065-459-012-289-989,Patent Application,no,0,0,49,50,0,C07D413/14;;C07D401/06;;A61K31/4709;;C07D401/14;;C07D417/14;;C07D409/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P37/00;;A61P37/02;;C07D401/06;;A61K31/4709;;A61K45/06;;C07D401/14;;C07D417/14;;C07D409/14;;C07D413/14,A61K31/4709;;A61P29/00;;C07D401/06;;C07D401/14;;C07D409/14;;C07D413/14;;C07D417/14,,0,0,,,,ACTIVE
184,US,A1,US 2014/0107094 A1,026-924-796-805-481,2014-04-17,2014,US 201314053653 A,2013-10-15,US 201314053653 A;;US 201361782257 P;;US 201261725528 P;;US 201261714419 P,2012-10-16,METHYLENE LINKED QUINOLINYL MODULATORS OF RORyt,"The present invention comprises compounds of Formula I. wherein: R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.",JANSSEN PHARMACEUTICA NV,LEONARD KRISTI A;;BARBAY KENT;;EDWARDS JAMES P;;KREUTTER KEVIN D;;KUMMER DAVID A;;MAHAROOF UMAR;;NISHIMURA RACHEL;;URBANSKI MAUD;;VENKATESAN HARIHARAN;;WANG AIHUA;;WOLIN RONALD L;;WOODS CRAIG R;;PIERCE JOAN;;GOLDBERG STEVEN;;FOURIE ANNE;;XUE XIAOHUA,JANSSEN PHARMACEUTICA NV (2013-11-21),https://lens.org/026-924-796-805-481,Patent Application,yes,2,10,49,50,9,C07D413/14;;C07D401/06;;A61K31/4709;;C07D401/14;;C07D417/14;;C07D409/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P37/00;;A61P37/02;;C07D401/06;;A61K31/4709;;A61K45/06;;C07D401/14;;C07D417/14;;C07D409/14;;C07D413/14,C07D401/06;;A61K31/4709;;A61K45/06;;C07D401/14;;C07D409/14;;C07D417/14,514/210.18;;546/176;;514/314;;546/157;;514/312;;546/159;;514/313;;546/155;;546/169;;514/210.21,1,1,084-843-025-849-979,21516112;;10.1038/ni.2027;;10.3410/f.10935956.11871057,"Codarri, Nature Immunology, June 2011, Vol 12(6), p 560-568.",ACTIVE
185,EC,A,EC SP15015022 A,087-620-992-451-246,2016-01-29,2016,EC PI201515022 A,2015-04-15,US 201261714419 P;;US 201261725528 P;;US 201361782257 P,2012-10-16,MODULADORES DE QUINOLINILO UNIDOS A METILENO DE ROR-GAMMA-T,"La presente invención comprende los compuestos de la Fórmula (I) (ver anexo) en donde: R1, R2, R3, R4, R5, R6, R7, R8 y R9 son tal como se definieron en la especificación. La invención comprende, además, un método para tratar o mejorar un síndrome, trastorno o enfermedad, en donde ese síndrome, trastorno o enfermedad es artritis reumatoide o soriasis. La invención comprende, además, un método para modular la actividad de RORyt en un mamífero por medio de la administración de una cantidad terapéuticamente eficaz de por lo menos un compuesto de la reivindicación 1.",JANSSEN PHARMACEUTICA NV,KREUTTER KEVIN D;;URBANSKI MAUD;;MAHAROOF UMAR;;KUMMER DAVID A;;GOLDBERG STEVEN;;LEONARD KRISTI A;;BARBAY KENT;;VENKATESAN HARIHARAN;;EDWARDS JAMES P;;WANG AIHUA;;PIERCE JOAN;;WOLIN RONALD L;;NISHIMURA RACHEL;;FOURIE ANNE;;XUE XIAOHUA;;WOODS CRAIG R,,https://lens.org/087-620-992-451-246,Patent Application,no,0,0,49,50,0,C07D413/14;;C07D401/06;;A61K31/4709;;C07D401/14;;C07D417/14;;C07D409/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P37/00;;A61P37/02;;C07D401/06;;A61K31/4709;;A61K45/06;;C07D401/14;;C07D417/14;;C07D409/14;;C07D413/14,C07D401/14;;A61K31/4709;;A61P29/00;;C07D401/06;;C07D409/14;;C07D413/14;;C07D417/14,,0,0,,,,PENDING
186,NI,A,NI 201500053 A,155-721-476-921-19X,2020-03-18,2020,NI 201500053 A,2015-04-15,US 201261714419 P;;US 201261725528 P;;US 201361782257 P,2012-10-16,MODULADORES DE QUINOLINILO UNIDOS A METILENO DE ROR-GAMMA-T,"La presente invención comprende los compuestos de la Fórmula (I), en donde: R1, R2, R3, R4, R5, R6, R7, R8 y R9 son tal como se definieron en la especificación. La invención comprende, además, un método para tratar o mejorar un síndrome, trastornos o enfermedades, en donde ese síndrome, trastorno o enfermedad es artritis reumatoide o soriasis. La invención comprende, además, un método para modular la actividad de ROR?t en un mamífero por medio de la administración de una cantidad terapéuticamente eficaz de por lo menos un compuesto de la reivindicación 1.",JANSSEN PHARMACEUTICA NV,KRISTI A LEONARD;;KENT BARBAY;;JAMES P EDWARDS;;KEVIN D KREUTTER;;DAVID A KUMMER;;UMAR MAHAROOF;;RACHEL NISHIMURA;;MAUD URBANSKI;;HARIHARAN VENKATESAN;;AIHUA WANG;;RONALD L WOLIN;;CRAIG R WOODS;;JOAN PIERCE;;STEVEN GOLDBERG;;ANNE FOURIE;;XIAOHUA XUE,,https://lens.org/155-721-476-921-19X,Granted Patent,no,0,0,49,50,0,C07D413/14;;C07D401/06;;A61K31/4709;;C07D401/14;;C07D417/14;;C07D409/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P37/00;;A61P37/02;;C07D401/06;;A61K31/4709;;A61K45/06;;C07D401/14;;C07D417/14;;C07D409/14;;C07D413/14,C07D401/14;;A61K31/4709;;A61P29/00;;C07D401/06;;C07D409/14;;C07D413/14;;C07D417/14,,0,0,,,,ACTIVE
187,AU,B2,AU 2013/331496 B2,034-126-298-883-149,2017-07-27,2017,AU 2013/331496 A,2013-10-15,US 201261714419 P;;US 201261725528 P;;US 201361782257 P;;US 2013/0065013 W,2012-10-16,Methylene linked quinolinyl modulators of ROR-gamma-t,"The present invention comprises compounds of Formula (I), wherein: R",JANSSEN PHARMACEUTICA NV,LEONARD KRISTI A;;BARBAY KENT;;EDWARDS JAMES P;;KREUTTER KEVIN D;;KUMMER DAVID A;;MAHAROOF UMAR;;NISHIMURA RACHEL;;URBANSKI MAUD;;VENKATESAN HARIHARAN;;WANG AIHUA;;WOLIN RONALD L;;WOODS CRAIG R;;PIERCE JOAN;;GOLDBERG STEVEN;;FOURIE ANNE;;XUE XIAOHUA,,https://lens.org/034-126-298-883-149,Granted Patent,no,1,0,49,50,0,C07D413/14;;C07D401/06;;A61K31/4709;;C07D401/14;;C07D417/14;;C07D409/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P37/00;;A61P37/02;;C07D401/06;;A61K31/4709;;A61K45/06;;C07D401/14;;C07D417/14;;C07D409/14;;C07D413/14,C07D401/06;;A61K31/4709;;A61P29/00;;C07D401/14;;C07D409/14;;C07D413/14;;C07D417/14,,0,0,,,,INACTIVE
188,KR,A,KR 20150070347 A,188-644-147-414-980,2015-06-24,2015,KR 20157012838 A,2013-10-15,US 201261714419 P;;US 201261725528 P;;US 201361782257 P;;US 2013/0065013 W,2012-10-16,METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T,"본 발명은 화학식 (I)의 화합물을 포함한다:화학식 I 상기 식에서, R, R, R, R, R, R, R, R및 R은 본 명세서에 정의된 바와 같다. 본 발명은 또한 류머티스성 관절염 또는 건선인 증후군, 장애 또는 질환을 치료하거나 개선시키는 방법을 포함한다. 본 발명은 또한 적어도 하나의 제1항의 화합물의 치료적 유효량을 투여함으로써 포유동물에서 RORγt 활성을 조절하는 방법을 포함한다.",JANSSEN PHARMACEUTICA NV,LEONARD KRISTI A;;BARBAY KENT;;EDWARDS JAMES P;;KREUTTER KEVIN D;;KUMMER DAVID A;;MAHAROOF UMAR;;NISHIMURA RACHEL;;URBANSKI MAUD;;VENKATESAN HARIHARAN;;WANG AIHUA;;WOLIN RONALD L;;WOODS CRAIG R;;PIERCE JOAN;;GOLDBERG STEVEN;;FOURIE ANNE;;XUE XIAOHUA,,https://lens.org/188-644-147-414-980,Patent Application,no,0,0,49,50,0,C07D413/14;;C07D401/06;;A61K31/4709;;C07D401/14;;C07D417/14;;C07D409/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P37/00;;A61P37/02;;C07D401/06;;A61K31/4709;;A61K45/06;;C07D401/14;;C07D417/14;;C07D409/14;;C07D413/14,A61K31/4709;;A61K45/06;;C07D401/10;;C07D409/14;;C07D417/14,,0,0,,,,ACTIVE
189,PT,T,PT 2909192 T,193-336-583-891-835,2017-08-04,2017,PT 13786564 T,2013-10-15,US 201261714419 P;;US 201261725528 P;;US 201361782257 P,2012-10-16,METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T,,JANSSEN PHARMACEUTICA NV,KRISTI A LEONARD;;KENT BARBAY;;JAMES P EDWARDS;;KEVIN D KREUTTER;;DAVID A KUMMER;;UMAR MAHAROOF;;RACHEL NISHIMURA;;MAUD URBANSKI;;HARIHARAN VENKATESAN;;AIHUA WANG;;RONALD L WOLIN;;CRAIG R WOODS;;JOAN PIERCE;;STEVEN GOLDBERG;;ANNE FOURIE;;XIAOHUA XUE,,https://lens.org/193-336-583-891-835,Patent Application,no,0,0,49,50,0,C07D413/14;;C07D401/06;;A61K31/4709;;C07D401/14;;C07D417/14;;C07D409/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P37/00;;A61P37/02;;C07D401/06;;A61K31/4709;;A61K45/06;;C07D401/14;;C07D417/14;;C07D409/14;;C07D413/14,C07D401/14;;A61K31/4709;;A61P29/00;;C07D401/06;;C07D409/14;;C07D413/14;;C07D417/14,,0,0,,,,PENDING
190,ME,B,ME 02794 B,033-623-803-278-785,2018-01-20,2018,ME P2017151 A,2013-10-15,US 201261714419 P;;US 201261725528 P;;US 201361782257 P;;EP 13786564 A;;US 2013/0065013 W,2012-10-16,METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T,,JANSSEN PHARMACEUTICA NV,LEONARD KRISTI A;;BARBAY KENT;;EDWARDS JAMES P;;KREUTTER KEVIN D;;KUMMER DAVID A;;MAHAROOF UMAR;;NISHIMURA RACHEL;;URBANSKI MAUD;;VENKATESAN HARIHARAN;;WANG AIHUA;;WOLIN RONALD L;;WOODS CRAIG R;;PIERCE JOAN;;GOLDBERG STEVEN;;FOURIE ANNE;;XUE XIAOHUA,,https://lens.org/033-623-803-278-785,Granted Patent,no,0,0,49,50,0,C07D413/14;;C07D401/06;;A61K31/4709;;C07D401/14;;C07D417/14;;C07D409/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P37/00;;A61P37/02;;C07D401/06;;A61K31/4709;;A61K45/06;;C07D401/14;;C07D417/14;;C07D409/14;;C07D413/14,A61K31/4709;;A61P29/00;;C07D401/06;;C07D401/14;;C07D409/14;;C07D413/14;;C07D417/14,,0,0,,,,ACTIVE
191,RS,B1,RS 56283 B1,156-184-141-248-306,2017-12-29,2017,RS P20170741 A,2013-10-15,US 201261714419 P;;US 201261725528 P;;US 201361782257 P;;US 2013/0065013 W;;EP 13786564 A,2012-10-16,METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T,,JANSSEN PHARMACEUTICA NV,LEONARD KRISTI A;;BARBAY KENT;;EDWARDS JAMES P;;KREUTTER KEVIN D;;KUMMER DAVID A;;MAHAROOF UMAR;;NISHIMURA RACHEL;;URBANSKI MAUD;;VENKATESAN HARIHARAN;;WANG AIHUA;;WOLIN RONALD L;;WOODS CRAIG R;;PIERCE JOAN;;GOLDBERG STEVEN;;FOURIE ANNE;;XUE XIAOHUA,,https://lens.org/156-184-141-248-306,Granted Patent,no,0,0,49,50,0,C07D413/14;;C07D401/06;;A61K31/4709;;C07D401/14;;C07D417/14;;C07D409/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P37/00;;A61P37/02;;C07D401/06;;A61K31/4709;;A61K45/06;;C07D401/14;;C07D417/14;;C07D409/14;;C07D413/14,C07D401/14;;A61K31/4709;;A61P29/00;;C07D401/06;;C07D409/14;;C07D413/14;;C07D417/14,,0,0,,,,ACTIVE
192,TW,A,TW 201427969 A,196-444-670-020-197,2014-07-16,2014,TW 102137062 A,2013-10-15,US 201261714419 P;;US 201261725528 P;;US 201361782257 P,2012-10-16,Methylene linked quinolinyl modulators of ROR γ t,"The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR γ t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.",JANSSEN PHARMACEUTICA NV,LEONARD KRISTI A;;BARBAY KENT;;EDWARDS JAMES P;;KREUTTER KEVIN D;;KUMMER DAVID A;;MAHAROOF UMAR;;NISHIMURA RACHEL;;URBANSKI MAUD;;VENKATESAN HARIHARAN;;WANG AIHUA;;WOLIN RONALD L;;WOODS CRAIG R;;PIERCE JOAN;;GOLDBERG STEVEN;;FOURIE ANNE;;XUE XIAOHUA,,https://lens.org/196-444-670-020-197,Patent of Addition,no,0,0,49,50,0,C07D413/14;;C07D401/06;;A61K31/4709;;C07D401/14;;C07D417/14;;C07D409/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P37/00;;A61P37/02;;C07D401/06;;A61K31/4709;;A61K45/06;;C07D401/14;;C07D417/14;;C07D409/14;;C07D413/14,C07D401/10;;A61K31/4709;;A61P17/06;;A61P19/02;;C07D401/14;;C07D409/14;;C07D417/14,,0,0,,,,INACTIVE
193,ZA,B,ZA 201503418 B,000-860-891-819-802,2017-11-29,2017,ZA 201503418 A,2015-05-15,US 201261714419 P;;US 201261725528 P;;US 201361782257 P;;US 2013/0065013 W,2012-10-16,METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T,,JANSSEN PHARMACEUTICA NV,LEONARD KRISTI A;;XUE XIAOHUA;;FOURIE ANNE;;GOLDBERG STEVEN;;PIERCE JOAN;;WOODS CRAIG R;;WOLIN RONALD L;;WANG AIHUA;;URBANSKI MAUD;;NISHIMURA RACHEL;;KUMMER DAVID A;;KREUTTER KEVIN D;;BARBAY KENT;;VENKATESAN HARIHARAN;;EDWARDS JAMES P;;MAHAROOF UMAR,,https://lens.org/000-860-891-819-802,Granted Patent,no,0,0,49,50,0,C07D413/14;;C07D401/06;;A61K31/4709;;C07D401/14;;C07D417/14;;C07D409/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P37/00;;A61P37/02;;C07D401/06;;A61K31/4709;;A61K45/06;;C07D401/14;;C07D417/14;;C07D409/14;;C07D413/14,,,0,0,,,,ACTIVE
194,ES,T3,ES 2632269 T3,006-988-835-625-81X,2017-09-12,2017,ES 13786564 T,2013-10-15,US 201261714419 P;;US 201261725528 P;;US 201361782257 P;;US 2013/0065013 W,2012-10-16,Moduladores de quinolinailo enlazados a metileno de ROR-gamma-t,"Un compuesto de Fórmula I en la que:**Fórmula** R1 es pirrolilo, pirazolilo, imidazolilo, triazolilo, tiazolilo, piridilo, piridilo N-óxido, pirazinilo, pirimidinilo, piridazilo, piperidinilo, quinazolinilo, cinolinilo, bcnzotiazolilo, indazolilo, tetrahidropiranilo, tetrahidrofuranilo, furanilo, fenilo, oxazolilo, isoxazolilo, tiofenilo, benzoxazolilo, bencimidazolilo, indolilo, tiadiazolilo, oxadiazolilo o quinolinilo; en el que dicho piridilo, piridilo N-óxido, pirazinilo, pirimidinilo, piridazilo, piperidinilo, quinazolinilo, cinolinilo, benzotiazolilo, indazolilo, imidazolilo, fenilo, tiofenilo, benzoxazolilo, bencimidazolilo, indolilo, quinolinilo, y pirazolilo están opcionalmente sustituidos con C(O)C(1-4)alquilo, C(O)NH2, C(O)NHC(1-2)alquilo, C(O)N(C(1-2)alquilo)2, NHC(O)C(1-4)alquilo, NHSO2C(1-4)alquilo, C(1-4)alquilo, CF3, CH2CF3, Cl, F, -CN, OC(1-4)alquilo, N(C(1-4)alquilo)2, (CH2)3OCH3, SC(1-4)alquilo, OH, CO2H, CO2C(1-4)alquilo, C(O)CF3, SO2CF3, OCF3, OCHF2, SO2CH3, SO2NH2, SO2NHC(1-2)alquilo, SO2N(C(1-2)alquilo)2, C(O)NHSO2CH3, o OCH2OCH3; y opcionalmente sustituidos con hasta dos sustituyentes adicionales seleccionados independientemente del grupo que consiste en Cl, C(1-2)alquilo, SCH3, OC(1-2)alquilo, CF3, -CN, y F; y en donde dichos triazolilo, oxazolilo, isoxazolilo, pirrolilo, y tiazolilo están opcionalmente sustituidos con hasta dos sustituyentes seleccionados independientemente del grupo que consiste en SO2CH3, SO2NH2, alquilo C(O)NH2, -CN, OC(1-2), (CH2)(2-3)OCH3, SCH3, CF3, F, Cl, y C(1-2)alquilo; y dicho tiadiazolilo y oxadiazolilo están opcionalmente sustituidos con C(1-2)alquilo; y dichos piridilo, piridilo-N-óxido, pirimidinilo, piridazilo, y pirazinilo están opcionalmente sustituidos con hasta tres sustituyentes adicionales seleccionados independientemente del grupo que consiste en C(O)NHC(1-2)alquilo, C(O)N(C(1-2)alquilo)2, NHC(O)C(1-4)alquilo, NHSO2C(1-4)alquilo, C(O)CF3, SO2CF3, SO2NHC(1-2)alquilo, SO2N(C(1-2)NHC alquilo)2, C(O)NHSO2CH3, SO2CH3, SO2NH2, C(O)NH2, -CN, OC(1-4)alquilo, (CH2)(2-3)OCH3, SC(1-4)alquilo, CF3, F, Cl, y C(1-4)alquilo; R2 es triazolilo, piridilo, piridilo-N-óxido, pirazolilo, pirimidinilo, oxazolilo, isoxazolilo, azetidina-3-ilo, N-acetilo-azetidina-3-ilo, N-metilosulfonilo-azetidina-3-ilo, N-Boc-azetidina-3-ilo, N-acetilo piperidinilo, 1-H-piperidinilo, N-Boc-piperidinilo, NC(1-3)alquilo-piperidinilo, tiazolilo, piridazilo, pirazinilo, 1-(3-metoxipropilo)-imidazolilo, tiadiazolilo, oxadiazolilo, o imidazolilo; en el que dicho imidazolilo está opcionalmente sustituido con hasta tres sustituyentes adicionales seleccionados independientemente del grupo que consiste en C(1-2)alquilo, SCH3, OC(1-2)alquilo, CF3, -CN, F, y Cl; y dichos piridilo, piridilo-N-óxido, pirimidinilo, piridazilo, y pirazinilo, están opcionalmente sustituidos con hasta tres sustituyentes adicionales seleccionados independientemente del grupo que consiste en SO2CH3, SO2NH2, C(O)NH2, -CN, OC(1-2)alquilo, (CH2)(2-3)OCH3, SCH3, CF3, F, Cl, o C(1-2)alquilo; y dichos triazolilo, tiazolilo, oxazolilo e isoxazolilo están opcionalmente sustituidos con hasta dos sustituyentes seleccionados independientemente del grupo que consiste en OC(1-2)alquilo SO2CH3, SO2NH2, C(O)NH2, -CN, (CH2)(2-3)OCH3, SCH, CF3, F, alquilo Cl, y C(1-2)alquilo; y dichos tiadiazolilo y oxadiazolilo están opcionalmente sustituidos con C(1-2)alquilo; y dicho pirazolilo está opcionalmente sustituido con hasta tres grupos CH3; R3 es H, OH, OCH3, o NH2; R4 es H o F; R5 es H, Cl, -CN, CF3, SC(1-4)alquilo, OC(1-4)alquilo, OH, C(1-4)alquilo, N(CH3)OCH3, NH(C(1-4)alquilo), N(C(1-4)alquilo)2, o 4-hidroxi-piperidinilo; R6 es fenilo, piridilo, benzotiofenilo, tiofenilo, pirimidinilo, piridazilo, o pirazinilo; donde dichos pirimidinilo, piridazilo, pirazinilo o están opcionalmente sustituidos con Cl, F, CH3, SCH, OC(1-4)alquilo, -CN, CONH2, SO2NH2, o SO2CH3; y en el que dicho fenilo o dicho piridilo está opcionalmente sustituido hasta dos veces con OCF3, SO2C(1-4)alquilo, CF3, CHF2, pirazolilo, triazolilo, imidazolilo, tetrazolilo, oxazolilo, tiazolilo, C(1-4)alquilo, C(3-4)cicloalquilo, OC(1-4)alquilo, N(CH3)2, SO2NH2, SO2NHCH3, SO2N(CH3)2, CONH2, CONHCH3, CON(CH3)2, Cl, F, -CN, CO2H, OH, CH2OH, 55 NHCO(1-2)alquilo, COC(1-2)alquilo, SCH3, CO2C(1-4)alquilo, NH2, NHC(1-2)alquilo, o OCH2CF3; en el que la selección de cada sustituyente opcional es independiente; y en donde dichos pirazolilo, triazolilo, imidazolilo, tetrazolilo, oxazolilo, y tiazolilo están opcionalmente sustituidos con CH3; R7 es H, Cl, -CN, C(1-4)alquilo, OC(1-4)alquiloCF3, OCF3, OCHF2, OCH2CH2OC(1-4)alquilo, CF3, SCH3, C(1-4)alquiloNA1A2, CH2OC(2-3)alquiloNA1A2, NA1A2, C(O)NA1A2, CH2NHC(2-3)alquiloNA1A2, CH2N(CH3)C(2-3)alquiloNA1A2, NHC(2-3)alquiloNA1A2, N(CH3)C(2-4)alquiloNA1A2, OC(2-4)alquiloNA1A2, OC(1-4)aIquilo, OCH2-(1-metilo)-imidazol-2-ilo, fenilo, tiofenilo, furilo, pirazolilo, imidazolilo, piridilo, piridazilo, pirazinilo o pirimidinilo; en el que dichos fenilo, tiofenilo, furilo, pirazolilo, imidazolilo, piridilo, piridazilo, pirazinilo, y pirimidinilo están opcionalmente sustituidos con hasta tres sustituyentes seleccionados independientemente entre el grupo que consiste en F, Cl, CH3, CF3, OCH3 y; A1 es H, o C(1-4)alquilo; A2 es H, alquilo C(1-4)alquilo, C(1-4)alquiloC(1-4)alquilo, C(1-4)alquiloH, C(O)C(1-4)alquilo, o OC(1-4)alquilo; o A1 y A2 pueden ser tomados juntos con su nitrógeno unido para formar un anillo seleccionado del grupo que consiste en:**Fórmula** Ra es H, OC(1-4)alquilo, CH2OH, NH(CH3), N(CH3)2, NH2, CH3, F, CF3, SO2CH3, o OH; Rb es H, CO2C(CH3), C(1-4)alquilo, C(O)C(1-4)alquilo, SO2C(1-4)alquilo, CH2CH2CF3, CH2CF3, CH2-ciclopropilo, fenilo, CH2-fenilo, o C(3-6)cicloalquilo; R8 es H, alquilo C(1-3)alquilo, OC(1-3), CF3, NH2, NHCH3, -CN, o F; R9 es H o F; y las sales farmacéuticamente aceptables de los mismos; siempre que (4-cloro-2-metoxi-3-(4-(trifluorometilo)bencilo)quinolina-6-ilo)bis(1,2,5-trimetilo-1H-imidazol-4-ilo)metanol, N-(2-((3-(4-(1 H-pirazol-1-ilo)bencilo)-6-((4-clorofenilo)(hidroxi)(1-metilo-1H-imidazol-5-ilo)metilo)-4-hidroxiquinolina-2-ilo)oxi)etilo)acetamida y (3-(4-(1H-pirazol-1-ilo)bencilo)-4-cloro-2-(4-metilopiperazina-1-ilo)quinolina-6-ilo)(1-metilo-1H-imidazol-5-ilo)(6-(trifluorometilo)piridina-3-ilo)metanol están excluidos de la reivindicación.",JANSSEN PHARMACEUTICA NV,LEONARD KRISTI A;;BARBAY KENT;;EDWARDS JAMES P;;KREUTTER KEVIN D;;KUMMER DAVID A;;MAHAROOF UMAR;;NISHIMURA RACHEL;;URBANSKI MAUD;;VENKATESAN HARIHARAN;;WANG AIHUA;;WOLIN RONALD L;;WOODS CRAIG R;;PIERCE JOAN;;GOLDBERG STEVEN;;FOURIE ANNE;;XUE XIAOHUA,,https://lens.org/006-988-835-625-81X,Granted Patent,no,0,0,49,50,0,C07D413/14;;C07D401/06;;A61K31/4709;;C07D401/14;;C07D417/14;;C07D409/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P37/00;;A61P37/02;;C07D401/06;;A61K31/4709;;A61K45/06;;C07D401/14;;C07D417/14;;C07D409/14;;C07D413/14,C07D401/14;;A61K31/4709;;A61P29/00;;C07D401/06;;C07D409/14;;C07D413/14;;C07D417/14,,0,0,,,,ACTIVE
195,TW,B,TW I606045 B,106-414-544-843-510,2017-11-21,2017,TW 102137062 A,2013-10-15,US 201261714419 P;;US 201261725528 P;;US 201361782257 P,2012-10-16,Methylene linked quinolinyl modulators of rorγt,,JANSSEN PHARMACEUTICA NV,LEONARD KRISTI A;;BARBAY KENT;;EDWARDS JAMES P;;KREUTTER KEVIN D;;KUMMER DAVID A;;MAHAROOF UMAR;;NISHIMURA RACHEL;;URBANSKI MAUD;;VENKATESAN HARIHARAN;;WANG AIHUA;;WOLIN RONALD L;;WOODS CRAIG R;;PIERCE JOAN;;GOLDBERG STEVEN;;FOURIE ANNE;;XUE XIAOHUA,,https://lens.org/106-414-544-843-510,Granted Patent,no,0,0,49,50,0,C07D413/14;;C07D401/06;;A61K31/4709;;C07D401/14;;C07D417/14;;C07D409/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P37/00;;A61P37/02;;C07D401/06;;A61K31/4709;;A61K45/06;;C07D401/14;;C07D417/14;;C07D409/14;;C07D413/14,,,0,0,,,,INACTIVE
196,BR,A2,BR 112015008308 A2,132-499-657-691-128,2017-12-05,2017,BR 112015008308 A,2013-10-15,US 2013/0065013 W;;US 201261714419 P;;US 201261725528 P;;US 201361782257 P,2012-10-16,moduladores de quinolinila ligados por metileno do ror-gama-t,"abstract the present invention comprises compounds of formula i. formula i wherein: r1, r2, r3, r4, r5, r6, r7, r8, and r9 are defined in the specification. the invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. the invention also comprises a method of modulating ror?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1. tradução do resumo resumo patente de invenção ""moduladores de quinolinila ligados por metileno do ror-gama-t"" a presente invenção refere-se a compostos de fórmula (i). fórmula i em que: r1, r2, r3, r4, r5, r6, r7, r8 e r9 são definidos no relatório descritivo. a invenção compreende também um método para tratamento ou alívio de uma síndrome, distúrbio ou doença, sendo que a dita síndrome, distúrbio ou doença é artrite reumatoide ou psoríase. a invenção compreende, também, um método de modulação da atividade de ror?t em um mamífero através da administração de uma quantidade terapeuticamente eficaz de ao menos um composto conforme definido na reivindicação 1.",JANSSEN PHARMACEUTICA NV,AIHUA WANG;;ANNE FOURIE;;CRAIG R WOODS;;DAVID A KUMMER;;HARIHARAN VENKATESAN;;JAMES P EDWARDS;;JOAN PIERCE;;KENT BARBAY;;KEVIN D KREUTTER;;KRISTI A LEONARD;;MAUD URBANSKI;;RACHEL NISHIMURA;;RONALD L WOLIN;;STEVEN GOLDBERG;;UMAR MAHAROOF;;XIAOHUA XUE,,https://lens.org/132-499-657-691-128,Patent Application,no,0,0,49,50,0,C07D413/14;;C07D401/06;;A61K31/4709;;C07D401/14;;C07D417/14;;C07D409/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P37/00;;A61P37/02;;C07D401/06;;A61K31/4709;;A61K45/06;;C07D401/14;;C07D417/14;;C07D409/14;;C07D413/14,C07D401/06;;A61K31/4709;;A61P29/00;;C07D401/14;;C07D409/14;;C07D413/14;;C07D417/14,,0,0,,,,DISCONTINUED
197,EA,B1,EA 026415 B1,015-323-092-054-103,2017-04-28,2017,EA 201590736 A,2013-10-15,US 201261714419 P;;US 201261725528 P;;US 201361782257 P;;US 2013/0065013 W,2012-10-16,METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-t,"The present invention comprises compounds of Formula Iwherein R, R, R, R, R, R, R, Rand Rare defined in the specification. The present invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The present invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.",JANSSEN PHARMACEUTICA NV,LEONARD KRISTI A;;BARBAY KENT;;EDWARDS JAMES P;;KREUTTER KEVIN D;;KUMMER DAVID A;;MAHAROOF UMAR;;NISHIMURA RACHEL;;URBANSKI MAUD;;VENKATESAN HARIHARAN;;WANG AIHUA;;WOLIN RONALD L;;WOODS CRAIG R;;PIERCE JOAN;;GOLDBERG STEVEN;;FOURIE ANNE;;XUE XIAOHUA,,https://lens.org/015-323-092-054-103,Granted Patent,no,1,0,49,50,0,C07D413/14;;C07D401/06;;A61K31/4709;;C07D401/14;;C07D417/14;;C07D409/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P37/00;;A61P37/02;;C07D401/06;;A61K31/4709;;A61K45/06;;C07D401/14;;C07D417/14;;C07D409/14;;C07D413/14,C07D401/14;;A61K31/4709;;A61P29/00;;C07D401/06;;C07D409/14;;C07D413/14;;C07D417/14,,0,0,,,,ACTIVE
198,HR,T1,HR P20171082 T1,053-550-951-824-46X,2017-10-06,2017,HR P20171082 T,2017-07-14,US 201261714419 P;;US 201261725528 P;;US 201361782257 P;;EP 13786564 A;;US 2013/0065013 W,2012-10-16,METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T,,JANSSEN PHARMACEUTICA NV,LEONARD KRISTI A;;BARBAY KENT;;EDWARDS JAMES P;;KREUTTER KEVIN D;;KUMMER DAVID A;;MAHAROOF UMAR;;NISHIMURA RACHEL;;URBANSKI MAUD;;VENKATESAN HARIHARAN;;WANG AIHUA;;WOLIN RONALD L;;WOODS CRAIG R;;PIERCE JOAN;;GOLDBERG STEVEN;;FOURIE ANNE;;XUE XIAOHUA,,https://lens.org/053-550-951-824-46X,Granted Patent,no,0,0,49,50,0,C07D413/14;;C07D401/06;;A61K31/4709;;C07D401/14;;C07D417/14;;C07D409/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P37/00;;A61P37/02;;C07D401/06;;A61K31/4709;;A61K45/06;;C07D401/14;;C07D417/14;;C07D409/14;;C07D413/14,C07D401/14;;A61K31/4709;;A61P29/00;;C07D401/06;;C07D409/14;;C07D413/14;;C07D417/14,,0,0,,,,ACTIVE
199,SI,T1,SI 2909192 T1,063-735-494-891-256,2017-08-31,2017,SI 201330702 T,2013-10-15,US 201261714419 P;;US 201261725528 P;;US 201361782257 P;;US 2013/0065013 W;;EP 13786564 A,2012-10-16,METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T,,JANSSEN PHARMACEUTICA NV,LEONARD KRISTI A;;BARBAY KENT;;EDWARDS JAMES P;;KREUTTER KEVIN D;;KUMMER DAVID A;;MAHAROOF UMAR;;NISHIMURA RACHEL;;URBANSKI MAUD;;VENKATESAN HARIHARAN;;WANG AIHUA;;WOLIN RONALD L;;WOODS CRAIG R;;PIERCE JOAN;;GOLDBERG STEVEN;;FOURIE ANNE;;XUE XIAOHUA,,https://lens.org/063-735-494-891-256,Granted Patent,no,0,0,49,50,0,C07D413/14;;C07D401/06;;A61K31/4709;;C07D401/14;;C07D417/14;;C07D409/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P37/00;;A61P37/02;;C07D401/06;;A61K31/4709;;A61K45/06;;C07D401/14;;C07D417/14;;C07D409/14;;C07D413/14,C07D401/00;;A61K31/00;;A61P29/00;;C07D409/00;;C07D413/00;;C07D417/00,,0,0,,,,ACTIVE
200,WO,A1,WO 2014/062658 A1,115-645-418-262-795,2014-04-24,2014,US 2013/0065013 W,2013-10-15,US 201261714419 P;;US 201261725528 P;;US 201361782257 P,2012-10-16,METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T,"The present invention comprises compounds of Formula (I), wherein: R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.",JANSSEN PHARMACEUTICA NV;;LEONARD KRISTI A,LEONARD KRISTI A;;BARBAY KENT;;EDWARDS JAMES P;;KREUTTER KEVIN D;;KUMMER DAVID A;;MAHAROOF UMAR;;NISHIMURA RACHEL;;URBANSKI MAUD;;VENKATESAN HARIHARAN;;WANG AIHUA;;WOLIN RONALD L;;WOODS CRAIG R;;PIERCE JOAN;;GOLDBERG STEVEN;;FOURIE ANNE;;XUE XIAOHUA,,https://lens.org/115-645-418-262-795,Patent Application,yes,1,8,49,50,9,C07D413/14;;C07D401/06;;A61K31/4709;;C07D401/14;;C07D417/14;;C07D409/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P37/00;;A61P37/02;;C07D401/06;;A61K31/4709;;A61K45/06;;C07D401/14;;C07D417/14;;C07D409/14;;C07D413/14,C07D401/14;;A61K31/4709;;A61P29/00;;C07D401/06;;C07D409/14;;C07D413/14;;C07D417/14,,0,0,,,,PENDING
201,EP,B1,EP 2909192 B1,145-353-410-882-950,2017-05-17,2017,EP 13786564 A,2013-10-15,US 201261714419 P;;US 201261725528 P;;US 201361782257 P;;US 2013/0065013 W,2012-10-16,METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T,,JANSSEN PHARMACEUTICA NV,LEONARD KRISTI A;;BARBAY KENT;;EDWARDS JAMES P;;KREUTTER KEVIN D;;KUMMER DAVID A;;MAHAROOF UMAR;;NISHIMURA RACHEL;;URBANSKI MAUD;;VENKATESAN HARIHARAN;;WANG AIHUA;;WOLIN RONALD L;;WOODS CRAIG R;;PIERCE JOAN;;GOLDBERG STEVEN;;FOURIE ANNE;;XUE XIAOHUA,JANSSEN PHARMACEUTICA NV (2016-10-05),https://lens.org/145-353-410-882-950,Granted Patent,yes,1,1,49,50,0,C07D413/14;;C07D401/06;;A61K31/4709;;C07D401/14;;C07D417/14;;C07D409/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P37/00;;A61P37/02;;C07D401/06;;A61K31/4709;;A61K45/06;;C07D401/14;;C07D417/14;;C07D409/14;;C07D413/14,C07D401/14;;A61K31/4709;;A61P29/00;;C07D401/06;;C07D409/14;;C07D413/14;;C07D417/14,,0,0,,,,ACTIVE
202,DK,T3,DK 2909192 T3,064-141-137-204-698,2017-08-07,2017,DK 13786564 T,2013-10-15,US 201261714419 P;;US 201261725528 P;;US 201361782257 P;;US 2013/0065013 W,2012-10-16,METHYLEN-FORBUNDNE QUINOLINYLMODULATORER AF ROR-GAMMA-T,,JANSSEN PHARMACEUTICA NV,LEONARD KRISTI A;;BARBAY KENT;;EDWARDS JAMES P;;KREUTTER KEVIN D;;KUMMER DAVID A;;MAHAROOF UMAR;;NISHIMURA RACHEL;;URBANSKI MAUD;;VENKATESAN HARIHARAN;;WANG AIHUA;;WOLIN RONALD L;;WOODS CRAIG R;;PIERCE JOAN;;GOLDBERG STEVEN;;FOURIE ANNE;;XUE XIAOHUA,,https://lens.org/064-141-137-204-698,Granted Patent,no,0,0,49,50,0,C07D413/14;;C07D401/06;;A61K31/4709;;C07D401/14;;C07D417/14;;C07D409/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P37/00;;A61P37/02;;C07D401/06;;A61K31/4709;;A61K45/06;;C07D401/14;;C07D417/14;;C07D409/14;;C07D413/14,C07D401/14;;A61K31/4709;;A61P29/00;;C07D401/06;;C07D409/14;;C07D413/14;;C07D417/14,,0,0,,,,ACTIVE
203,EP,A1,EP 2909192 A1,102-340-452-706-944,2015-08-26,2015,EP 13786564 A,2013-10-15,US 201261714419 P;;US 201261725528 P;;US 201361782257 P;;US 2013/0065013 W,2012-10-16,METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T,,JANSSEN PHARMACEUTICA NV,LEONARD KRISTI A;;BARBAY KENT;;EDWARDS JAMES P;;KREUTTER KEVIN D;;KUMMER DAVID A;;MAHAROOF UMAR;;NISHIMURA RACHEL;;URBANSKI MAUD;;VENKATESAN HARIHARAN;;WANG AIHUA;;WOLIN RONALD L;;WOODS CRAIG R;;PIERCE JOAN;;GOLDBERG STEVEN;;FOURIE ANNE;;XUE XIAOHUA,JANSSEN PHARMACEUTICA NV (2016-10-05),https://lens.org/102-340-452-706-944,Patent Application,yes,0,0,49,50,0,C07D413/14;;C07D401/06;;A61K31/4709;;C07D401/14;;C07D417/14;;C07D409/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P37/00;;A61P37/02;;C07D401/06;;A61K31/4709;;A61K45/06;;C07D401/14;;C07D417/14;;C07D409/14;;C07D413/14,C07D401/14;;A61K31/4709;;A61P29/00;;C07D401/06;;C07D409/14;;C07D413/14;;C07D417/14,,0,0,,,,ACTIVE
204,GT,A,GT 201500093 A,152-564-982-677-892,2017-09-26,2017,GT 201500093 A,2015-04-15,US 201261725528 P;;US 201361782257 P;;US 201261714419 P,2012-10-16,MODULADORES DE QUINOLINILO UNIDOS A METILENO DE ROR- GAMMA-T,"LA PRESENTE INVENCIÓN ESTÁ DIRIGIDA A COMPUESTOS DE QUINOLINA SUSTITUIDOS, QUE SON MODULADORES DEL RECEPTOR NUCLEAR ROR-GAMMA-T, A COMPOSICIONES FARMACÉUTICAS Y A MÉTODOS DE USO DE ESTOS, MÁS PARTICULARMENTE, LOS MODULADORES DEL ROR-GAMMA-T SON ÚTILES PARA PREVENIR, TRATAR O MEJORAR UN SÍNDROME INFLAMATORIO, TRASTORNO O ENFERMEDAD MEDIADOS POR ROR-GAMMA-T.",JANSSEN PHARMACEUTICA NV,KRISTI A LEONARD;;KENT BARBAY;;JAMES P EDWARDS;;KEVIN D KREUTTER;;DAVID A KUMMER;;UMAR MAHAROOF;;RACHEL NISHIMURA;;MAUD URBANSKI;;HARIHARAN VENKATESAN;;AIHUA WANG;;RONALD L WOLIN;;CRAIG R WOODS;;JOAN PIERCE;;STEVEN GOLDBERG;;ANNE FOURIE;;XIAOHUA XUE,,https://lens.org/152-564-982-677-892,Amended Application,no,0,0,49,50,0,C07D413/14;;C07D401/06;;A61K31/4709;;C07D401/14;;C07D417/14;;C07D409/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P37/00;;A61P37/02;;C07D401/06;;A61K31/4709;;A61K45/06;;C07D401/14;;C07D417/14;;C07D409/14;;C07D413/14,C07D401/14;;A61K31/4709;;A61P29/00,,0,0,,,,PENDING
205,PE,A1,PE 20150778 A1,168-114-903-888-150,2015-05-23,2015,PE 2015000491 A,2013-10-15,US 201261714419 P;;US 201261725528 P;;US 201361782257 P,2012-10-16,MODULADORES DE QUINOLINILO UNIDOS A METILENO DE ROR-GAMMA-T,"La invencion comprende los compuestos de la Formula (I); en donde: R1, R2, R3, R4, R5, R6, R7, R8 y R9 son tal como se definieron en la especificacion. Son compuestos preferidos: (4-cloro-2-metoxi-3-(4-(trifluorometil)bencil)quinolin-6-il)(4-clorofenil)(1-metil-1H-imidazol-5-il)metanol;6-((4-cianofenil)(hidroxi)(1-metil-1H-imidazol-5-il)metil)-2-metoxi-3-4-(trifluorometil)bencil)quinolin-4-carbonitrilo, entre otros. Dichos compuestos son moduladores del RORgamma-t siendo utiles en el tratamiento de psorisis, artritis reumatoide, lupus eritematoso, entre otros",JANSSEN PHARMACEUTICA NV,LEONARD KRISTI A;;BARBAY KENT;;EDWARDS JAMES P;;KREUTTER KEVIN D;;KUMMER DAVID A;;MAHAROOF UMAR;;NISHIMURA RACHEL;;URBANSKI MAUD;;VENKATESAN HARIHARAN;;WANG AIHUA;;WOLIN RONALD L;;WOODS CRAIG R;;PIERCE JOAN;;GOLDBERG STEVEN;;FOURIE ANNE;;XUE XIAOHUA,,https://lens.org/168-114-903-888-150,Patent Application,no,0,0,49,50,0,C07D413/14;;C07D401/06;;A61K31/4709;;C07D401/14;;C07D417/14;;C07D409/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P37/00;;A61P37/02;;C07D401/06;;A61K31/4709;;A61K45/06;;C07D401/14;;C07D417/14;;C07D409/14;;C07D413/14,C07D401/14;;C07D401/06;;C07D409/14;;C07D413/14;;C07D417/14,,0,0,,,,ACTIVE
206,CR,A,CR 20150193 A,017-304-646-892-555,2015-05-18,2015,CR 20150193 A,2015-04-13,US 201261714419 P;;US 201261725528 P;;US 201361782257 P;;US 2013/0065013 W,2012-10-16,MODULADORES DE QUINOLINILO UNIDOS A METILENO DE ROR-GAMMA-T,"La presente invención comprende los compuestos de la Fórmula (I). en donde: R1, R2, R3, R4, R5, R6, R7, R8 y R9 son tal como se definieron en la especificación. La invención comprende, además, un método para tratar o mejorar un síndrome, trastorno o enfermedad, en donde ese síndrome, trastorno o enfermedad es artritis reumatoide o soriasis.",JANSSEN PHARMACEUTICA NV,LEONARD KRISTI A;;BARBAY KENT;;EDWARDS JAMES P;;KREUTTER KEVIN D;;KUMMER DAVID A;;MAHAROOF UMAR;;NISHIMURA RACHEL;;URBANSKI MAUD;;VENKATESAN HARIHARAN;;WANG AIHUA;;WOLIN RONALD L;;WOODS CRAIG R;;PIERCE JOAN;;GOLDBERG STEVEN;;FOURIE ANNE;;XUE XIAOHUA,,https://lens.org/017-304-646-892-555,Patent Application,no,0,0,49,50,0,C07D413/14;;C07D401/06;;A61K31/4709;;C07D401/14;;C07D417/14;;C07D409/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P37/00;;A61P37/02;;C07D401/06;;A61K31/4709;;A61K45/06;;C07D401/14;;C07D417/14;;C07D409/14;;C07D413/14,C07D401/14;;A61K31/4709;;A61P29/00;;C07D401/06;;C07D409/14;;C07D413/14;;C07D417/14,,0,0,,,,PENDING
207,SG,A,SG 11201502369X A,034-218-983-627-934,2015-05-28,2015,SG 11201502369X A,2013-10-15,US 201261714419 P;;US 201261725528 P;;US 201361782257 P;;US 2013/0065013 W,2012-10-16,METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T,,JANSSEN PHARMACEUTICA NV,BARBAY KENT;;EDWARDS JAMES P;;LEONARD KRISTI A;;KREUTTER KEVIN D;;KUMMER DAVID A;;MAHAROOF UMAR;;NISHIMURA RACHEL;;URBANSKI MAUD;;VENKATESAN HARIHARAN;;WANG AIHUA;;WOLIN RONALD L;;WOODS CRAIG R;;PIERCE JOAN;;GOLDBERG STEVEN;;FOURIE ANNE;;XUE XIAOHUA,,https://lens.org/034-218-983-627-934,Unknown,no,0,0,49,50,0,C07D413/14;;C07D401/06;;A61K31/4709;;C07D401/14;;C07D417/14;;C07D409/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P37/00;;A61P37/02;;C07D401/06;;A61K31/4709;;A61K45/06;;C07D401/14;;C07D417/14;;C07D409/14;;C07D413/14,C07D401/14;;A61K31/4709;;A61P29/00;;C07D401/06;;C07D409/14;;C07D413/14;;C07D417/14,,0,0,,,,PENDING
208,UY,A,UY 35084 A,113-145-966-250-951,2014-04-30,2014,UY 35084 A,2013-10-15,US 201314053653 A;;US 201261714419 P;;US 201261725528 P;;US 201361782257 P,2012-10-16,MODULADORES DE RORyt DE QUINOLINILO UNIDOS POR METILENO,"La presente invención comprende compuestos de la Fórmula I.en donde: R1, R2, R3, R4, R5, R6, R7, R8 y R9 se definen en la especificación. La invención comprende, además, un medicamento para tratar o mejorar un síndrome, un trastorno o una enfermeda d, en donde el síndrome, el trastorno o la enfermedad es artritis reumatoide o soriasis. La invenci ón comprende, además, un medicamento para modular la actividad de RORyt en un mamífero mediante la administración de una cantidad terapéuticamente eficaz de al menos un compuesto de la reivindicació n 1.",JANSSEN PHARMACEUTICA NV,LEONARD KRISTI A;;KENT BARBAY;;EDWARDS JAMES P;;KREUTTER KEVIN D;;KUMMER DAVID A;;UMAR MAHAROOF;;RACHEL NISHIMURA;;MAUD URBANSKI;;HARIHARAN VENKATESAN;;AIGUA WANG;;WOLIN RONALD L;;WOODS CRAIG R;;JOAN PIERCE;;STEVEN GOLDBERG;;ANNE FOURIE;;XIAOHUA XUE,,https://lens.org/113-145-966-250-951,Patent Application,no,0,0,49,50,0,C07D413/14;;C07D401/06;;A61K31/4709;;C07D401/14;;C07D417/14;;C07D409/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P37/00;;A61P37/02;;C07D401/06;;A61K31/4709;;A61K45/06;;C07D401/14;;C07D417/14;;C07D409/14;;C07D413/14,A61P17/06;;A61K31/4155;;A61K31/4178;;A61K31/427;;A61K31/4427;;A61K31/4709;;A61P19/02;;A61P29/00;;A61P37/00;;C07D215/16;;C07D215/18;;C07D215/227;;C07D215/38;;C07D215/48;;C07D403/10;;C07D403/14;;C07D417/10,,0,0,,,,PENDING
209,LT,T,LT 2909192 T,185-509-284-542-574,2017-07-10,2017,LT 13786564 T,2013-10-15,US 201261714419 P;;US 201261725528 P;;US 201361782257 P;;US 2013/0065013 W,2012-10-16,METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T,,JANSSEN PHARMACEUTICA NV,LEONARD KRISTI A;;BARBAY KENT;;EDWARDS JAMES P;;KREUTTER KEVIN D;;KUMMER DAVID A;;MAHAROOF UMAR;;NISHIMURA RACHEL;;URBANSKI MAUD;;VENKATESAN HARIHARAN;;WANG AIHUA;;WOLIN RONALD L;;WOODS CRAIG R;;PIERCE JOAN;;GOLDBERG STEVEN;;FOURIE ANNE;;XUE XIAOHUA,,https://lens.org/185-509-284-542-574,Unknown,no,0,0,49,50,0,C07D413/14;;C07D401/06;;A61K31/4709;;C07D401/14;;C07D417/14;;C07D409/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P37/00;;A61P37/02;;C07D401/06;;A61K31/4709;;A61K45/06;;C07D401/14;;C07D417/14;;C07D409/14;;C07D413/14,C07D401/14;;A61K31/4709;;A61P29/00;;C07D401/06;;C07D409/14;;C07D413/14;;C07D417/14,,0,0,,,,PENDING
210,MY,A,MY 189505 A,044-216-203-516-12X,2022-02-16,2022,MY PI2015701186 A,2013-10-15,US 2013/0065013 W;;US 201261714419 P;;US 201261725528 P;;US 201361782257 P,2012-10-16,METHYLENE LINKED QUINOLINYL MODULATORS OF RORYT,"The present invention comprises compounds of Formula I. wherein: R1,R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORyt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.",JANSSEN PHARMACEUTICA NV,KRISTI A LEONARD;;KENT BARBAY;;JAMES P EDWARDS;;KEVIN D KREUTTER;;DAVID A KUMMER;;UMAR MAHAROOF;;RACHEL NISHIMURA;;MAUD URBANSKI;;HARIHARAN VENKATESAN;;AIHUA WANG;;RONALD L WOLIN;;CRAIG R WOODS;;JOAN PIERCE;;STEVEN GOLDBERG;;ANNE FOURIE;;XIAOHUA XUE,,https://lens.org/044-216-203-516-12X,Granted Patent,no,0,0,49,50,0,C07D413/14;;C07D401/06;;A61K31/4709;;C07D401/14;;C07D417/14;;C07D409/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P37/00;;A61P37/02;;C07D401/06;;A61K31/4709;;A61K45/06;;C07D401/14;;C07D417/14;;C07D409/14;;C07D413/14,C07D401/06;;A61K45/06;;C07D401/14;;C07D409/14;;C07D413/14;;C07D417/14,,0,0,,,,ACTIVE
211,AU,A1,AU 2013/331496 A1,110-778-132-123-084,2015-04-09,2015,AU 2013/331496 A,2013-10-15,US 201261714419 P;;US 201261725528 P;;US 201361782257 P;;US 2013/0065013 W,2012-10-16,MODULADORES DE QUINOLINILO UNIDOS A METILENO DE ROR-GAMMA-T,"The present invention comprises compounds of Formula (I), wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.",JANSSEN PHARMACEUTICA NV,LEONARD KRISTI A;;BARBAY KENT;;EDWARDS JAMES P;;KREUTTER KEVIN D;;KUMMER DAVID A;;MAHAROOF UMAR;;NISHIMURA RACHEL;;URBANSKI MAUD;;VENKATESAN HARIHARAN;;WANG AIHUA;;WOLIN RONALD L;;WOODS CRAIG R;;PIERCE JOAN;;GOLDBERG STEVEN;;FOURIE ANNE;;XUE XIAOHUA,,https://lens.org/110-778-132-123-084,Patent Application,no,0,0,49,50,0,C07D413/14;;C07D401/06;;A61K31/4709;;C07D401/14;;C07D417/14;;C07D409/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P37/00;;A61P37/02;;C07D401/06;;A61K31/4709;;A61K45/06;;C07D401/14;;C07D417/14;;C07D409/14;;C07D413/14,C07D401/06;;A61K31/4709;;A61P29/00;;C07D401/14;;C07D409/14;;C07D413/14;;C07D417/14,,0,0,,,,INACTIVE
212,CN,A,CN 105209453 A,172-077-270-798-87X,2015-12-30,2015,CN 201380065903 A,2013-10-15,US 2013/0065013 W;;US 201261714419 P;;US 201261725528 P;;US 201361782257 P,2012-10-16,Methylene linked quinolinyl modulators of ROR-gamma-T,"The present invention comprises compounds of Formula (I), wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR[gamma]t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.",JANSSEN PHARMACEUTICA NV,LEONARD KRISTI A;;BARBAY KENT;;EDWARDS JAMES P;;KREUTTER KEVIN D;;KUMMER DAVID A;;MAHAROOF UMAR;;NISHIMURA RACHEL;;URBANSKI MAUD;;VENKATESAN HARIHARAN;;WANG AIHUA;;WOLIN RONALD L;;WOODS CRAIG R;;PIERCE JOAN;;GOLDBERG STEVEN;;FOURIE ANNE;;XUE XIAOHUA,,https://lens.org/172-077-270-798-87X,Patent Application,no,0,4,49,50,0,C07D413/14;;C07D401/06;;A61K31/4709;;C07D401/14;;C07D417/14;;C07D409/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P37/00;;A61P37/02;;C07D401/06;;A61K31/4709;;A61K45/06;;C07D401/14;;C07D417/14;;C07D409/14;;C07D413/14,C07D401/14;;A61K31/4709;;A61P29/00;;C07D401/06;;C07D409/14;;C07D413/14;;C07D417/14,,0,0,,,,INACTIVE
213,PL,T3,PL 2909192 T3,199-151-176-352-241,2017-09-29,2017,PL 13786564 T,2013-10-15,US 201261714419 P;;US 201261725528 P;;US 201361782257 P,2012-10-16,METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T,,JANSSEN PHARMACEUTICA NV,LEONARD KRISTI A;;BARBAY KENT;;EDWARDS JAMES P;;KREUTTER KEVIN D;;KUMMER DAVID A;;MAHAROOF UMAR;;NISHIMURA RACHEL;;URBANSKI MAUD;;VENKATESAN HARIHARAN;;WANG AIHUA;;WOLIN RONALD L;;WOODS CRAIG R;;PIERCE JOAN;;GOLDBERG STEVEN;;FOURIE ANNE;;XUE XIAOHUA,,https://lens.org/199-151-176-352-241,Patent Application,no,0,0,49,50,0,C07D413/14;;C07D401/06;;A61K31/4709;;C07D401/14;;C07D417/14;;C07D409/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P37/00;;A61P37/02;;C07D401/06;;A61K31/4709;;A61K45/06;;C07D401/14;;C07D417/14;;C07D409/14;;C07D413/14,C07D401/14;;A61K31/4709;;A61P29/00;;C07D401/06;;C07D409/14;;C07D413/14;;C07D417/14,,0,0,,,,PENDING
214,PH,B1,PH 12015500817 B1,022-067-975-938-58X,2015-06-08,2015,PH 12015500817 A,2015-04-14,US 201361782257 P;;US 201261725528 P;;US 201261714419 P;;US 2013/0065013 W,2012-10-16,METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T,"The present invention comprises compounds of Formula I, wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.",JANSSEN PHARMACEUTICA NV,LEONARD KRISTI A;;BARBAY KENT;;EDWARDS JAMES P;;KREUTTER KEVIN D;;KUMMER DAVID A;;MAHAROOF UMAR;;NISHIMURA RACHEL;;URBANSKI MAUD;;VENKATESAN HARIHARAN;;WANG AIHUA;;WOLIN RONALD L;;WOODS CRAIG R;;PIERCE JOAN;;GOLDBERG STEVEN;;FOURIE ANNE;;XUE XIAOHUA,,https://lens.org/022-067-975-938-58X,Granted Patent,no,0,0,49,50,0,C07D413/14;;C07D401/06;;A61K31/4709;;C07D401/14;;C07D417/14;;C07D409/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P37/00;;A61P37/02;;C07D401/06;;A61K31/4709;;A61K45/06;;C07D401/14;;C07D417/14;;C07D409/14;;C07D413/14,A61K31/4709;;A61P29/00;;C07D401/06;;C07D401/14;;C07D409/14;;C07D413/14;;C07D417/14,,0,0,,,,ACTIVE
215,US,B2,US 9290476 B2,058-897-183-653-171,2016-03-22,2016,US 201314053653 A,2013-10-15,US 201314053653 A;;US 201361782257 P;;US 201261725528 P;;US 201261714419 P,2012-10-16,Methylene linked quinolinyl modulators of RORγt,"The present invention comprises compounds of Formula I. wherein: R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.",JANSSEN PHARMACEUTICA NV,LEONARD KRISTI A;;BARBAY KENT;;EDWARDS JAMES P;;KREUTTER KEVIN D;;KUMMER DAVID A;;MAHAROOF UMAR;;NISHIMURA RACHEL;;URBANSKI MAUD;;VENKATESAN HARIHARAN;;WANG AIHUA;;WOLIN RONALD L;;WOODS CRAIG R;;PIERCE JOAN;;GOLDBERG STEVEN;;FOURIE ANNE;;XUE XIAOHUA,JANSSEN PHARMACEUTICA NV (2013-11-21),https://lens.org/058-897-183-653-171,Granted Patent,yes,101,25,49,50,9,C07D413/14;;C07D401/06;;A61K31/4709;;C07D401/14;;C07D417/14;;C07D409/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P37/00;;A61P37/02;;C07D401/06;;A61K31/4709;;A61K45/06;;C07D401/14;;C07D417/14;;C07D409/14;;C07D413/14,A61K31/4709;;A61K45/06;;C07D401/06;;C07D401/14;;C07D409/14;;C07D413/14;;C07D417/14,,82,39,084-843-025-849-979;;027-264-766-337-299;;117-948-696-800-494;;005-296-732-298-701;;005-216-737-509-018;;093-303-130-222-691;;002-046-645-408-510;;013-258-562-870-922;;013-740-155-925-960;;064-399-651-040-903;;016-505-509-019-957;;014-408-820-938-035;;066-119-584-271-19X;;035-586-215-470-490;;039-460-067-637-00X;;118-307-749-079-773;;048-384-949-179-543;;000-649-437-049-891;;018-908-523-184-712;;093-144-517-257-295;;167-457-447-044-074;;110-622-320-158-427;;110-556-689-717-601;;163-436-001-999-281;;068-508-663-743-396;;020-545-279-619-551;;078-205-757-883-386;;011-733-947-435-777;;030-303-530-555-166;;006-384-711-859-473;;028-713-636-085-561;;011-663-094-062-663;;156-601-101-421-818;;042-371-686-427-160;;095-361-043-889-533;;150-196-683-295-748;;004-514-663-069-206;;063-405-380-326-046;;045-406-285-588-795,21516112;;10.1038/ni.2027;;10.3410/f.10935956.11871057;;20726898;;10.1111/j.1567-1364.2010.00663.x;;20403696;;10.1016/j.bmcl.2010.03.115;;10.1016/j.bmcl.2010.01.094;;20167488;;19842138;;10.1002/cbdv.200800268;;10.1021/jm900460z;;19719237;;10.3987/com-05-s(k)48;;10.1021/jm00273a007;;5059208;;10.1016/j.tetlet.2005.11.128;;10.1038/nri1807;;16557264;;10.1016/j.it.2005.10.003;;16290228;;16990136;;10.1016/j.cell.2006.07.035;;12610626;;10.1038/nature01355;;pmc2212798;;10.1084/jem.20041257;;15657292;;20956338;;pmc3776381;;10.4049/jimmunol.1001538;;12814161;;10.1053/rmed.2003.1507;;11984595;;10.1038/nm0502-500;;22455412;;10.1056/nejmoa1109017;;22455413;;10.1056/nejmoa1109997;;20926833;;10.1126/scitranslmed.3001107;;10.1080/00397910903013713;;10.1002/0471264180.or057.02;;10.1007/bf00798414;;10.1002/ejoc.200701014;;10.1146/annurev.immunol.021908.132710;;19132915;;15485625;;10.1016/j.immuni.2004.08.018;;14984588;;10.1111/j.1440-1711.2004.01212.x;;10.1039/c3md00005b;;16670770;;pmc1451201;;10.1172/jci21404;;10.1136/gut.52.1.65;;pmc1773503;;12477762;;10.1016/j.jaci.2012.04.024;;pmc3470466;;22677045;;10.1038/gene.2008.16;;18368064;;20875338;;20453841;;10.1038/ng.583;;21747375;;10.1038/nbt.1906;;10.1016/j.bmcl.2004.12.037;;15686903;;pmc2852824;;10.3748/wjg.v16.i14.1753;;20380008;;10.1016/0040-4039(95)01802-o;;10.1002/(sici)1520-6017(200002)89:2<145::aid-jps2>3.0.co;2-6;;10688744,"Codarri, Nature Immunology, Jun. 2011, vol. 12(6), p. 560-568.;;U.S. Appl. No. 14/053,797, filed Oct. 2013, Leonard et al.;;International Search Report-PCT/US2013/065007, Jan. 7, 2014.;;International Search Report-PCT/US2013/065013, Dec. 16, 2013.;;International Search Report-PCT/US2013/065031, Dec. 13, 2013.;;International Search Report-PCT/US2013/065040, Dec. 16, 2013.;;International Search Report-PCT/US2013/065048, Dec. 3, 2013.;;International Search Report-PCT/US2013/065053, Jan. 7, 2014.;;U.S. Appl. No. 14/053,736.;;U.S. Appl. No. 14/053,773.;;U.S. Appl. No. 14/053,797.;;U.S. Appl. No. 14/053,906.;;U.S. Appl. No. 14/053,682.;;U.S. Appl. No. 14/053,707.;;Bink A, (A fungicidal piperazine-1-carboxamidine induces mitochondrial fission-dependent apoptosis in yeast), FEMS Yeast Research (2010), 10(7), 812-818.;;Nieman J, (Modifications of C-2 on the pyrroloquinoline template aimed at the development of potent herpes virus antivirals with improved aqueous solubility), Bioorganic & Medicinal Chemistry Letters (2010), 20(10), 3039-3042.;;Tanis S, (The design and development of 2-aryl-2-hydroxy ethylamine substituted 1H,7H-pyrido[1,2,3-de]quinoxaline-6-carboxamides as inhibitors of human cytomegalovirus polymerase), Bioorganic & Medicinal Chemistry Letters (2010), 20(6), 1994-2000.;;Mao D, (Synthesis and Na+/H+ Exchanger-1 Inhibitory Activity of Substituted (Quinolinecarbonyl)guanidine Derivatives), Chemistry & Biodiversity (2009), 6(10), 1727-1736.;;Sato M, (Quinolone Carboxylic Acids as a Novel Monoketo Acid Class of Human Immunodeficiency Virus Type 1 Integrase Inhibitors), Journal of Medicinal Chemistry (2009), 52(15), 4869-4882.;;Aghera V, (Synthesis, spectral and microbial studies of some novel quinoline derivatives via Vilsmeier-Haack reagent) Journal; (online computer file) URL: http://www.arkat-usa.org/get-file/25177/.;;Inada T, (One-step synthesis of ethyl quinaldates by Lewis acid-catalyzed three-component coupling reaction of aromatic amines, aliphatic aldehydes, and ethyl glyoxylate), Heterocycles (2005), 66, 611-619.;;Zelenin A, (Reaction of polyfluoro carbonyl compounds with 1,2,3,4-tetrahydroquinoline), Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya (1986), (9), 2074-80 Abstract Only.;;Hirao I, (Studies on the synthesis of quinoline compounds. I. Syntheses of 3,3'-dicarboxy-1,1'-diethyl-4,4'-dioxo-1,1',4,4'-tetrahydrobiquinolines), Memoirs of the Kyushu Institute of Technology, Engineering (1984), 14,13-16.;;Abdul-Ahad P, (Trends in dehydrogenase inhibitory potencies of some quinolones, using quantum chemical indices), European Journal of Medicinal Chemistry (1982), 17(4), 301-6.;;Baker B, (Irreversible enzyme inhibitors. 191. Hydrophobic bonding to some dehydrogenases by 6-, 7-, or 8-substituted-4-hydroxyquinoline-3-carboxylic acids), Journal of Medicinal Chemistry (1972), 15(3), 235-7.;;Ramachary D, (A novel and green protocol for two-carbon homologation: a direct amino acid/K2CO3-catalyzed four-component reaction of aldehydes, active methylenes, Hantzsch esters and alkyl halides), Tetrahedron Letters (2006) 47, 651-656.;;Dong C, (Diversification of T-helper-cell lineages: finding the family root of IL-17-producing cells), Nat Rev Immunol (2006), 6(4), 329-333.;;McKenzie B, (Understanding the IL-23-IL-17 immune pathway), Trends Immunol (2006), 27(1), 17-23.;;Ivanov II B, (The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+T helper cells), Cell (2006), 126(6), 1121-33.;;Cua, D (Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain), Nature (2003), 421(6924), 744-748.;;Langrish C, (IL-23 drives a pathogenic T cell population that induces autoimmune inflammation), J Exp Med (2005), 201(2), 233-240.;;Tonel G, (Cutting edge: A critical functional role for IL-23 in psoriasis), J Immunol (2010), 185(10), 5688-5691.;;Barczyk A, (Interleukin-17 in sputum correlates with airway hyperresponsiveness to methacholine), Respir Med (2003), 97(6), 726-733.;;Lock C, (Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis) Nat Med (2002), 8(5), 500-8.;;Papp K, (Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis), N Engl J Med (2012), 366(13), 1181-1189.;;Leonardi C, (Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis), N Engl J Med (2012), 366(13), 1190-1199.;;Hueber W, (Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis), Sci Transl Med (2010), 2, 5272.;;Gao W, (Clean and Convienient One-Pot Synthesis of 4-Hydroxycoumarin and 4-Hydroxy-2-Quinolone Derivatives), Synthetic Communications (2010) 40, 732-738.;;Moriarty R, Organic Reactions (2001), 57, 327-415.;;Kappe T, (Ylide von Heterocyclen, VIII Reaktionen von Iodonium-Yliden mit Säuren), Monatshefte fur Chemie (1984) 115(2), 231-242.;;Osborne A, (Regioselective Al koxydehalogenation of 2,4-Di halogenoquinolines and a Reinvestigation of the Bromination of 2-Methoxyquinoline), J Chem Soc Perkin Trans 1 (1993), 181-184.;;Osborne A, (Further studies of regioselective alkoxydehalogenation of 2,4-dichloroquinolines, 2,6-dichloropyridine and 2,4-dichloronitrobenzene), J Chem Research (S) (2002), 4.;;Ramachary D, (Development of Pharmaceutical Drugs, Drug Intermediates and Ingredients by Using Direct Organo-Click Reactions), Eur. J. Org. Chem. (2008), 975-993.;;Korn T, (IL-17 and Th17 Cells), Annual Reviews of Immunology (2009), 27, 485-517.;;Kolls J, (Interleukin-17 family members and inflammation), Immunity (2004), 21(4), 467-476.;;Stamp L, (Interleukin-17: the missing link between T-cell accumulation and effector cell actions in rheumatoid arthritis), Immunol Cell Biol (2004), 82(1), 1-9.;;Kamenecka T, (Synthetic modulators of the retinoic acid receptorrelated orphan receptors), Med Chem Commun (2013), 4, 764-776.;;International Search Report-PCT/US2013/065026, Feb. 21, 2014.;;Yen D. (IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6), J Clin Invest (2006), 116(5), 1310-1316.;;Fujino S, (Increased expression of interleukin 17 in inflammatory bowel disease) Gut (2003), 52(1), 65-70.;;Krueger J, (IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis) J Allergy Clin Immunol (2012), 130(1), 145-154.;;Nunez C, (IL23R: a susceptibility locus for celiac disease and multiple sclerosis?) Genes Immun (2008), 9(4), 239-93.;;Bowes J, (The genetics of psoriatic arthritis: lessons from genome-wide association studies), Discov Med (2010), 10(52), 177-83.;;Kochi Y, (A regulatory variant in CCR6 is associated with rheumatoid arthritis susceptibility), Nat Genet (2010), 42(6), 515-9.;;Garber K, (Psoriasis: from bed to bench and back), Nat Biotech (2011), 29, 563-566.;;Guy R, (Synthesis of ring-substituted 4-aminoquinolines and evaluation of their antimalarial activities), Bioorganic & Medicinal Chemistry Letters (2005), 15, 1015-1018.;;Gore T, (Synthesis of substituted 6,6'-biquinolines from ethyl ethoxy-methyleneacetoacetate), Indian Journal of Chemistry (1965), 3(2), 90-1.;;Gazouli, M, (NOD2/CARD15, ATG16L1 and IL23R gene polymorphisms and childhood-onset of Crohn's disease) World J. Gastroenterol (2010) 16(14), 1753-8.;;Knochel, P. (Preparation of Polyfunctional Ketones by a Cobalt (II) Mediated Carbonylation of Organozinc Reagents), Tetrahedron Letters (1995), 36(46), 8411-8414.;;U.S. Appl. No. 14/513,426.;;U.S. Appl. No. 14/513,455.;;International Search Report-PCT/US2014/60372, Mar. 27, 2015.;;International Search Report-PCT/US2014/60375, Mar. 26, 2015.;;U.S. Appl. No. 14/053,653, Office Action dated Sep. 15, 2014.;;U.S. Appl. No. 14/053,653, Notice of Allowance dated Mar. 30, 2015.;;U.S. Appl. No. 14/053,682, Office Action dated Sep. 12, 2014.;;U.S. Appl. No. 14/053,682, Notice of Allowance dated Sep. 12, 2014.;;U.S. Appl. No. 14/053,707, Office Action dated Sep. 11, 2014.;;U.S. Appl. No. 14/053,707, Notice of Allowance dated Sep. 11, 2014.;;U.S. Appl. No. 12/053,736, Office action dated Mar. 26, 2015.;;U.S. Appl. No. 14/053,736, Office Action dated Oct. 3, 2014.;;U.S. Appl. No. 14/053,773, Office Action dated Apr. 6, 2015.;;U.S. Appl. No. 14/053,773, Office Action dated Jan. 9, 2015.;;U.S. Appl. No. 14/053,797, Office Action dated Sep. 12, 2014.;;U.S. Appl. No. 14/053,797, Notice of Allowance Apr. 7, 2015.;;U.S. Appl. No. 14/513,426, Office Action dated Apr. 16, 2015.;;U.S. Appl. No. 14/513,455, Office Action dated Apr. 28, 2015.;;U.S. Appl. No. 14/053,906, Office Action dated 9/12/204.;;U.S. Appl. No. 14/053,906, Notice of Allowance dated Mar. 23, 2015.;;Dorwald F. A. ""Slide Reactions in Organic Synthesis"", 2005, Wiley: VCH, Weinheim p. IX of Preface pp. 1-15.;;Venkatesh, et al. ""Role of the Development Scientist in Compound Lead Selection and Optimization"", J. Pharm. Sci. vol. 89, No. 2, pp. 145-154 2000.;;STN Search Report Mar. 12, 2015, RN 1347913-41-0.",ACTIVE
216,WO,A8,WO 2014/062658 A8,138-124-882-373-73X,2014-07-10,2014,US 2013/0065013 W,2013-10-15,US 201261714419 P;;US 201261725528 P;;US 201361782257 P,2012-10-16,METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T,"The present invention comprises compounds of Formula (I), wherein: R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.",JANSSEN PHARMACEUTICA NV;;LEONARD KRISTI A,LEONARD KRISTI A;;BARBAY KENT;;EDWARDS JAMES P;;KREUTTER KEVIN D;;KUMMER DAVID A;;MAHAROOF UMAR;;NISHIMURA RACHEL;;URBANSKI MAUD;;VENKATESAN HARIHARAN;;WANG AIHUA;;WOLIN RONALD L;;WOODS CRAIG R;;PIERCE JOAN;;GOLDBERG STEVEN;;FOURIE ANNE;;XUE XIAOHUA,,https://lens.org/138-124-882-373-73X,Amended Application,yes,0,0,49,50,0,C07D413/14;;C07D401/06;;A61K31/4709;;C07D401/14;;C07D417/14;;C07D409/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P37/00;;A61P37/02;;C07D401/06;;A61K31/4709;;A61K45/06;;C07D401/14;;C07D417/14;;C07D409/14;;C07D413/14,C07D401/14;;A61K31/4709;;A61P29/00;;C07D401/06;;C07D409/14;;C07D413/14;;C07D417/14,,0,0,,,,PENDING
217,CL,A1,CL 2015000945 A1,066-183-701-713-871,2015-08-28,2015,CL 2015000945 A,2015-04-15,US 201261714419 P;;US 201261725528 P;;US 201361782257 P,2012-10-16,"Compuestos derivados de quinolina, como moduladores del receptor nuclear ror-gammat; composicion farmaceutica que los comprende; su proceso de elaboracion, util para el tratamiento de una enfermedad inflamatoria tal como artritis reumatoide, soriasis, epoc, enfermedad de crohn, esclerosis multiple, lupus eritematoso sistemico y colitis ulcerativa.",,JANSSEN PHARMACEUTICA NV,LEONARD KRISTI A;;BARBAY KENT;;EDWARDS JAMES P;;KREUTTER KEVIN D;;KUMMER DAVID A;;MAHAROOF UMAR;;NISHIMURA RACHEL;;URBANSKI MAUD;;VENKATESAN HARIHARAN;;WANG AIHUA;;WOLIN RONALD L;;WOODS CRAIG R;;PIERCE JOAN;;GOLDBERG STEVEN;;FOURIE ANNE;;WUE XIAOHUA,,https://lens.org/066-183-701-713-871,Patent Application,no,0,0,49,50,0,C07D413/14;;C07D401/06;;A61K31/4709;;C07D401/14;;C07D417/14;;C07D409/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P37/00;;A61P37/02;;C07D401/06;;A61K31/4709;;A61K45/06;;C07D401/14;;C07D417/14;;C07D409/14;;C07D413/14,C07D401/06;;A61K31/4709;;A61P29/00;;C07D401/14;;C07D409/14;;C07D413/14;;C07D417/14,,0,0,,,,PENDING
218,CA,C,CA 2888210 C,188-503-567-401-239,2021-02-09,2021,CA 2888210 A,2013-10-15,US 201261714419 P;;US 201261725528 P;;US 201361782257 P;;US 2013/0065013 W,2012-10-16,METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T,"The present invention comprises compounds of Formula (I), wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.",JANSSEN PHARMACEUTICA NV,LEONARD KRISTI A;;BARBAY KENT;;EDWARDS JAMES P;;KREUTTER KEVIN D;;KUMMER DAVID A;;MAHAROOF UMAR;;NISHIMURA RACHEL;;URBANSKI MAUD;;VENKATESAN HARIHARAN;;WANG AIHUA;;WOLIN RONALD L;;WOODS CRAIG R;;PIERCE JOAN;;GOLDBERG STEVEN;;FOURIE ANNE;;XUE XIAOHUA,,https://lens.org/188-503-567-401-239,Granted Patent,no,0,0,49,50,9,C07D413/14;;C07D401/06;;A61K31/4709;;C07D401/14;;C07D417/14;;C07D409/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P37/00;;A61P37/02;;C07D401/06;;A61K31/4709;;A61K45/06;;C07D401/14;;C07D417/14;;C07D409/14;;C07D413/14,C07D401/14;;A61K31/4709;;A61P29/00;;C07D401/06;;C07D409/14;;C07D413/14;;C07D417/14,,0,0,,,,ACTIVE
219,MX,A,MX 2015004783 A,151-666-436-255-896,2015-08-14,2015,MX 2015004783 A,2013-10-15,US 201261714419 P;;US 201261725528 P;;US 201361782257 P;;US 2013/0065013 W,2012-10-16,METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T.,"The present invention comprises compounds of Formula (I), wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORÎ³t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.",JANSSEN PHARMACEUTICA NV,GOLDBERG STEVEN;;FOURIE ANNE;;WANG AIHUA;;EDWARDS JAMES P;;BARBAY KENT;;VENKATESAN HARIHARAN;;WOLIN RONALD L;;PIERCE JOAN M;;LEONARD KRISTI A;;KREUTTER KEVIN D;;KUMMER DAVID A;;MAHAROOF UMAR;;NISHIMURA RACHEL;;URBANSKI MAUD;;WOODS CRAIG R;;XUE XIAOHUA,,https://lens.org/151-666-436-255-896,Patent Application,no,0,0,49,50,0,C07D413/14;;C07D401/06;;A61K31/4709;;C07D401/14;;C07D417/14;;C07D409/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P37/00;;A61P37/02;;C07D401/06;;A61K31/4709;;A61K45/06;;C07D401/14;;C07D417/14;;C07D409/14;;C07D413/14,C07D401/14;;A61K31/4709;;A61P29/00;;C07D401/06;;C07D409/14;;C07D413/14;;C07D417/14,,0,0,,,,ACTIVE
220,MX,B,MX 358508 B,098-910-320-255-562,2018-08-22,2018,MX 2015004783 A,2013-10-15,US 201261714419 P;;US 201261725528 P;;US 201361782257 P;;US 2013/0065013 W,2012-10-16,METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T.,"The present invention comprises compounds of Formula (I), wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORyt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.",JANSSEN PHARMACEUTICA NV,GOLDBERG STEVEN;;FOURIE ANNE;;WANG AIHUA;;EDWARDS JAMES P;;BARBAY KENT;;VENKATESAN HARIHARAN;;WOLIN RONALD L;;PIERCE JOAN M;;LEONARD KRISTI A;;KREUTTER KEVIN D;;KUMMER DAVID A;;MAHAROOF UMAR;;NISHIMURA RACHEL;;URBANSKI MAUD;;WOODS CRAIG R;;XUE XIAOHUA,,https://lens.org/098-910-320-255-562,Granted Patent,no,0,0,49,50,0,C07D413/14;;C07D401/06;;A61K31/4709;;C07D401/14;;C07D417/14;;C07D409/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/06;;A61P19/02;;A61P25/00;;A61P29/00;;A61P37/00;;A61P37/02;;C07D401/06;;A61K31/4709;;A61K45/06;;C07D401/14;;C07D417/14;;C07D409/14;;C07D413/14,C07D401/14;;A61K31/4709;;A61P29/00;;C07D401/06;;C07D409/14;;C07D413/14;;C07D417/14,,0,0,,,,ACTIVE
221,WO,A8,WO 2002/052445 A8,164-393-312-258-180,2002-09-26,2002,US 0146812 W,2001-12-03,US 74801000 A,2000-12-27,INTERACTIVE SEARCH PROCESS FOR PRODUCT INQUIRIES,"Un processus commercial utilise un logiciel informatique et des connexions client/fournisseur électroniques permettant de fournir des informations, recevoir des demandes de devis, des devis de fournisseur, des offres d'achat et de réaliser des fonctions commerciales et techniques associées à la distribution de ces offres d'achat ou de ces devis par rapport à un environnement et à l'utilisation de produits spécifiques. Ces produits nécessitent un évaluation technique unique d'application de l'entreprise ou du client et/ou un traitement commercial de façon à assurer son applicabilité à une application de client spécifique. Ce système offre un moyen permettant de rechercher des parties prévues qui nécessitent cette étude technique.",GEN ELECTRIC,COOLEY WALTER H JR;;TRAINA GARY JAMES;;WELLS JULIE SUZANNE;;CAGLEY GEORGE DAVID;;KHINDA MANJEET KAUR;;VILLAGOMEZ ROGER CHARLENE ECLA;;IKEMOTO FRED MASATO;;STOTTS WAYNE ALLEN;;SWAIN STEPHEN ARTHUR;;TETIRICK CRAIG WESLEY;;PHILLIPS COLIN TERRY;;COX DONNA MARIE;;OSE LESLIE JEAN;;LEIGHTY CRAIG ERNEST;;PANETTA THOMAS STEVEN;;GOLDBERG CRAIG SCOTT;;WONG CAROLYN ELIZABETH;;SCHUSTER ROBERT MERLE;;CORY RICHARD LANCE;;DULEY JAMES MICHAEL SR;;GAY JAMES STEPHENS;;DAHLIN RONALD SCOTT;;SCHOCKLEY CAROLYN RUTH,,https://lens.org/164-393-312-258-180,Patent Application,no,0,0,13,13,0,G06Q10/087;;G06Q10/0875;;G06Q10/087;;G06Q10/0875;;Y10S707/99933,G21C17/00;;G06F17/30;;G06Q10/08,,0,0,,,,PENDING
222,WO,A2,WO 2002/052445 A2,196-790-527-173-862,2002-07-04,2002,US 0146812 W,2001-12-03,US 74801000 A,2000-12-27,INTERACTIVE SEARCH PROCESS FOR PRODUCT INQUIRIES,"Un processus commercial utilise un logiciel informatique et des connexions client/fournisseur �lectroniques permettant de fournirdes informations, recevoir des demandes de devis, des devis de fournisseur, des offres d'achat et de r�aliser des fonctions commerciales et techniques associ�es � la distribution de ces offres d'achat ou de ces devis par rapport � un environnement et � l'utilisation de produits sp�cifiques. Ces produits n�cessitent un �valuation technique unique d'application de l'entreprise ou du client et/ou un traitement commercial de fa�on � assurer son applicabilit� � une application de client sp�cifique. Ce syst�me offre un moyen permettant de rechercher des parties pr�vues qui n�cessitent cette �tude technique.",GEN ELECTRIC,COOLEY WALTER H JR;;TRAINA GARY JAMES;;WELLS JULIE SUZANNE;;CAGLEY GEORGE DAVID;;KHINDA MANJEET KAUR;;VILLAGOMEZ ROGER CHARLENE ECLA;;IKEMOTO FRED MASATO;;STOTTS WAYNE ALLEN;;SWAIN STEPHEN ARTHUR;;TETIRICK CRAIG WESLEY;;PHILLIPS COLIN TERRY;;COX DONNA MARIE;;OSE LESLIE JEAN;;LEIGHTY CRAIG ERNEST;;PANETTA THOMAS STEVEN;;GOLDBERG CRAIG SCOTT;;WONG CAROLYN ELIZABETH;;SCHUSTER ROBERT MERLE;;CORY RICHARD LANCE;;DULEY JAMES MICHAEL SR;;GAY JAMES STEPHENS;;DAHLIN RONALD SCOTT;;SCHOCKLEY CAROLYN RUTH,,https://lens.org/196-790-527-173-862,Patent Application,yes,0,0,13,13,0,G06Q10/087;;G06Q10/0875;;G06Q10/087;;G06Q10/0875;;Y10S707/99933,G21C17/00;;G06F17/30;;G06Q10/08,,0,0,,,,PENDING
223,AU,A1,AU 2002/230638 A1,160-157-689-965-002,2002-07-08,2002,AU 2002/230638 A,2001-12-03,US 74801000 A;;US 0146812 W,2000-12-27,Interactive search process for product inquiries,,GEN ELECTRIC,WELLS JULIE SUZANNE;;CAGLEY GEORGE DAVID;;KHINDA MANJEET KAUR;;ROGER CHARLENE ECLAVEA VILLAGO;;IKEMOTO FRED MASATO;;STOTTS WAYNE ALLEN;;SWAIN STEPHEN ARTHUR;;TETIRICK CRAIG WESLEY;;PHILLIPS COLIN TERRY;;COX DONNA MARIE;;OSE LESLIE JEAN;;LEIGHTY CRAIG ERNEST;;PANETTA THOMAS STEVEN;;GOLDBERG CRAIG SCOTT;;WONG CAROLYN ELIZABETH;;SCHUSTER ROBERT MERLE;;CORY RICHARD LANCE;;DULEY JAMES MICHAEL SR;;GAY JAMES STEPHENS;;DAHLIN RONALD SCOTT;;SCHOCKLEY CAROLYN RUTH;;COOLEY WALTER H JR;;TRAINA GARY JAMES,,https://lens.org/160-157-689-965-002,Patent Application,no,0,0,13,13,0,G06Q10/087;;G06Q10/0875;;G06Q10/087;;G06Q10/0875;;Y10S707/99933,G21C17/00;;G06F17/30;;G06Q10/08,,0,0,,,,DISCONTINUED
224,BR,A,BR 0108690 A,031-279-769-397-680,2003-01-28,2003,BR 0108690 A,2001-12-03,US 74801000 A;;US 0146812 W,2000-12-27,Processo de busca interativa para consultas de produto,"""PROCESSO DE BUSCA INTERATIVA PARA CONSULTAS DE PRODUTO"". Um processo comercial utiliza software de computador e conexões eletrónicas cliente/fornecedor para fornecer informações, receber pedidos para cotação, fornecer cotações, receber ordens de compra e realizar funções comerciais e técnicas associadas com a liberação de tais ordens de compra ou cotações com relação ao meio ambiente e produtos de uso específico. Tais produtos requerem avaliação técnica do cliente ou aplicação na usina e/ou processamento comercial, para garantir aplicabilidade para uma aplicação específica do cliente. O sistema proporciona um veículo para busca para peças requerendo tal revisão técnica abrangendo uso antecipado.",GEN ELECTRIC,COOLEY WALTER H JR;;TRAINA GARY JAMES;;WELLS JULIE SUZANNE;;CAGLEY GEORGE DAVID;;KHINDA MANJEET KAUR;;VILLAGOMEZ ROGER CHARLENE ECLA;;IKEMOTO FRED MASATO;;STOTTS WAYNE ALLEN;;SWAIN STEPHEN ARTHUR;;TETIRICK CRAIG WESLEY;;PHILLIPS COLIN TERRY;;COX DONNA MARIE;;OSE LESLIE JEAN;;LEIGHTY CRAIG ERNEST;;PANETTA THOMAS STEVEN;;GOLDBERG CRAIG SCOTT;;WONG CAROLYN ELIZABETH;;SCHUSTER ROBERT MERLE;;CORY RICHARD LANCE;;DULEY JAMES MICHAEL SR;;GAY JAMES STEPHENS;;DAHLIN RONALD SCOTT;;SCHOCKLEY CAROLYN RUTH,,https://lens.org/031-279-769-397-680,Patent Application,no,0,0,13,13,0,G06Q10/087;;G06Q10/0875;;G06Q10/087;;G06Q10/0875;;Y10S707/99933,G21C17/00;;G06F17/30;;G06Q10/08,,0,0,,,,DISCONTINUED
225,US,B2,US 6856968 B2,168-243-639-811-066,2005-02-15,2005,US 74801000 A,2000-12-27,US 74801000 A,2000-12-27,Interactive search process for product inquiries,"A business process utilizes computer software and electronic customer/supplier connections to supply information, receive requests for quotation, supply quotations, receive purchase orders, and perform commercial and technical functions associated with delivery of such purchase orders or quotations with respect to environment and use specific products. Such products require customer or plant application unique technical evaluation and/or commercial processing to ensure applicability to a specific customer application. The system provides a vehicle to search for parts requiring such technical review encompassing anticipated product use.",GEN ELECTRIC,COOLEY WALTER HENING;;TRAINA GARY JAMES;;WELLS JULIE SUZANNE;;CAGLEY II GEORGE DAVID;;KHINDA MANJEET KAUR;;ROGER CHARLENE ECLAVEA VILLAGO;;IKEMOTO FRED MASATO;;STOTTS WAYNE ALLEN;;SWAIN STEPHEN ARTHUR;;TETIRICK CRAIG WESLEY;;PHILLIPS COLIN TERRY;;COX DONNA MARIE;;OSE LESLIE JEAN;;LEIGHTY CRAIG ERNEST;;PANETTA THOMAS S;;GOLDBERG CRAIG SCOTT;;WONG CAROLYN ELIZABETH;;SCHUSTER ROBERT MERLE;;CORY RICHARD LANCE;;DULEY SR JAMES MICHAEL;;GAY JAMES STEPHENS;;DAHLIN RONALD SCOTT;;SHOCKLEY CAROLYN R,GENERAL ELECTRIC COMPANY (2000-12-07),https://lens.org/168-243-639-811-066,Granted Patent,yes,17,47,13,13,0,G06Q10/087;;G06Q10/0875;;G06Q10/087;;G06Q10/0875;;Y10S707/99933,G21C17/00;;G06F17/30;;G06Q10/08,705/28;;707/3,4,0,,,"Derfler, Frank J. et. al. How Networks Work, Millennium Ed., Que Corporation, Jan. 2000.*;;White, Ron, How Computers Work Millennium Ed. Que Corporation, Sep. 1999.*;;Gralla, Preston, How the Internet Works, Millennium Ed., Que Corporation, Aug. 1999.*;;Blue Chip Inventory Serviess from www.count-it.com, webpage, Jan. 19, 1998.",EXPIRED
226,CA,A1,CA 2399563 A1,064-681-423-548-368,2002-07-04,2002,CA 2399563 A,2001-12-03,US 74801000 A;;US 0146812 W,2000-12-27,INTERACTIVE SEARCH PROCESS FOR PRODUCT INQUIRIES,"A business process utilzes computer software and electronic customer/supplie r connections to supply information, receive requests for quotation, supply quotations, receive purchase orders, and perform commerical and technical functiosn associated with delivery of such purchase orders or quotations wit h respect to envirnoment and use specific products. Such products require customer or plant application unique technical evaluation and/or commerical processing to ensure applicability to a specific customer application. The system provides a vehicle to search for parts requiring such technical revie w encompassing anticipated.",GEN ELECTRIC,CAGLEY GEORGE DAVID;;PANETTA THOMAS STEVEN;;KHINDA MANJEET KAUR;;LEIGHTY CRAIG ERNEST;;PHILLIPS COLIN TERRY;;TETIRICK CRAIG WESLEY;;COX DONNA MARIE;;OSE LESLIE JEAN;;GOLDBERG CRAIG SCOTT;;IKEMOTO FRED MASATO;;STOTTS WAYNE ALLEN;;SWAIN STEPHEN ARTHUR;;VILLAGOMEZ ROGER CHARLENE ECLA;;COOLEY WALTER H JR;;CORY RICHARD LANCE;;TRAINA GARY JAMES;;WELLS JULIE SUZANNE;;WONG CAROLYN ELIZABETH;;SCHUSTER ROBERT MERLE;;DAHLIN RONALD SCOTT;;SCHOCKLEY CAROLYN RUTH;;DULEY JAMES MICHAEL SR;;GAY JAMES STEPHENS,,https://lens.org/064-681-423-548-368,Patent Application,no,0,0,13,13,0,G06Q10/087;;G06Q10/0875;;G06Q10/087;;G06Q10/0875;;Y10S707/99933,G21C17/00;;G06F17/30;;G06Q10/08,,0,0,,,,DISCONTINUED
227,WO,A1,WO 2015/057205 A1,076-918-866-144-483,2015-04-23,2015,US 2013/0065048 W,2013-10-15,US 2013/0065048 W,2013-10-15,METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T,"The present invention comprises compounds of Formula (I). wherein: R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.",JANSSEN PHARMACEUTICA NV;;LEONARD KRISTI A,LEONARD KRISTI A;;BARBAY KENT;;EDWARDS JAMES P;;KREUTTER KEVIN D;;KUMMER DAVID A;;MAHAROOF UMAR;;NISHIMURA RACHEL;;URBANSKI MAUD;;VENKATESAN HARIHARAN;;WANG AIHUA;;WOLIN RONALD L;;WOODS CRAIG R;;FOURIE ANNE;;XUE XIAOHUA;;CUMMINGS MAXWELL D;;JONES WILLIAM MOORE;;GOLDBERG STEVEN,,https://lens.org/076-918-866-144-483,Patent Application,yes,6,5,16,16,9,C07D401/14;;C07D413/14;;C07D403/14;;C07D407/14;;C07D417/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P11/14;;A61P17/06;;A61P19/02;;A61P19/08;;A61P25/00;;A61P29/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61K31/4709;;A61K31/4725;;C07D401/14;;C07D403/14;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/14,C07D401/14;;A61K31/4709;;A61P1/00;;A61P11/06;;A61P17/06;;A61P19/02;;C07D403/14;;C07D407/14;;C07D413/14;;C07D417/14,,0,0,,,,PENDING
228,EP,B1,EP 3057951 B1,124-847-171-116-631,2019-11-20,2019,EP 13786779 A,2013-10-15,US 2013/0065048 W,2013-10-15,METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T,,JANSSEN PHARMACEUTICA NV,LEONARD KRISTI A;;BARBAY KENT;;EDWARDS JAMES P;;KREUTTER KEVIN D;;KUMMER DAVID A;;MAHAROOF UMAR;;NISHIMURA RACHEL;;URBANSKI MAUD;;VENKATESAN HARIHARAN;;WANG AIHUA;;WOLIN RONALD L;;WOODS CRAIG R;;FOURIE ANNE;;XUE XIAOHUA;;CUMMINGS MAXWELL D;;JONES WILLIAM MOORE;;GOLDBERG STEVEN,JANSSEN PHARMACEUTICA NV (2017-03-15),https://lens.org/124-847-171-116-631,Granted Patent,yes,1,0,16,16,0,C07D401/14;;C07D413/14;;C07D403/14;;C07D407/14;;C07D417/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P11/14;;A61P17/06;;A61P19/02;;A61P19/08;;A61P25/00;;A61P29/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61K31/4709;;A61K31/4725;;C07D401/14;;C07D403/14;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/14,C07D401/14;;A61K31/4709;;A61P1/00;;A61P11/06;;A61P19/02;;C07D403/14;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/14,,0,0,,,,ACTIVE
229,US,A1,US 2023/0289034 A1,182-388-039-845-152,2023-09-14,2023,US 202318199574 A,2023-05-19,US 202318199574 A;;US 202117505916 A;;US 202017030804 A;;US 202063032970 P;;US 202063022869 P;;US 202063008586 P,2020-04-10,USER INTERFACES FOR ENABLING AN ACTIVITY,"The present disclosure generally relates to user interfaces for enabling an activity using a computer system. In some embodiments, exemplary user interfaces for invoking an activity associated with an application are described. In some embodiments, exemplary user interfaces for customizing displayed content based on circumstances under which the content was invoked are described. In some embodiments, exemplary user interfaces for managing applications that were used to enable activities are described. In some embodiments, exemplary user interfaces for managing settings for applications used to enable activities are described.",APPLE INC,ZHANG YONGJUN;;ABBASIAN REZA;;ADLER DARIN;;COFFMAN PATRICK L;;DOHERTY NICHOLAS STEPHEN;;FALKENBURG STEVEN;;FEDERIGHI CRAIG M;;FERRY KENNETH ARTHUR ABRAHAM;;FOSS CHRISTOPHER PATRICK;;GOLDBERG BRIAN ERIK;;KO HEENA;;PAUL GRANT;;RITCHIE GRANT C;;STACK CAELAN G;;YING CHARLES H;;ZHANG XIAOYUE,,https://lens.org/182-388-039-845-152,Patent Application,yes,0,0,10,37,0,G06F3/048;;G06F21/00;;H04M1/00;;H04W4/00;;H04L67/34;;G06F3/0488;;G06F3/04842;;G06F3/04883;;G06F3/04886;;G06F9/451;;G06F3/04817;;G06F8/38;;G06F3/04842;;G06F3/0488;;G06F9/44568;;G06F9/54;;H04L67/34;;H04L67/5651,G06F3/04817;;G06F3/04842;;G06F3/0488;;G06F8/38;;G06F9/445;;G06F9/54;;H04L67/00;;H04L67/5651,,0,0,,,,PENDING
230,US,B2,US 9284308 B2,062-259-786-007-927,2016-03-15,2016,US 201314053797 A,2013-10-15,US 201314053797 A,2013-10-15,Methylene linked quinolinyl modulators of RORγt,"The present invention comprises compounds of Formula I. wherein: R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.",JANSSEN PHARMACEUTICA NV,LEONARD KRISTI A;;BARBAY KENT;;EDWARDS JAMES P;;KREUTTER KEVIN D;;KUMMER DAVID A;;MAHAROOF UMAR;;NISHIMURA RACHEL;;URBANSKI MAUD;;VENKATESAN HARIHARAN;;WANG AIHUA;;WOLIN RONALD L;;WOODS CRAIG R;;FOURIE ANNE;;XUE XIAOHUA;;CUMMINGS MAXWELL D;;JONES WILLIAM MOORE;;GOLDBERG STEVEN,JANSSEN PHARMACEUTICA NV (2013-11-20),https://lens.org/062-259-786-007-927,Granted Patent,yes,102,6,2,2,9,A61K31/4709;;A61K31/4709;;A61K31/506;;A61K31/506;;A61K31/5377;;A61K31/5377;;A61K45/06;;A61K45/06;;C07D417/14;;C07D417/14;;C07D401/06;;C07D401/06;;C07D401/14;;C07D401/14;;C07D405/14;;C07D405/14;;C07D409/14;;C07D409/14;;C07D413/14;;C07D413/14,A61K31/4709;;A61K31/506;;A61K31/5377;;A61K45/06;;C07D401/06;;C07D401/14;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/14,,81,39,084-843-025-849-979;;027-264-766-337-299;;117-948-696-800-494;;005-296-732-298-701;;005-216-737-509-018;;093-303-130-222-691;;002-046-645-408-510;;013-258-562-870-922;;013-740-155-925-960;;064-399-651-040-903;;016-505-509-019-957;;014-408-820-938-035;;066-119-584-271-19X;;035-586-215-470-490;;039-460-067-637-00X;;118-307-749-079-773;;048-384-949-179-543;;000-649-437-049-891;;018-908-523-184-712;;093-144-517-257-295;;167-457-447-044-074;;110-622-320-158-427;;110-556-689-717-601;;163-436-001-999-281;;068-508-663-743-396;;020-545-279-619-551;;078-205-757-883-386;;011-733-947-435-777;;030-303-530-555-166;;006-384-711-859-473;;028-713-636-085-561;;011-663-094-062-663;;156-601-101-421-818;;042-371-686-427-160;;095-361-043-889-533;;150-196-683-295-748;;004-514-663-069-206;;063-405-380-326-046;;045-406-285-588-795,21516112;;10.1038/ni.2027;;10.3410/f.10935956.11871057;;20726898;;10.1111/j.1567-1364.2010.00663.x;;20403696;;10.1016/j.bmcl.2010.03.115;;10.1016/j.bmcl.2010.01.094;;20167488;;19842138;;10.1002/cbdv.200800268;;10.1021/jm900460z;;19719237;;10.3987/com-05-s(k)48;;10.1021/jm00273a007;;5059208;;10.1016/j.tetlet.2005.11.128;;10.1038/nri1807;;16557264;;10.1016/j.it.2005.10.003;;16290228;;16990136;;10.1016/j.cell.2006.07.035;;12610626;;10.1038/nature01355;;pmc2212798;;10.1084/jem.20041257;;15657292;;20956338;;pmc3776381;;10.4049/jimmunol.1001538;;12814161;;10.1053/rmed.2003.1507;;11984595;;10.1038/nm0502-500;;22455412;;10.1056/nejmoa1109017;;22455413;;10.1056/nejmoa1109997;;20926833;;10.1126/scitranslmed.3001107;;10.1080/00397910903013713;;10.1002/0471264180.or057.02;;10.1007/bf00798414;;10.1002/ejoc.200701014;;10.1146/annurev.immunol.021908.132710;;19132915;;15485625;;10.1016/j.immuni.2004.08.018;;14984588;;10.1111/j.1440-1711.2004.01212.x;;10.1039/c3md00005b;;16670770;;pmc1451201;;10.1172/jci21404;;10.1136/gut.52.1.65;;pmc1773503;;12477762;;10.1016/j.jaci.2012.04.024;;pmc3470466;;22677045;;10.1038/gene.2008.16;;18368064;;20875338;;20453841;;10.1038/ng.583;;21747375;;10.1038/nbt.1906;;10.1016/j.bmcl.2004.12.037;;15686903;;pmc2852824;;10.3748/wjg.v16.i14.1753;;20380008;;10.1016/0040-4039(95)01802-o;;10.1002/(sici)1520-6017(200002)89:2<145::aid-jps2>3.0.co;2-6;;10688744,"Codarri, Nature Innumology, Jun. 2011, vol. 12(6), p. 560-568.;;International Search Report-PCT/US2013/065007, Jan. 7, 2014.;;International Search Report-PCT/US2013/065013, Dec. 16, 2013.;;International Search Report-PCT/US2013/065031, Dec. 13, 2013.;;International Search Report-PCT/US2013/065040, Dec. 16, 2013.;;International Search Report-PCT/US2013/065048, Dec. 3, 2013.;;International Search Report-PCT/US2013/065053, Jan. 7, 2014.;;International Search Report-PCT/US2013/065026, Feb. 21, 2014.;;U.S. Appl. No. 14/053,682.;;U.S. Appl. No. 14/053,736.;;U.S. Appl. No. 14/053,773.;;U.S. Appl. No. 14/053,906.;;U.S. Appl. No. 14/053,653.;;U.S. Appl. No. 14/053,707.;;Bink A, (A fungicidal piperazine-1-carboxamidine induces mitochondrial fission-dependent apoptosis in yeast), FEMS Yeast Research (2010), 10(7), 812-818.;;Nieman J, (Modifications of C-2 on the pyrroloquinoline template aimed at the development of potent herpes virus antivirals with improved aqueous solubility), Bioorganic & Medicinal Chemistry Letters (2010), 20(10), 3039-3042.;;Tanis S, (The design and development of 2-aryl-2-hydroxy ethylamine substituted 1H,7H-pyrido[1,2,3-de]quinoxaline-6-carboxamides as inhibitors of human cytomegalovirus polymerase), Bioorganic & Medicinal Chemistry Letters (2010), 20(6), 1994-2000.;;Mao D, (Synthesis and Na+/H+ Exchanger-1 Inhibitory Activity of Substituted (Quinolinecarbonyl)guanidine Derivatives), Chemistry & Biodiversity (2009), 6(10), 1727-1736.;;Sato M, (Quinolone Carboxylic Acids as a Novel Monoketo Acid Class of Human Immunodeficiency Virus Type 1 Integrase Inhibitors), Journal of Medicinal Chemistry (2009), 52(15), 4869-4882.;;Aghera V, (Synthesis, spectral and microbial studies of some novel quinoline derivatives via Vilsmeier-Haack reagent) Journal; (online computer file) URL:http://www.arkat-usa.org/get-file/25177/, 2010.;;Inada T, (One-step synthesis of ethyl quinaldates by Lewis acid-catalyzed three-component coupling reaction of aromatic amines, aliphatic aldehydes, and ethyl glyoxylate), Heterocycles (2005), 66, 611-619.;;Zelenin A, (Reaction of polyfluoro carbonyl compounds with 1,2,3,4-tetrahydroquinoline), Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya (1986), (9), 2074-80 Abstract Only.;;Hirao I, (Studies on the synthesis of quinoline compounds. I. Syntheses of 3,3'-dicarboxy-1,1'-diethyl-4,4'-dioxo-1,1',4,4'-tetrahydrobiquinolines), Memoirs of the Kyushu Institute of Technology, Engineering (1984), 14, 13-16.;;Abdul-Ahad P, (Trends in dehydrogenase inhibitory potencies of some quinolones, using quantum chemical indices), European Journal of Medicinal Chemistry (1982), 17(4), 301-6.;;Baker B, (Irreversible enzyme inhibitors. 191. Hydrophobic bonding to some dehydrogenases by 6-, 7-, or 8-substituted-4-hydroxyquinoline-3-carboxylic acids), Journal of Medicinal Chemistry (1972), 15(3), 235-7.;;Ramachary D, (A novel and green protocol for two-carbon homologation: a direct amino acid/K2CO3-catalyzed four-component reaction of aldehydes, active methylenes, Hantzsch esters and alkyl halides), Tetrahedron Letters (2006) 47, 651-656.;;Dong C, (Diversification of T-helper-cell lineages: finding the family root of IL-17-producing cells), Nat Rev Immunol (2006), 6(4), 329-333.;;McKenzie B, (Understanding the IL-23-IL-17 immune pathway), Trends Immunol (2006), 27(1), 17-23.;;Ivanov II B, (The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells), Cell (2006), 126(6), 1121-33.;;Cua, D (Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain), Nature (2003), 421(6924), 744-748.;;Langrish C, (IL-23 drives a pathogenic T cell population that induces autoimmune inflammation), J Exp Med (2005), 201(2), 233-240.;;Tonel G, (Cutting edge: A critical functional role for IL-23 in psoriasis), J Immunol (2010), 185(10), 5688-5691.;;Barczyk A, (Interleukin-17 in sputum correlates with airway hyperresponsiveness to methacholine), Respir Med (2003), 97(6), 726-733.;;Lock C, (Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis) Nat Med (2002), 8(5), 500-8.;;Papp K, (Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis), N Engl J Med (2012), 366(13), 1181-1189.;;Leonardi C, (Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis), N Engl J Med (2012), 366(13), 1190-1199.;;Hueber W, (Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis), Sci Transl Med (2010), 2, 5272.;;Gao W, (Clean and Convienient One-Pot Synthesis of 4-Hydroxycoumarin and 4-Hydroxy-2-Quinolone Derivatives), Synthetic Communications (2010) 40, 732-738.;;Moriarty R, Organic Reactions (2001), 57, 327-415.;;Pongratz E, et al., (Ylide von Heterocyclen, VIII Reaktionen von Iodonium-Yliden mit Säuren), Monatshefte fur Chemie (1984) 115(2), 231-242.;;Osborne A, (Regioselective AI koxydehalogenation of 2,4- Di halogenoquinolines and a Reinvestigation of the Bromination of 2-Methoxyquinoline), J Chem Soc Perkin Trans 1 (1993), 181-184.;;Osborne A, (Further studies of regioselective alkoxydehalogenation of 2,4- dichloroquinolines, 2,6-dichloropyridine and 2,4-dichloronitrobenzene), J Chem Research (S) (2002), 4.;;Ramachary D, (Development of Pharmaceutical Drugs, Drug Intermediates and Ingredients by Using Direct Organo-Click Reactions), Eur. J. Org. Chem. (2008), 975-993.;;Korn T, (IL-17 and Th17 Cells), Annual Reviews of Immunology (2009), 27, 485-517.;;Kolls J, (Interleukin-17 family members and inflammation), Immunity (2004), 21(4), 467-476.;;Stamp L, (Interleukin-17: the missing link between T-cell accumulation and effector cell actions in rheumatoid arthritis), Immunol Cell Biol (2004), 82(1), 1-9.;;Kamenecka T, (Synthetic modulators of the retinoic acid receptorrelated orphan receptors), Med Chem Commun (2013), 4, 764-776.;;Yen D, (IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6), J Clin Invest (2006), 116(5), 1310-1316.;;Fujino S, (Increased expression of interleukin 17 in inflammatory bowel disease) Gut (2003), 52(1), 65-70.;;Krueger J, (IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis) J Allergy Clin Immunol (2012), 130(1), 145-154.;;Nunez C, (IL23R: a susceptibility locus for celiac disease and multiple sclerosis?) Genes Immun (2008), 9(4), 289-93.;;Bowes J, (The genetics of psoriatic arthritis: lessons from genome-wide association studies), Discov Med (2010), 10(52), 177-83.;;Kochi Y, (A regulatory variant in CCR6 is associated with rheumatoid arthritis susceptibility), Nat Genet (2010), 42(6), 515-9.;;Garber K, (Psoriasis: from bed to bench and back), Nat Biotech (2011), 29, 563-566.;;Madrid P, et al. (Synthesis of ring-substituted 4-aminoquinolines and evaluation of their antimalarial activities), Bioorganic & Medicinal Chemistry Letters (2005), 15, 1015-1018.;;Gore T, (Synthesis of substituted 6,6'-biquinolines from ethyl ethoxy-methyleneacetoacetate), Indian Journal of Chemistry (1965), 3(2), 90-1.;;Gazouli, M, (NOD2/CARD15, ATG16L1 and IL23R gene polymorphisms and childhood-onset of Crohn's disease) World J. Gastroenterol (2010) 16(14), 1753-8.;;Knochel P, (Preparation of Polyfunctional Ketones by a Cobalt(II) Mediated Carbonylation of Organozinc Reagents), Tetrahedron Letters (1995), 36(46), 8411-8414.;;U.S. Appl. No. 14/513,426.;;U.S. Appl. No. 14/513,455.;;International Search Report-PCT/US2014/60372, Mar. 27, 2015.;;International Search Report-PCT/US2014/60375, Mar. 26, 2015.;;U.S. Appl. No. 14/053,653, Office Action dated Sep. 15, 2014.;;U.S. Appl. No. 14/053,653, Notice of Allowance dated Mar. 30, 2015.;;U.S. Appl. No. 14/053,682, Office Action dated Sep. 12, 2014.;;U.S. Appl. No. 14/053,682, Notice of Allowance dated Sep. 12, 2014.;;U.S. Appl. No. 14/053,707, Office Action dated Sep. 11, 2014.;;U.S. Appl. No. 14/053,707, Notice of Allowance dated Sep. 11, 2014.;;U.S. Appl. No. 12/053,736, Office action dated Mar. 26, 2015.;;U.S. Appl. No. 14/053,736, Office Action dated Oct. 3, 2014.;;U.S. Appl. No. 14/053,773, Office Action dated Apr. 6, 2015.;;U.S. Appl. No. 14/053,773, Office Action dated Jan. 9, 2015.;;U.S. Appl. No. 14/053,797, Office Action dated Sep. 12, 2014.;;U.S. Appl. No. 14/053,797, Notice of Allowance Apr. 7, 2015.;;U.S. Appl. No. 14/513,426, Office Action dated Apr. 16, 2015.;;U.S. Appl. No. 14/513,455, Office Action dated Apr. 28, 2015.;;U.S. Appl. No. 14/053,906, Office Action dated Sep. 12, 204.;;U.S. Appl. No. 14/053,906, Notice of Allowance dated Mar. 23, 2015.;;Dorwald F. A. ""SLIDE Reactions in Organic Synthesis"", 2005, Wiley: VCH, Weinheim p. IX of Preface p. 1-15.;;Venkatesh, et al. ""Role of the Development Scientist in Compound Lead Selection and Optimization"", J. Pharm. Sci. vol. 89, No. 2, pp. 145-154 2000.;;STN Search Report Mar. 12, 2015, RN 1347913-41-0.",ACTIVE
231,AU,B2,AU 2013/403335 B2,009-048-406-123-546,2018-11-15,2018,AU 2013/403335 A,2013-10-15,US 201361782257 P;;US 201261714419 P;;US 201261725528 P;;US 2013/0065048 W,2012-10-16,Methylene linked quinolinyl modulators of ROR-gamma-t,The present invention comprises compounds of Formula (I). wherein: R,JANSSEN PHARMACEUTICA NV,LEONARD KRISTI A;;BARBAY KENT;;EDWARDS JAMES P;;KREUTTER KEVIN D;;KUMMER DAVID A;;MAHAROOF UMAR;;NISHIMURA RACHEL;;URBANSKI MAUD;;VENKATESAN HARIHARAN;;WANG AIHUA;;WOLIN RONALD L;;WOODS CRAIG R;;FOURIE ANNE;;XUE XIAOHUA;;CUMMINGS MAXWELL D;;JONES WILLIAM MOORE;;GOLDBERG STEVEN,,https://lens.org/009-048-406-123-546,Granted Patent,no,1,0,16,16,0,C07D401/14;;C07D413/14;;C07D403/14;;C07D407/14;;C07D417/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P11/14;;A61P17/06;;A61P19/02;;A61P19/08;;A61P25/00;;A61P29/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61K31/4709;;A61K31/4725;;C07D401/14;;C07D403/14;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/14,C07D401/14;;A61K31/4709;;A61P1/00;;A61P11/06;;A61P17/06;;A61P19/02;;C07D403/14;;C07D407/14;;C07D413/14;;C07D417/14,,0,0,,,,INACTIVE
232,AU,A1,AU 2019/200726 A1,164-145-019-474-834,2019-02-21,2019,AU 2019/200726 A,2019-02-04,AU 2019/200726 A;;AU 2013/403335 A;;US 201361782257 P;;US 201261714419 P;;US 201261725528 P;;US 2013/0065048 W,2012-10-16,Methylene linked quinolinyl modulators of ROR-gamma-T,"METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T Abstract The present invention comprises compounds of Formula (I). wherein: R1, R2 , R3 , R4 , R5 , R6 , R7 , R"", and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORyt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim Ra",JANSSEN PHARMACEUTICA NV,VENKATESAN HARIHARAN;;WANG AIHUA;;WOLIN RONALD L;;WOODS CRAIG R;;FOURIE ANNE;;XUE XIAOHUA;;CUMMINGS MAXWELL D;;JONES WILLIAM MOORE;;GOLDBERG STEVEN;;NISHIMURA RACHEL;;BARBAY KENT;;LEONARD KRISTI A;;EDWARDS JAMES P;;KREUTTER KEVIN D;;KUMMER DAVID A;;MAHAROOF UMAR;;URBANSKI MAUD,,https://lens.org/164-145-019-474-834,Patent Application,no,0,0,16,16,0,C07D401/14;;C07D413/14;;C07D403/14;;C07D407/14;;C07D417/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P11/14;;A61P17/06;;A61P19/02;;A61P19/08;;A61P25/00;;A61P29/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61K31/4709;;A61K31/4725;;C07D401/14;;C07D403/14;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/14,C07D401/14;;A61K31/4709;;A61P1/00;;A61P11/06;;A61P17/06;;A61P19/02;;C07D403/14;;C07D407/14;;C07D413/14;;C07D417/14,,0,0,,,,DISCONTINUED
233,AU,A1,AU 2013/403335 A1,189-293-099-900-179,2016-04-28,2016,AU 2013/403335 A,2013-10-15,US 201361782257 P;;US 201261714419 P;;US 201261725528 P;;US 2013/0065048 W,2012-10-16,Methylene linked quinolinyl modulators of ROR-gamma-t,The present invention comprises compounds of Formula (I). wherein: R,JANSSEN PHARMACEUTICA NV,LEONARD KRISTI A;;BARBAY KENT;;EDWARDS JAMES P;;KREUTTER KEVIN D;;KUMMER DAVID A;;MAHAROOF UMAR;;NISHIMURA RACHEL;;URBANSKI MAUD;;VENKATESAN HARIHARAN;;WANG AIHUA;;WOLIN RONALD L;;WOODS CRAIG R;;FOURIE ANNE;;XUE XIAOHUA;;CUMMINGS MAXWELL D;;JONES WILLIAM MOORE;;GOLDBERG STEVEN,,https://lens.org/189-293-099-900-179,Patent Application,no,0,0,16,16,0,C07D401/14;;C07D413/14;;C07D403/14;;C07D407/14;;C07D417/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P11/14;;A61P17/06;;A61P19/02;;A61P19/08;;A61P25/00;;A61P29/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61K31/4709;;A61K31/4725;;C07D401/14;;C07D403/14;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/14,C07D401/14;;A61K31/4709;;A61P1/00;;A61P11/06;;A61P17/06;;A61P19/02;;C07D403/14;;C07D407/14;;C07D413/14;;C07D417/14,,0,0,,,,INACTIVE
234,KR,A,KR 20160068957 A,054-056-306-284-82X,2016-06-15,2016,KR 20167012744 A,2013-10-15,US 2013/0065048 W,2013-10-15,METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T,"본 발명은 화학식 I의 화합물을 포함한다.화학식 I 상기 식에서: R, R, R, R, R, R, R, R및 R은 본 명세서에서 정의된다. 본 발명은 또한 류머티스성 관절염 또는 건선인 증후군, 장애 또는 질환을 치료하거나 개선시키는 방법을 포함한다. 본 발명은 또한 적어도 하나의 제1항의 화합물의 치료적 유효량을 투여함으로써 포유동물에서 RORγt 활성을 조절하는 방법을 포함한다.",JANSSEN PHARMACEUTICA NV,LEONARD KRISTI A;;BARBAY KENT;;EDWARDS JAMES P;;KREUTTER KEVIN D;;KUMMER DAVID A;;MAHAROOF UMAR;;NISHIMURA RACHEL;;URBANSKI MAUD;;VENKATESAN HARIHARAN;;WANG AIHUA;;WOLIN RONALD L;;WOODS CRAIG R;;FOURIE ANNE;;XUE XIAOHUA;;CUMMINGS MAXWELL D;;JONES WILLIAM MOORE;;GOLDBERG STEVEN,,https://lens.org/054-056-306-284-82X,Patent Application,no,0,0,16,16,18,C07D401/14;;C07D413/14;;C07D403/14;;C07D407/14;;C07D417/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P11/14;;A61P17/06;;A61P19/02;;A61P19/08;;A61P25/00;;A61P29/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61K31/4709;;A61K31/4725;;C07D401/14;;C07D403/14;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/14,A61K31/4709;;A61K31/4725;;C07D403/14;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/14,,0,0,,,,DISCONTINUED
235,CA,A1,CA 2927153 A1,120-110-633-602-924,2015-04-23,2015,CA 2927153 A,2013-10-15,US 2013/0065048 W,2013-10-15,METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T,"The present invention comprises compounds of Formula (I). wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.",JANSSEN PHARMACEUTICA NV,LEONARD KRISTI A;;BARBAY KENT;;EDWARDS JAMES P;;KREUTTER KEVIN D;;KUMMER DAVID A;;MAHAROOF UMAR;;NISHIMURA RACHEL;;URBANSKI MAUD;;VENKATESAN HARIHARAN;;WANG AIHUA;;WOLIN RONALD L;;WOODS CRAIG R;;FOURIE ANNE;;XUE XIAOHUA;;CUMMINGS MAXWELL D;;JONES WILLIAM MOORE;;GOLDBERG STEVEN,,https://lens.org/120-110-633-602-924,Patent Application,no,0,0,16,16,9,C07D401/14;;C07D413/14;;C07D403/14;;C07D407/14;;C07D417/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P11/14;;A61P17/06;;A61P19/02;;A61P19/08;;A61P25/00;;A61P29/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61K31/4709;;A61K31/4725;;C07D401/14;;C07D403/14;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/14,C07D401/14;;A61K31/4709;;A61P1/00;;A61P11/06;;A61P17/06;;A61P19/02;;C07D403/14;;C07D407/14;;C07D413/14;;C07D417/14,,0,0,,,,DISCONTINUED
236,ES,T3,ES 2770676 T3,054-662-844-064-533,2020-07-02,2020,ES 13786779 T,2013-10-15,US 2013/0065048 W,2013-10-15,Moduladores de quinolina enlazados a metileno de ROR-gamma-T,"Un compuesto de Fórmula I en donde: **(Ver fórmula)** R1 es azetidinilo, pirrolilo, pirazolilo, imidazolilo, triazolilo, tiazolilo, piridilo, N-óxido de piridilo, pirazinilo, pirimidinilo, piridacilo, piperidinilo, tetrahidropiranilo, fenilo, oxazolilo, isoxazolilo, tiofenilo, benzoxazolilo o quinolinilo; en donde dicho piperidinilo, piridilo, N-óxido de piridilo, imidazolilo, fenilo, tiofenilo, benzoxazolilo y pirazolilo están opcionalmente sustituidos con SO2CH3, C(O)CH3, C(O)NH2, CH3, CH2CH3, CF3, Cl, F, -CN, OCH3, N(CH3)2, - (CH2)3OCH3, SCH3, OH, CO2H, CO2C(CH3)3, o OCH2OCH3; y opcionalmente sustituido con hasta dos sustituyentes adicionales seleccionados independientemente del grupo que consiste en Cl, OCH3 y CH3; y en donde dicho triazolilo, oxazolilo, isoxazolilo, tiazolilo y están opcionalmente sustituidos con uno o dos grupos CH3; y en donde dicho azetidinilo está opcionalmente sustituido con CO2C(CH3)3, C(O)NH2, CH3, SO2CH3 o C(O)CH3; R2 es 1-metilo-1,2,3-triazolilo, piridilo, piridilo-N-óxido, 1-metilo pirazol-4-ilo, pirimidina-5-ilo, piridacilo, pirazina-2-ilo, oxazolilo, isoxazolilo, N-acetilo-acetidina-3-ilo, N-metilsulfonilo-acetidina-3-ilo, N-Boc-acetidina-3-ilo, N-metilacetidina- 3-ilo, N-acetamidilo-acetidina-3-ilo, 1-H-acetidina-3-ilo, N-acetilo piperidinilo, 1-H-piperidinilo, N-Boc-piperidinilo, N-C(1-2) alquilo-piperidinilo, tiazol-5-ilo, 1-(3-metoxipropilo)-imidazol-5-ilo, o 1-C(1-2) alquilo imidazol-5-ilo; en donde dicho 1- C(1-2) alquilo imidazol-5-ilo está opcionalmente sustituido con hasta dos grupos CH3 adicionales, o un sustituyente seleccionado del grupo que consiste en SCH3, y Cl; y dicho piridilo, y piridilo N-óxido están opcionalmente sustituidos con hasta dos sustituyentes seleccionados independientemente del grupo que consiste en C(O)NH2, -CN, OCH3, CF3, Cl, y CH3; y dicho tiazol-5-ilo, oxazolilo, isoxazolilo y están opcionalmente sustituidos con hasta dos grupos CH3; y dicho 1-metilo pirazol-4-ilo está opcionalmente sustituido con hasta dos grupos CH3 adicionales; R3 es H, OH, OCH3, NHCH3, N(CH3)2, o NH2; R4 es H, o F; R5 es H, Cl, -CN, CF3, SCH3, OC(1-3) alquilo, OH, C(1-4) alquilo, N(CH3)OCH3, NH (alquilo C(1-2)), N (alquilo C(1-2))2, NHciclopropilo, OCHF2,4-hidroxi-piperidinilo, acetidina-1-ilo, o fur-2-ilo; R6 es piridilo, pirimidinilo, fenilo, benzotiofenilo, o tiofenilo; en donde dichos piridilo o fenilo está opcionalmente sustituido con N(CH3)2, SCH3, OCF3, SO2CH3, CF3, CHF2, imidazol-1-ilo, pirazol-1-ilo, 1,2,4 triazol-1-ilo, CH3, OCH3, Cl, F, o -CN; y dicho tiofenilo está opcionalmente sustituido con CF3; R7 es H, Cl, -CN, C(1-4) alquilo, OCH2CF3, OCH2CH2OCH3, CF3, SCH3, SO2CH3, OCHF2, NA1A2, C(O)NHCH3, N(CH3)CH2CH2NA1A2, OCH2CH2NA1A2, OC(1-3) alquilo, OCH2-(1-metilo)-imidazol-2-ilo, imidazol-2-ilo, fur-2-ilo, pirazol-1-ilo, pirazol-4-ilo, pirid-3-ilo o pirimidina-5-ilo; tiofeno-3-ilo, 1-metilo-indazol-5-ilo, 1-metilo-indazol-6-ilo, fenilo, o",JANSSEN PHARMACEUTICA NV,LEONARD KRISTI A;;BARBAY KENT;;EDWARDS JAMES P;;KREUTTER KEVIN D;;KUMMER DAVID A;;MAHAROOF UMAR;;NISHIMURA RACHEL;;URBANSKI MAUD;;VENKATESAN HARIHARAN;;WANG AIHUA;;WOLIN RONALD L;;WOODS CRAIG R;;FOURIE ANNE;;XUE XIAOHUA;;CUMMINGS MAXWELL D;;JONES WILLIAM MOORE;;GOLDBERG STEVEN,,https://lens.org/054-662-844-064-533,Granted Patent,no,0,0,16,16,0,C07D401/14;;C07D413/14;;C07D403/14;;C07D407/14;;C07D417/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P11/14;;A61P17/06;;A61P19/02;;A61P19/08;;A61P25/00;;A61P29/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61K31/4709;;A61K31/4725;;C07D401/14;;C07D403/14;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/14,C07D401/14;;A61K31/4709;;A61P1/00;;A61P11/06;;A61P19/02;;C07D403/14;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/14,,0,0,,,,ACTIVE
237,US,A1,US 2015/0105366 A1,150-021-910-777-882,2015-04-16,2015,US 201314053797 A,2013-10-15,US 201314053797 A,2013-10-15,METHYLENE LINKED QUINOLINYL MODULATORS OF RORyt,"The present invention comprises compounds of Formula I. wherein: R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.",JANSSEN PHARMACEUTICA NV,LEONARD KRISTI A;;BARBAY KENT;;EDWARDS JAMES P;;KREUTTER KEVIN D;;KUMMER DAVID A;;MAHAROOF UMAR;;NISHIMURA RACHEL;;URBANSKI MAUD;;VENKATESAN HARIHARAN;;WANG AIHUA;;WOLIN RONALD L;;WOODS CRAIG R;;FOURIE ANNE;;XUE XIAOHUA;;CUMMINGS MAXWELL D;;JONES WILLIAM MOORE;;GOLDBERG STEVEN,JANSSEN PHARMACEUTICA NV (2013-11-20),https://lens.org/150-021-910-777-882,Patent Application,yes,3,8,2,2,9,A61K31/4709;;A61K31/4709;;A61K31/506;;A61K31/506;;A61K31/5377;;A61K31/5377;;A61K45/06;;A61K45/06;;C07D417/14;;C07D417/14;;C07D401/06;;C07D401/06;;C07D401/14;;C07D401/14;;C07D405/14;;C07D405/14;;C07D409/14;;C07D409/14;;C07D413/14;;C07D413/14,C07D417/14;;A61K31/4709;;A61K31/506;;A61K31/5377;;A61K45/06;;C07D401/06;;C07D401/14;;C07D405/14;;C07D409/14;;C07D413/14,514/210.18;;546/157;;514/312;;546/176;;514/314;;546/175;;546/172;;544/333;;514/256;;514/210.21;;546/153;;546/159;;514/313;;544/128;;514/235.2,1,0,,,"Codarri, Nature Innumology, June 2011, Vol12(6), p560-568.",ACTIVE
238,EP,A1,EP 3057951 A1,064-746-852-914-957,2016-08-24,2016,EP 13786779 A,2013-10-15,US 2013/0065048 W,2013-10-15,METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T,,JANSSEN PHARMACEUTICA NV,LEONARD KRISTI A;;BARBAY KENT;;EDWARDS JAMES P;;KREUTTER KEVIN D;;KUMMER DAVID A;;MAHAROOF UMAR;;NISHIMURA RACHEL;;URBANSKI MAUD;;VENKATESAN HARIHARAN;;WANG AIHUA;;WOLIN RONALD L;;WOODS CRAIG R;;FOURIE ANNE;;XUE XIAOHUA;;CUMMINGS MAXWELL D;;JONES WILLIAM MOORE;;GOLDBERG STEVEN,JANSSEN PHARMACEUTICA NV (2017-03-15),https://lens.org/064-746-852-914-957,Patent Application,yes,0,0,16,16,0,C07D401/14;;C07D413/14;;C07D403/14;;C07D407/14;;C07D417/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P11/14;;A61P17/06;;A61P19/02;;A61P19/08;;A61P25/00;;A61P29/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61K31/4709;;A61K31/4725;;C07D401/14;;C07D403/14;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/14,C07D401/14;;A61K31/4709;;A61P1/00;;A61P11/06;;A61P17/06;;A61P19/02;;C07D403/14;;C07D407/14;;C07D413/14;;C07D417/14,,0,0,,,,ACTIVE
239,CN,A,CN 105829294 A,041-172-128-536-452,2016-08-03,2016,CN 201380081638 A,2013-10-15,US 2013/0065048 W,2013-10-15,METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T,"The present invention comprises compounds of Formula (I), wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR[gamma]t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.",JANSSEN PHARMACEUTICA NV,LEONARD KRISTI A;;BARBAY KENT;;EDWARDS JAMES P;;KREUTTER KEVIN D;;KUMMER DAVID A;;MAHAROOF UMAR;;NISHIMURA RACHEL;;URBANSKI MAUD;;VENKATESAN HARIHARAN;;A WANG;;WOLIN RONALD L;;WOODS CRAIG R;;FOURIE ANNE;;X XUE;;CUMMINGS MAXWELL D;;JONES WILLIAM MOORE;;GOLDBERG STEVEN,,https://lens.org/041-172-128-536-452,Patent Application,no,7,0,16,16,0,C07D401/14;;C07D413/14;;C07D403/14;;C07D407/14;;C07D417/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P11/14;;A61P17/06;;A61P19/02;;A61P19/08;;A61P25/00;;A61P29/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61K31/4709;;A61K31/4725;;C07D401/14;;C07D403/14;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/14,C07D401/14;;A61K31/4709;;A61P1/00;;A61P11/06;;A61P17/06;;A61P19/02;;C07D403/14;;C07D407/14;;C07D413/14;;C07D417/14,,0,0,,,,INACTIVE
240,BR,A2,BR 112016008158 A2,055-823-518-492-71X,2017-10-03,2017,BR 112016008158 A,2013-10-15,US 2013/0065048 W,2013-10-15,MODULADORES DE ROR-GAMA-T DE QUINOLINILA LIGADOS A METILENO,"MODULADORES DE ROR-GAMA-T DE QUINOLINILA LIGADOS A METILENO, SEUS USOS, COMPOSIÇÃO FARMACÊUTICA E SEU PROCESSO DE FABRICAÇÃO. Apresente invenção compreende compostos de Formula (I) FÓRMULA (I) Em que: R1, R2, R3, R4, R5, R6, R7, R8, e R9 são definidos no relatório descritivo. A invenção compreende, também, um método de tratamento ou melhora de uma síndrome, distúrbio ou doença, sendo que a dita síndrome, distúrbio ou doença é artrite reumatoide ou psoríase. A invenção também compreende um método para modular a atividade de ROR?t em um mamífero através da administração de uma quantidade terapeuticamente eficaz de pelo menos um composto de ao menos um composto, conforme definido na reivindicação 1.",JANSSEN PHARMACEUTICA NV,KRISTI A LEONARD;;KENT BARBAY;;JAMES P EDWARDS;;KEVIN D KREUTTER;;DAVID A KUMMER;;UMAR MAHAROOF;;RACHEL NISHIMURA;;MAUD URBANSKI;;HARIHARAN VENKATESAN;;AIHUA WANG;;RONALD L WOLIN;;CRAIG R WOODS;;ANNE FOURIE;;XIAOHUA XUE;;MAXWELL D CUMMINGS;;WILLIAM MOORE JONES;;STEVEN GOLDBERG,,https://lens.org/055-823-518-492-71X,Patent Application,no,0,0,16,16,0,C07D401/14;;C07D413/14;;C07D403/14;;C07D407/14;;C07D417/14;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P11/14;;A61P17/06;;A61P19/02;;A61P19/08;;A61P25/00;;A61P29/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61K31/4709;;A61K31/4725;;C07D401/14;;C07D403/14;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/14,C07D401/14;;A61K31/4709;;A61P1/00;;A61P11/06;;A61P17/06;;A61P19/02;;C07D403/14;;C07D407/14;;C07D413/14;;C07D417/14,,0,0,,,,DISCONTINUED
241,US,A1,US 2021/0318893 A1,167-783-429-684-59X,2021-10-14,2021,US 202017030804 A,2020-09-24,US 202017030804 A;;US 202063032970 P;;US 202063022869 P;;US 202063008586 P,2020-04-10,USER INTERFACES FOR ENABLING AN ACTIVITY,"The present disclosure generally relates to user interfaces for enabling an activity using a computer system. In some embodiments, exemplary user interfaces for invoking an activity associated with an application are described. In some embodiments, exemplary user interfaces for customizing displayed content based on circumstances under which the content was invoked are described. In some embodiments, exemplary user interfaces for managing applications that were used to enable activities are described. In some embodiments, exemplary user interfaces for managing settings for applications used to enable activities are described.",APPLE INC,ZHANG YONGJUN;;ABBASIAN REZA;;ADLER DARIN;;CHAN ADA;;DUBOIS DANA J;;FALKENBURG STEVEN;;FEDERIGHI CRAIG M;;FERRY KENNETH ARTHUR ABRAHAM;;FOSS CHRISTOPHER PATRICK;;GHARABALLY SAM H;;GOLDBERG BRIAN ERIK;;DOHERTY NICHOLAS;;KO HEENA;;KOWALCYKOWSKI KEITH;;PAUL GRANT;;ROBBIN JEFFREY L;;SAVAGE JAMES S;;SIBSON MATTHEW;;SINGH GURSHAMNJOT;;STACK CAELAN G;;YIN LUMING;;YING CHARLES H;;XUE MARK M;;ZHANG HENGLIANG;;ZHANG SELINA,APPLE INC (2021-09-06),https://lens.org/167-783-429-684-59X,Patent Application,yes,0,8,10,37,0,G06F3/048;;G06F21/00;;H04M1/00;;H04W4/00;;H04L67/34;;G06F3/0488;;G06F3/04842;;G06F3/04883;;G06F3/04886;;G06F9/451;;G06F3/04817;;G06F8/38;;G06F3/04842;;G06F3/0488;;G06F9/44568;;G06F9/54;;H04L67/34;;H04L67/5651,G06F9/445;;G06F3/0488;;G06F9/54;;H04L29/08,,0,0,,,,ACTIVE
242,US,B2,US 11175929 B2,106-414-047-662-647,2021-11-16,2021,US 202017030804 A,2020-09-24,US 202017030804 A;;US 202063032970 P;;US 202063022869 P;;US 202063008586 P,2020-04-10,User interfaces for enabling an activity,"The present disclosure generally relates to user interfaces for enabling an activity using a computer system. In some embodiments, exemplary user interfaces for invoking an activity associated with an application are described. In some embodiments, exemplary user interfaces for customizing displayed content based on circumstances under which the content was invoked are described. In some embodiments, exemplary user interfaces for managing applications that were used to enable activities are described. In some embodiments, exemplary user interfaces for managing settings for applications used to enable activities are described.",APPLE INC,ZHANG YONGJUN;;ABBASIAN REZA;;ADLER DARIN;;CHAN ADA;;DUBOIS DANA J;;FALKENBURG STEVEN;;FEDERIGHI CRAIG M;;FERRY KENNETH ARTHUR ABRAHAM;;FOSS CHRISTOPHER PATRICK;;GHARABALLY SAM H;;GOLDBERG BRIAN ERIK;;DOHERTY NICHOLAS STEPHEN;;KO HEENA;;KOWALCZYKOWSKI KEITH P;;PAUL GRANT;;ROBBIN JEFFREY L;;SAVAGE JAMES S;;SIBSON MATTHEW;;SINGH GURSHAMNJOT;;STACK CAELAN G;;YIN LUMING;;YING CHARLES H;;XUE MARK M;;ZHANG HENGLIANG;;ZHANG XIAOYUE;;COFFMAN PATRICK L,APPLE INC (2021-09-06),https://lens.org/106-414-047-662-647,Granted Patent,yes,52,0,10,37,0,G06F3/048;;G06F21/00;;H04M1/00;;H04W4/00;;H04L67/34;;G06F3/0488;;G06F3/04842;;G06F3/04883;;G06F3/04886;;G06F9/451;;G06F3/04817;;G06F8/38;;G06F3/04842;;G06F3/0488;;G06F9/44568;;G06F9/54;;H04L67/34;;H04L67/5651,G06F9/54;;G06F3/0488;;G06F9/445;;H04L29/08,,19,0,,,"Applicant-Initiated Interview Summary received for U.S. Appl. No. 17/031,687, dated Mar. 5, 2021, 4 pages.;;Final Office Action received for U.S. Appl. No. 17/031,687, dated Mar. 24, 2021, 32 pages.;;Applicant-Initiated Interview Summary received for U.S. Appl. No. 14/960,279, dated Nov. 17, 2020, 4 pages.;;Search Report and Opinion received for Danish Patent Application No. PA202070634, dated Jan. 6, 2021, 9 pages.;;Non-Final Office Action received for U.S. Appl. No. 17/031,687, dated Dec. 21, 2020, 28 pages.;;Search Report and Opinion received for Danish Patent Application No. PA202070633, dated Dec. 21, 2020, 10 pages.;;Storehub, “QR Table Ordering and Cashback—Beep Order & Cashback”, Available online on: < https://www.youtube.com/watch?v=TCukF45kOU8&ab_channel=StoreHub>, Jul. 25, 2019, 3 pages.;;Final Office Action received for U.S. Appl. No. 14/960,279, dated Feb. 9, 2021, 26 pages.;;Advisory Action received for U.S. Appl. No. 14/960,279, dated Apr. 13, 2021, 3 pages.;;Applicant-Initiated Interview Summary received for U.S. Appl. No. 17/031,687, dated May 28, 2021, 4 pages.;;Office Action received for Australian Patent Application No. 2020239759, dated Jun. 3, 2021, 6 pages.;;Office Action received for Danish Patent Application No. PA202070634, dated Jun. 4, 2021, 3 pages.;;Android Developers, “Android App Bundle”, Online available at: http://web.archive.org/web/20200303021924/https:/developer.android.com/platform/technology/app-bundle, Mar. 3, 2020, 5 pages.;;Android Developers, “Deliver features on-demand with dynamic features”, Online available at: https://www.youtube.com/watch?v=httqEshsBk, May 23, 2018, 3 pages.;;Howtoinstall, “How to Download and Install Winamp 5.6 on Windows 2017”, Online available at: https://www.youtube.com/watch?v=-6YDT9UkuEg, Oct. 17, 2017, 3 pages.;;Office Action received for Danish Patent Application No. PA202070633, dated May 6, 2021, 6 pages.;;Invitation to Pay Additional Fees received for PCT Patent Application No. PCT/US2021/025051, dated Jul. 28, 2021, 17 pages.;;Office Action received for Australian Patent Application No. 2020239747, dated Jul. 29, 2021, 9 pages.;;International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2021/025051, dated Sep. 23, 2021, 21 pages.",ACTIVE
243,AU,A1,AU 2020/239759 A1,187-032-254-129-217,2021-10-28,2021,AU 2020/239759 A,2020-09-24,DK PA202070634 A;;US 202063008586 P;;US 202063022869 P;;DK PA202070633 A;;US 202063032970 P,2020-04-10,User interfaces for enabling an activity,"The present disclosure generally relates to user interfaces for enabling an activity using a computer system. In some embodiments, exemplary user interfaces for invoking an activity associated with an application are described. In some embodiments, exemplary user interfaces for customizing displayed content based on circumstances under which the content was invoked are described. In some embodiments, exemplary user interfaces for managing applications that were used to enable activities are described. In some embodiments, exemplary user interfaces for managing settings for applications used to enable activities are described. N -y 7cr - -42 - ~ C 3* o A~ 0 -G",APPLE INC,ZHANG YONGJUN;;ABBASIAN REZA;;ADLER DARIN;;CHAN ADA;;DUBOIS DANA J;;ETZEL CHARLES B;;FERRY KENNETH ARTHUR ABRAHAM;;FALKENBURG STEVEN;;FEDERIGHI CRAIG M;;FOSS CHRISTOPHER PATRICK;;GHARABALLY SAM H;;GOLDBERG BRIAN ERIK;;DOHERTY NICHOLAS STEPHEN;;KHAN NAHIR A;;KO HEENA;;KOWALCZYKOWSKI KEITH P;;MEHRA RISHAB;;PAUL GRANT;;RAMASWAMY PALLAVIKA;;ROBBIN JEFFREY L;;SAVAGE JAMES S;;SIBSON MATTHEW;;SINGH SHAMAN;;STACK CAELAN G;;YIN LUMING;;YING CHARLES H;;XUE MARK M;;ZHANG HENGLIANG;;ZHANG XIAOYUE,,https://lens.org/187-032-254-129-217,Patent Application,no,0,0,27,37,0,G06F3/04817;;G06F3/0488;;G06F8/61;;G06F9/445;;H04M1/72472;;G06F9/451;;G06F8/61;;G06F9/44568;;G06F9/52;;G06F9/54;;G06F3/04842;;G06F3/04883;;G06F3/04886;;G06F8/38;;H04L67/34;;H04L67/5651,G06F3/048;;G06F9/451,,0,0,,,,ACTIVE
244,KR,A,KR 20210126476 A,009-082-525-938-536,2021-10-20,2021,KR 20200123889 A,2020-09-24,US 202063008586 P;;US 202063022869 P;;US 202063032970 P;;DK PA202070633 A;;DK PA202070634 A,2020-04-10,USER INTERFACES FOR ENABLING AN ACTIVITY,"The present disclosure generally relates to user interfaces for enabling an activity using a computer system. In some embodiments, exemplary user interfaces for invoking an activity associated with an application are described. In some embodiments, exemplary user interfaces for customizing displayed content based on circumstances under which the content was invoked are described. In some embodiments, exemplary user interfaces for managing applications which were used to enable activities are described. In some embodiments, exemplary user interfaces for managing settings for applications used to enable activities are described.",APPLE INC,ZHANG YONGJUN;;ABBASIAN REZA;;ADLER DARIN;;CHAN ADA;;DUBOIS DANA J;;ETZEL CHARLES B;;FERRY KENNETH ARTHUR ABRAHAM;;FALKENBURG STEVEN;;FEDERIGHI CRAIG M;;FOSS CHRISTOPHER PATRICK;;GHARABALLY SAM H;;GOLDBERG BRIAN ERIK;;DOHERTY NICHOLAS STEPHEN;;KHAN NAHIR A;;KO HEENA;;KOWALCZYKOWSKI KEITH P;;MEHRA RISHAB;;PAUL GRANT;;RAMASWAMY PALLAVIKA;;ROBBIN JEFFREY L;;SAVAGE JAMES S;;SIBSON MATTHEW;;SINGH SHAMAN;;STACK CAELAN G;;YIN LUMING;;YING CHARLES H;;XUE MARK M;;ZHANG HENGLIANG;;ZHANG XIAOYUE,,https://lens.org/009-082-525-938-536,Patent Application,no,4,0,27,37,0,G06F3/04817;;G06F3/0488;;G06F8/61;;G06F9/445;;H04M1/72472;;G06F9/451;;G06F8/61;;G06F9/44568;;G06F9/52;;G06F9/54;;G06F3/04842;;G06F3/04883;;G06F3/04886;;G06F8/38;;H04L67/34;;H04L67/5651,G06F9/451;;G06F3/041;;G06F3/048;;G06F3/14;;G06F8/61;;G06F9/445,,0,0,,,,ACTIVE
245,JP,A,JP 2021168104 A,120-656-493-603-97X,2021-10-21,2021,JP 2020159957 A,2020-09-24,US 202063008586 P;;US 202063022869 P;;US 202063032970 P;;DK PA202070633 A;;DK PA202070634 A,2020-04-10,USER INTERFACE FOR ENABLING ACTIVITY,"To provide faster and more efficient methods and interfaces for enabling an activity.SOLUTION: User interfaces invoke an activity associated with an application, customize displayed content based on circumstances under which the content was invoked, manage applications that were used to enable activities, and manage settings for applications used to enable activities.SELECTED DRAWING: Figure 11M",APPLE INC,ZHANG YONGJUN;;REZA ABBASIAN;;DARIN ADLER;;CHAN ADA;;DANA J DUBOIS;;CHARLES B ETZEL;;KENNETH ARTHUR ABRAHAM FERRY;;STEVEN FALKENBURG;;CRAIG M FEDERIGHI;;CHRISTOPHER PATRICK FOSS;;SAM H GHARABALLY;;BRIAN ERIK GOLDBERG;;NICHOLAS STEPHEN DOHERTY;;NAHIR A KHAN;;KO HEENA;;KEITH P KOWALCZYKOWSKI;;RISHAB MEHRA;;GRANT PAUL;;PALLAVIKA RAMASWAMY;;JEFFREY L ROBBIN;;JAMES S SAVAGE;;MATTHEW SIBSON;;SINGH SHAMAN;;CAELAN G STACK;;YIN LUMING;;CHARLES H YING;;MARK M XUE;;ZHANG HENGLIANG;;ZHANG XIAOYUE,,https://lens.org/120-656-493-603-97X,Patent Application,no,6,0,27,37,0,G06F3/04817;;G06F3/0488;;G06F8/61;;G06F9/445;;H04M1/72472;;G06F9/451;;G06F8/61;;G06F9/44568;;G06F9/52;;G06F9/54;;G06F3/04842;;G06F3/04883;;G06F3/04886;;G06F8/38;;H04L67/34;;H04L67/5651,G06F3/0484;;G06F3/0481,,0,0,,,,ACTIVE
246,DK,A1,DK 202070633 A1,150-425-774-124-596,2021-11-12,2021,DK PA202070633 A,2020-09-23,US 202063008586 P;;US 202063022869 P;;US 202063032970 P,2020-04-10,USER INTERFACES FOR ENABLING AN ACTIVITY,"The present disclosure generally relates to user interfaces for enabling an activity using a computer system. In some embodiments, exemplary user interfaces for invoking an activity associated with an application are described. In some embodiments, exemplary user interfaces for customizing displayed content based on circumstances under which the content was invoked are described. In some embodiments, exemplary user interfaces for managing applications that were used to enable activities are described. In some embodiments, exemplary user interfaces for managing settings for applications used to enable activities are described.",APPLE INC,YONGJUN ZHANG;;REZA ABBASIAN;;DARIN ADLER;;ADA CHAN;;DANA J DUBOIS;;CHARLES B ETZEL;;KENNETH ARTHUR ABRAHAM FERRY;;STEVEN FALKENBURG;;CRAIG M FEDERIGHI;;CHRISTOPHER PATRICK FOSS;;SAM H GHARABALLY;;BRIAN ERIK GOLDBERG;;HEENA KO;;RISHAB MEHRA;;GRANT PAUL;;JEFFREY L ROBBIN;;JAMES S SAVAGE;;MATTHEW SIBSON;;SHAMAN SINGH;;CAELAN G STACK;;LUMING YIN;;CHARLES H YING;;MARK M XUE;;HENGLIANG ZHANG;;NICHOLAS STEPHEN DOHERTY;;NAHIR A KHAN;;KEITH P KOWALCZYKOWSKI;;PALLAVIKA RAMASWAMY;;XIAOYUE ZHANG,,https://lens.org/150-425-774-124-596,Unknown,no,0,0,10,37,0,G06F3/048;;G06F21/00;;H04M1/00;;H04W4/00;;H04L67/34;;G06F3/0488;;G06F3/04842;;G06F3/04883;;G06F3/04886;;G06F9/451;;G06F3/04817;;G06F8/38;;G06F3/04842;;G06F3/0488;;G06F9/44568;;G06F9/54;;H04L67/34;;H04L67/5651,G06Q50/12;;G06Q30/06;;H04W4/021,,0,0,,,,DISCONTINUED
247,DK,A1,DK 202070634 A1,056-544-296-276-96X,2021-11-12,2021,DK PA202070634 A,2020-09-23,US 202063008586 P;;US 202063022869 P;;US 202063032970 P,2020-04-10,USER INTERFACES FOR ENABLING AN ACTIVITY,"The present disclosure generally relates to user interfaces for enabling an activity using a computer system. In some embodiments, exemplary user interfaces for invoking an activity associated with an application are described. In some embodiments, exemplary user interfaces for customizing displayed content based on circumstances under which the content was invoked are described. In some embodiments, exemplary user interfaces for managing applications that were used to enable activities are described. In some embodiments, exemplary user interfaces for managing settings for applications used to enable activities are described.",APPLE INC,YONGJUN ZHANG;;REZA ABBASIAN;;DARIN ADLER;;ADA CHAN;;DANA J DUBOIS;;CHARLES B ETZEL;;KENNETH ARTHUR ABRAHAM FERRY;;STEVEN FALKENBURG;;CRAIG M FEDERIGHI;;CHRISTOPHER PATRICK FOSS;;SAM H GHARABALLY;;BRIAN ERIK GOLDBERG;;HEENA KO;;RISHAB MEHRA;;GRANT PAUL;;JEFFREY L ROBBIN;;JAMES S SAVAGE;;MATTHEW SIBSON;;SHAMAN SINGH;;CAELAN G STACK;;LUMING YIN;;CHARLES H YING;;MARK M XUE;;HENGLIANG ZHANG;;NICHOLAS STEPHEN DOHERTY;;NAHIR A KHAN;;KEITH P KOWALCZYKOWSKI;;PALLAVIKA RAMASWAMY;;XIAOYUE ZHANG,,https://lens.org/056-544-296-276-96X,Unknown,no,0,0,10,37,0,G06F3/048;;G06F21/00;;H04M1/00;;H04W4/00;;H04L67/34;;G06F3/0488;;G06F3/04842;;G06F3/04883;;G06F3/04886;;G06F9/451;;G06F3/04817;;G06F8/38;;G06F3/04842;;G06F3/0488;;G06F9/44568;;G06F9/54;;H04L67/34;;H04L67/5651,H04W4/00;;G06F3/048;;G06F21/00;;H04M1/00,,0,0,,,,ACTIVE
248,AU,B2,AU 2020/239759 B2,094-073-737-764-02X,2022-01-27,2022,AU 2020/239759 A,2020-09-24,DK PA202070634 A;;US 202063008586 P;;US 202063022869 P;;DK PA202070633 A;;US 202063032970 P,2020-04-10,User interfaces for enabling an activity,"The present disclosure generally relates to user interfaces for enabling an activity using a computer system. In some embodiments, exemplary user interfaces for invoking an activity associated with an application are described. In some embodiments, exemplary user interfaces for customizing displayed content based on circumstances under which the content was invoked are described. In some embodiments, exemplary user interfaces for managing applications that were used to enable activities are described. In some embodiments, exemplary user interfaces for managing settings for applications used to enable activities are described. N -y 7cr - -42 - ~ C 3* o A~ 0 -G",APPLE INC,ZHANG YONGJUN;;ABBASIAN REZA;;ADLER DARIN;;CHAN ADA;;DUBOIS DANA J;;ETZEL CHARLES B;;FERRY KENNETH ARTHUR ABRAHAM;;FALKENBURG STEVEN;;FEDERIGHI CRAIG M;;FOSS CHRISTOPHER PATRICK;;GHARABALLY SAM H;;GOLDBERG BRIAN ERIK;;DOHERTY NICHOLAS STEPHEN;;KHAN NAHIR A;;KO HEENA;;KOWALCZYKOWSKI KEITH P;;MEHRA RISHAB;;PAUL GRANT;;RAMASWAMY PALLAVIKA;;ROBBIN JEFFREY L;;SAVAGE JAMES S;;SIBSON MATTHEW;;SINGH SHAMAN;;STACK CAELAN G;;YIN LUMING;;YING CHARLES H;;XUE MARK M;;ZHANG HENGLIANG;;ZHANG XIAOYUE,,https://lens.org/094-073-737-764-02X,Granted Patent,no,2,0,27,37,0,G06F3/04817;;G06F3/0488;;G06F8/61;;G06F9/445;;H04M1/72472;;G06F9/451;;G06F8/61;;G06F9/44568;;G06F9/52;;G06F9/54;;G06F3/04842;;G06F3/04883;;G06F3/04886;;G06F8/38;;H04L67/34;;H04L67/5651,G06F3/048;;G06F9/451,,0,0,,,,ACTIVE
249,AU,A1,AU 2020/239747 A1,144-513-324-520-287,2021-10-28,2021,AU 2020/239747 A,2020-09-24,DK PA202070633 A;;DK PA202070634 A;;US 202063008586 P;;US 202063022869 P;;US 202063032970 P,2020-04-10,User interfaces for enabling an activity,"The present disclosure generally relates to user interfaces for enabling an activity using a computer system. In some embodiments, exemplary user interfaces for invoking an activity associated with an application are described. In some embodiments, exemplary user interfaces for customizing displayed content based on circumstances under which the content was invoked are described. In some embodiments, exemplary user interfaces for managing applications that were used to enable activities are described. In some embodiments, exemplary user interfaces for managing settings for applications used to enable activities are described. /r r B>4 oo",APPLE INC,ZHANG YONGJUN;;ABBASIAN REZA;;ADLER DARIN;;CHAN ADA;;DUBOIS DANA J;;ETZEL CHARLES B;;FERRY KENNETH ARTHUR ABRAHAM;;FALKENBURG STEVEN;;FEDERIGHI CRAIG M;;FOSS CHRISTOPHER PATRICK;;GHARABALLY SAM H;;GOLDBERG BRIAN ERIK;;DOHERTY NICHOLAS STEPHEN;;KHAN NAHIR A;;KO HEENA;;KOWALCZYKOWSKI KEITH P;;MEHRA RISHAB;;PAUL GRANT;;RAMASWAMY PALLAVIKA;;ROBBIN JEFFREY L;;SAVAGE JAMES S;;SIBSON MATTHEW;;SINGH SHAMAN;;STACK CAELAN G;;YIN LUMING;;YING CHARLES H;;XUE MARK M;;ZHANG HENGLIANG;;ZHANG XIAOYUE,,https://lens.org/144-513-324-520-287,Patent Application,no,0,0,27,37,0,G06F3/04817;;G06F3/0488;;G06F8/61;;G06F9/445;;H04M1/72472;;G06F9/451;;G06F8/61;;G06F9/44568;;G06F9/52;;G06F9/54;;G06F3/04842;;G06F3/04883;;G06F3/04886;;G06F8/38;;H04L67/34;;H04L67/5651,G06F3/048;;G06F9/06,,0,0,,,,ACTIVE
250,KR,A,KR 20210126475 A,033-245-385-309-802,2021-10-20,2021,KR 20200123866 A,2020-09-24,US 202063008586 P;;US 202063022869 P;;US 202063032970 P;;DK PA202070633 A;;DK PA202070634 A,2020-04-10,USER INTERFACES FOR ENABLING AN ACTIVITY,"This disclosure relates to generally to a user interface for enabling activity using a computer system. In some embodiments, exemplary user interfaces for invoking activity associated with application are described. In some embodiments, exemplary user interfaces are described for customizing displayed contents based on circumstances in which the contents were invoked. In some embodiments, exemplary user interfaces for managing the applications which were used to enable the activities are described. In some embodiments, exemplary user interfaces for managing settings for the application used to enable the activities are described.",APPLE INC,ZHANG YONGJUN;;ABBASIAN REZA;;ADLER DARIN;;CHAN ADA;;DUBOIS DANA J;;ETZEL CHARLES B;;FERRY KENNETH ARTHUR ABRAHAM;;FALKENBURG STEVEN;;FEDERIGHI CRAIG M;;FOSS CHRISTOPHER PATRICK;;GHARABALLY SAM H;;GOLDBERG BRIAN ERIK;;DOHERTY NICHOLAS STEPHEN;;KHAN NAHIR A;;KO HEENA;;KOWALCZYKOWSKI KEITH P;;MEHRA RISHAB;;PAUL GRANT;;RAMASWAMY PALLAVIKA;;ROBBIN JEFFREY L;;SAVAGE JAMES S;;SIBSON MATTHEW;;SINGH SHAMAN;;STACK CAELAN G;;YIN LUMING;;YING CHARLES H;;XUE MARK M;;ZHANG HENGLIANG;;ZHANG XIAOYUE,,https://lens.org/033-245-385-309-802,Patent Application,no,4,0,27,37,0,G06F3/04817;;G06F3/0488;;G06F8/61;;G06F9/445;;H04M1/72472;;G06F9/451;;G06F8/61;;G06F9/44568;;G06F9/52;;G06F9/54;;G06F3/04842;;G06F3/04883;;G06F3/04886;;G06F8/38;;H04L67/34;;H04L67/5651,G06F9/451;;G06F3/041;;G06F3/048;;G06F3/14;;G06F8/61;;G06F9/445,,0,0,,,,ACTIVE
251,AU,B2,AU 2020/239747 B2,163-192-893-166-307,2021-11-04,2021,AU 2020/239747 A,2020-09-24,DK PA202070633 A;;DK PA202070634 A;;US 202063008586 P;;US 202063022869 P;;US 202063032970 P,2020-04-10,User interfaces for enabling an activity,"The present disclosure generally relates to user interfaces for enabling an activity using a computer system. In some embodiments, exemplary user interfaces for invoking an activity associated with an application are described. In some embodiments, exemplary user interfaces for customizing displayed content based on circumstances under which the content was invoked are described. In some embodiments, exemplary user interfaces for managing applications that were used to enable activities are described. In some embodiments, exemplary user interfaces for managing settings for applications used to enable activities are described. /r r B>4 oo",APPLE INC,ZHANG YONGJUN;;ABBASIAN REZA;;ADLER DARIN;;CHAN ADA;;DUBOIS DANA J;;ETZEL CHARLES B;;FERRY KENNETH ARTHUR ABRAHAM;;FALKENBURG STEVEN;;FEDERIGHI CRAIG M;;FOSS CHRISTOPHER PATRICK;;GHARABALLY SAM H;;GOLDBERG BRIAN ERIK;;DOHERTY NICHOLAS STEPHEN;;KHAN NAHIR A;;KO HEENA;;KOWALCZYKOWSKI KEITH P;;MEHRA RISHAB;;PAUL GRANT;;RAMASWAMY PALLAVIKA;;ROBBIN JEFFREY L;;SAVAGE JAMES S;;SIBSON MATTHEW;;SINGH SHAMAN;;STACK CAELAN G;;YIN LUMING;;YING CHARLES H;;XUE MARK M;;ZHANG HENGLIANG;;ZHANG XIAOYUE,,https://lens.org/163-192-893-166-307,Granted Patent,no,2,0,27,37,0,G06F3/04817;;G06F3/0488;;G06F8/61;;G06F9/445;;H04M1/72472;;G06F9/451;;G06F8/61;;G06F9/44568;;G06F9/52;;G06F9/54;;G06F3/04842;;G06F3/04883;;G06F3/04886;;G06F8/38;;H04L67/34;;H04L67/5651,G06F3/048;;G06F9/06,,0,0,,,,ACTIVE
252,JP,A,JP 2021168103 A,104-710-327-417-711,2021-10-21,2021,JP 2020159956 A,2020-09-24,US 202063008586 P;;US 202063022869 P;;US 202063032970 P;;DK PA202070633 A;;DK PA202070634 A,2020-04-10,USER INTERFACE FOR ENABLING ACTIVITY,"To provide faster and more efficient methods and interfaces for enabling an activity.SOLUTION: User interfaces invoke an activity associated with an application. In some embodiments, the user interfaces customize displayed content based on circumstances under which the content was invoked, manage applications that were used to enable activities, and manage settings for applications used to enable activities.SELECTED DRAWING: Figure 7C",APPLE INC,ZHANG YONGJUN;;REZA ABBASIAN;;DARIN ADLER;;CHAN ADA;;DANA J DUBOIS;;CHARLES B ETZEL;;KENNETH ARTHUR ABRAHAM FERRY;;STEVEN FALKENBURG;;CRAIG M FEDERIGHI;;CHRISTOPHER PATRICK FOSS;;SAM H GHARABALLY;;BRIAN ERIK GOLDBERG;;NICHOLAS STEPHEN DOHERTY;;NAHIR A KHAN;;KO HEENA;;KEITH P KOWALCZYKOWSKI;;RISHAB MEHRA;;GRANT PAUL;;PALLAVIKA RAMASWAMY;;JEFFREY L ROBBIN;;JAMES S SAVAGE;;MATTHEW SIBSON;;SINGH SHAMAN;;CAELAN G STACK;;YIN LUMING;;CHARLES H YING;;MARK M XUE;;ZHANG HENGLIANG;;ZHANG XIAOYUE,,https://lens.org/104-710-327-417-711,Patent Application,no,7,0,27,37,0,G06F3/04817;;G06F3/0488;;G06F8/61;;G06F9/445;;H04M1/72472;;G06F9/451;;G06F8/61;;G06F9/44568;;G06F9/52;;G06F9/54;;G06F3/04842;;G06F3/04883;;G06F3/04886;;G06F8/38;;H04L67/34;;H04L67/5651,G06F3/0481;;G06F3/0484,,0,0,,,,ACTIVE
253,WO,A4,WO 2021/206976 A4,162-219-308-057-11X,2022-01-06,2022,US 2021/0025051 W,2021-03-31,US 202063008586 P;;US 202063022869 P;;US 202063032970 P;;DK PA202070633 A;;DK PA202070634 A,2020-04-10,USER INTERFACES FOR ENABLING AN ACTIVITY,"The present disclosure generally relates to user interfaces for enabling an activity using a computer system. In some embodiments, exemplary user interfaces for invoking an activity associated with an application are described. In some embodiments, exemplary user interfaces for customizing displayed content based on circumstances under which the content was invoked are described. In some embodiments, exemplary user interfaces for managing applications that were used to enable activities are described. In some embodiments, exemplary user interfaces for managing settings for applications used to enable activities are described.",APPLE INC,ZHANG YONGJUN;;ABBASIAN REZA;;ADLER DARIN;;CHAN ADA;;DOHERTY NICHOLAS STEPHEN;;DUBOIS DANA J;;ETZEL CHARLES B;;FALKENBURG STEVEN;;FEDERIGHI CRAIG M;;FERRY KENNETH ARTHUR ABRAHAM;;FOSS CHRISTOPHER PATRICK;;GHARABALLY SAM H;;GOLDBERG BRIAN ERIK;;KHAN NAHIR A;;KO HEENA;;KOWALCZYKOWSKI KEITH P;;MEHRA RISHAB;;PAUL GRANT;;RAMASWAMY PALLAVIKA;;RITCHIE GRANT;;ROBBIN JEFFREY L;;SAVAGE JAMES S;;SIBSON MATTHEW;;SINGH GURSHAMNJOT;;STACK CAELAN G;;XUE MARK M;;YIN LUMING;;YING CHARLES H;;ZHANG HENGLIANG;;ZHANG XIAOYUE,,https://lens.org/162-219-308-057-11X,Patent Application,yes,0,0,27,37,0,G06F3/04817;;G06F3/0488;;G06F8/61;;G06F9/445;;H04M1/72472;;G06F9/451;;G06F8/61;;G06F9/44568;;G06F9/52;;G06F9/54;;G06F3/04842;;G06F3/04883;;G06F3/04886;;G06F8/38;;H04L67/34;;H04L67/5651,G06F3/0481;;G06F3/0488;;G06F8/61;;G06F9/445,,0,0,,,,PENDING
254,EP,A1,EP 4028869 A1,176-608-306-696-185,2022-07-20,2022,EP 21724821 A,2021-03-31,US 2021/0025051 W;;US 202063008586 P;;US 202063022869 P;;US 202063032970 P;;DK PA202070633 A;;DK PA202070634 A,2020-04-10,USER INTERFACES FOR ENABLING AN ACTIVITY,,APPLE INC,ZHANG YONGJUN;;ABBASIAN REZA;;ADLER DARIN;;CHAN ADA;;COFFMAN PATRICK L;;DOHERTY NICHOLAS STEPHEN;;DUBOIS DANA J;;ETZEL CHARLES B;;FALKENBURG STEVEN;;FEDERIGHI CRAIG M;;FERRY KENNETH ARTHUR ABRAHAM;;FOSS CHRISTOPHER PATRICK;;GHARABALLY SAM H;;GOLDBERG BRIAN ERIK;;KHAN NAHIR A;;KO HEENA;;KOWALCZYKOWSKI KEITH P;;MEHRA RISHAB;;PAUL GRANT;;RAMASWAMY PALLAVIKA;;RITCHIE GRANT;;ROBBIN JEFFREY L;;SAVAGE JAMES S;;SIBSON MATTHEW;;SINGH GURSHAMNJOT;;STACK CAELAN G;;XUE MARK M;;YIN LUMING;;YING CHARLES H;;ZHANG HENGLIANG;;ZHANG XIAOYUE,APPLE INC. (2023-07-12),https://lens.org/176-608-306-696-185,Patent Application,yes,0,0,27,37,0,G06F3/04817;;G06F3/0488;;G06F8/61;;G06F9/445;;H04M1/72472;;G06F9/451;;G06F8/61;;G06F9/44568;;G06F9/52;;G06F9/54;;G06F3/04842;;G06F3/04883;;G06F3/04886;;G06F8/38;;H04L67/34;;H04L67/5651,G06F3/0481;;G06F3/0488;;G06F8/61;;G06F9/445,,0,0,,,,ACTIVE
255,DK,B1,DK 180985 B1,130-430-494-825-997,2022-09-02,2022,DK PA202070634 A,2020-09-23,US 202063008586 P;;US 202063022869 P;;US 202063032970 P,2020-04-10,Brugergrænseflader for muliggørelse af en aktivitet,"The present disclosure generally relates to user interfaces for enabling an activity using a computer system. In some embodiments, exemplary user interfaces for invoking an activity associated with an application are described. In some embodiments, exemplary user interfaces for customizing displayed content based on circumstances under which the content was invoked are described. In some embodiments, exemplary user interfaces for managing applications that were used to enable activities are described. In some embodiments, exemplary user interfaces for managing settings for applications used to enable activities are described.",APPLE INC,PATRICK L COFFMAN;;YONGJUN ZHANG;;REZA ABBASIAN;;DARIN ADLER;;ADA CHAN;;DANA J DUBOIS;;CHARLES B ETZEL;;KENNETH ARTHUR ABRAHAM FERRY;;STEVEN FALKENBURG;;CRAIG M FEDERIGHI;;CHRISTOPHER PATRICK FOSS;;SAM H GHARABALLY;;BRIAN ERIK GOLDBERG;;HEENA KO;;RISHAB MEHRA;;GRANT PAUL;;JEFFREY L ROBBIN;;JAMES S SAVAGE;;MATTHEW SIBSON;;GURSHAMNJOT SINGH;;CAELAN G STACK;;LUMING YIN;;CHARLES H YING;;MARK M XUE;;HENGLIANG ZHANG;;NICHOLAS STEPHEN DOHERTY;;NAHIR A KHAN;;KEITH P KOWALCZYKOWSKI;;PALLAVIKA RAMASWAMY;;XIAOYUE ZHANG;;GRANT RITCHIE,,https://lens.org/130-430-494-825-997,Granted Patent,no,0,0,10,37,0,G06F3/048;;G06F21/00;;H04M1/00;;H04W4/00;;H04L67/34;;G06F3/0488;;G06F3/04842;;G06F3/04883;;G06F3/04886;;G06F9/451;;G06F3/04817;;G06F8/38;;G06F3/04842;;G06F3/0488;;G06F9/44568;;G06F9/54;;H04L67/34;;H04L67/5651,H04W4/00;;G06F3/048;;G06F21/00;;H04M1/00,,0,0,,,,ACTIVE
256,AU,B9,AU 2020/239759 B9,160-796-982-823-645,2022-09-22,2022,AU 2020/239759 A,2020-09-24,DK PA202070634 A;;US 202063008586 P;;US 202063022869 P;;DK PA202070633 A;;US 202063032970 P,2020-04-10,User interfaces for enabling an activity,"The present disclosure generally relates to user interfaces for enabling an activity using a computer system. In some embodiments, exemplary user interfaces for invoking an activity associated with an application are described. In some embodiments, exemplary user interfaces for customizing displayed content based on circumstances under which the content was invoked are described. In some embodiments, exemplary user interfaces for managing applications that were used to enable activities are described. In some embodiments, exemplary user interfaces for managing settings for applications used to enable activities are described. N -y 7cr - -42 - ~ C 3* o A~ 0 -G",APPLE INC,ZHANG YONGJUN;;ABBASIAN REZA;;ADLER DARIN;;CHAN ADA;;DUBOIS DANA J;;ETZEL CHARLES B;;FERRY KENNETH ARTHUR ABRAHAM;;FALKENBURG STEVEN;;FEDERIGHI CRAIG M;;FOSS CHRISTOPHER PATRICK;;GHARABALLY SAM H;;GOLDBERG BRIAN ERIK;;DOHERTY NICHOLAS STEPHEN;;KHAN NAHIR A;;KO HEENA;;KOWALCZYKOWSKI KEITH P;;MEHRA RISHAB;;PAUL GRANT;;RAMASWAMY PALLAVIKA;;ROBBIN JEFFREY L;;SAVAGE JAMES S;;SIBSON MATTHEW;;SINGH GURSHAMNJOT;;STACK CAELAN G;;YIN LUMING;;YING CHARLES H;;XUE MARK M;;ZHANG HENGLIANG;;ZHANG XIAOYUE;;COFFMAN PATRICK L,,https://lens.org/160-796-982-823-645,Amended Patent,no,2,0,27,37,0,G06F3/04817;;G06F3/0488;;G06F8/61;;G06F9/445;;H04M1/72472;;G06F9/451;;G06F8/61;;G06F9/44568;;G06F9/52;;G06F9/54;;G06F3/04842;;G06F3/04883;;G06F3/04886;;G06F8/38;;H04L67/34;;H04L67/5651,G06F3/048;;G06F9/451,,0,0,,,,ACTIVE
257,WO,A1,WO 2021/206976 A1,129-832-370-218-26X,2021-10-14,2021,US 2021/0025051 W,2021-03-31,US 202063008586 P;;US 202063022869 P;;US 202063032970 P;;DK PA202070633 A;;DK PA202070634 A,2020-04-10,USER INTERFACES FOR ENABLING AN ACTIVITY,"The present disclosure generally relates to user interfaces for enabling an activity using a computer system. In some embodiments, exemplary user interfaces for invoking an activity associated with an application are described. In some embodiments, exemplary user interfaces for customizing displayed content based on circumstances under which the content was invoked are described. In some embodiments, exemplary user interfaces for managing applications that were used to enable activities are described. In some embodiments, exemplary user interfaces for managing settings for applications used to enable activities are described.",APPLE INC,ZHANG YONGJUN;;ABBASIAN REZA;;ADLER DARIN;;CHAN ADA;;DOHERTY NICHOLAS STEPHEN;;DUBOIS DANA J;;ETZEL CHARLES B;;FALKENBURG STEVEN;;FEDERIGHI CRAIG M;;FERRY KENNETH ARTHUR ABRAHAM;;FOSS CHRISTOPHER PATRICK;;GHARABALLY SAM H;;GOLDBERG BRIAN ERIK;;KHAN NAHIR A;;KO HEENA;;KOWALCZYKOWSKI KEITH P;;MEHRA RISHAB;;PAUL GRANT;;RAMASWAMY PALLAVIKA;;RITCHIE GRANT;;ROBBIN JEFFREY L;;SAVAGE JAMES S;;SIBSON MATTHEW;;SINGH GURSHAMNJOT;;STACK CAELAN G;;XUE MARK M;;YIN LUMING;;YING CHARLES H;;ZHANG HENGLIANG;;ZHANG XIAOYUE,,https://lens.org/129-832-370-218-26X,Patent Application,yes,31,0,27,37,0,G06F3/04817;;G06F3/0488;;G06F8/61;;G06F9/445;;H04M1/72472;;G06F9/451;;G06F8/61;;G06F9/44568;;G06F9/52;;G06F9/54;;G06F3/04842;;G06F3/04883;;G06F3/04886;;G06F8/38;;H04L67/34;;H04L67/5651,G06F3/0481;;G06F3/0488;;G06F8/61;;G06F9/445,,0,0,,,,PENDING
258,AU,A1,AU 2022/202261 A1,017-134-750-408-517,2022-04-21,2022,AU 2022/202261 A,2022-04-05,AU 2022/202261 A;;AU 2020/239759 A;;DK PA202070634 A;;US 202063008586 P;;US 202063022869 P;;DK PA202070633 A;;US 202063032970 P,2020-04-10,User interfaces for enabling an activity,"The present disclosure generally relates to user interfaces for enabling an activity using a computer system. In some embodiments, exemplary user interfaces for invoking an activity associated with an application are described. In some embodiments, exemplary user interfaces for customizing displayed content based on circumstances under which the content was invoked are described. In some embodiments, exemplary user interfaces for managing applications that were used to enable activities are described. In some embodiments, exemplary user interfaces for managing settings for applications used to enable activities are described.",APPLE INC,ZHANG YONGJUN;;ABBASIAN REZA;;ADLER DARIN;;CHAN ADA;;COFFMAN PATRICK L;;DOHERTY NICHOLAS STEPHEN;;DUBOIS DANA J;;ETZEL CHARLES B;;FALKENBURG STEVEN;;FEDERIGHI CRAIG M;;FERRY KENNETH ARTHUR ABRAHAM;;FOSS CHRISTOPHER PATRICK;;GHARABALLY SAM H;;GOLDBERG BRIAN ERIK;;KHAN NAHIR A;;KO HEENA;;KOWALCZYKOWSKI KEITH P;;MEHRA RISHAB;;PAUL GRANT;;RAMASWAMY PALLAVIKA;;RITCHIE GRANT;;ROBBIN JEFFREY L;;SAVAGE JAMES S;;SIBSON MATTHEW;;SINGH SHAMAN;;STACK CAELAN G;;XUE MARK M;;YIN LUMING;;YING CHARLES H;;ZHANG HENGLIANG;;ZHANG XIAOYUE,,https://lens.org/017-134-750-408-517,Patent Application,no,0,0,27,37,0,G06F3/04817;;G06F3/0488;;G06F8/61;;G06F9/445;;H04M1/72472;;G06F9/451;;G06F8/61;;G06F9/44568;;G06F9/52;;G06F9/54;;G06F3/04842;;G06F3/04883;;G06F3/04886;;G06F8/38;;H04L67/34;;H04L67/5651,G06F3/048;;G06F9/451,,0,0,,,,ACTIVE
259,AU,A1,AU 2023/203678 A1,169-118-303-656-131,2023-07-06,2023,AU 2023/203678 A,2023-06-13,AU 2023/203678 A;;AU 2022/202261 A;;AU 2020/239759 A;;DK PA202070634 A;;US 202063008586 P;;US 202063022869 P;;DK PA202070633 A;;US 202063032970 P,2020-04-10,User interfaces for enabling an activity,"The present disclosure generally relates to user interfaces for enabling an activity using a computer system. In some embodiments, exemplary user interfaces for invoking an activity associated with an application are described. In some embodiments, exemplary user interfaces for customizing displayed content based on circumstances under which the content was invoked are described. In some embodiments, exemplary user interfaces for managing applications that were used to enable activities are described. In some embodiments, exemplary user interfaces for managing settings for applications used to enable activities are described.",APPLE INC,ZHANG YONGJUN;;ABBASIAN REZA;;ADLER DARIN;;CHAN ADA;;COFFMAN PATRICK L;;DOHERTY NICHOLAS STEPHEN;;DUBOIS DANA J;;ETZEL CHARLES B;;FALKENBURG STEVEN;;FEDERIGHI CRAIG M;;FERRY KENNETH ARTHUR ABRAHAM;;FOSS CHRISTOPHER PATRICK;;GHARABALLY SAM H;;GOLDBERG BRIAN ERIK;;KHAN NAHIR A;;KO HEENA;;KOWALCZYKOWSKI KEITH P;;MEHRA RISHAB;;PAUL GRANT;;RAMASWAMY PALLAVIKA;;RITCHIE GRANT;;ROBBIN JEFFREY L;;SAVAGE JAMES S;;SIBSON MATTHEW;;SINGH GURSHAMNJOT;;STACK CAELAN G;;XUE MARK M;;YIN LUMING;;YING CHARLES H;;ZHANG HENGLIANG;;ZHANG XIAOYUE;;DYE ALAN C,,https://lens.org/169-118-303-656-131,Patent Application,no,0,0,27,37,0,G06F3/04817;;G06F3/0488;;G06F8/61;;G06F9/445;;H04M1/72472;;G06F9/451;;G06F8/61;;G06F9/44568;;G06F9/52;;G06F9/54;;G06F3/04842;;G06F3/04883;;G06F3/04886;;G06F8/38;;H04L67/34;;H04L67/5651,G06F3/048;;G06F9/451,,0,0,,,,PENDING
260,EP,A3,EP 4277252 A3,159-976-532-192-447,2024-01-10,2024,EP 23199956 A,2021-03-31,US 202063032970 P;;DK PA202070633 A;;US 202063008586 P;;US 202063022869 P;;DK PA202070634 A;;EP 21724821 A;;US 2021/0025051 W,2020-04-10,USER INTERFACES FOR ENABLING AN ACTIVITY,"The present disclosure generally relates to user interfaces for enabling an activity using a computer system. In some embodiments, exemplary user interfaces for invoking an activity associated with an application are described. In some embodiments, exemplary user interfaces for customizing displayed content based on circumstances under which the content was invoked are described. In some embodiments, exemplary user interfaces for managing applications that were used to enable activities are described. In some embodiments, exemplary user interfaces for managing settings for applications used to enable activities are described.
",APPLE INC,ZHANG YONGJUN;;ABBASIAN REZA;;ADLER DARIN;;CHAN ADA;;COFFMAN PATRICK L;;DOHERTY NICHOLAS STEPHEN;;DUBOIS DANA J;;ETZEL CHARLES B;;FALKENBURG STEVEN;;FEDERIGHI CRAIG M;;FERRY KENNETH ARTHUR ABRAHAM;;FOSS CHRISTOPHER PATRICK;;GHARABALLY SAM H;;GOLDBERG BRIAN ERIK;;KHAN NAHIR A;;KO HEENA;;KOWALCZYKOWSKI KEITH P;;MEHRA RISHAB;;PAUL GRANT;;RAMASWAMY PALLAVIKA;;RITCHIE GRANT;;ROBBIN JEFFREY L;;SAVAGE JAMES S;;SIBSON MATTHEW;;SINGH GURSHAMNJOT;;STACK CAELAN G;;XUE MARK M;;YIN LUMING;;YING CHARLES H;;ZHANG HENGLIANG;;ZHANG XIAOYUE;;DYE ALAN C,,https://lens.org/159-976-532-192-447,Search Report,yes,3,0,27,37,0,G06F3/04817;;G06F3/0488;;G06F8/61;;G06F9/445;;H04M1/72472;;G06F9/451;;G06F8/61;;G06F9/44568;;G06F9/52;;G06F9/54;;G06F3/04842;;G06F3/04883;;G06F3/04886;;G06F8/38;;H04L67/34;;H04L67/5651,G06F3/0481;;G06F3/0488;;G06F8/61;;G06F9/445,,0,0,,,,PENDING
261,EP,A2,EP 4277252 A2,083-807-923-040-050,2023-11-15,2023,EP 23199956 A,2021-03-31,US 202063032970 P;;DK PA202070633 A;;US 202063008586 P;;US 202063022869 P;;DK PA202070634 A;;EP 21724821 A;;US 2021/0025051 W,2020-04-10,USER INTERFACES FOR ENABLING AN ACTIVITY,"The present disclosure generally relates to user interfaces for enabling an activity using a computer system. In some embodiments, exemplary user interfaces for invoking an activity associated with an application are described. In some embodiments, exemplary user interfaces for customizing displayed content based on circumstances under which the content was invoked are described. In some embodiments, exemplary user interfaces for managing applications that were used to enable activities are described. In some embodiments, exemplary user interfaces for managing settings for applications used to enable activities are described.
",APPLE INC,ZHANG YONGJUN;;ABBASIAN REZA;;ADLER DARIN;;CHAN ADA;;COFFMAN PATRICK L;;DOHERTY NICHOLAS STEPHEN;;DUBOIS DANA J;;ETZEL CHARLES B;;FALKENBURG STEVEN;;FEDERIGHI CRAIG M;;FERRY KENNETH ARTHUR ABRAHAM;;FOSS CHRISTOPHER PATRICK;;GHARABALLY SAM H;;GOLDBERG BRIAN ERIK;;KHAN NAHIR A;;KO HEENA;;KOWALCZYKOWSKI KEITH P;;MEHRA RISHAB;;PAUL GRANT;;RAMASWAMY PALLAVIKA;;RITCHIE GRANT;;ROBBIN JEFFREY L;;SAVAGE JAMES S;;SIBSON MATTHEW;;SINGH GURSHAMNJOT;;STACK CAELAN G;;XUE MARK M;;YIN LUMING;;YING CHARLES H;;ZHANG HENGLIANG;;ZHANG XIAOYUE;;DYE ALAN C,,https://lens.org/083-807-923-040-050,Patent Application,yes,28,0,27,37,0,G06F3/04817;;G06F3/0488;;G06F8/61;;G06F9/445;;H04M1/72472;;G06F9/451;;G06F8/61;;G06F9/44568;;G06F9/52;;G06F9/54;;G06F3/04842;;G06F3/04883;;G06F3/04886;;G06F8/38;;H04L67/34;;H04L67/5651,H04M1/72472,,0,0,,,,PENDING
262,CN,A,CN 116027943 A,174-725-016-239-402,2023-04-28,2023,CN 202310042931 A,2021-03-31,DK PA202070633 A;;DK PA202070634 A;;US 202063008586 P;;US 202063022869 P;;US 202063032970 P;;CN 202180040304 A;;US 2021/0025051 W,2020-04-10,User interface for enabling activities,"The present disclosure generally relates to user interfaces for enabling activities. In some embodiments, an exemplary user interface for invoking activities associated with an application is described. In some embodiments, an exemplary user interface is described for customizing display content based on a situation in which the content is invoked. In some embodiments, an exemplary user interface for managing an application for enabling an activity is described. In some embodiments, an exemplary user interface is described for managing settings for an activity-enabled application.",APPLE INC,ZHANG YU;;ABBASIAN REZA;;ADLER DORON;;CHEN ALVIN;;COFFMAN PATRICK L;;DOHERTY NIRANJAN S;;DUBOIS DANIEL J;;ETZEL CHRISTOPHER B;;FALKENBURG STEVEN;;FEDERIGHI CRAIG M;;FERRY KAREN A A;;FOSS CHRISTOPHER PATRICK;;GARABALLI SAM H;;GOLDBERG BRIAN E;;KHAN NAWAZ A;;KO HEENA;;KOWALCZYKOWSKI KEVIN P;;MEHRA RAJDEEP;;PAUL GRANT;;RAMASWAMY PRASANNA;;RICCI GIOVANNI;;ROBBIN JEFFREY L;;SAVAGE JOHN S;;SIBSON MICHAEL;;SINGH GURPREET;;STACK CAELAN G;;XUE MINGZHE M;;YIN LUMING;;YING CHANGHAN HOBIE;;ZHANG HENGLIANG;;ZHANG XIAOYUE;;A C DAY,,https://lens.org/174-725-016-239-402,Patent Application,no,0,0,27,37,0,G06F3/04817;;G06F3/0488;;G06F8/61;;G06F9/445;;H04M1/72472;;G06F9/451;;G06F8/61;;G06F9/44568;;G06F9/52;;G06F9/54;;G06F3/04842;;G06F3/04883;;G06F3/04886;;G06F8/38;;H04L67/34;;H04L67/5651,G06F3/04817;;G06F3/0482;;G06F3/0488,,0,0,,,,PENDING
263,AU,B2,AU 2022/202261 B2,066-776-999-893-871,2023-04-13,2023,AU 2022/202261 A,2022-04-05,AU 2022/202261 A;;AU 2020/239759 A;;DK PA202070634 A;;US 202063008586 P;;US 202063022869 P;;DK PA202070633 A;;US 202063032970 P,2020-04-10,User interfaces for enabling an activity,"The present disclosure generally relates to user interfaces for enabling an activity using a computer system. In some embodiments, exemplary user interfaces for invoking an activity associated with an application are described. In some embodiments, exemplary user interfaces for customizing displayed content based on circumstances under which the content was invoked are described. In some embodiments, exemplary user interfaces for managing applications that were used to enable activities are described. In some embodiments, exemplary user interfaces for managing settings for applications used to enable activities are described.",APPLE INC,ZHANG YONGJUN;;ABBASIAN REZA;;ADLER DARIN;;CHAN ADA;;COFFMAN PATRICK L;;DOHERTY NICHOLAS STEPHEN;;DUBOIS DANA J;;ETZEL CHARLES B;;FALKENBURG STEVEN;;FEDERIGHI CRAIG M;;FERRY KENNETH ARTHUR ABRAHAM;;FOSS CHRISTOPHER PATRICK;;GHARABALLY SAM H;;GOLDBERG BRIAN ERIK;;KHAN NAHIR A;;KO HEENA;;KOWALCZYKOWSKI KEITH P;;MEHRA RISHAB;;PAUL GRANT;;RAMASWAMY PALLAVIKA;;RITCHIE GRANT;;ROBBIN JEFFREY L;;SAVAGE JAMES S;;SIBSON MATTHEW;;SINGH GURSHAMNJOT;;STACK CAELAN G;;XUE MARK M;;YIN LUMING;;YING CHARLES H;;ZHANG HENGLIANG;;ZHANG XIAOYUE;;DYE ALAN C,,https://lens.org/066-776-999-893-871,Granted Patent,no,5,0,27,37,0,G06F3/04817;;G06F3/0488;;G06F8/61;;G06F9/445;;H04M1/72472;;G06F9/451;;G06F8/61;;G06F9/44568;;G06F9/52;;G06F9/54;;G06F3/04842;;G06F3/04883;;G06F3/04886;;G06F8/38;;H04L67/34;;H04L67/5651,G06F3/048;;G06F9/451,,0,0,,,,ACTIVE
264,EP,B1,EP 4028869 B1,040-155-157-623-984,2024-02-21,2024,EP 21724821 A,2021-03-31,US 2021/0025051 W;;US 202063008586 P;;US 202063022869 P;;US 202063032970 P;;DK PA202070633 A;;DK PA202070634 A,2020-04-10,USER INTERFACES FOR ENABLING AN ACTIVITY,,APPLE INC,ZHANG YONGJUN;;ABBASIAN REZA;;ADLER DARIN;;CHAN ADA;;COFFMAN PATRICK L;;DOHERTY NICHOLAS STEPHEN;;DUBOIS DANA J;;ETZEL CHARLES B;;FALKENBURG STEVEN;;FEDERIGHI CRAIG M;;FERRY KENNETH ARTHUR ABRAHAM;;FOSS CHRISTOPHER PATRICK;;GHARABALLY SAM H;;GOLDBERG BRIAN ERIK;;KHAN NAHIR A;;KO HEENA;;KOWALCZYKOWSKI KEITH P;;MEHRA RISHAB;;PAUL GRANT;;RAMASWAMY PALLAVIKA;;RITCHIE GRANT;;ROBBIN JEFFREY L;;SAVAGE JAMES S;;SIBSON MATTHEW;;SINGH GURSHAMNJOT;;STACK CAELAN G;;XUE MARK M;;YIN LUMING;;YING CHARLES H;;ZHANG HENGLIANG;;ZHANG XIAOYUE;;DYE ALAN C,APPLE INC. (2023-07-12),https://lens.org/040-155-157-623-984,Granted Patent,yes,8,0,27,37,0,G06F3/04817;;G06F3/0488;;G06F8/61;;G06F9/445;;H04M1/72472;;G06F9/451;;G06F8/61;;G06F9/44568;;G06F9/52;;G06F9/54;;G06F3/04842;;G06F3/04883;;G06F3/04886;;G06F8/38;;H04L67/34;;H04L67/5651,G06F3/0481;;G06F3/0488;;G06F8/61;;G06F9/445;;H04M1/72472,,0,0,,,,ACTIVE
265,WO,A9,WO 2021/206976 A9,187-069-044-419-012,2022-11-10,2022,US 2021/0025051 W,2021-03-31,US 202063008586 P;;US 202063022869 P;;US 202063032970 P;;DK PA202070633 A;;DK PA202070634 A,2020-04-10,USER INTERFACES FOR ENABLING AN ACTIVITY,"The present disclosure generally relates to user interfaces for enabling an activity using a computer system. In some embodiments, exemplary user interfaces for invoking an activity associated with an application are described. In some embodiments, exemplary user interfaces for customizing displayed content based on circumstances under which the content was invoked are described. In some embodiments, exemplary user interfaces for managing applications that were used to enable activities are described. In some embodiments, exemplary user interfaces for managing settings for applications used to enable activities are described.",APPLE INC,ZHANG YONGJUN;;ABBASIAN REZA;;ADLER DARIN;;CHAN ADA;;COFFMAN PATRICK L;;DOHERTY NICHOLAS STEPHEN;;DUBOIS DANA J;;ETZEL CHARLES B;;FALKENBURG STEVEN;;FEDERIGHI CRAIG M;;FERRY KENNETH ARTHUR ABRAHAM;;FOSS CHRISTOPHER PATRICK;;GHARABALLY SAM H;;GOLDBERG BRIAN ERIK;;KHAN NAHIR A;;KO HEENA;;KOWALCZYKOWSKI KEITH P;;MEHRA RISHAB;;PAUL GRANT;;RAMASWAMY PALLAVIKA;;RITCHIE GRANT;;ROBBIN JEFFREY L;;SAVAGE JAMES S;;SIBSON MATTHEW;;SINGH GURSHAMNJOT;;STACK CAELAN G;;XUE MARK M;;YIN LUMING;;YING CHARLES H;;ZHANG HENGLIANG;;ZHANG XIAOYUE;;DYE ALAN C,,https://lens.org/187-069-044-419-012,Search Report,yes,0,0,27,37,0,G06F3/04817;;G06F3/0488;;G06F8/61;;G06F9/445;;H04M1/72472;;G06F9/451;;G06F8/61;;G06F9/44568;;G06F9/52;;G06F9/54;;G06F3/04842;;G06F3/04883;;G06F3/04886;;G06F8/38;;H04L67/34;;H04L67/5651,G06F3/0481;;G06F3/0488;;G06F8/61;;G06F9/445,,0,0,,,,PENDING
266,CN,A,CN 115943359 A,003-912-882-819-30X,2023-04-07,2023,CN 202180040304 A,2021-03-31,DK PA202070633 A;;DK PA202070634 A;;US 202063008586 P;;US 202063022869 P;;US 202063032970 P;;US 2021/0025051 W,2020-04-10,User interface for enabling activities,"The present disclosure generally relates to a user interface for enabling activities using a computer system. In some embodiments, an exemplary user interface for invoking activities associated with an application is described. In some embodiments, an exemplary user interface is described for customizing display content based on a situation in which the content is invoked. In some embodiments, an exemplary user interface for managing an application for enabling an activity is described. In some embodiments, an exemplary user interface is described for managing settings for an activity-enabled application.",APPLE INC,ZHANG YU;;ABBASIAN REZA;;ADLER DORON;;CHEN ALVIN;;COFFMAN PATRICK L;;DOHERTY NIRANJAN S;;DUBOIS DANIEL J;;ETZEL CHRISTOPHER B;;FALKENBURG STEVEN;;FEDERIGHI CRAIG M;;FERRY KAREN A A;;FOSS CHRISTOPHER PATRICK;;GARABALLI SAM H;;GOLDBERG BRIAN E;;KHAN NAWAZ A;;KO HEENA;;KOWALCZYKOWSKI KEVIN P;;MEHRA RAJDEEP;;PAUL GRANT;;RAMASWAMY PRASANNA;;RICCI GIOVANNI;;ROBBIN JEFFREY L;;SAVAGE JOHN S;;SIBSON MICHAEL;;SINGH GURPREET;;STACK CAELAN G;;XUE MINGZHE M;;YIN LUMING;;YING CHANGHAN HOBIE;;ZHANG HENGLIANG;;ZHANG XIAOYUE;;A C DAY,,https://lens.org/003-912-882-819-30X,Patent Application,no,0,0,27,37,0,G06F3/04817;;G06F3/0488;;G06F8/61;;G06F9/445;;H04M1/72472;;G06F9/451;;G06F8/61;;G06F9/44568;;G06F9/52;;G06F9/54;;G06F3/04842;;G06F3/04883;;G06F3/04886;;G06F8/38;;H04L67/34;;H04L67/5651,G06F3/0481;;G06F3/0488;;G06F8/61;;G06F9/445,,0,0,,,,PENDING
267,KR,A,KR 20230019187 A,112-803-802-204-313,2023-02-07,2023,KR 20230010187 A,2023-01-26,US 202063008586 P;;US 202063022869 P;;US 202063032970 P;;DK PA202070633 A;;DK PA202070634 A;;KR 20200123866 A,2020-04-10,USER INTERFACES FOR ENABLING AN ACTIVITY,"The present disclosure generally relates to user interfaces for enabling an activity using a computer system. In some embodiments, exemplary user interfaces for invoking an activity associated with an application are described. In some embodiments, exemplary user interfaces for customizing displayed content based on circumstances under which the content was invoked are described. In some embodiments, exemplary user interfaces for managing applications that were used to enable activities are described. In some embodiments, exemplary user interfaces for managing settings for applications used to enable activities are described.",APPLE INC,ZHANG YONGJUN;;ABBASIAN REZA;;ADLER DARIN;;CHAN ADA;;DUBOIS DANA J;;ETZEL CHARLES B;;FERRY KENNETH ARTHUR ABRAHAM;;FALKENBURG STEVEN;;FEDERIGHI CRAIG M;;FOSS CHRISTOPHER PATRICK;;GHARABALLY SAM H;;GOLDBERG BRIAN ERIK;;DOHERTY NICHOLAS STEPHEN;;KHAN NAHIR A;;KO HEENA;;KOWALCZYKOWSKI KEITH P;;MEHRA RISHAB;;PAUL GRANT;;RAMASWAMY PALLAVIKA;;ROBBIN JEFFREY L;;SAVAGE JAMES S;;SIBSON MATTHEW;;SINGH GURSHAMNJOT;;STACK CAELAN G;;YIN LUMING;;YING CHARLES H;;XUE MARK M;;ZHANG HENGLIANG;;ZHANG XIAOYUE;;COFFMAN PATRICK L;;RITCHIE GRANT;;DYE ALAN C,,https://lens.org/112-803-802-204-313,Patent Application,no,0,0,27,37,0,G06F3/04817;;G06F3/0488;;G06F8/61;;G06F9/445;;H04M1/72472;;G06F9/451;;G06F8/61;;G06F9/44568;;G06F9/52;;G06F9/54;;G06F3/04842;;G06F3/04883;;G06F3/04886;;G06F8/38;;H04L67/34;;H04L67/5651,G06F9/451;;G06F3/04842;;G06F3/04883;;G06F3/04886;;G06F8/38;;G06F8/61;;G06F9/445;;G06F9/52;;G06F9/54;;H04L67/00;;H04L67/5651,,0,0,,,,DISCONTINUED
